date,evidence,pmids,regimen,comparator,condition,context,endpoint,endpoint_type,answer,ground truth,closed question 1,closed question 2,closed question 3,closed question m,closed question m answer,open question 1,open generation 1,option 1,option 2,option 3,year,locality_question,locality_ground_truth,conflicting_edit 1976-07-15,"Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study. In January, 1972, the Southwest Oncology Group initiated two randomized studies for patients with advanced breast cancer. The study for patients with prior chemotherapy showed a 33% response rate with adriamycin. The study for patients without previous chemotherapy consisted of three treatment regimens; a weekly repeated combination of cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone; these same five drugs given in courses of 5 days repeated every 4 weeks; and adriamycin as a single agent every 3 weeks. For the 283 evaluable patients, the response rates were: weekly combination 63/106 (59%); intermittent combination 39/98 (40%); and adriamycin 31/79 (39%). The median duration of response was 8 months for weekly combination, 10 months for intermittent therapy and only 4 months for adriamycin. Leukopenia was the dose-limiting toxicity with all three regimens. The weekly combination is the most effective therapy for patients with advanced disease. Extensive trails of combinations that include adriamycin are underway.",947510,CMFVP,Doxorubicin monotherapy,Breast cancer,Non-curative therapy,ORR,Undesignated,superior,CMFVP superior to Doxorubicin monotherapy for Breast cancer (Non-curative therapy) [endpoint: ORR],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the ORR outcome of CMFVP compared to Doxorubicin monotherapy when used to treat Breast cancer (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the ORR outcome of CMFVP versus Doxorubicin monotherapy in treating Breast cancer (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the ORR results of CMFVP compared to Doxorubicin monotherapy for Breast cancer (Non-curative therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the ORR outcome of Doxorubicin monotherapy compared to CMFVP when used to treat Breast cancer (Non-curative therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer, Context: Non-curative therapy, Endpoint: ORR, Treatment 1: CMFVP, Treatment 2: Doxorubicin monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Breast cancer, Context: Non-curative therapy Treatment: ",superior,inferior,no difference,1976,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer (Node Positive), Context: Adjuvant therapy, Endpoint: RFS, Treatment 1: CMF, Treatment 2: CMFT Response:",CMF inferior to CMFT for Breast cancer (Node Positive) (Adjuvant therapy) [endpoint: RFS],False 1978-06-15,"Adriamycin in combination for the treatment of breast cancer: a Southwest Oncology Group study. Patients with advanced breast cancer who had not previously received chemotherapy were treated on a three-arm prospective study: adriamycin day 1 plus 5-FU on day 1 and 8 (AF), adriamycin day 1, plus 5-FU day 1 and 8, and cyclophosphamide day 1 (AFC), and adriamycin day 1 plus 5-FU day 1 and 8, cyclophosphamide day 1 and methotrexate day 1 (AFCM). These courses were repeated every 21 days. The response rate was 44/105 (42%) AF, 44/103 (43%) AFC and 52/105 (49%) AFCM. The length of response was 22, 33 and 35 weeks, respectively, for AF, AFC and AFCM (P = 0.21). The median survival, 64 weeks, was equal in all three limbs. The major toxicity was leukopenia. Twenty-eight percent developed a WBC of less than 2,000/microliter, which resulted in seven deaths (2.2%).",657081,Doxorubicin and Fluorouracil (FA),CAMF,Breast cancer,Non-curative therapy,ORR,Primary,no difference,Doxorubicin and Fluorouracil (FA) no difference to CAMF for Breast cancer (Non-curative therapy) [endpoint: ORR],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the ORR outcome of Doxorubicin and Fluorouracil (FA) compared to CAMF when used to treat Breast cancer (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the ORR outcome of Doxorubicin and Fluorouracil (FA) versus CAMF in treating Breast cancer (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the ORR results of Doxorubicin and Fluorouracil (FA) compared to CAMF for Breast cancer (Non-curative therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the ORR outcome of CAMF compared to Doxorubicin and Fluorouracil (FA) when used to treat Breast cancer (Non-curative therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer, Context: Non-curative therapy, Endpoint: ORR, Treatment 1: Doxorubicin and Fluorouracil (FA), Treatment 2: CAMF Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Breast cancer, Context: Non-curative therapy Treatment: ",superior,inferior,no difference,1978,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer (Node Positive), Context: Adjuvant therapy, Endpoint: RFS, Treatment 1: CMF, Treatment 2: CMFT Response:",CMF inferior to CMFT for Breast cancer (Node Positive) (Adjuvant therapy) [endpoint: RFS],False 1983-07-01,"Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer. After total mastectomy and partial axillary dissection, 805 premenopausal women with stage II breast cancer were randomized to receive postoperative radiotherapy (RT) alone, RT + cyclophosphamide (C) for 12 monthly cycles, or RT + cyclophosphamide/methotrexate/5-fluorouracil (CMF) for 12 monthly cycles. At 3 years actuarial relapse-free survival for RT + C and RT + CMF was significantly better than for RT alone (p = 0.0009 and 0.0001, respectively). There was no significant difference in relapse-free survival between RT + C and RT + CMF. C resulted in more pronounced haematologic toxicity and a higher frequency of amenorrhoea and of alopecia than CMF, while CMF resulted in more pronounced nausea and stomatitis than C. In the preliminary results, C alone may be as effective as CMF in prolonging relapse-free survival in premenopausal women with stage II breast cancer. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer. The Danish Breast Cancer Cooperative Group (DBCG) 77B trial examined the relative efficacy of levamisole, single-agent oral cyclophosphamide, and the classic combination of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) against no adjuvant systemic therapy in high-risk breast cancer patients. The authors report the results from that trial after a potential follow-up of 25 years. Between 1977 and 1983, 1146 premenopausal patients who had tumors >5 cm or positive axillary lymph nodes were assigned randomly to 1 of 4 options: no systemic therapy, levamisole 5 mg weekly for 48 weeks (the levamisole arm), oral cyclophosphamide 130 mg/m(2) on Days 1 through 14 every 4 weeks for 12 cycles (the C arm), or oral cyclophosphamide 80 mg/m(2) on Days 1 through 14 plus methotrexate 30 mg/m(2) and fluorouracil 500 mg/m(2) intravenously on Days 1 and 8 every 4 weeks for 12 cycles (the CMF arm). The 10-year invasive disease-free survival (IDFS) rate was 38.6% in the control arm compared with 55.5% in the C arm, 48.8% in the CMF arm, and 35.2% in the levamisole arm. Compared with the control arm, the hazard ratio for an IDFS event was 0.62 in the C arm (P = .001) and 0.70 in the CMF arm (P = .01). The hazard ratio for death was 0.70 in both the C arm (P = .02) and the CMF arm (P = .02) at 10 years, and the overall survival (OS) benefit was maintained during 25 years of follow-up. No significant differences were observed in IDFS or OS between the C arm and the CMF arm or between the levamisole arm and the control arm. Compared with controls, both cyclophosphamide and CMF significantly improved disease-free survival and OS, and the benefits persisted for at least 25 years in premenopausal patients who had high-risk breast cancer.",6347278;20186830,Levamisole monotherapy,Observation,Breast cancer,Adjuvant therapy,OS,Co-primary,no difference,Levamisole monotherapy no difference to Observation for Breast cancer (Adjuvant therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Levamisole monotherapy compared to Observation when used to treat Breast cancer (Adjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Levamisole monotherapy versus Observation in treating Breast cancer (Adjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Levamisole monotherapy compared to Observation for Breast cancer (Adjuvant therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Observation compared to Levamisole monotherapy when used to treat Breast cancer (Adjuvant therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer, Context: Adjuvant therapy, Endpoint: OS, Treatment 1: Levamisole monotherapy, Treatment 2: Observation Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Breast cancer, Context: Adjuvant therapy Treatment: ",superior,inferior,no difference,1983,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer (Metastatic), Context: Non-curative therapy, Endpoint: PFS, Treatment 1: Tamoxifen monotherapy, Treatment 2: Bilateral oophorectomy monotherapy Response:",Tamoxifen monotherapy superior to Bilateral oophorectomy monotherapy for Breast cancer (Metastatic) (Non-curative therapy) [endpoint: PFS],False 1985-11-30,"Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Safety and efficacy of a slow-release formulation of D-Trp-6-luteinising-hormone-releasing-hormone (D-Trp-6-LHRH) microcapsules were compared with orchidectomy in the initial treatment of advanced prostatic carcinoma. 41 patients were randomly assigned to D-Trp-6-LHRH and 38 to orchidectomy. Suppression of testosterone and reduction in prostatic acid phosphatase levels were similar in both groups. 87% of patients in the D-Trp-6-LHRH group and 81% in the orchidectomy group responded to treatment or showed no deterioration. Side-effects related to the decrease in testosterone were similar in both groups. 3 patients given D-Trp-6-LHRH had a disease ""flare"" in the first ten days of treatment which resolved completely when testosterone fell to castrate levels. Results of psychological assessment were similar in both groups before treatment, and on follow-up there was a weak trend towards decreased psychological morbidity in the hormone group. The slow-release preparation of D-Trp-6-LHRH microcapsules offers an important alternative in the management of advanced prostatic carcinoma.",2866289,Castration,D-Trp-6-LHRH monotherapy,Prostate cancer,Non-curative therapy,Could not be determined,Undesignated,no difference,Castration no difference to D-Trp-6-LHRH monotherapy for Prostate cancer (Non-curative therapy) [endpoint: Could not be determined],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the efficacy of Castration compared to D-Trp-6-LHRH monotherapy when used to treat Prostate cancer (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the effectiveness of Castration versus D-Trp-6-LHRH monotherapy in treating Prostate cancer (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the comparative efficacy of Castration and D-Trp-6-LHRH monotherapy for managing Prostate cancer (Non-curative therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the efficacy of D-Trp-6-LHRH monotherapy compared to Castration when used to treat Prostate cancer (Non-curative therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Prostate cancer, Context: Non-curative therapy, Treatment 1: Castration, Treatment 2: D-Trp-6-LHRH monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Prostate cancer, Context: Non-curative therapy Treatment: ",superior,inferior,no difference,1985,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Wilms tumor, Context: Adjuvant therapy, Endpoint: RFS, Treatment 1: Vincristine monotherapy, Treatment 2: Dactinomycin and Vincristine Response:",Vincristine monotherapy inferior to Dactinomycin and Vincristine for Wilms tumor (Adjuvant therapy) [endpoint: RFS],False 1990-05-17,"Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. The use of interferon for the induction treatment of multiple myeloma has been shown to be effective in about 20 percent of patients. We studied its effects on long-term survival when it was used for maintenance treatment. Between April 1985 and May 1988, 101 patients with symptomatic multiple myeloma who had had a substantial objective response or a lesser objective response with disappearance of symptoms (""disease stabilization"") after 12 courses of induction chemotherapy were randomly assigned to receive recombinant interferon alfa-2b as maintenance therapy (n = 50) or to receive no treatment (n = 51). As of December 1989, 66 of the 101 patients have relapsed (25 given interferon and 41 not treated). The median duration of response (from the time of randomization) was 26 months in the patients given interferon and 14 months in the untreated patients (P = 0.0002). A total of 37 patients have died (14 given interferon and 23 not treated). The median duration of survival (from randomization) was 52 months in the interferon group and 39 months in the control group (P = 0.0526). Among the patients who had had a substantial objective response to induction chemotherapy, the difference in survival time was statistically significant (P = 0.03526). Interferon had to be stopped because of toxic effects in 3 of 12 patients initially treated with 10 MU (megaunits) per square meter of body-surface area. After the dose was reduced to 3 MU per square meter, the only toxic effect was a mild influenza-like syndrome lasting two to three weeks. We conclude that maintenance treatment with interferon prolongs response and survival in patients with multiple myeloma who have responded to conventional induction chemotherapy.",2184356,Interferon alfa-2b monotherapy,Observation,Multiple myeloma,Non-curative first-line maintenance therapy,OS,Undesignated,superior,Interferon alfa-2b monotherapy superior to Observation for Multiple myeloma (Non-curative first-line maintenance therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Interferon alfa-2b monotherapy compared to Observation when used to treat Multiple myeloma (Non-curative first-line maintenance therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Interferon alfa-2b monotherapy versus Observation in treating Multiple myeloma (Non-curative first-line maintenance therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Interferon alfa-2b monotherapy compared to Observation for Multiple myeloma (Non-curative first-line maintenance therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Observation compared to Interferon alfa-2b monotherapy when used to treat Multiple myeloma (Non-curative first-line maintenance therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Multiple myeloma, Context: Non-curative first-line maintenance therapy, Endpoint: OS, Treatment 1: Interferon alfa-2b monotherapy, Treatment 2: Observation Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Multiple myeloma, Context: Non-curative first-line maintenance therapy Treatment: ",superior,inferior,no difference,1990,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 1990-09-01,"A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. In a multicenter Phase III trial 264 patients with advanced prostatic cancer were randomized to either bilateral orchiectomy or treatment with zoladex supplemented by flutamide. Presently, median follow-up time is 30 months. A small difference in objective response was recorded in favor of the combination therapy, whereas no statistically significant difference was found in subjective response to therapy, time to progression, and overall survival. Adverse effects were more commonly encountered in the pharmacologically treated patients. It is concluded that the combination of zoladex plus flutamide is not clinically superior to orchiectomy in the treatment of patients with advanced carcinoma of the prostate.",2144207,Castration,Flutamide and Goserelin,Prostate cancer,Non-curative therapy,OS,Co-primary,no difference,Castration no difference to Flutamide and Goserelin for Prostate cancer (Non-curative therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Castration compared to Flutamide and Goserelin when used to treat Prostate cancer (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Castration versus Flutamide and Goserelin in treating Prostate cancer (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Castration compared to Flutamide and Goserelin for Prostate cancer (Non-curative therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Flutamide and Goserelin compared to Castration when used to treat Prostate cancer (Non-curative therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Prostate cancer, Context: Non-curative therapy, Endpoint: OS, Treatment 1: Castration, Treatment 2: Flutamide and Goserelin Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Prostate cancer, Context: Non-curative therapy Treatment: ",superior,inferior,no difference,1990,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Wilms tumor, Context: Adjuvant therapy, Endpoint: RFS, Treatment 1: Vincristine monotherapy, Treatment 2: Dactinomycin and Vincristine Response:",Vincristine monotherapy inferior to Dactinomycin and Vincristine for Wilms tumor (Adjuvant therapy) [endpoint: RFS],True 1992-01-25,"Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. Both melphalan and cyclophosphamide increase life expectancy in patients with myelomatosis, but few large randomised studies have compared combination chemotherapy regimens with these single agents. In the Vth MRC myelomatosis trial, the survival of 314 patients randomised to receive ABCM (adriamycin, BCNU, cyclophosphamide, and melphalan) as first-line treatment was significantly longer than that of 316 patients given intermittent melphalan (M7) (p = 0.0003). The 75%, median, and 25% survivals were 7, 24, and 42 months, respectively, with M7 and 10, 32, and 56 months, respectively, with ABCM. Stable disease with few symptoms (plateau) was achieved by 61% of patients given ABCM and 49% of those given M7 (p = 0.004). Myelotoxicity was comparable between regimens. Cross-trial analysis suggests that M7 is comparable to melphalan and prednisone or melphalan, prednisone, and vincristine; that the efficacy of ABCM in the Vth trial and VIth MRC trials is comparable; and that ABCM gave better survival than intermittent melphalan regimens in the prognostic groups analysed. The results indicate that ABCM is an acceptable regimen that is more effective than melphalan, with or without prednisone, for first-line treatment of myelomatosis.",1346171,Melphalan monotherapy,ABCM,Multiple myeloma,Non-curative first-line therapy,OS,Undesignated,inferior,Melphalan monotherapy inferior to ABCM for Multiple myeloma (Non-curative first-line therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Melphalan monotherapy compared to ABCM when used to treat Multiple myeloma (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Melphalan monotherapy versus ABCM in treating Multiple myeloma (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Melphalan monotherapy compared to ABCM for Multiple myeloma (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of ABCM compared to Melphalan monotherapy when used to treat Multiple myeloma (Non-curative first-line therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Multiple myeloma, Context: Non-curative first-line therapy, Endpoint: OS, Treatment 1: Melphalan monotherapy, Treatment 2: ABCM Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Multiple myeloma, Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,1992,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 1992-07-15,"A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. A randomized clinical trial was undertaken to compare the therapeutic effectiveness of idarubicin (IDR) to daunorubicin (DNR), and both were given in combination with cytarabine (CA) in acute myelogenous leukemic (AML) patients. Newly diagnosed patients were given a daily infusion of CA (100 mg/m2) for 7 days and were assigned randomly to receive DNR (45 mg/m2) or IDR (12 mg/m2) daily for the first 3 days. Those patients who achieved a complete remission (CR) were given three consolidation courses that consisted of CA (100 mg/m2 intravenously [IV]) and thioguanine (TG; 100 mg/m2 orally) every 12 hours for 5 days and either DNR (50 mg/m2) or IDR (15 mg/m2) on the first day of each cycle. After consolidation, patients received late intensification, which consisted of the same drugs used for induction except that the CA was given for 5 days and the anthracycline for 2 days. Four courses were planned at 13-week intervals. The CR rates were 75 of 105 (71%) on the IDR arm and 65 of 113 (58%) on the DNR arm (P = .03). The median survival and median remission durations were 297 and 433 days, respectively, on the IDR arm. The median survival and median remission durations were 277 and 328 days, respectively, on the DNR arm. Six deaths occurred during late intensification, five on IDR and one on DNR; this approach was abandoned after 47 patients were entered. The median survival was significantly longer for patients who received late intensification. This trial demonstrated that IDR was more effective than DNR in remission induction in AML.",1607916,7+3d,7+3i,Acute myeloid leukemia,Induction therapy,CR rate,Undesignated,inferior,7+3d inferior to 7+3i for Acute myeloid leukemia (Induction therapy) [endpoint: CR rate],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the CR rate outcome of 7+3d compared to 7+3i when used to treat Acute myeloid leukemia (Induction therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the CR rate outcome of 7+3d versus 7+3i in treating Acute myeloid leukemia (Induction therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the CR rate results of 7+3d compared to 7+3i for Acute myeloid leukemia (Induction therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the CR rate outcome of 7+3i compared to 7+3d when used to treat Acute myeloid leukemia (Induction therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia, Context: Induction therapy, Endpoint: CR rate, Treatment 1: 7+3d, Treatment 2: 7+3i Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Acute myeloid leukemia, Context: Induction therapy Treatment: ",superior,inferior,no difference,1992,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Multiple myeloma, Context: Non-curative therapy, Endpoint: OS, Treatment 1: Placebo, Treatment 2: Urethane monotherapy Response:",Placebo superior to Urethane monotherapy for Multiple myeloma (Non-curative therapy) [endpoint: OS],False 1992-11-19,"Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) has been the standard treatment for Hodgkin's disease for almost 20 years. In a randomized, multicenter trial, we compared three regimens of primary systemic therapy for newly diagnosed advanced Hodgkin's disease in Stages IIIA2, IIIB, and IVA or IVB: (1) MOPP alone given for 6 to 8 cycles, (2) MOPP alternating with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) for 12 cycles, and (3) ABVD alone for 6 to 8 cycles. Patients in a first relapse after radiation therapy were eligible. No additional radiation therapy was given. Patients who did not have a complete response or who had a relapse with either MOPP alone or ABVD alone were switched to the opposite regimen. Of 361 eligible patients, 123 received MOPP, 123 received MOPP alternating with ABVD, and 115 received ABVD alone. The patients were stratified according to age, stage, previous radiation, histologic features, and performance status. The overall response rate was 93 percent, with complete responses in 77 percent: 67 percent in the MOPP group, 82 percent in the ABVD group, and 83 percent in the MOPP-ABVD group (P = 0.006 for the comparison of MOPP with the other two regimens, both of which contained doxorubicin). The rates of failure-free survival at five years were 50 percent for MOPP, 61 percent for ABVD, and 65 percent for MOPP-ABVD. Age, stage (III vs. IV), and regimen influenced failure-free survival significantly. Overall survival at five years was 66 percent for MOPP, 73 percent for ABVD, and 75 percent for MOPP-ABVD (P = 0.28 for the comparison of MOPP with the doxorubicin regimens). MOPP had more severe toxic effects on bone marrow than ABVD and was associated with greater reductions in the prescribed dose. In this trial, ABVD therapy for 6 to 8 months was as effective as 12 months of MOPP alternating with ABVD, and both were superior to MOPP alone in the treatment of advanced Hodgkin's disease. ABVD was less myelotoxic than MOPP or ABVD alternating with MOPP. Long-term follow-up of Hodgkin's disease trial. Long-term follow-up of survival in Hodgkin's lymphoma.",1383821;11986425;20007568,MOPP,ABVD,Classical Hodgkin lymphoma,Induction therapy,EFS,Secondary,inferior,MOPP inferior to ABVD for Classical Hodgkin lymphoma (Induction therapy) [endpoint: EFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the EFS outcome of MOPP compared to ABVD when used to treat Classical Hodgkin lymphoma (Induction therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the EFS outcome of MOPP versus ABVD in treating Classical Hodgkin lymphoma (Induction therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the EFS results of MOPP compared to ABVD for Classical Hodgkin lymphoma (Induction therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the EFS outcome of ABVD compared to MOPP when used to treat Classical Hodgkin lymphoma (Induction therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Classical Hodgkin lymphoma, Context: Induction therapy, Endpoint: EFS, Treatment 1: MOPP, Treatment 2: ABVD Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Classical Hodgkin lymphoma, Context: Induction therapy Treatment: ",superior,inferior,no difference,1992,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Multiple myeloma, Context: Non-curative therapy, Endpoint: OS, Treatment 1: Placebo, Treatment 2: Urethane monotherapy Response:",Placebo superior to Urethane monotherapy for Multiple myeloma (Non-curative therapy) [endpoint: OS],False 1994-07-15,"Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. The EORTC Head and Neck Cancer Cooperative Group conducted a randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in chemotherapy naive patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The primary objectives of this study were to investigate whether the CF regimen was in anyway superior to the CABO regimen and to detect any superiority of these two combinations over cisplatin alone. Three hundred eighty-two patients were randomized to one of three treatments: (1) methotrexate (40 mg/m2) days 1 and 15, bleomycin (10 mg) and vincristine (2 mg) days 1, 8 and 15, cisplatin (50 mg/m2) day 4, repeated every 21 days, (2) cisplatin (100 mg/m2) and 5-FU (1 g/m2 x 4), repeated every 21 days, and (3) cisplatin (50 mg/m2) days 1 and 8, repeated every 28 days. After 3 cycles, all responding and stable disease patients in the three arms of the study continued with cisplatin alone. The overall response rates to CABO (34%) and CF (31%) were superior to C (15%) (p < 0.001, p = 0.003, respectively). In addition, complete response rate to CABO (9.5%) was superior to that of C (2.5%) (p = 0.02), and also superior to that of CF (1.7%) (p = 0.01). Response was associated with performance status and prior treatment, but by multivariate analysis treatment type was the important determinant of response (p = 0.0006). Although CABO and CF were superior to C with respect to time to progression within the first 6 to 8 months after randomization, there was no overall difference in progression-free survival or survival between the three arms of the study. Both hematologic and non-hematologic toxicity were worse in the combination chemotherapy arms. We conclude that the CF regimen has no advantage over the CABO regimen, which in fact showed a higher complete response rate. Both combinations showed improved response rates but also more toxicity and no improvement in overall survival in comparison with cisplatin alone.",7522527,Cisplatin monotherapy,CABO,Head and neck cancer,Non-curative first-line therapy,ORR,Undesignated,inferior,Cisplatin monotherapy inferior to CABO for Head and neck cancer (Non-curative first-line therapy) [endpoint: ORR],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the ORR outcome of Cisplatin monotherapy compared to CABO when used to treat Head and neck cancer (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the ORR outcome of Cisplatin monotherapy versus CABO in treating Head and neck cancer (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the ORR results of Cisplatin monotherapy compared to CABO for Head and neck cancer (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the ORR outcome of CABO compared to Cisplatin monotherapy when used to treat Head and neck cancer (Non-curative first-line therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Head and neck cancer, Context: Non-curative first-line therapy, Endpoint: ORR, Treatment 1: Cisplatin monotherapy, Treatment 2: CABO Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Head and neck cancer, Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,1994,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Nasopharyngeal carcinoma, Context: Definitive therapy, Endpoint: OS, Treatment 1: Cisplatin and RT, Treatment 2: Radiation therapy Response:",Cisplatin and RT superior to Radiation therapy for Nasopharyngeal carcinoma (Definitive therapy) [endpoint: OS],False 1997-01-15,"Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. We report the results of a prospectively randomized study that compared the combination of epirubicin, cisplatin, and protracted venous infusion fluorouracil (5-FU) (ECF regimen) with the standard combination of 5-FU, doxorubicin, and methotrexate (FAMTX) in previously untreated patients with advanced esophagogastric cancer. Two hundred seventy-four patients with adenocarcinoma or undifferentiated carcinoma were randomized and analyzed for survival, tumor response, toxicity, and quality of life (QL). The overall response rate was 45% (95% confidence interval [CI], 36% to 54%) with ECF and 21% (95% CI, 13% to 29%) with FAMTX (P = .0002). Toxicity was tolerable and there were only three toxic deaths. The FAMTX regimen caused more hematologic toxicity and serious infections, but ECF caused more emesis and alopecia. The median survival duration was 8.9 months with ECF and 5.7 months with FAMTX (P = .0009); at 1 year, 36% (95% CI, 27% to 45%) of ECF and 21% (95% CI, 14% to 29%) of FAMTX patients were alive. The median failure-free survival duration was 7.4 months with ECF and 3.4 months with FAMTX (P = .00006). The global QL scores were better for ECF at 24 weeks, but the remaining QL data showed no differences between either arm of the study. Hospital-based cost analysis on a subset of patients was similar for each arm and translated into an increment cost of $975 per life-year gained. The ECF regimen results in a survival and response advantage, tolerable toxicity, better QL and cost-effectiveness compared with FAMTX chemotherapy. This regimen should now be considered the standard treatment for advanced esophagogastric cancer. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. We report the final results of a prospectively randomized study that compared the combination of epirubicin, cisplatin and protracted venous infusion fluorouracil (5-FU) (ECF regimen) with the standard combination of 5-FU, doxorubicin and methotrexate (FAMTX) in previously untreated patients with advanced oesophagogastric cancer. Between 1992 and 1995, 274 patients with adenocarcinoma or undifferentiated carcinoma were randomized from eight oncology centres in the UK and analysed for response and survival. The overall response rate was 46% (95% confidence interval (CI), 37-55%) with ECF, and 21% (95% CI, 13-28%) with FAMTX (P = 0.00003). The median survival was 8.7 months with ECF and 6.1 months with FAMTX (P = 0.0005). The 2-year survival rates were 14% (95% CI, 8-20%) for the ECF arm, and 5% (95% CI, 2-10%) for the FAMTX arm (P = 0.03). Histologically complete surgical resection following chemotherapy was achieved in ten patients in the ECF arm (three pathological complete responses to chemotherapy) and three patients in the FAMTX arm (no pathological complete responses). The ECF regimen resulted in a response and survival advantage compared with FAMTX chemotherapy. The probability of long-term survival following surgical resection of residual disease is increased by this treatment. The high response rates seen with ECF support its use in the neoadjuvant setting.",8996151;10390007,FAMTX,ECF,Gastric cancer,Non-curative first-line therapy,OS,Primary,inferior,FAMTX inferior to ECF for Gastric cancer (Non-curative first-line therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of FAMTX compared to ECF when used to treat Gastric cancer (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of FAMTX versus ECF in treating Gastric cancer (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of FAMTX compared to ECF for Gastric cancer (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of ECF compared to FAMTX when used to treat Gastric cancer (Non-curative first-line therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Gastric cancer, Context: Non-curative first-line therapy, Endpoint: OS, Treatment 1: FAMTX, Treatment 2: ECF Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Gastric cancer, Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,1997,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Colon cancer, Context: Adjuvant therapy, Endpoint: DFS, Treatment 1: Fluorouracil monotherapy, Treatment 2: Observation Response:",Fluorouracil monotherapy superior to Observation for Colon cancer (Adjuvant therapy) [endpoint: DFS],False 1997-03-15,"Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. Although androgen suppression results in a tumor response/remission in the majority of patients with carcinoma of the prostate, its potential value as an adjuvant has not been substantiated. In 1987, the Radiation Therapy Oncology Group (RTOG) initiated a randomized phase III trial of adjuvant goserelin in definitively irradiated patients with carcinoma of the prostate. A total of 977 patients had been accessioned to the study. Of these, 945 remained analyzable: 477 on the adjuvant arm and 468 on the observation arm. Actuarial projections show that at 5 years, 84% of patients on the adjuvant goserelin arm and 71% on the observation arm remain without evidence of local recurrence (P < .0001). The corresponding figures for freedom from distant metastases and disease-free survival are 83% versus 70% (P < .001) and 60% and 44% (P < .0001). If prostate-specific antigen (PSA) level greater than 1.5 ng is included as a failure (after > or = 1 year), the 5-year disease-free survival rate on the adjuvant goserelin arm is 53% versus 20% on the observation arm (P < .0001). The 5-year survival rate (for the entire population) is 75% on the adjuvant arm versus 71% on the observation arm (P = .52). However, in patients with centrally reviewed tumors with a Gleason score of 8 to 10, the difference in actuarial 5-year survival (66% on the adjuvant goserelin arm v 55% on the observation arm) reaches statistical significance (P = .03). Application of androgen suppression as an adjuvant to definitive radiotherapy has been associated with a highly significant improvement in local control and freedom from disease progression. At this point, with a median follow-up time of 4.5 years, a significant improvement in survival has been observed only in patients with centrally reviewed tumors with a Gleason score of 8 to 10. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. To determine the potential advantage of androgen ablation following standard external-beam radiation therapy in patients with locally advanced (clinical or pathologic T3; clinical or pathologic node positive) carcinoma of the prostate. In 1987 the RTOG initiated a Phase III trial of long-term adjuvant goserelin in definitively irradiated patients with carcinoma of the prostate. A total of 977 patients were accrued to the study of which 945 remain analyzable: 477 on the adjuvant hormone arm (Arm I); and 468 on the radiation only arm (Arm II) with hormones initiated at relapse. The initial results were reported in the Journal of Clinical Oncology in 1997. With a median follow up of 5.6 years for all patients and 6.0 years for living patients local failure at 8 years was 23% for Arm I and 37% for Arm II (p < 0.0001). Distant metastasis was likewise favorably impacted with the immediate use of hormonal manipulation with a distant metastasis rate in Arm I of 27% and 37% in Arm II (p < 0.0001). Disease-free survival (NED survival) and NED survival with PSA of 1.5 ng/mL (bNED) or less were both statistically significant in favor of the immediate hormone arm (both p < 0.0001). Cause-specific failure was not statistically different with a cause-specific failure of 16% for Arm I and 21% in Arm II (p = 0.23). Overall survival was likewise not statistically different between two arms, with a 49% overall survival at 8 years in Arm I and 47% in Arm II (p = 0.36). Subset analysis of centrally reviewed Gleason 8-10 patients who did not undergo prostatectomy showed that for patients receiving radiation therapy plus adjuvant hormones there was a statistically significant improvement in both absolute (p = 0.036) and cause-specific survival (p = 0.019). Use of long-term adjuvant androgen deprivation in addition to definitive radiation therapy results in a highly significant improvement in regards to local control, freedom from distant metastasis, and biochemical free survival in unfavorable prognosis patients with carcinoma of the prostate. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Radiation Therapy Oncology Group protocol 85-31 was designed to evaluate the effectiveness of adjuvant androgen suppression, using goserelin, in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy (RT). Eligible patients were those with palpable primary tumor extending beyond the prostate (clinical Stage T3) or those with regional lymphatic involvement. Patients who had undergone prostatectomy were eligible if penetration through the prostatic capsule to the margin of resection and/or seminal vesicle involvement was documented histologically. Stratification was based on histologic differentiation, nodal status, acid phosphatase status, and prior prostatectomy. The patients were randomized to either RT and adjuvant goserelin (Arm I) or RT alone followed by observation and application of goserelin at relapse (Arm II). In Arm I, the drug was to be started during the last week of RT and was to be continued indefinitely or until signs of progression. Between 1987 and 1992, when the study was closed, 977 patients were entered: 488 to Arm I and 489 to Arm II. As of July 2003, the median follow-up for all patients was 7.6 years and for living patients was 11 years. At 10 years, the absolute survival rate was significantly greater for the adjuvant arm than for the control arm: 49% vs. 39%, respectively (p = 0.002). The 10-year local failure rate for the adjuvant arm was 23% vs. 38% for the control arm (p <0.0001). The corresponding 10-year rates for the incidence of distant metastases and disease-specific mortality was 24% vs. 39% (p <0.001) and 16% vs. 22% (p = 0.0052), respectively, both in favor of the adjuvant arm. In a population of patients with unfavorable prognosis carcinoma of the prostate, androgen suppression applied as an adjuvant after definitive RT was associated not only with a reduction in disease progression but in a statistically significant improvement in absolute survival. The improvement in survival appeared preferentially in patients with a Gleason score of 7-10.",9060541;11240234;15817329,Radiation therapy,Goserelin and RT,Prostate cancer,Definitive therapy,DFS,Undesignated,inferior,Radiation therapy inferior to Goserelin and RT for Prostate cancer (Definitive therapy) [endpoint: DFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the DFS outcome of Radiation therapy compared to Goserelin and RT when used to treat Prostate cancer (Definitive therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the DFS outcome of Radiation therapy versus Goserelin and RT in treating Prostate cancer (Definitive therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the DFS results of Radiation therapy compared to Goserelin and RT for Prostate cancer (Definitive therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the DFS outcome of Goserelin and RT compared to Radiation therapy when used to treat Prostate cancer (Definitive therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Prostate cancer, Context: Definitive therapy, Endpoint: DFS, Treatment 1: Radiation therapy, Treatment 2: Goserelin and RT Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Prostate cancer, Context: Definitive therapy Treatment: ",superior,inferior,no difference,1997,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Wilms tumor, Context: Adjuvant therapy, Endpoint: RFS, Treatment 1: Dactinomycin and Vincristine, Treatment 2: Vincristine monotherapy Response:",Dactinomycin and Vincristine superior to Vincristine monotherapy for Wilms tumor (Adjuvant therapy) [endpoint: RFS],False 1998-04-15,"Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. A prospective randomized multicenter trial was performed to evaluate the contribution of simultaneously administered chemotherapy (CT) and radiotherapy (RT) in previously untreated patients with unresectable stage III/IV head and neck cancer. Patients with locoregionally advanced head and neck cancer were treated either with RT alone (arm A) or simultaneous RT plus CT (RCT; arm B). RT was identical in both arms and administered in three courses with 13 fractions of 1.8 Gy each twice daily. During one course, from day 3 to 11, 23.4 Gy was delivered. In arm B, cisplatin (CDDP) 60 mg/m2, fluorouracil (5-FU) 350 mg/m2 by intravenous (i.v.) bolus, and leucovorin (LV) 50 mg/m2 by i.v. bolus were given on day 2, and 5-FU 350 mg/m2/24 hour by continuous infusion and LV 100 mg/m2/24 hours by continuous infusion were given from day 2 to 5. Treatment was repeated on days 22 and 44; a total RT dose of 70.2 Gy was administered. Treatment breaks were scheduled from days 12 to 21 and days 34 to 43. From 1989 to 1993, 298 patients were enrolled and 270 patients were assessable. Acute mucositis grade 3 or 4 was more frequent in arm B (38%) than in arm A (16%) (P < .001). Total treatment time was significantly longer in arm B than in arm A (P < .001) due to prolonged breaks. According to hematologic toxicity, scheduled drug doses were given in 74% of patients for the second course and 46% for the third course. The 3-year overall survival rate was 24% in arm A and 48% in arm B (P < .0003). The 3-year locoregional control rate was 17% in arm A and 36% in arm B (P < .004). Both arms showed similar distant failure patterns (arm A, 13 of 140; arm B, 12 of 130). Serious late side effects were not significantly different between treatment arms (arm A, 6.4%; arm B, 10%; not significant). Concomitant CT offered improved disease control and survival in advanced head and neck cancer patients. Due to increased acute toxicity, more supportive care is demanded when CT is given simultaneously. Increased total treatment time does not exert a negative impact on outcome in this combined modality regimen.",9552032,"Cisplatin, Fluorouracil, Folinic acid, RT",Radiation therapy,Head and neck cancer,Definitive therapy,OS,Undesignated,superior,"Cisplatin, Fluorouracil, Folinic acid, RT superior to Radiation therapy for Head and neck cancer (Definitive therapy) [endpoint: OS]","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Cisplatin, Fluorouracil, Folinic acid, RT compared to Radiation therapy when used to treat Head and neck cancer (Definitive therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Cisplatin, Fluorouracil, Folinic acid, RT versus Radiation therapy in treating Head and neck cancer (Definitive therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Cisplatin, Fluorouracil, Folinic acid, RT compared to Radiation therapy for Head and neck cancer (Definitive therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Radiation therapy compared to Cisplatin, Fluorouracil, Folinic acid, RT when used to treat Head and neck cancer (Definitive therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Head and neck cancer, Context: Definitive therapy, Endpoint: OS, Treatment 1: Cisplatin, Fluorouracil, Folinic acid, RT, Treatment 2: Radiation therapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Head and neck cancer, Context: Definitive therapy Treatment: ",superior,inferior,no difference,1998,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Nasopharyngeal carcinoma, Context: Induction therapy, Endpoint: OS, Treatment 1: No induction, Treatment 2: Cisplatin and Epirubicin Response:",No induction inferior to Cisplatin and Epirubicin for Nasopharyngeal carcinoma (Induction therapy) [endpoint: OS],False 1999-08-15,"Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. The aim of this study was to compare the efficacy and tolerability of docetaxel to methotrexate and 5-fluorouracil in advanced breast cancer after anthracycline failure. A randomised multicentre trial was conducted in 283 patients with advanced breast cancer who had failed previous anthracycline treatment. Docetaxel at a dose of 100 mg/m2 every 3 weeks (n = 143) was compared with sequential methotrexate and 5-fluorouracil (MF; n = 139) given at day 1 and 8 every 3 weeks at dosages of 200 mg/ m2 and 600 mg/m2, respectively. After progression, crossover to the alternative treatment group was recommended. There was a significantly higher overall response rate in the docetaxel 42% (CR 8% + PR 34%) than in the MF arm 21% (CR 3% + PR 18%) (P < 0.001). The median time to progression (TTP) was 6.3 months in the docetaxel arm and 3.0 months in the MF arm (P < 0.001). Docetaxel also had a significantly higher response rate of 27% following crossover compared with MF (12%). Significantly more side-effects (leucopenia, infections, neuropathy, oedema, asthenia, skin, nail changes, alopecia) were seen in the docetaxel than in the MF group. However, grade 3 and 4 side-effects were infrequent with both drugs, with the exception of fatigue, alopecia and infections. Median overall survival (OS) including crossover phase was 10.4 months in the docetaxel and 11.1 months in the MF arm (P = 0.79). Based on the response rate and the primary endpoint of TTP, docetaxel is superior to sequential methotrexate and 5-fluorouracil in advanced breast cancer after anthracycline failure.",10615229,Docetaxel monotherapy,Fluorouracil and Methotrexate (MF),Breast cancer,Non-curative therapy,TTP,Primary,superior,Docetaxel monotherapy superior to Fluorouracil and Methotrexate (MF) for Breast cancer (Non-curative therapy) [endpoint: TTP],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the TTP outcome of Docetaxel monotherapy compared to Fluorouracil and Methotrexate (MF) when used to treat Breast cancer (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the TTP outcome of Docetaxel monotherapy versus Fluorouracil and Methotrexate (MF) in treating Breast cancer (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the TTP results of Docetaxel monotherapy compared to Fluorouracil and Methotrexate (MF) for Breast cancer (Non-curative therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the TTP outcome of Fluorouracil and Methotrexate (MF) compared to Docetaxel monotherapy when used to treat Breast cancer (Non-curative therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer, Context: Non-curative therapy, Endpoint: TTP, Treatment 1: Docetaxel monotherapy, Treatment 2: Fluorouracil and Methotrexate (MF) Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Breast cancer, Context: Non-curative therapy Treatment: ",superior,inferior,no difference,1999,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer (Node Positive), Context: Adjuvant therapy, Endpoint: RFS, Treatment 1: CMF, Treatment 2: CMFT Response:",CMF inferior to CMFT for Breast cancer (Node Positive) (Adjuvant therapy) [endpoint: RFS],False 1999-08-15,"A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. All transretinoic acid (ATRA) followed by daunorubicin (DNR)-AraC chemotherapy (CT) has improved the outcome of acute promyelocytic leukemia (APL) by comparison to CT alone. In a randomized trial, (1) we compared 2 induction schedules (ATRA followed by CT [ATRA-->CT] and ATRA plus CT [ATRA+CT, with CT added on day 3 of ATRA treatment]) and (2) we assessed the role of maintenance treatment. Four hundred thirteen patients CT and ATRA+CT (initially randomized patients); patients with a WBC count greater than (high WBC count group, n = 163) and patients 66 to 75 years of age with a WBC count greater than 5,000/microL (elderly group, n = 42) were not initially randomized and received ATRA+CT from day 1 and ATRA -->CT, respectively. All patients achieving CR received 2 additional DNR-AraC courses (only 1 in patients 66 to 75 years of age) and were then randomized for maintenance between no treatment, intermittent ATRA (15 days every 3 months) for 2 years, continuous low-dose CT (6 mercaptopurine + methotrexate) for 2 years, or both, using a 2-by-2 factorial design. Overall, 381 (92%) of the patients achieved complete remission (CR), 31 (7%) suffered an early death, and only 1 patient had leukemic resistance. ATRA syndrome occurred in 64 patients (15%) and was fatal in 5 cases. The CR rate was similar in all induction treatment groups. Event-free survival (EFS) was significantly lower in the high WBC group (P =.0002) and close to significance in the elderly group (P =.086) as compared with initially randomized patients. Relapse at 2 years was estimated at 6% in the ATRA+CT group, versus 16% in the ATRA-->CT group (P =.04, relative risk [RR] =.41). EFS at 2 years was estimated at 84% in the ATRA+CT group, versus 77% in the ATRA-->CT group (P =.1, RR =.62). Two hundred eighty-nine patients were randomized for maintenance. The 2-year relapse rate was 11% in patients randomized to continuous maintenance CT and 27% in patients randomized to no CT (P =.0002) and 13% in patients randomized to intermittent ATRA and 25% in patients randomized to no ATRA (P =.02). An additive effect of continuous maintenance CT and intermittent ATRA was seen, and only 6 of the 74 patients who received both maintenance treatments had relapsed. Overall survival was improved in patients who received maintenance CT (P =.01), and there was a trend for better survival in patients who received maintenance ATRA (P =.22). Our findings strongly suggest that early addition of chemotherapy to ATRA and maintenance therapy combining continuous CT and intermittent ATRA can reduce the incidence of relapse in APL. This effect already translates into significantly better survival for maintenance treatment with continuous CT. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Acute promyelocytic leukemia (APL) is highly curable with the combination of all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy (CT), but very long-term results of this treatment, when CT should be added to ATRA and the role of maintenance treatment, remain uncertain. In our APL93 trial that included 576 newly diagnosed APL patients, with a median follow-up of 10 years, 10-year survival was 77%. Maintenance treatment significantly reduced 10-year cumulative incidence of relapses, from 43.2% to 33%, 23.4%, and 13.4% with no maintenance, maintenance using intermittent ATRA, continuous 6 mercaptopurine plus methotrexate, and both treatments, respectively (P < .001). Maintenance particularly benefited patients with white blood cell (WBC) count higher than 5 x 10(9)/L (5000/microL). Early addition of CT to ATRA significantly improved 10-year event-free survival (EFS), but without significant effect on overall survival (OS). The 10-year cumulative incidence of deaths in complete response (CR), resulting mainly from myelosuppression, was 5.7%, 15.4%, and 21.7% in patients younger than 55, 55 to 65, and older than 65 years, respectively, supporting the need for less myelosuppressive treatments, particularly for consolidation therapy. This study is registered at http://clinicaltrials.gov as NCT00599937.",10438706;20018913,Observation,Mercaptopurine and Methotrexate,Acute promyelocytic leukemia,Maintenance after upfront therapy,2-year relapse rate,Primary,superior,Observation superior to Mercaptopurine and Methotrexate for Acute promyelocytic leukemia (Maintenance after upfront therapy) [endpoint: 2-year relapse rate],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the 2-year relapse rate outcome of Observation compared to Mercaptopurine and Methotrexate when used to treat Acute promyelocytic leukemia (Maintenance after upfront therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the 2-year relapse rate outcome of Observation versus Mercaptopurine and Methotrexate in treating Acute promyelocytic leukemia (Maintenance after upfront therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the 2-year relapse rate results of Observation compared to Mercaptopurine and Methotrexate for Acute promyelocytic leukemia (Maintenance after upfront therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the 2-year relapse rate outcome of Mercaptopurine and Methotrexate compared to Observation when used to treat Acute promyelocytic leukemia (Maintenance after upfront therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute promyelocytic leukemia, Context: Maintenance after upfront therapy, Endpoint: 2-year relapse rate, Treatment 1: Observation, Treatment 2: Mercaptopurine and Methotrexate Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Acute promyelocytic leukemia, Context: Maintenance after upfront therapy Treatment: ",superior,inferior,no difference,1999,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 2000-01-15,"Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. The Hoosier Oncology Group has previously reported the results of its phase II trial of the combination of cisplatin plus gemcitabine. In that study of 27 assessable patients with advanced or metastatic non-small-cell lung cancer (NSCLC), the response rate was 33%, with a median survival of 8.4 months. Based on such favorable results, the Hoosier Oncology Group designed this randomized phase III study of gemcitabine plus cisplatin compared with cisplatin alone in chemotherapy-naive patients with advanced NSCLC. Patients were randomized to receive either cisplatin (100 mg/m(2) intravenously on day 1 of a 28-day cycle) or the combination of cisplatin (100 mg/m(2) intravenously on day 1) plus gemcitabine (1,000 mg/m(2) administered intravenously on days 1, 8, and 15 of a 28-day cycle). From August 1995 to February 1997, 522 assessable chemotherapy-naive patients were randomized. Toxicity was predominantly hematologic and was more pronounced in the combination arm, with grade 4 neutropenia occurring in 35.3% of patients compared with 1.2% of patients on the cisplatin monotherapy arm. The incidence of neutropenic fevers was less than 5% in both arms. Grade 4 thrombocytopenia occurred in 25. 4% of patients on the combination arm compared with 0.8% of patients on the cisplatin monotherapy arm. No serious hemorrhagic events related to thrombocytopenia were reported for either arm. The combination of gemcitabine plus cisplatin demonstrated a significant improvement over single-agent cisplatin with regard to response rate (30.4% compared with 11.1%, respectively; P <.0001), median time to progressive disease (5.6 months compared with 3.7 months, respectively; P =.0013), and overall survival (9.1 months compared with 7.6 months, respectively; P =.004). For the first-line treatment of NSCLC, the regimen of gemcitabine plus cisplatin is superior to cisplatin alone in terms of response rate, time to disease progression, and overall survival.",10623702,Cisplatin and Gemcitabine (GC),Cisplatin monotherapy,Non-small cell lung cancer (Inoperable Locally Advanced or Metastatic),Non-curative first-line therapy,OS,Undesignated,superior,Cisplatin and Gemcitabine (GC) superior to Cisplatin monotherapy for Non-small cell lung cancer (Inoperable Locally Advanced or Metastatic) (Non-curative first-line therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Cisplatin and Gemcitabine (GC) compared to Cisplatin monotherapy when used to treat Non-small cell lung cancer (Inoperable Locally Advanced or Metastatic) (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Cisplatin and Gemcitabine (GC) versus Cisplatin monotherapy in treating Non-small cell lung cancer (Inoperable Locally Advanced or Metastatic) (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Cisplatin and Gemcitabine (GC) compared to Cisplatin monotherapy for Non-small cell lung cancer (Inoperable Locally Advanced or Metastatic) (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Cisplatin monotherapy compared to Cisplatin and Gemcitabine (GC) when used to treat Non-small cell lung cancer (Inoperable Locally Advanced or Metastatic) (Non-curative first-line therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Non-small cell lung cancer (Inoperable Locally Advanced or Metastatic), Context: Non-curative first-line therapy, Endpoint: OS, Treatment 1: Cisplatin and Gemcitabine (GC), Treatment 2: Cisplatin monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Non-small cell lung cancer (Inoperable Locally Advanced or Metastatic), Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2000,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 2001-07-15,"Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study. Three previous mitomycin-cisplatin-based chemotherapy trials conducted within the EORTC Gynecological Cancer Cooperative Group (GCCG) in patients with disseminated squamous-cell carcinoma of the uterine cervix (SCCUC) suggested that with such regimens a higher overall response rate and a higher complete response rate could be obtained compared to what might have been expected from cisplatin alone. In that respect the combination of bleomycin, vindesine (Eldesine), mitomycin C and cisplatin (BEMP) was the most promising. In the present study BEMP has been compared with the best single agent, cisplatin (P) in the expectation that improved response rates might translate into a better survival. Eligible patients were those with SCCUC and disseminated measurable disease outside previously irradiated areas, aged < or = 75 years, with a WHO performance status < or = 2 and adequate bone marrow, renal, hepatic and pulmonary function, who gave consent according to regulations followed in individual institutions. Patients were randomized to BEMP: E 3 mg/m2 day 1, P 50 mg/m2 day 1, B 15 mg (24-hour infusion) day 2-4 and M 8 mg/m2 (at alternate cycles), or P 50 mg/m2. The first four cycles were given every 3 weeks (induction phase). Subsequent cycles were given every four weeks (maintenance phase), during which B was deleted from BEMP (MEP). Patients failing on P could be treated with BEM. Of the 287 patients entered, 235 were eligible and 201 evaluable for response. BEMP induced a significantly higher response rate than P (42% vs. 25%, P = 0.006). There was no difference in complete response rate (11% vs. 7%). BEMP was significantly more toxic than P (+/- BEM), both with respect to hematologic and nonhematologic toxicities. After a median follow-up of 6.1 years, survival curves were not significantly different. Median progression-free survival and overall survival were 5.3 and 10.1 months with BEMP and 4.5 and 9.3 months with P (+/- BEM), respectively. In a multivariate analysis of prognostic factors for survival, a lower age (P = 0.003), a lower performance status (P = 0.0001) and a short (<1 year) interval since diagnosis (P = 0.0152) were all associated with an increased risk of dying. For progression-free survival, lower age, prior radiotherapy, locoregional involvement and no prior surgery were associated with a high risk. Treatment with BEMP or P had no significant impact on survival, but for progression-free survival there was a trend in favor of BEMP (P = 0.0893). Adjusting for prognostic factors did not change the effect of treatment. Combination chemotherapy with BEMP produces more toxicity and more responses compared with cisplatin alone in patients with disseminated SCCUC, but this does not translate into a better survival. Therefore, in the palliative setting single-agent cisplatin should remain the standard therapy for these patients.",11521804,BEMP,Cisplatin monotherapy,Cervical cancer,Non-curative first-line therapy,ORR,Primary,no difference,BEMP no difference to Cisplatin monotherapy for Cervical cancer (Non-curative first-line therapy) [endpoint: ORR],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the ORR outcome of BEMP compared to Cisplatin monotherapy when used to treat Cervical cancer (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the ORR outcome of BEMP versus Cisplatin monotherapy in treating Cervical cancer (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the ORR results of BEMP compared to Cisplatin monotherapy for Cervical cancer (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the ORR outcome of Cisplatin monotherapy compared to BEMP when used to treat Cervical cancer (Non-curative first-line therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Cervical cancer, Context: Non-curative first-line therapy, Endpoint: ORR, Treatment 1: BEMP, Treatment 2: Cisplatin monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Cervical cancer, Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2001,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Ovarian cancer, Context: Adjuvant therapy, Endpoint: DFS, Treatment 1: Melphalan monotherapy, Treatment 2: Radiation therapy Response:",Melphalan monotherapy superior to Radiation therapy for Ovarian cancer (Adjuvant therapy) [endpoint: DFS],False 2002-03-15,"Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. Despite technical improvements that have minimized the morbidity and mortality of hepatic surgery, the long-term outcome of resection of hepatic metastases of colorectal cancer remains poor, with the majority of patients experiencing treatment failure in the liver. Because arterial chemotherapy regimens targeted to the liver have demonstrated high response rates, an intergroup trial of adjuvant therapy for patients undergoing hepatic resection of liver metastases from colorectal cancer was initiated. Patients with one to three potentially resectable metastases were randomized preoperatively to receive no further therapy (control arm, 56 patients) or postoperative hepatic arterial floxuridine combined with intravenous continuous-infusion fluorouracil (chemotherapy arm, 53 patients). After exclusion of patients identified as ineligible for the planned treatment at the time of surgery, there were 45 control patients and 30 on the chemotherapy arm. The study was powered to evaluate improvement in time to recurrence and hepatic disease-free survival, not overall survival. The 4-year recurrence-free rate was 25% for the control arm and 46% for the chemotherapy group (P =.04). The 4-year liver recurrence-free rate was 43% in the control group and 67% in the chemotherapy group (P =.03). The median survival of the 75 assessable patients was 49 months for the control arm and 63.7 months for the chemotherapy arm (P =.60). The median survival of all 109 patients was 47 months for the control arm compared with 34 months for the chemotherapy arm (P =.19) These data demonstrate that adjuvant intra-arterial and intravenous chemotherapy was beneficial in prolonging time to recurrence and pre-venting hepatic recurrence after hepatic resection of colorectal cancer.",11896097,Intrahepatic floxuridine and IV 5-FU,Observation,Colorectal cancer,Non-curative therapy,RFS,Undesignated,superior,Intrahepatic floxuridine and IV 5-FU superior to Observation for Colorectal cancer (Non-curative therapy) [endpoint: RFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the RFS outcome of Intrahepatic floxuridine and IV 5-FU compared to Observation when used to treat Colorectal cancer (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the RFS outcome of Intrahepatic floxuridine and IV 5-FU versus Observation in treating Colorectal cancer (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the RFS results of Intrahepatic floxuridine and IV 5-FU compared to Observation for Colorectal cancer (Non-curative therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the RFS outcome of Observation compared to Intrahepatic floxuridine and IV 5-FU when used to treat Colorectal cancer (Non-curative therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Colorectal cancer, Context: Non-curative therapy, Endpoint: RFS, Treatment 1: Intrahepatic floxuridine and IV 5-FU, Treatment 2: Observation Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Colorectal cancer, Context: Non-curative therapy Treatment: ",superior,inferior,no difference,2002,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Colon cancer, Context: Adjuvant therapy, Endpoint: DFS, Treatment 1: Observation, Treatment 2: Fluorouracil monotherapy Response:",Observation inferior to Fluorouracil monotherapy for Colon cancer (Adjuvant therapy) [endpoint: DFS],False 2003-03-15,"Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. In the current study, we sought to determine whether the addition of DFMO (alpha-difluoromethyl ornithine; eflornithine), an inhibitor of ornithine decarboxylase, to a nitrosourea-based therapy procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, vincristine (PCV) would be more effective as a postirradiation adjuvant therapy for anaplastic gliomas (AG) than PCV alone. After conventional radiation therapy, 249 AG patients were randomized to receive either DFMO-PCV (125 patients) or PCV alone (124 patients), with survival being the primary endpoint and progression-free survival being an important secondary endpoint. The starting dosage of DFMO was 3 grams/m(2) p.o. q. 8 h for 14 days before and 4 weeks after 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea; PCV was administered as described previously (1). Clinical and radiological (gadolinium-enhanced magnetic resonance imaging) follow-ups were nominally at the end of each 6- or 8-week cycle (PCV at 6 weeks; DFMO-PCV at 8 weeks). Laboratory evaluations for hematological and other adverse effects were at 2-week intervals. In the DFMO-PCV arm, there were 114 evaluable patients with 78.1% anaplastic astrocytoma (AA), 3.5% anaplastic oligoastrocytoma (AOA), 14% anaplastic oligodendroglioma (AO), and 4.4% other malignant gliomas. These histological groupings were comparable with those of the 114 patients in the PCV arm: (a) 69.3% AA; (b) 7% AOA; (c) 21.1% AO; and (d) 2.6% malignant gliomas. Although improved survival estimates for the DFMO-PCV treatment group persisted over the course of the study, analysis of survival differences over the entire follow-up period did not yield significance (P = 0.11). However, careful analysis of the corresponding hazard and hazard ratio functions indicated that the real treatment difference was limited to the first 24 months of follow-up (P = 0.02). The median progression-free survival for the two treatment groups, as measured from postradiotherapy registration, was 71.1 months for the DFMO-PCV arm and 37.5 months for the PCV-only arm. Median survival, measured from registration, was 75.8 and 61.1 months, respectively, for the DFMO-PCV and PCV arms. The treatment effect persisted when the AA histology was separated from AO and AOA histologies. This effect persisted even after adjusting for the covariates of age, Karnofsky performance status, and extent of surgery. There was a statistically significant increase in grade 3 adverse events for diarrhea and anemia associated with DFMO-PCV. Grade 3 or 4 adverse events of nausea, ototoxicity, and thrombocytopenia were not significantly increased among groups. The addition of DFMO to the nitrosourea-based PCV regimen in this Phase III study demonstrated a sustained benefit in survival probabilities for AG patients but not in the corresponding hazard rates. Survival analysis from registration found a DFMO-PCV median survival of 6.3 years (49 of 114 events), whereas that for PCV alone was 5.1 years (55 of 114 events). The hazard function demonstrated a difference over the first 2 years of study (hazard ratio 0.53, P = 0.02) but not after 2 years (hazard ratio 1.06, P = 0.84), supporting the conclusion that DFMO adds to the survival advantage of PCV chemotherapy for AG patients by direct temporal interaction with PCV.",12631596,PCV and DMFO,PCV,Anaplastic glioma,Non-curative first-line therapy,OS,Primary,no difference,PCV and DMFO no difference to PCV for Anaplastic glioma (Non-curative first-line therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of PCV and DMFO compared to PCV when used to treat Anaplastic glioma (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of PCV and DMFO versus PCV in treating Anaplastic glioma (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of PCV and DMFO compared to PCV for Anaplastic glioma (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of PCV compared to PCV and DMFO when used to treat Anaplastic glioma (Non-curative first-line therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Anaplastic glioma, Context: Non-curative first-line therapy, Endpoint: OS, Treatment 1: PCV and DMFO, Treatment 2: PCV Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Anaplastic glioma, Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2003,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Glioblastoma, Context: Non-curative therapy, Endpoint: OS, Treatment 1: Gliadel wafer monotherapy, Treatment 2: Placebo Response:",Gliadel wafer monotherapy superior to Placebo for Glioblastoma (Non-curative therapy) [endpoint: OS],False 2003-04-15,"Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients. A randomised, controlled clinical trial was initiated in 1984 to test whether 1 cycle of anthracycline-containing adjuvant chemotherapy improves the outcome of breast cancer patients presenting with stage II disease and negative oestrogen and progesterone receptors (ER, PgR), as compared with 6 cycles of dose-reduced CMF. Within 7 years 263 women with stage II breast cancer were randomised either to receive 1 cycle of doxorubicin, vinblastine, cyclophosphamide, methotrexate and 5- fluorouracil (AV-CMF) or to receive 6 cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Patients were stratified for tumour stage, nodal stage, menopausal status, type of surgery and participating centre. After a median follow-up of 100 months, neither disease-free (DFS) nor overall survival (OS) differed significantly between the two groups. Compared to 6 cycles of a non-standard low-dose CMF regimen 1 cycle of anthracycline- containing adjuvant chemotherapy failed to improve the outcome in women with stage II receptor-negative breast cancer in terms of DFS and OS.",12771518,CMF,AV-CMF,Breast cancer,Adjuvant therapy,OS,Undesignated,no difference,CMF no difference to AV-CMF for Breast cancer (Adjuvant therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of CMF compared to AV-CMF when used to treat Breast cancer (Adjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of CMF versus AV-CMF in treating Breast cancer (Adjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of CMF compared to AV-CMF for Breast cancer (Adjuvant therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of AV-CMF compared to CMF when used to treat Breast cancer (Adjuvant therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer, Context: Adjuvant therapy, Endpoint: OS, Treatment 1: CMF, Treatment 2: AV-CMF Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Breast cancer, Context: Adjuvant therapy Treatment: ",superior,inferior,no difference,2003,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer (Metastatic), Context: Non-curative therapy, Endpoint: PFS, Treatment 1: Tamoxifen monotherapy, Treatment 2: Bilateral oophorectomy monotherapy Response:",Tamoxifen monotherapy superior to Bilateral oophorectomy monotherapy for Breast cancer (Metastatic) (Non-curative therapy) [endpoint: PFS],False 2003-12-09,"Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. The combination of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) represents the standard regimen for inoperable or metastatic urothelial cancer, but its toxicity is significant. We previously reported a 52% response rate (RR) using a docetaxel and cisplatin (DC) combination. The toxicity of this regimen compared favorably with that reported for MVAC. We thus designed a randomized phase III trial to compare DC with MVAC. Patients with inoperable or metastatic urothelial carcinoma; adequate bone marrow, renal, liver, and cardiac function; and Eastern Cooperative Oncology Group performance status < or = 2 were randomly assigned to receive MVAC at standard doses or docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2) every 3 weeks. All patients received prophylactic granulocyte colony-stimulating factor (G-CSF) support. Two hundred twenty patients were randomly assigned (MVAC, 109 patients; DC, 111 patients). Treatment with MVAC resulted in superior RR (54.2% v 37.4%; P =.017), median time to progression (TTP; 9.4 v 6.1 months; P =.003) and median survival (14.2 v 9.3 months; P =.026). After adjusting for prognostic factors, difference in TTP remained significant (hazard ratio [HR], 1.61; P =.005), whereas survival difference was nonsignificant at the 5% level (HR, 1.31; P =.089). MVAC caused more frequent grade 3 or 4 neutropenia (35.4% v 19.2%; P =.006), thrombocytopenia (5.7% v 0.9%; P =.046), and neutropenic sepsis (11.6% v 3.8%; P =.001). Toxicity of MVAC was considerably lower than that previously reported for MVAC administered without G-CSF. MVAC is more effective than DC in advanced urothelial cancer. G-CSF-supported MVAC is well tolerated and could be used instead of classic MVAC as first-line treatment in advanced urothelial carcinoma.",14665607,Cisplatin and Docetaxel (DC),MVAC,Urothelial carcinoma,Non-curative first-line therapy,OS,Primary,inferior,Cisplatin and Docetaxel (DC) inferior to MVAC for Urothelial carcinoma (Non-curative first-line therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Cisplatin and Docetaxel (DC) compared to MVAC when used to treat Urothelial carcinoma (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Cisplatin and Docetaxel (DC) versus MVAC in treating Urothelial carcinoma (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Cisplatin and Docetaxel (DC) compared to MVAC for Urothelial carcinoma (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of MVAC compared to Cisplatin and Docetaxel (DC) when used to treat Urothelial carcinoma (Non-curative first-line therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Urothelial carcinoma, Context: Non-curative first-line therapy, Endpoint: OS, Treatment 1: Cisplatin and Docetaxel (DC), Treatment 2: MVAC Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Urothelial carcinoma, Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2003,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Wilms tumor, Context: Adjuvant therapy, Endpoint: RFS, Treatment 1: Dactinomycin and Vincristine, Treatment 2: Vincristine monotherapy Response:",Dactinomycin and Vincristine superior to Vincristine monotherapy for Wilms tumor (Adjuvant therapy) [endpoint: RFS],False 2004-03-15,"Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Patients with advanced biliary tract carcinoma face a particularly dismal prognosis, and no standard palliative chemotherapy has yet been defined. Among several different single agents, mitomycin C and, more recently, the oral fluoropyrimidine capecitabine and the nucleoside analogue gemcitabine, have been reported to exert antitumour activity. In view of a potential drug synergy, the present randomised phase II trial was initiated. The aim was to investigate the therapeutic efficacy and tolerance of mitomycin C (MMC) in combination with gemcitabine (GEM) or capecitabine (CAPE) in previously untreated patients with advanced biliary tract cancer. A total of 51 patients were entered in this study and randomly allocated to treatment with MMC 8 mg/m2 on day 1 in combination with GEM 2000 mg/m2 on days 1 and 15 every 4 weeks, or MMC 8 mg/m2 on day 1 plus CAPE 2000 mg/m2/day on days 1-14, every 4 weeks. In both arms, chemotherapy was administered for a total of 6 months unless progressive disease occurred earlier. Pretreatment characteristics were well balanced between the two treatment arms. The overall independent review committee-confirmed response rate among those treated with MMC + GEM was 20% (five of 25) compared with 31% (eight of 26) among those treated with MMC + CAPE. Similarly, median progression-free survival (PFS; 4.2 versus 5.3 months) and median overall survival (OS; 6.7 versus 9.25 months) tended to be superior in the latter combination arm. Chemotherapy was fairly well tolerated in both arms, with a comparably low rate of only grade 1 and 2 non-haematological adverse reactions. Also, only four (17%) patients in both treatment arms experienced grade 3 leukocytopenia, and three (13%) and four (17%) had grade 3 thrombocytopenia in the MMC + GEM and MMC + CAPE arm, respectively. The results of this study indicate that both combination regimens are feasible, tolerable and clinically active. The MMC + CAPE arm, however, seems to be superior in terms of response rate, PFS and OS, and should therefore be selected for further clinical investigation in advanced biliary tract cancer.",14998852,Capecitabine and Mitomycin,Gemcitabine and Mitomycin,Biliary tract cancer,Non-curative first-line therapy,ORR,Primary,superior,Capecitabine and Mitomycin superior to Gemcitabine and Mitomycin for Biliary tract cancer (Non-curative first-line therapy) [endpoint: ORR],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the ORR outcome of Capecitabine and Mitomycin compared to Gemcitabine and Mitomycin when used to treat Biliary tract cancer (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the ORR outcome of Capecitabine and Mitomycin versus Gemcitabine and Mitomycin in treating Biliary tract cancer (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the ORR results of Capecitabine and Mitomycin compared to Gemcitabine and Mitomycin for Biliary tract cancer (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the ORR outcome of Gemcitabine and Mitomycin compared to Capecitabine and Mitomycin when used to treat Biliary tract cancer (Non-curative first-line therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Biliary tract cancer, Context: Non-curative first-line therapy, Endpoint: ORR, Treatment 1: Capecitabine and Mitomycin, Treatment 2: Gemcitabine and Mitomycin Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Biliary tract cancer, Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2004,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Colon cancer, Context: Adjuvant therapy, Endpoint: DFS, Treatment 1: Observation, Treatment 2: Fluorouracil monotherapy Response:",Observation inferior to Fluorouracil monotherapy for Colon cancer (Adjuvant therapy) [endpoint: DFS],False 2006-03-27,"A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma. The management of older patients with aggressive non-Hodgkin's lymphoma presents a challenge to the physician. Age is a poor prognostic indicator, due to reduced ability to tolerate and maintain dose-intensive chemotherapy. Generally, older patients demonstrate a lower response rate, reduced survival and increased toxicity, although the majority of large randomised trials exclude older patients. This randomised trial was conducted in patients 60 years or over to compare CHOP (cyclophosphamide 750 mg m(-2), doxorubicin 50 mg m(-2), vincristine 1.4 mg m(-2), prednisolone 100 mg) with PMitCEBO (mitoxantrone 7 mg m(-2), cyclophosphamide 300 mg m(-2), etoposide 150 mg m(-2), vincristine 1.4 mg m(-2), bleomycin 10 mg m(-2) and prednisolone 50 mg). Due to the myelosuppressive nature of these regimens, patients were also randomised to the addition of G-CSF. The formal results of this trial with long-term follow-up are now reported. Data were analysed to assess efficacy and toxicity. Overall response rate was 84% in the CHOP arm and 83% in the PMitCEBO arm, with overall response rates of 83% for the use of G-CSF and 84% for no G-CSF. At median 44 months follow-up, there was no significant difference in failure-free, progression-free or overall survival between the CHOP and PMitCEBO arms. At 3 years, the actuarial failure-free survival was 44% in CHOP recipients and 42% in PMitCEBO recipients and the 3-year actuarial overall survival was 46% and 45% respectively. There was no significant difference in the failure-free, progression-free or overall survival with the addition of G-CSF.",16508640,CHOP (Prednisolone),PMitCEBO,Diffuse large B-cell lymphoma,Induction therapy,FFS,Primary,no difference,CHOP (Prednisolone) no difference to PMitCEBO for Diffuse large B-cell lymphoma (Induction therapy) [endpoint: FFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the FFS outcome of CHOP (Prednisolone) compared to PMitCEBO when used to treat Diffuse large B-cell lymphoma (Induction therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the FFS outcome of CHOP (Prednisolone) versus PMitCEBO in treating Diffuse large B-cell lymphoma (Induction therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the FFS results of CHOP (Prednisolone) compared to PMitCEBO for Diffuse large B-cell lymphoma (Induction therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the FFS outcome of PMitCEBO compared to CHOP (Prednisolone) when used to treat Diffuse large B-cell lymphoma (Induction therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Diffuse large B-cell lymphoma, Context: Induction therapy, Endpoint: FFS, Treatment 1: CHOP (Prednisolone), Treatment 2: PMitCEBO Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Diffuse large B-cell lymphoma, Context: Induction therapy Treatment: ",superior,inferior,no difference,2006,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Multiple myeloma, Context: Non-curative therapy, Endpoint: OS, Treatment 1: Placebo, Treatment 2: Urethane monotherapy Response:",Placebo superior to Urethane monotherapy for Multiple myeloma (Non-curative therapy) [endpoint: OS],False 2006-08-01,"Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. The MITO-2 (Multicentre Italian Trials in Ovarian cancer) study is a randomized phase III trial comparing carboplatin plus paclitaxel to carboplatin plus pegylated liposomal doxorubicin in first-line chemotherapy of patients with ovarian cancer. Due to the paucity of published phase I data on the 3-weekly experimental schedule used, an early safety analysis was planned. Patients with ovarian cancer (stage Ic-IV), aged < 75 years, ECOG performance status P = .32). At the end of treatment, B-DRC and DRC induced major responses in 80.6% versus 69.9% and a complete response/very good partial response in 17.2% versus 9.6% of patients, respectively. The median time to first response was shorter for B-DRC with 3.0 (95% CI, 2.8 to 3.2) versus 5.5 (95% CI, 2.9 to 5.8) months for DRC. This resulted in higher major response rates (57.0% v 32.5%; P < .01) after three cycles of B-DRC compared with DRC. At best response, the complete response/very good partial response increased to 32.6% for B-DRC. Both treatments were well tolerated: grade ≥ 3 adverse events occurred in 49.2% of all patients (B-DRC, 49.5%; DRC, 49.0%). Peripheral sensory neuropathy grade 3 occurred in two patients treated with B-DRC and in none with DRC. This large randomized study illustrates that B-DRC is highly effective and well tolerated in WM. The data demonstrate that fixed duration immunochemotherapy remains an important pillar in the clinical management of WM.",17577016;26359434;36763945,DRC (SC rituximab),B-DRC,Waldenstroem macroglobulinemia,Non-curative first-line therapy,PFS,Primary,no difference,DRC (SC rituximab) no difference to B-DRC for Waldenstroem macroglobulinemia (Non-curative first-line therapy) [endpoint: PFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of DRC (SC rituximab) compared to B-DRC when used to treat Waldenstroem macroglobulinemia (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the PFS outcome of DRC (SC rituximab) versus B-DRC in treating Waldenstroem macroglobulinemia (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the PFS results of DRC (SC rituximab) compared to B-DRC for Waldenstroem macroglobulinemia (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of B-DRC compared to DRC (SC rituximab) when used to treat Waldenstroem macroglobulinemia (Non-curative first-line therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Waldenstroem macroglobulinemia, Context: Non-curative first-line therapy, Endpoint: PFS, Treatment 1: DRC (SC rituximab), Treatment 2: B-DRC Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Waldenstroem macroglobulinemia, Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2007,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Classical Hodgkin lymphoma, Context: Induction therapy, Endpoint: ORR, Treatment 1: Vinblastine monotherapy, Treatment 2: Cyclophosphamide monotherapy Response:",Vinblastine monotherapy superior to Cyclophosphamide monotherapy for Classical Hodgkin lymphoma (Induction therapy) [endpoint: ORR],False 2007-09-15,"Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. This prospective randomized study compared overall survival (OS) in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) when treated with the platinum agent-based triple drug combination of paclitaxel/carboplatin/gemcitabine (PCG) versus the nonplatinum agent-based doublet drug combination of gemcitabine/vinorelbine. Advanced (stages IIIB, IV, and recurrent) chemotherapy-naive patients with NSCLC and performance status 0-2 were randomly assigned to the PCG arm (paclitaxel 200 mg/m(2) on day 1, carboplatin area under the concentration-time curve of 5 on day 1, and gemcitabine 1000 mg/m(2) on days 1 and 8, every 21 days) or to the gemcitabine/vinorelbine arm (gemcitabine 1000 mg/m(2) on days 1, 8, and 15 and vinorelbine 25 mg/m(2) on days 1, 8, and 15, every 28 days). A total of 337 patients were randomly assigned to the 2 arms. The median time to progression was 6 months for PCG and 3.9 months for gemcitabine/vinorelbine with 1- and 2-year progression-free survival rates of 13% and 2% versus 14% and 4% (P = .324 log rank). Median OS for PCG was 10.3 months versus 10.7 months for gemcitabine/vinorelbine with 1-, 2-, and 3-year OS rates of 38%, 12%, and 2% versus 45%, 12%, and 6%, respectively (P = 0.269 log rank). Grade 3/4 thrombocytopenia, nausea/vomiting, myalgia/arthralgia, and neuropathy were significantly greater in the PCG arm. There was no difference in OS or progression-free survival when comparing PCG and gemcitabine/vinorelbine, and gemcitabine/vinorelbine was significantly less toxic. Gemcitabine/vinorelbine is a reasonable nonplatinum agent-based doublet therapy for patients with advanced NSCLC.",17922972,PCG (Carboplatin),Gemcitabine and Vinorelbine,Non-small cell lung cancer,Non-curative first-line therapy,OS,Primary,no difference,PCG (Carboplatin) no difference to Gemcitabine and Vinorelbine for Non-small cell lung cancer (Non-curative first-line therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of PCG (Carboplatin) compared to Gemcitabine and Vinorelbine when used to treat Non-small cell lung cancer (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of PCG (Carboplatin) versus Gemcitabine and Vinorelbine in treating Non-small cell lung cancer (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of PCG (Carboplatin) compared to Gemcitabine and Vinorelbine for Non-small cell lung cancer (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Gemcitabine and Vinorelbine compared to PCG (Carboplatin) when used to treat Non-small cell lung cancer (Non-curative first-line therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Non-small cell lung cancer, Context: Non-curative first-line therapy, Endpoint: OS, Treatment 1: PCG (Carboplatin), Treatment 2: Gemcitabine and Vinorelbine Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Non-small cell lung cancer, Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2007,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Classical Hodgkin lymphoma, Context: Induction therapy, Endpoint: ORR, Treatment 1: Vinblastine monotherapy, Treatment 2: Cyclophosphamide monotherapy Response:",Vinblastine monotherapy superior to Cyclophosphamide monotherapy for Classical Hodgkin lymphoma (Induction therapy) [endpoint: ORR],False 2007-10-06,"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. In multiple myeloma, combination chemotherapy with melphalan plus prednisone is still regarded as the standard of care in elderly patients. We assessed whether the addition of thalidomide to this combination, or reduced-intensity stem cell transplantation, would improve survival. Between May 22, 2000, and Aug 8, 2005, 447 previously untreated patients with multiple myeloma, who were aged between 65 and 75 years, were randomly assigned to receive either melphalan and prednisone (MP; n=196), melphalan and prednisone plus thalidomide (MPT; n=125), or reduced-intensity stem cell transplantation using melphalan 100 mg/m2 (MEL100; n=126). The primary endpoint was overall survival. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00367185. After a median follow-up of 51.5 months (IQR 34.4-63.2), median overall survival times were 33.2 months (13.8-54.8) for MP, 51.6 months (26.6-not reached) for MPT, and 38.3 months (13.0-61.6) for MEL100. The MPT regimen was associated with a significantly better overall survival than was the MP regimen (hazard ratio 0.59, 95% CI 0.46-0.81, p=0.0006) or MEL100 regimen (0.69, 0.49-0.96, p=0.027). No difference was seen for MEL100 versus MP (0.86, 0.65-1.15, p=0.32). The results of our trial provide strong evidence to indicate that the use of thalidomide in combination with melphalan and prednisone should, at present, be the reference treatment for previously untreated elderly patients with multiple myeloma.",17920916,"Melphalan monotherapy, then auto SCT",MPT,Multiple myeloma,Non-curative first-line therapy,OS,Primary,inferior,"Melphalan monotherapy, then auto SCT inferior to MPT for Multiple myeloma (Non-curative first-line therapy) [endpoint: OS]","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Melphalan monotherapy, then auto SCT compared to MPT when used to treat Multiple myeloma (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Melphalan monotherapy, then auto SCT versus MPT in treating Multiple myeloma (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Melphalan monotherapy, then auto SCT compared to MPT for Multiple myeloma (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of MPT compared to Melphalan monotherapy, then auto SCT when used to treat Multiple myeloma (Non-curative first-line therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Multiple myeloma, Context: Non-curative first-line therapy, Endpoint: OS, Treatment 1: Melphalan monotherapy, then auto SCT, Treatment 2: MPT Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Multiple myeloma, Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2007,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 2007-12-01,"Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Few randomized trials have compared the survival benefit of interferon-alfa over controls in metastatic renal cell carcinoma, and none has been performed using interleukin-2. The Programme Etude Rein Cytokines (PERCY) Quattro trial was designed to evaluate both cytokines for their survival benefit to intermediate prognosis patients, who represent the majority of candidates for these treatments. Patients were randomized in a 2-by-2 factorial design to medroxyprogesterone acetate 200 mg daily, interferon-alfa 9 million IU 3 times a week, subcutaneous interleukin-2 9 million IU daily, or a combination of both cytokines. Tumor response was evaluated at Week 12 and Month 6; progression-free patients received further identical treatment for a maximum of 3 additional months. Primary endpoint was overall survival; secondary endpoints were disease-free survival, response rate, toxicity, and quality of life. Survival was analyzed on an intent-to-treat basis. From January 2000 to July 2004, 492 patients were enrolled. Analysis was performed after a 29.2-month median follow-up (range, 0 months to 54.6 months). There were no significant survival differences between the 244 interferon-alfa-treated patients and 248 noninterferon-alfa patients (hazard ratio, 1.00; 95% CI, 0.81-1.24) or between the 247 interleukin-2 and 245 noninterleukin-2-treated patients (hazard ratio, 1.07; 95% CI, 0.87-1.33; log rank, 0.99 and 0.52, respectively). Grade 3-4 toxicities were significantly more frequent in cytokine-treated patients than in medroxyprogesterone-treated patients. Subcutaneous interleukin-2 and/or interferon-alfa provide no survival benefit in metastatic renal cancers of intermediate prognosis, and they induce a significant risk of toxicity. Newly available angiogenesis inhibitors should be preferred for these patients.",17932908,Medroxyprogesterone acetate monotherapy,Interferon alfa-2a and Interleukin-2,Renal cell carcinoma,Non-curative first-line therapy,OS,Primary,no difference,Medroxyprogesterone acetate monotherapy no difference to Interferon alfa-2a and Interleukin-2 for Renal cell carcinoma (Non-curative first-line therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Medroxyprogesterone acetate monotherapy compared to Interferon alfa-2a and Interleukin-2 when used to treat Renal cell carcinoma (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Medroxyprogesterone acetate monotherapy versus Interferon alfa-2a and Interleukin-2 in treating Renal cell carcinoma (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Medroxyprogesterone acetate monotherapy compared to Interferon alfa-2a and Interleukin-2 for Renal cell carcinoma (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Interferon alfa-2a and Interleukin-2 compared to Medroxyprogesterone acetate monotherapy when used to treat Renal cell carcinoma (Non-curative first-line therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Renal cell carcinoma, Context: Non-curative first-line therapy, Endpoint: OS, Treatment 1: Medroxyprogesterone acetate monotherapy, Treatment 2: Interferon alfa-2a and Interleukin-2 Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Renal cell carcinoma, Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2007,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Wilms tumor, Context: Adjuvant therapy, Endpoint: RFS, Treatment 1: Vincristine monotherapy, Treatment 2: Dactinomycin and Vincristine Response:",Vincristine monotherapy inferior to Dactinomycin and Vincristine for Wilms tumor (Adjuvant therapy) [endpoint: RFS],False 2008-02-06,"Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). To determine the effect of posttransplantation immunotherapy with IL-2 on the progression-free survival (PFS) and overall survival (OS) of patients with non-Hodgkin lymphoma (NHL) after autologous stem-cell transplantation (PBSCT), patients with previously treated NHL were treated with cyclophosphamide, etoposide, total body irradiation (TBI), and PBSCT. Twenty-eight to 80 days after PBSCT, patients were randomized to IL-2 versus observation. Three hundred seventy-six eligible patients were registered (with 4-year PFS of 34% and 4-year OS of 52%), and 194 eligible patients were randomized to continuous infusion intravenous IL-2 (9 million units/m(2)/day for 4 days followed 5 days later by 1.6 million units/m(2)/day for 10 days) versus observation. In randomized patients, there was no significant difference in PFS (hazard ratio of IL-2 to observation = 0.90; P =.56) or in OS (hazard ratio of IL-2 to observation = 0.88; P =.55). There were no deaths related to IL-2 treatment. Grade 4 IL-2-related toxicities (n = 14) were reversible. These results confirm earlier SWOG findings that cyclophosphamide, etoposide, TBI, and PBSCT can be administered to patients with relapsed/refractory NHL with encouraging PFS and OS. Posttransplantation IL-2 given at this dose and schedule of administration had no significant effect on PFS or OS. This study is registered at www.clinicaltrials.gov as NCT00002649.",18256325,Interleukin-2 monotherapy,Observation,Diffuse large B-cell lymphoma,Maintenance after salvage therapy,OS,Co-primary,no difference,Interleukin-2 monotherapy no difference to Observation for Diffuse large B-cell lymphoma (Maintenance after salvage therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Interleukin-2 monotherapy compared to Observation when used to treat Diffuse large B-cell lymphoma (Maintenance after salvage therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Interleukin-2 monotherapy versus Observation in treating Diffuse large B-cell lymphoma (Maintenance after salvage therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Interleukin-2 monotherapy compared to Observation for Diffuse large B-cell lymphoma (Maintenance after salvage therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Observation compared to Interleukin-2 monotherapy when used to treat Diffuse large B-cell lymphoma (Maintenance after salvage therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Diffuse large B-cell lymphoma, Context: Maintenance after salvage therapy, Endpoint: OS, Treatment 1: Interleukin-2 monotherapy, Treatment 2: Observation Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Diffuse large B-cell lymphoma, Context: Maintenance after salvage therapy Treatment: ",superior,inferior,no difference,2008,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Classical Hodgkin lymphoma, Context: Induction therapy, Endpoint: ORR, Treatment 1: Vinblastine monotherapy, Treatment 2: Cyclophosphamide monotherapy Response:",Vinblastine monotherapy superior to Cyclophosphamide monotherapy for Classical Hodgkin lymphoma (Induction therapy) [endpoint: ORR],False 2008-04-20,"Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. To evaluate whether capecitabine plus oxaliplatin (XELOX) is noninferior to fluorouracil. folinic acid, and oxaliplatin (FOLFOX-4) as first-line therapy in metastatic colorectal cancer (MCRC). The initial design of this trial was a randomized, two-arm, noninferiority, phase III comparison of XELOX versus FOLFOX-4. After patient accrual had begun, the trial design was amended in 2003 after bevacizumab phase III data became available. The resulting 2 x 2 factorial design randomly assigned patients to XELOX versus FOLFOX-4, and then to also receive either bevacizumab or placebo. We report here the results of the analysis of the XELOX versus FOLFOX-4 arms. The analysis of bevacizumab versus placebo with oxaliplatin-based chemotherapy is reported separately. The prespecified primary end point for the noninferiority analysis was progression-free survival. The intent-to-treat population comprised 634 patients from the original two-arm portion of the study, plus an additional 1,400 patients after the start of the amended 2 x 2 design, for a total of 2,034 patients. The median PFS was 8.0 months in the pooled XELOX-containing arms versus 8.5 months in the FOLFOX-4-containing arms (hazard ratio [HR], 1.04; 97.5% CI, 0.93 to 1.16). The median overall survival was 19.8 months with XELOX versus 19.6 months with FOLFOX-4 (HR, 0.99; 97.5% CI, 0.88 to 1.12). FOLFOX-4 was associated with more grade 3/4 neutropenia/granulocytopenia and febrile neutropenia than XELOX, and XELOX with more grade 3 diarrhea and grade 3 hand-foot syndrome than FOLFOX-4. XELOX is noninferior to FOLFOX-4 as a first-line treatment for MCRC, and may be considered as a routine treatment option for appropriate patients. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid plus oxaliplatin [FOLFOX-4]) in patients with metastatic colorectal cancer (MCRC). Patients with MCRC were randomly assigned, in a 2 x 2 factorial design, to XELOX versus FOLFOX-4, and then to bevacizumab versus placebo. The primary end point was progression-free survival (PFS). A total of 1,401 patients were randomly assigned in this 2 x 2 analysis. Median progression-free survival (PFS) was 9.4 months in the bevacizumab group and 8.0 months in the placebo group (hazard ratio [HR], 0.83; 97.5% CI, 0.72 to 0.95; P = .0023). Median overall survival was 21.3 months in the bevacizumab group and 19.9 months in the placebo group (HR, 0.89; 97.5% CI, 0.76 to 1.03; P = .077). Response rates were similar in both arms. Analysis of treatment withdrawals showed that, despite protocol allowance of treatment continuation until disease progression, only 29% and 47% of bevacizumab and placebo recipients, respectively, were treated until progression. The toxicity profile of bevacizumab was consistent with that documented in previous trials. The addition of bevacizumab to oxaliplatin-based chemotherapy significantly improved PFS in this first-line trial in patients with MCRC. Overall survival differences did not reach statistical significance, and response rate was not improved by the addition of bevacizumab. Treatment continuation until disease progression may be necessary in order to optimize the contribution of bevacizumab to therapy. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. We report updated overall survival (OS) data from study NO16966, which compared capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX4) as first-line therapy in metastatic colorectal cancer. NO16966 was a randomised, two-arm, non-inferiority, phase III comparison of XELOX vs FOLFOX4, which was subsequently amended to a 2 × 2 factorial design with further randomisation to bevacizumab or placebo. A planned follow-up exploratory analysis of OS was performed. The intent-to-treat (ITT) population comprised 2034 patients (two-arm portion, n=634; 2 × 2 factorial portion, n=1400). For the whole NO16966 study population, median OS was 19.8 months in the pooled XELOX/XELOX-placebo/XELOX-bevacizumab arms vs 19.5 months in the pooled FOLFOX4/FOLFOX4-placebo/FOLFOX4-bevacizumab arms (hazard ratio 0.95 (97.5% CI 0.85-1.06)). In the pooled XELOX/XELOX-placebo arms, median OS was 19.0 vs 18.9 months in the pooled FOLFOX4/FOLFOX4-placebo arms (hazard ratio 0.95 (97.5% CI 0.83-1.09)). FOLFOX4 was associated with more grade 3/4 neutropenia/granulocytopenia and febrile neutropenia than XELOX, and XELOX with more grade 3 diarrhoea and grade 3 hand-foot syndrome than FOLFOX4. Updated survival data from study NO16966 show that XELOX is similar to FOLFOX4, confirming the primary analysis of progression-free survival. XELOX can be considered as a routine first-line treatment option for patients with metastatic colorectal cancer.",18421053;18421054;21673685,FOLFOX4|FOLFOX4 and Bevacizumab,CapeOx and Bevacizumab,Colorectal cancer (Unresectable or Metastatic),Non-curative first-line therapy,PFS,Primary,no difference,FOLFOX4|FOLFOX4 and Bevacizumab no difference to CapeOx and Bevacizumab for Colorectal cancer (Unresectable or Metastatic) (Non-curative first-line therapy) [endpoint: PFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of FOLFOX4|FOLFOX4 and Bevacizumab compared to CapeOx and Bevacizumab when used to treat Colorectal cancer (Unresectable or Metastatic) (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the PFS outcome of FOLFOX4|FOLFOX4 and Bevacizumab versus CapeOx and Bevacizumab in treating Colorectal cancer (Unresectable or Metastatic) (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the PFS results of FOLFOX4|FOLFOX4 and Bevacizumab compared to CapeOx and Bevacizumab for Colorectal cancer (Unresectable or Metastatic) (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of CapeOx and Bevacizumab compared to FOLFOX4|FOLFOX4 and Bevacizumab when used to treat Colorectal cancer (Unresectable or Metastatic) (Non-curative first-line therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Colorectal cancer (Unresectable or Metastatic), Context: Non-curative first-line therapy, Endpoint: PFS, Treatment 1: FOLFOX4|FOLFOX4 and Bevacizumab, Treatment 2: CapeOx and Bevacizumab Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Colorectal cancer (Unresectable or Metastatic), Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2008,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Colon cancer, Context: Adjuvant therapy, Endpoint: DFS, Treatment 1: Observation, Treatment 2: Fluorouracil monotherapy Response:",Observation inferior to Fluorouracil monotherapy for Colon cancer (Adjuvant therapy) [endpoint: DFS],False 2008-08-01,"Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. Preoperative chemoradiotherapy is considered standard treatment for locally advanced rectal cancer, although the scientific evidence for the chemotherapy addition is limited. This trial investigated whether chemotherapy as part of a multidisciplinary treatment approach would improve downstaging, survival, and relapse rate. The randomized study included 207 patients with locally nonresectable T4 primary rectal carcinoma or local recurrence from rectal carcinoma in the period 1996 to 2003. The patients received either chemotherapy (fluorouracil/leucovorin) administered concurrently with radiotherapy (50 Gy) and adjuvant for 16 weeks after surgery (CRT group, n = 98) or radiotherapy alone (50 Gy; RT group, n = 109). The two groups were well balanced according to pretreatment characteristics. An R0 resection was performed in 82 patients (84%) in the CRT group and in 74 patients (68%) in the RT group (P = .009). Pathologic complete response was seen in 16% and 7%, respectively. After an R0 + R1 resection, local recurrence was found in 5% and 7%, and distant metastases in 26% and 39%, respectively. Local control (82% v 67% at 5 years; log-rank P = .03), time to treatment failure (63% v 44%; P = .003), cancer-specific survival (72% v 55%; P = .02), and overall survival (66% v 53%; P = .09) all favored the CRT group. Grade 3 or 4 toxicity, mainly GI, was seen in 28 (29%) of 98 and six (6%) of 109, respectively (P = .001). There was no difference in late toxicity. CRT improved local control, time to treatment failure, and cancer-specific survival compared with RT alone in patients with nonresectable rectal cancer. The treatments were well tolerated. Health-related quality of life (HRQoL) after multimodal treatment for primarily non-resectable rectal cancer. Long-term results from a phase III study. A randomised study in non-resectable rectal cancer showed that preoperative chemoradiotherapy (CRT) resulted in better local control and disease-specific survival, but not overall survival than radiotherapy alone. The present paper presents long-term (>4 years) health-related quality of life (HRQoL) and a comparison between the results and reference values from the Norwegian general population. A total of 207 patients with primarily non-resectable rectal cancer were randomised to preoperative CRT (2Gyx25+5FU/leucovorin) or RT (2Gyx25) before surgery. HRQoL was assessed using EORTC QLQ-C30, completed at baseline and sent to all patients alive in Norway and Sweden (n=105) after a minimum of 4 years post treatment. A difference of ≥5 points on the 0-100 scales was considered clinically significant. Seventy-six (72%) patients answered at follow-up. No statistically significant differences between the CRT and RT groups appeared at follow-up, although clinically significant differences in social functioning, dyspnoea and diarrhoea were found. Over time, a clinically significant reduction in physical functioning was found in both groups. Moreover, reduced social functioning and less diarrhoea in the CRT group and better role functioning and more diarrhoea in the RT group were found. Comparisons between the study group and age and gender matched reference values indicate impaired social functioning and more diarrhoea among the patients. There were no statistically significant differences in HRQoL between the randomisation groups. In general, despite having impaired social functioning and more diarrhoea, patients reported HRQoL comparable with the reference population several years after treatment. Preoperative radiotherapy or chemoradiotherapy in rectal cancer - Is survival improved? An update of the ""Nordic"" LARC study in non-resectable cancers. The randomized ""Nordic"" LARC study compared preoperative long-course radiotherapy alone (RT) or with chemotherapy (CRT) in the most locally advanced/ugly rectal cancers. Despite significantly better local control in the CRT group, no overall survival benefit was seen after 10 years follow-up. The relations between local control and survival are discussed.",18669453;21782418;29778486,FULV and RT,Radiation therapy,Rectal cancer,Neoadjuvant therapy,OS,Primary,superior,FULV and RT superior to Radiation therapy for Rectal cancer (Neoadjuvant therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of FULV and RT compared to Radiation therapy when used to treat Rectal cancer (Neoadjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of FULV and RT versus Radiation therapy in treating Rectal cancer (Neoadjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of FULV and RT compared to Radiation therapy for Rectal cancer (Neoadjuvant therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Radiation therapy compared to FULV and RT when used to treat Rectal cancer (Neoadjuvant therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Rectal cancer, Context: Neoadjuvant therapy, Endpoint: OS, Treatment 1: FULV and RT, Treatment 2: Radiation therapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Rectal cancer, Context: Neoadjuvant therapy Treatment: ",superior,inferior,no difference,2008,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Colon cancer, Context: Adjuvant therapy, Endpoint: DFS, Treatment 1: Observation, Treatment 2: Fluorouracil monotherapy Response:",Observation inferior to Fluorouracil monotherapy for Colon cancer (Adjuvant therapy) [endpoint: DFS],True 2008-08-08,"Adjuvant perioperative portal vein or peripheral intravenous chemotherapy for potentially curative colorectal cancer: long-term results of a randomized controlled trial. The perioperative use of a single course adjuvant portal vein infusion chemotherapy in patients with potentially curable colorectal cancer has been shown to significantly improve overall survival but did not reduce the occurrence of liver metastases (SAKK 40/81) [Swiss Group for Clinical Cancer Research (SAKK) Lancet 345(8946):349-353, 1995]. The objective of the present prospective, three-arm randomized multicenter trial was to assess whether peripheral venous administration of adjuvant chemotherapy regimen based on 5-fluorouracil (5-FU) and mitomycin C decreases the occurrence of liver metastases as well as prolongs disease-free and overall survival. Stages I-III colorectal cancer patients (n = 753) were randomized to receive either surgery alone (control arm), surgery plus postoperative portal venous infusion of 5-FU 500 mg/m(2) plus heparin given for 24 hours for seven consecutive days plus mitomycin C 10 mg/m(2) given on the first day (arm 2), or surgery and the same chemotherapy regimen administered by peripheral venous route (arm 3). The 5-year disease-free survival for the three treatment groups were 65% (control group), 60% (portal vein infusion, hazard ratio 1.18, p = 0.23), and 64% (intravenous infusion, hazard ratio 1.04, p = 0.76); the 5-year overall survival was 72% (control group), 69% (portal vein infusion, hazard ratio 1.21, p = 0.2), and 74% (intravenous infusion, hazard ratio 1.03, p = 0.86), respectively. A significant accumulation of early deaths were observed in the portal vein infusion group (p = 0.015). The present prospective randomized multicenter trial provides compelling evidence that short-term perioperative chemotherapy does not improve disease-free and overall survival in patients with potentially curative colorectal cancer. In contrary, the chemotherapy regimen administered in the present investigation seems to have potentially harmful effects, a finding which should be carefully considered in the planning of future trials. Postoperative short-term administration of 5-FU plus mitomycin C either through portal infusion or a central venous catheter is not recommended for routine use in patients with potentially curable colorectal cancer.",18688620,Observation,Fluorouracil and Mitomycin,Colon cancer,Adjuvant therapy,OS,Primary,no difference,Observation no difference to Fluorouracil and Mitomycin for Colon cancer (Adjuvant therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Observation compared to Fluorouracil and Mitomycin when used to treat Colon cancer (Adjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Observation versus Fluorouracil and Mitomycin in treating Colon cancer (Adjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Observation compared to Fluorouracil and Mitomycin for Colon cancer (Adjuvant therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Fluorouracil and Mitomycin compared to Observation when used to treat Colon cancer (Adjuvant therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Colon cancer, Context: Adjuvant therapy, Endpoint: OS, Treatment 1: Observation, Treatment 2: Fluorouracil and Mitomycin Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Colon cancer, Context: Adjuvant therapy Treatment: ",superior,inferior,no difference,2008,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Colorectal cancer, Context: Non-curative first-line therapy, Endpoint: ORR, Treatment 1: Fluorouracil monotherapy, Treatment 2: Fluorouracil and Semustine Response:",Fluorouracil monotherapy inferior to Fluorouracil and Semustine for Colorectal cancer (Non-curative first-line therapy) [endpoint: ORR],False 2009-02-21,"Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Few randomised studies have compared intermittent hormonal therapy (IHT) with continuous therapy for the treatment of advanced prostate cancer (PCa). To determine whether intermittent therapy is associated with a shorter time to progression. 766 patients with locally advanced or metastatic PCa received a 3-mo induction treatment. The 626 patients whose prostate-specific antigen (PSA) level decreased to <4 ng/ml or to 80% below the initial value were randomised. Patients received cyproterone acetate (CPA) 200mg for 2 wk and then monthly depot injections of a luteinising hormone-releasing hormone (LHRH) analogue plus 200mg of CPA daily during induction. Patients randomised to the intermittent arm ceased treatment, while those randomised to the continuous arm received 200mg of CPA daily plus an LHRH analogue. Primary outcome measurement was time to subjective or objective progression. Secondary outcomes were survival and quality of life (QoL). Time off therapy in the intermittent arm was also recorded. 127 patients from the intermittent arm and 107 patients from the continuous arm progressed, with a hazard ratio (HR) of 0.81 (95% confidence interval [CI]: 0.63-1.05, p=0.11). There was no difference in survival, with an HR of 0.99 (95% CI: 0.80-1.23) and 170 deaths in the intermittent arm and 169 deaths in the continuous arm. The greater number of cancer deaths in the intermittent treatment arm (106 vs 84) was balanced by a greater number of cardiovascular deaths in the continuous arm (52 vs 41). Side-effects were more pronounced in the continuous arm. Men treated with intermittent therapy reported better sexual function. Median time off therapy for the intermittent patients was 52 wk (95% CI: 39.4-65.7). IHT should be considered for use in routine practice because it is associated with no reduction in survival, no clinically meaningful impairment in QoL, better sexual activity, and considerable economic benefit to the individual and the community.",19249153,Intermittent ADT,ADT,Prostate cancer,Non-curative therapy,TTP,Primary,no difference,Intermittent ADT no difference to ADT for Prostate cancer (Non-curative therapy) [endpoint: TTP],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the TTP outcome of Intermittent ADT compared to ADT when used to treat Prostate cancer (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the TTP outcome of Intermittent ADT versus ADT in treating Prostate cancer (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the TTP results of Intermittent ADT compared to ADT for Prostate cancer (Non-curative therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the TTP outcome of ADT compared to Intermittent ADT when used to treat Prostate cancer (Non-curative therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Prostate cancer, Context: Non-curative therapy, Endpoint: TTP, Treatment 1: Intermittent ADT, Treatment 2: ADT Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Prostate cancer, Context: Non-curative therapy Treatment: ",superior,inferior,no difference,2009,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Wilms tumor, Context: Adjuvant therapy, Endpoint: RFS, Treatment 1: Vincristine monotherapy, Treatment 2: Dactinomycin and Vincristine Response:",Vincristine monotherapy inferior to Dactinomycin and Vincristine for Wilms tumor (Adjuvant therapy) [endpoint: RFS],False 2009-03-19,"Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. A previous study reported a significant survival benefit for octreotide compared with no treatment in patients with advanced hepatocellular carcinoma (HCC). This was investigated further in this multicentre study. Two hundred and seventy two patients with HCC who were ineligible for curative treatments or had relapsed following potentially curative therapies were randomised to receive long-acting octreotide, 30 mg as an intramuscular injection once every 4 weeks for up to 2 years, or placebo. At the time of the final analysis, median overall survival (OS) was 6.53 months (95% confidence interval [CI], 4.8-8.3) for octreotide versus 7.03 months (95% CI, 5.43-8.53) for placebo (p=0.34). Progression-free survival (p=0.26) also did not differ significantly between the two treatment groups. No objective responses were achieved in the octreotide group but 33% of patients achieved disease stabilisation for a mean time of 5.5 months (95% CI, 1.1-9.9). The median time until definitive global health score deterioration (according to QLQ-C30) was 2.3 months (95% CI, 1.4-3.7) in the octreotide and 4 months (95% CI, 2.2-5.7) in the placebo group (p=0.09). There were four objective responses in the placebo group. Octreotide was well tolerated; seven patients reported severe adverse events possibly related to octreotide and there were no cases of haematoma or cholecystitis. In patients with advanced HCC, octreotide has a favourable safety profile but does not improve OS and could have a negative impact on quality of life.",19303768,Placebo,Octreotide LAR monotherapy,Hepatocellular carcinoma,Non-curative subsequent-line therapy,OS,Primary,no difference,Placebo no difference to Octreotide LAR monotherapy for Hepatocellular carcinoma (Non-curative subsequent-line therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Placebo compared to Octreotide LAR monotherapy when used to treat Hepatocellular carcinoma (Non-curative subsequent-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Placebo versus Octreotide LAR monotherapy in treating Hepatocellular carcinoma (Non-curative subsequent-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Placebo compared to Octreotide LAR monotherapy for Hepatocellular carcinoma (Non-curative subsequent-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Octreotide LAR monotherapy compared to Placebo when used to treat Hepatocellular carcinoma (Non-curative subsequent-line therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Hepatocellular carcinoma, Context: Non-curative subsequent-line therapy, Endpoint: OS, Treatment 1: Placebo, Treatment 2: Octreotide LAR monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Hepatocellular carcinoma, Context: Non-curative subsequent-line therapy Treatment: ",superior,inferior,no difference,2009,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Colon cancer, Context: Adjuvant therapy, Endpoint: DFS, Treatment 1: Observation, Treatment 2: Fluorouracil monotherapy Response:",Observation inferior to Fluorouracil monotherapy for Colon cancer (Adjuvant therapy) [endpoint: DFS],False 2009-09-21,"Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. Although chemoradiotherapy plus resection is considered standard treatment for operable rectal carcinoma, the optimal time to administer this therapy is not clear. The NSABP R-03 (National Surgical Adjuvant Breast and Bowel Project R-03) trial compared neoadjuvant versus adjuvant chemoradiotherapy in the treatment of locally advanced rectal carcinoma. Patients with clinical T3 or T4 or node-positive rectal cancer were randomly assigned to preoperative or postoperative chemoradiotherapy. Chemotherapy consisted of fluorouracil and leucovorin with 45 Gy in 25 fractions with a 5.40-Gy boost within the original margins of treatment. In the preoperative group, surgery was performed within 8 weeks after completion of radiotherapy. In the postoperative group, chemotherapy began after recovery from surgery but no later than 4 weeks after surgery. The primary end points were disease-free survival (DFS) and overall survival (OS). From August 1993 to June 1999, 267 patients were randomly assigned to NSABP R-03. The intended sample size was 900 patients. Excluding 11 ineligible and two eligible patients without follow-up data, the analysis used data on 123 patients randomly assigned to preoperative and 131 to postoperative chemoradiotherapy. Surviving patients were observed for a median of 8.4 years. The 5-year DFS for preoperative patients was 64.7% v 53.4% for postoperative patients (P = .011). The 5-year OS for preoperative patients was 74.5% v 65.6% for postoperative patients (P = .065). A complete pathologic response was achieved in 15% of preoperative patients. No preoperative patient with a complete pathologic response has had a recurrence. Preoperative chemoradiotherapy, compared with postoperative chemoradiotherapy, significantly improved DFS and showed a trend toward improved OS.",19770376,Fluorouracil and RT,FULV and RT,Rectal cancer,Neoadjuvant therapy,OS,Co-primary,inferior,Fluorouracil and RT inferior to FULV and RT for Rectal cancer (Neoadjuvant therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Fluorouracil and RT compared to FULV and RT when used to treat Rectal cancer (Neoadjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Fluorouracil and RT versus FULV and RT in treating Rectal cancer (Neoadjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Fluorouracil and RT compared to FULV and RT for Rectal cancer (Neoadjuvant therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of FULV and RT compared to Fluorouracil and RT when used to treat Rectal cancer (Neoadjuvant therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Rectal cancer, Context: Neoadjuvant therapy, Endpoint: OS, Treatment 1: Fluorouracil and RT, Treatment 2: FULV and RT Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Rectal cancer, Context: Neoadjuvant therapy Treatment: ",superior,inferior,no difference,2009,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Colon cancer, Context: Adjuvant therapy, Endpoint: DFS, Treatment 1: Fluorouracil monotherapy, Treatment 2: Observation Response:",Fluorouracil monotherapy superior to Observation for Colon cancer (Adjuvant therapy) [endpoint: DFS],False 2010-03-06,"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Low-molecular-weight heparins such as enoxaparin are preferred for prevention of venous thromboembolism after major joint replacement. Apixaban, an orally active factor Xa inhibitor, might be as effective, have lower bleeding risk, and be easier to use than is enoxaparin. We assessed efficacy and safety of these drugs after elective total knee replacement. In ADVANCE-2, a multicentre, randomised, double-blind phase 3 study, patients undergoing elective unilateral or bilateral total knee replacement were randomly allocated through an interactive central telephone system to receive oral apixaban 2.5 mg twice daily (n=1528) or subcutaneous enoxaparin 40 mg once daily (1529). The randomisation schedule was generated by the Bristol-Myers Squibb randomisation centre and stratified by study site and by unilateral or bilateral surgery with a block size of four. Investigators, patients, statisticians, adjudicators, and steering committee were masked to allocation. Apixaban was started 12-24 h after wound closure and enoxaparin 12 h before surgery; both drugs were continued for 10-14 days, when bilateral ascending venography was scheduled. Primary outcome was the composite of asymptomatic and symptomatic deep vein thrombosis, non-fatal pulmonary embolism, and all-cause death during treatment. The statistical plan required non-inferiority of apixaban before testing for superiority; analysis was by intention to treat for non-inferiority testing. The study is registered at ClinicalTrials.gov, number NCT00452530. 1973 of 3057 patients allocated to treatment (1528 apixaban, 1529 enoxaparin) were eligible for primary efficacy analysis. The primary outcome was reported in 147 (15%) of 976 apixaban patients and 243 (24%) of 997 enoxaparin patients (relative risk 0.62 [95% CI 0.51-0.74]; p<0.0001; absolute risk reduction 9.3% [5.8-12.7]). Major or clinically relevant non-major bleeding occurred in 53 (4%) of 1501 patients receiving apixaban and 72 (5%) of 1508 treated with enoxaparin (p=0.09). Apixaban 2.5 mg twice daily, starting on the morning after total knee replacement, offers a convenient and more effective orally administered alternative to 40 mg per day enoxaparin, without increased bleeding. Bristol-Myers Squibb; Pfizer.",20206776,Apixaban monotherapy,Enoxaparin monotherapy,Venous thromboembolism,Prophylaxis,"rate of asymptomatic and symptomatic deep vein thrombosis, non-fatal pulmonary embolism, and all-cause death during treatment",Primary,inferior,"Apixaban monotherapy inferior to Enoxaparin monotherapy for Venous thromboembolism (Prophylaxis) [endpoint: rate of asymptomatic and symptomatic deep vein thrombosis, non-fatal pulmonary embolism, and all-cause death during treatment]","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the rate of asymptomatic and symptomatic deep vein thrombosis, non-fatal pulmonary embolism, and all-cause death during treatment outcome of Apixaban monotherapy compared to Enoxaparin monotherapy when used to treat Venous thromboembolism (Prophylaxis). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the rate of asymptomatic and symptomatic deep vein thrombosis, non-fatal pulmonary embolism, and all-cause death during treatment outcome of Apixaban monotherapy versus Enoxaparin monotherapy in treating Venous thromboembolism (Prophylaxis). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the rate of asymptomatic and symptomatic deep vein thrombosis, non-fatal pulmonary embolism, and all-cause death during treatment results of Apixaban monotherapy compared to Enoxaparin monotherapy for Venous thromboembolism (Prophylaxis)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the rate of asymptomatic and symptomatic deep vein thrombosis, non-fatal pulmonary embolism, and all-cause death during treatment outcome of Enoxaparin monotherapy compared to Apixaban monotherapy when used to treat Venous thromboembolism (Prophylaxis). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Venous thromboembolism, Context: Prophylaxis, Endpoint: rate of asymptomatic and symptomatic deep vein thrombosis, non-fatal pulmonary embolism, and all-cause death during treatment, Treatment 1: Apixaban monotherapy, Treatment 2: Enoxaparin monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Venous thromboembolism, Context: Prophylaxis Treatment: ",superior,inferior,no difference,2010,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 2010-06-08,"Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer. Breast cancer patients with >3 involved nodes (N+) have a poor outcome. Chemotherapy (CT), alone or combined with endocrine therapy (ET) in hormone receptor (HOR)-positive patients, is the standard for these women. However, there are still questions surrounding the optimal adjuvant CT regimen. 244 patients with >3 N+ were randomized to receive either four 3-weekly courses of epirubicin (E: 100 mg/m(2), day 1) followed by four 4-weekly cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF: 600, 40, 600 mg/m(2), days 1, 8: n = 122) or four 3-weekly courses of paclitaxel (T: 175 mg/m(2), day 1) followed by four 3-weekly cycles of epirubicin and vinorelbine (E: 75 mg/m(2), day 1; V: 25 mg/m(2), days 1, 8: n = 122). After CT, tamoxifen (plus an LH-RH analog in menstruating women) was given to all HOR-positive patients over a period of 5 years. Overall survival (OS) was the primary end point. Relapse-free survival (RFS) and toxicity were secondary end points. At a median follow-up time of 102 months (range 3-146), OS and RFS did not differ significantly between groups (E-CMF vs. T-EV: OS, HR 0.94, 95% CI 0.59-1.48, p = 0.8; RFS, HR 0.86, 95% CI 0.57-1.29, p = 0.45). The lack of any difference between assigned treatments was confirmed by multivariate analysis (E-CMF vs. T-EV: RFS, HR 0.98, 95% CI 0.64-1.48, p = 0.9). The 2 regimens showed different toxicity profiles. In fact, significantly more women assigned to E-CMF were affected by stomatitis (p = 0.001) while significantly more women in the T-EV group developed peripheral neuropathy (p < 0.0001) and musculoskeletal disorders (p < 0.0001). However, side effects were moderate and manageable and no toxic death occurred in either arm of the study. T-EV was safe and moderately toxic but was not superior to E-CMF.",20530973,E-CMF,T-EV,Breast cancer,Adjuvant therapy,OS,Primary,no difference,E-CMF no difference to T-EV for Breast cancer (Adjuvant therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of E-CMF compared to T-EV when used to treat Breast cancer (Adjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of E-CMF versus T-EV in treating Breast cancer (Adjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of E-CMF compared to T-EV for Breast cancer (Adjuvant therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of T-EV compared to E-CMF when used to treat Breast cancer (Adjuvant therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer, Context: Adjuvant therapy, Endpoint: OS, Treatment 1: E-CMF, Treatment 2: T-EV Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Breast cancer, Context: Adjuvant therapy Treatment: ",superior,inferior,no difference,2010,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer (Metastatic), Context: Non-curative therapy, Endpoint: PFS, Treatment 1: Tamoxifen monotherapy, Treatment 2: Bilateral oophorectomy monotherapy Response:",Tamoxifen monotherapy superior to Bilateral oophorectomy monotherapy for Breast cancer (Metastatic) (Non-curative therapy) [endpoint: PFS],False 2010-08-23,"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Bortezomib plus melphalan and prednisone (VMP) is significantly better than melphalan plus prednisone alone for elderly patients with untreated multiple myeloma; however, toxic effects are high. We investigated a novel and less intensive bortezomib-based regimen to maintain efficacy and to reduce toxic effects. Between March, 2006, and October, 2008, 260 patients with untreated multiple myeloma, 65 years and older, from 63 Spanish centres, were randomly assigned to receive six cycles of VMP (n=130) or bortezomib plus thalidomide and prednisone (VTP; n=130) as induction therapy, consisting of one cycle of bortezomib twice per week for 6 weeks (1·3 mg/m² on days 1, 4, 8, 11, 22, 25, 29, and 32), plus either melphalan (9 mg/m² on days 1-4) or daily thalidomide (100 mg), and prednisone (60 mg/m² on days 1-4). The first cycle was followed by five cycles of bortezomib once per week for 5 weeks (1·3 mg/m² on days 1, 8, 15, and 22) plus the same doses of melphalan plus prednisone and thalidomide plus prednisone. 178 patients completed the six induction cycles and were randomly assigned to maintenance therapy with bortezomib plus prednisone (n=87) or bortezomib plus thalidomide (n=91), consisting of one conventional cycle of bortezomib for 3 weeks (1·3 mg/m² on days 1, 4, 8, and 11) every 3 months, plus either prednisone (50 mg every other day) or thalidomide (50 mg per day), for up to 3 years. Treatment codes were generated with a computerised random number generator, and neither participants nor study personnel were masked to treatment. The primary endpoint was response rate in induction and maintenance phases. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00443235. In the induction phase, 105 (81%) patients in the VTP group and 104 (80%) in the VMP group achieved partial responses or better (p=0·9), including 36 (28%) and 26 (20%) complete remissions, respectively (p=0·2). Treatment with VTP resulted in more serious adverse events (40 [31%] vs 20 [15%], p=0·01) and discontinuations (22 [17%] vs 15 [12%], p=0·03) than did treatment with VMP. The most common toxicities (grade 3 or worse) were infections (one [1%] in the VTP group vs nine [7%] in the VMP group), cardiac events (11 [8%] vs 0), and peripheral neuropathy (nine [7%] vs 12 [9%]). After maintenance therapy, the complete remission rate was 42% (40 [44%] patients in complete remission in the bortezomib plus thalidomide group, 34 [39%] in the bortezomib plus prednisone group). No grade 3 or worse haematological toxicities were recorded during maintenance therapy; two (2%) patients in the bortezomib plus prednisone group and six (7%) in the bortezomib plus thalidomide group developed peripheral neuropathy. Reduced-intensity induction with a bortezomib-based regimen, followed by maintenance, is a safe and effective treatment for elderly patients with multiple myeloma. Pethema (Spanish Program for the Treatment of Hematologic Diseases). Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. Cytogenetic abnormalities (CAs) such as t(4;14), t(14;16) or del(17p), and nonhyperdiploidy are associated with poor prognosis in multiple myeloma. We evaluated the influence of CAs by FISH and DNA ploidy by flow cytometry on response and survival in 232 elderly, newly diagnosed multiple myeloma patients receiving an induction with weekly bortezomib followed by maintenance therapy with bortezomib-based combinations. Response was similar in the high-risk and standard-risk CA groups, both after induction (21% vs 27% complete responses [CRs]) and maintenance (39% vs 45% CR). However, high-risk patients showed shorter progression-free survival (PFS) than standard-risk patients, both from the first (24 vs 33 months; P = .04) and second randomization (17 vs 27 months; P = .01). This also translated into shorter overall survival (OS) for high-risk patients (3-year OS: 55% vs 77%; P = .001). This adverse prognosis applied to either t(4;14) or del(17p). Concerning DNA ploidy, hyperdiploid patients showed longer OS than nonhyperdiploid patients (77% vs 63% at 3 years; P = .04), and this was more evident in patients treated with bortezomib, thalidomide, and prednisone (77% vs 53% at 3 years; P = .02). The present schema does not overcome the negative prognosis of high-risk CAs and nonhyperdiploidy. This trial was registered with www.ClinicalTrials.gov as NCT00443235. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Maintenance therapy has become a hot field in myeloma, and it may be particularly relevant in elderly patients because the major benefit results from the initial therapy. We report the results of a randomized comparison of maintenance with bortezomib plus thalidomide (VT) or prednisone (VP) in 178 elderly untreated myeloma patients who had received 6 induction cycles with bortezomib plus either melphalan and prednisone or thalidomide and prednisone. The complete response (CR) rate increased from 24% after induction up to 42%, higher for VT versus VP (46% vs 39%). Median progression-free survival (PFS) was superior for VT (39 months) compared with VP (32 months) and overall survival (OS) was also longer in VT patients compared with VP (5-year OS of 69% and 50%, respectively) but the differences did not reach statistical significance. CR achievement was associated with a significantly longer PFS (P < .001) and 5-year OS (P < .001). The incidence of G3-4 peripheral neuropathy was 9% for VT and 3% for VP. Unfortunately, this approach was not able to overcome the adverse prognosis of cytogenetic abnormalities. In summary, these maintenance regimens result in a significant increase in CR rate, remarkably long PFS, and acceptable toxicity profile. The trial is registered at www.clinicaltrials.gov as NCT00443235. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Melphalan (M), in combination with prednisone (MP), has been the backbone of new combinations, including bortezomib plus MP (VMP). However, new alkylator-free schemes, such as lenalidomide plus low-dose dexamethasone, are challenging the role of alkylators in myeloma treatment of elderly patients. Here we have updated, after a long follow-up (median 6 years), the results of the GEM2005 study that addressed this question by comparing VMP with bortezomib plus thalidomide and prednisone (VTP) as induction. Between April 2005 and October 2008, 260 patients were randomized to receive 6 cycles of VMP or VTP as induction. The median progression-free survival was 32 months for the VMP and 23 months for the VTP arms (P 5 .09). VMP significantly prolonged the overall survival (OS) compared with VTP (median of 63 and 43 months, respectively; hazard ratio [HR]: 0.67, P 5 .01). Achieving immunophenotypic complete response was associated with a significantly longer OS, especially in the VMP arm (66%remain alive after 8 years). Melphalan, plus bortezomib, should be maintained as standard care for the treatment of elderly multiple myeloma patients. This trial was registered at www.clinicaltrials.gov as #NCT00443235.",20739218;21900193;22889759;25102853,Bortezomib and Prednisone (VP),VT,Multiple myeloma,Non-curative first-line maintenance therapy,ORR,Primary,no difference,Bortezomib and Prednisone (VP) no difference to VT for Multiple myeloma (Non-curative first-line maintenance therapy) [endpoint: ORR],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the ORR outcome of Bortezomib and Prednisone (VP) compared to VT when used to treat Multiple myeloma (Non-curative first-line maintenance therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the ORR outcome of Bortezomib and Prednisone (VP) versus VT in treating Multiple myeloma (Non-curative first-line maintenance therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the ORR results of Bortezomib and Prednisone (VP) compared to VT for Multiple myeloma (Non-curative first-line maintenance therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the ORR outcome of VT compared to Bortezomib and Prednisone (VP) when used to treat Multiple myeloma (Non-curative first-line maintenance therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Multiple myeloma, Context: Non-curative first-line maintenance therapy, Endpoint: ORR, Treatment 1: Bortezomib and Prednisone (VP), Treatment 2: VT Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Multiple myeloma, Context: Non-curative first-line maintenance therapy Treatment: ",superior,inferior,no difference,2010,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Classical Hodgkin lymphoma, Context: Induction therapy, Endpoint: ORR, Treatment 1: Vinblastine monotherapy, Treatment 2: Cyclophosphamide monotherapy Response:",Vinblastine monotherapy superior to Cyclophosphamide monotherapy for Classical Hodgkin lymphoma (Induction therapy) [endpoint: ORR],False 2010-09-08,"Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. Adjuvant fluorouracil has been shown to be of benefit for patients with resected pancreatic cancer. Gemcitabine is known to be the most effective agent in advanced disease as well as an effective agent in patients with resected pancreatic cancer. To determine whether fluorouracil or gemcitabine is superior in terms of overall survival as adjuvant treatment following resection of pancreatic cancer. The European Study Group for Pancreatic Cancer (ESPAC)-3 trial, an open-label, phase 3, randomized controlled trial conducted in 159 pancreatic cancer centers in Europe, Australasia, Japan, and Canada. Included in ESPAC-3 version 2 were 1088 patients with pancreatic ductal adenocarcinoma who had undergone cancer resection; patients were randomized between July 2000 and January 2007 and underwent at least 2 years of follow-up. Patients received either fluorouracil plus folinic acid (folinic acid, 20 mg/m(2), intravenous bolus injection, followed by fluorouracil, 425 mg/m(2) intravenous bolus injection given 1-5 days every 28 days) (n = 551) or gemcitabine (1000 mg/m(2) intravenous infusion once a week for 3 of every 4 weeks) (n = 537) for 6 months. Primary outcome measure was overall survival; secondary measures were toxicity, progression-free survival, and quality of life. Final analysis was carried out on an intention-to-treat basis after a median of 34.2 (interquartile range, 27.1-43.4) months' follow-up after 753 deaths (69%). Median survival was 23.0 (95% confidence interval [CI], 21.1-25.0) months for patients treated with fluorouracil plus folinic acid and 23.6 (95% CI, 21.4-26.4) months for those treated with gemcitabine (chi(1)(2) = 0.7; P = .39; hazard ratio, 0.94 [95% CI, 0.81-1.08]). Seventy-seven patients (14%) receiving fluorouracil plus folinic acid had 97 treatment-related serious adverse events, compared with 40 patients (7.5%) receiving gemcitabine, who had 52 events (P < .001). There were no significant differences in either progression-free survival or global quality-of-life scores between the treatment groups. Compared with the use of fluorouracil plus folinic acid, gemcitabine did not result in improved overall survival in patients with completely resected pancreatic cancer. clinicaltrials.gov Identifier: NCT00058201.",20823433,Gemcitabine monotherapy,FULV,Pancreatic cancer,Adjuvant therapy,OS,Primary,no difference,Gemcitabine monotherapy no difference to FULV for Pancreatic cancer (Adjuvant therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Gemcitabine monotherapy compared to FULV when used to treat Pancreatic cancer (Adjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Gemcitabine monotherapy versus FULV in treating Pancreatic cancer (Adjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Gemcitabine monotherapy compared to FULV for Pancreatic cancer (Adjuvant therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of FULV compared to Gemcitabine monotherapy when used to treat Pancreatic cancer (Adjuvant therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Pancreatic cancer, Context: Adjuvant therapy, Endpoint: OS, Treatment 1: Gemcitabine monotherapy, Treatment 2: FULV Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Pancreatic cancer, Context: Adjuvant therapy Treatment: ",superior,inferior,no difference,2010,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Colorectal cancer, Context: Non-curative first-line therapy, Endpoint: ORR, Treatment 1: Fluorouracil monotherapy, Treatment 2: Fluorouracil and Semustine Response:",Fluorouracil monotherapy inferior to Fluorouracil and Semustine for Colorectal cancer (Non-curative first-line therapy) [endpoint: ORR],False 2010-09-20,"Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG). No prospective comparison with nitrosourea-based chemotherapy exists. We report, to our knowledge, the first randomized trial of procarbazine, lomustine, and vincristine (PCV) versus TMZ in chemotherapy-naive patients with recurrent HGG. Four hundred forty-seven patients were randomly assigned to PCV (224 patients) or TMZ (sub-random assignment: TMZ-5 [200 mg/m(2) for 5 days, 112 patients] or TMZ-21 [100 mg/m(2) for 21 days, 111 patients]) for up to 9 months or until progression. The primary outcomes were survival (PCV v TMZ) and 12-week progression-free survival (PFS; TMZ-5 v TMZ-21). This study is registered as ISRCTN83176944. Percentages of patients completing 9 months of treatment in the PCV, TMZ-5, and TMZ-21 arms were 17%, 26%, and 13%, respectively. Major toxicity was similar across all three groups. With a median follow-up time of 12 months and 382 deaths, there was no clear survival benefit when comparing PCV with TMZ (hazard ratio [HR], 0.91; 95% CI, 0.74 to 1.11; P = .350). For TMZ-5 versus TMZ-21, 12-week PFS rates were similar (63.6% and 65.7%, respectively; P = .745), but TMZ-5 improved overall PFS (HR, 1.38; 95% CI, 1.05 to 1.82; P = .023), survival (HR, 1.32; 95% CI, 0.99 to 1.75; P = .056), and global quality of life (49% v 19% improved > 10 points at 6 months, respectively; P = .005). Although TMZ (both arms combined) did not show a clear benefit compared with PCV, comparison of the TMZ schedules demonstrated that the 21-day schedule was inferior to the 5-day schedule in this setting. This challenges the current understanding of increasing TMZ dose-intensity by prolonged scheduling.",20855843,Temozolomide monotherapy,PCV,Glioblastoma,Non-curative therapy,OS,Co-primary,no difference,Temozolomide monotherapy no difference to PCV for Glioblastoma (Non-curative therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Temozolomide monotherapy compared to PCV when used to treat Glioblastoma (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Temozolomide monotherapy versus PCV in treating Glioblastoma (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Temozolomide monotherapy compared to PCV for Glioblastoma (Non-curative therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of PCV compared to Temozolomide monotherapy when used to treat Glioblastoma (Non-curative therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Glioblastoma, Context: Non-curative therapy, Endpoint: OS, Treatment 1: Temozolomide monotherapy, Treatment 2: PCV Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Glioblastoma, Context: Non-curative therapy Treatment: ",superior,inferior,no difference,2010,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Anaplastic glioma, Context: Non-curative first-line therapy, Endpoint: OS, Treatment 1: Carmustine monotherapy, Treatment 2: PCV Response:",Carmustine monotherapy inferior to PCV for Anaplastic glioma (Non-curative first-line therapy) [endpoint: OS],False 2010-11-24,"Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. We present results of a phase 3 randomized trial of autografting in chronic lymphocytic leukemia versus observation for responding patients after first- or second-line treatment. The primary objective was to demonstrate that autografting improves the 5-year event-free survival (EFS) from 30% to 50%. There were 223 enrolled patients, 72% men and 28% women, 83% after first and 17% after second-line treatment. Binet stages were progressive A 13%, B 67%, C 20%; at randomization, 59% were in complete remission, and 41% in less than complete remission. Patients were randomized between autografting (n = 112) and observation (n = 111). Median EFS was 24.4 months (range, 16.7-32 months) in the observation group and 51.2 months (39.8-62.5 months) in the autografting group; the 5-year EFS was 24% and 42%, respectively (P < .001). Accordingly, the 5-year relapse incidence was 76% versus 54% (P < .001). Median time to relapse requiring therapy or death was 40 months (25-56 months) in the observation arm and 65 months (59-71 months) after autografting (P = .002). Cox modeling confirmed that autografting significantly improved EFS (hazard ratio 0.44, 95% confidence interval 0.30-0.65; P < .001). At 5 years, the probability of OS was 85.5% and 84.3% for autografting and observation, respectively (P = .77). In chronic lymphocytic leukemia, consolidating autografting reduces the risk of progression by more than 50% but has no effect on overall survival.",21106985,Observation,"Cyclophosphamide and TBI, then auto HSCT",Chronic lymphocytic leukemia,Non-curative first-line consolidation therapy,EFS,Undesignated,inferior,"Observation inferior to Cyclophosphamide and TBI, then auto HSCT for Chronic lymphocytic leukemia (Non-curative first-line consolidation therapy) [endpoint: EFS]","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the EFS outcome of Observation compared to Cyclophosphamide and TBI, then auto HSCT when used to treat Chronic lymphocytic leukemia (Non-curative first-line consolidation therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the EFS outcome of Observation versus Cyclophosphamide and TBI, then auto HSCT in treating Chronic lymphocytic leukemia (Non-curative first-line consolidation therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the EFS results of Observation compared to Cyclophosphamide and TBI, then auto HSCT for Chronic lymphocytic leukemia (Non-curative first-line consolidation therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the EFS outcome of Cyclophosphamide and TBI, then auto HSCT compared to Observation when used to treat Chronic lymphocytic leukemia (Non-curative first-line consolidation therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Chronic lymphocytic leukemia, Context: Non-curative first-line consolidation therapy, Endpoint: EFS, Treatment 1: Observation, Treatment 2: Cyclophosphamide and TBI, then auto HSCT Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Chronic lymphocytic leukemia, Context: Non-curative first-line consolidation therapy Treatment: ",superior,inferior,no difference,2010,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 2011-01-24,"Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. There is no consensus on the best regimen for the primary treatment of low-risk gestational trophoblastic neoplasia (GTN). Two commonly used single-drug regimens were compared with respect to the proportion of patients meeting the criteria for a complete response (CR) in a randomized phase III trial conducted by the Gynecologic Oncology Group. Eligibility was purposefully broad to maximize the generalizability of the results and included patients with a WHO risk score of 0 to 6 and patients with metastatic disease (limited to lung lesions < 2 cm, adnexa, or vagina) or choriocarcinoma. Two hundred forty women were enrolled, and 216 were deemed eligible. Biweekly intravenous dactinomycin 1.25 mg/m² was statistically superior to weekly intramuscular (IM) methotrexate 30 mg/m² (CR: 70% v 53%; P = .01). Similarly, in patients with low-risk GTN as defined before the 2002 WHO risk score revisions (risk score of 0 to 4 and excluding choriocarcinoma), response was 58% and 73% in the methotrexate and dactinomycin arms, respectively (P = .03). Both regimens were less effective if the WHO risk score was 5 or 6 or if the diagnosis was choriocarcinoma (CR: 9% and 42%, respectively). There were two potential recurrences; one at 4 months (dactinomycin) and one at 22 months (methotrexate). Not all patients completed follow-up. Both regimens were well tolerated. The biweekly dactinomycin regimen has a higher CR rate than the weekly IM methotrexate regimen in low-risk GTN, a generally curable disease.",21263100,Dactinomycin monotherapy,Methotrexate monotherapy,Gestational trophoblastic neoplasia,All lines of therapy,CR rate,Primary,superior,Dactinomycin monotherapy superior to Methotrexate monotherapy for Gestational trophoblastic neoplasia (All lines of therapy) [endpoint: CR rate],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the CR rate outcome of Dactinomycin monotherapy compared to Methotrexate monotherapy when used to treat Gestational trophoblastic neoplasia (All lines of therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the CR rate outcome of Dactinomycin monotherapy versus Methotrexate monotherapy in treating Gestational trophoblastic neoplasia (All lines of therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the CR rate results of Dactinomycin monotherapy compared to Methotrexate monotherapy for Gestational trophoblastic neoplasia (All lines of therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the CR rate outcome of Methotrexate monotherapy compared to Dactinomycin monotherapy when used to treat Gestational trophoblastic neoplasia (All lines of therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Gestational trophoblastic neoplasia, Context: All lines of therapy, Endpoint: CR rate, Treatment 1: Dactinomycin monotherapy, Treatment 2: Methotrexate monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Gestational trophoblastic neoplasia, Context: All lines of therapy Treatment: ",superior,inferior,no difference,2011,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Ovarian cancer, Context: Non-curative first-line therapy, Endpoint: OS, Treatment 1: Melphalan monotherapy, Treatment 2: Hexa-CAF Response:",Melphalan monotherapy inferior to Hexa-CAF for Ovarian cancer (Non-curative first-line therapy) [endpoint: OS],True 2011-03-07,"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. This phase III study compared the efficacy and safety of bevacizumab (BV) when combined with several standard chemotherapy regimens versus those regimens alone for first-line treatment of patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. Patients were randomly assigned in 2:1 ratio to chemotherapy plus BV or chemotherapy plus placebo. Before random assignment, investigators chose capecitabine (Cape; 2,000 mg/m(2) for 14 days), taxane (Tax) -based (nab-paclitaxel 260 mg/m(2), docetaxel 75 or 100 mg/m(2)), or anthracycline (Anthra) -based (doxorubicin or epirubicin combinations [doxorubicin/cyclophosphamide, epirubicin/cyclophosphamide, fluorouracil/epirubicin/cyclophosphamide, or fluorouracil/doxorubicin/cyclophosphamide]) chemotherapy administered every 3 weeks. BV or placebo was administered at 15 mg/kg every 3 weeks. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), 1-year survival rate, objective response rate, duration of objective response, and safety. Two independently powered cohorts defined by the choice of chemotherapy (Cape patients or pooled Tax/Anthra patients) were analyzed in parallel. RIBBON-1 (Regimens in Bevacizumab for Breast Oncology) enrolled 1,237 patients (Cape cohort, n = 615; Tax/Anthra cohort, n = 622). Median PFS was longer for each BV combination (Cape cohort: increased from 5.7 months to 8.6 months; hazard ratio [HR], 0.69; 95% CI, 0.56 to 0.84; log-rank P < .001; and Tax/Anthra cohort: increased from 8.0 months to 9.2 months; HR, 0.64; 95% CI, 0.52 to 0.80; log-rank P < .001). No statistically significant differences in OS between the placebo- and BV-containing arms were observed. Safety was consistent with results of prior BV trials. The combination of BV with Cape, Tax, or Anthra improves clinical benefit in terms of increased PFS in first-line treatment of metastatic breast cancer, with a safety profile comparable to prior phase III studies.",21383283,"Cyclophosphamide and Doxorubicin (AC) and Bevacizumab|Docetaxel and Bevacizumab|Cyclophosphamide and Epirubicin (EC) and Bevacizumab|FAC and Bevacizumab|FEC and Bevacizumab|Paclitaxel, nanoparticle albumin-bound and Bevacizumab",Cyclophosphamide and Doxorubicin (AC),Breast cancer (Not Applicable),Non-curative first-line therapy,PFS,Primary,superior,"Cyclophosphamide and Doxorubicin (AC) and Bevacizumab|Docetaxel and Bevacizumab|Cyclophosphamide and Epirubicin (EC) and Bevacizumab|FAC and Bevacizumab|FEC and Bevacizumab|Paclitaxel, nanoparticle albumin-bound and Bevacizumab superior to Cyclophosphamide and Doxorubicin (AC) for Breast cancer (Not Applicable) (Non-curative first-line therapy) [endpoint: PFS]","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of Cyclophosphamide and Doxorubicin (AC) and Bevacizumab|Docetaxel and Bevacizumab|Cyclophosphamide and Epirubicin (EC) and Bevacizumab|FAC and Bevacizumab|FEC and Bevacizumab|Paclitaxel, nanoparticle albumin-bound and Bevacizumab compared to Cyclophosphamide and Doxorubicin (AC) when used to treat Breast cancer (Not Applicable) (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the PFS outcome of Cyclophosphamide and Doxorubicin (AC) and Bevacizumab|Docetaxel and Bevacizumab|Cyclophosphamide and Epirubicin (EC) and Bevacizumab|FAC and Bevacizumab|FEC and Bevacizumab|Paclitaxel, nanoparticle albumin-bound and Bevacizumab versus Cyclophosphamide and Doxorubicin (AC) in treating Breast cancer (Not Applicable) (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the PFS results of Cyclophosphamide and Doxorubicin (AC) and Bevacizumab|Docetaxel and Bevacizumab|Cyclophosphamide and Epirubicin (EC) and Bevacizumab|FAC and Bevacizumab|FEC and Bevacizumab|Paclitaxel, nanoparticle albumin-bound and Bevacizumab compared to Cyclophosphamide and Doxorubicin (AC) for Breast cancer (Not Applicable) (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of Cyclophosphamide and Doxorubicin (AC) compared to Cyclophosphamide and Doxorubicin (AC) and Bevacizumab|Docetaxel and Bevacizumab|Cyclophosphamide and Epirubicin (EC) and Bevacizumab|FAC and Bevacizumab|FEC and Bevacizumab|Paclitaxel, nanoparticle albumin-bound and Bevacizumab when used to treat Breast cancer (Not Applicable) (Non-curative first-line therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer (Not Applicable), Context: Non-curative first-line therapy, Endpoint: PFS, Treatment 1: Cyclophosphamide and Doxorubicin (AC) and Bevacizumab|Docetaxel and Bevacizumab|Cyclophosphamide and Epirubicin (EC) and Bevacizumab|FAC and Bevacizumab|FEC and Bevacizumab|Paclitaxel, nanoparticle albumin-bound and Bevacizumab, Treatment 2: Cyclophosphamide and Doxorubicin (AC) Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Breast cancer (Not Applicable), Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2011,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer, Context: Adjuvant therapy, Endpoint: RR, Treatment 1: Thiotepa monotherapy, Treatment 2: Placebo Response:",Thiotepa monotherapy no difference to Placebo for Breast cancer (Adjuvant therapy) [endpoint: RR],False 2011-07-13,"A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. This phase 3, randomized, double-blind study assessed the efficacy and safety of lenalidomide in 205 red blood cell (RBC) transfusion-dependent patients with International Prognostic Scoring System Low-/Intermediate-1-risk del5q31 myelodysplastic syndromes. Patients received lenalidomide 10 mg/day on days 1-21 (n = 69) or 5 mg/day on days 1-28 (n = 69) of 28-day cycles; or placebo (n = 67). Crossover to lenalidomide or higher dose was allowed after 16 weeks. More patients in the lenalidomide 10- and 5-mg groups achieved RBC-transfusion independence (TI) for ≥ 26 weeks (primary endpoint) versus placebo (56.1% and 42.6% vs 5.9%; both P < .001). Median duration of RBC-TI was not reached (median follow-up, 1.55 years), with 60% to 67% of responses ongoing in patients without progression to acute myeloid leukemia (AML). Cytogenetic response rates were 50.0% (10 mg) versus 25.0% (5 mg; P = .066). For the lenalidomide groups combined, 3-year overall survival and AML risk were 56.5% and 25.1%, respectively. RBC-TI for ≥ 8 weeks was associated with 47% and 42% reductions in the relative risks of death and AML progression or death, respectively (P = .021 and .048). The safety profile was consistent with previous reports. Lenalidomide is beneficial and has an acceptable safety profile in transfusion-dependent patients with Low-/Intermediate-1-risk del5q myelodysplastic syndrome. This trial was registered at www.clinicaltrials.gov as #NCT00179621. Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial. We report health-related quality of life (HRQL) outcomes assessed using the Functional Assessment of Cancer Therapy-Anemia (FACT-An) among 167 RBC transfusion-dependent patients with IPSS Low-/Intermediate-1-risk del5q31 MDS treated with lenalidomide versus placebo in a randomized phase 3 clinical trial, MDS-004. Mean baseline to 12 week changes in FACT-An Total scores improved following treatment with lenalidomide 5 and 10mg (+5.7 and +5.7, respectively) versus placebo (-2.8) (both p<0.05). Clinically important changes in HRQL from baseline were observed at weeks 12, 24, 36, and 48 among RBC-TI≥26 week responders in both treatment groups. Lenalidomide treatment may be effective in improving HRQL outcomes.",21753188;23273538,Lenalidomide monotherapy,Placebo,Myelodysplastic syndrome,All lines of therapy,RBC-TI,Primary,superior,Lenalidomide monotherapy superior to Placebo for Myelodysplastic syndrome (All lines of therapy) [endpoint: RBC-TI],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the RBC-TI outcome of Lenalidomide monotherapy compared to Placebo when used to treat Myelodysplastic syndrome (All lines of therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the RBC-TI outcome of Lenalidomide monotherapy versus Placebo in treating Myelodysplastic syndrome (All lines of therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the RBC-TI results of Lenalidomide monotherapy compared to Placebo for Myelodysplastic syndrome (All lines of therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the RBC-TI outcome of Placebo compared to Lenalidomide monotherapy when used to treat Myelodysplastic syndrome (All lines of therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Myelodysplastic syndrome, Context: All lines of therapy, Endpoint: RBC-TI, Treatment 1: Lenalidomide monotherapy, Treatment 2: Placebo Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Myelodysplastic syndrome, Context: All lines of therapy Treatment: ",superior,inferior,no difference,2011,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 2012-08-09,"Treatment of older patients with mantle-cell lymphoma. The long-term prognosis for older patients with mantle-cell lymphoma is poor. Chemoimmunotherapy results in low rates of complete remission, and most patients have a relapse. We investigated whether a fludarabine-containing induction regimen improved the complete-remission rate and whether maintenance therapy with rituximab prolonged remission. We randomly assigned patients 60 years of age or older with mantle-cell lymphoma, stage II to IV, who were not eligible for high-dose therapy to six cycles of rituximab, fludarabine, and cyclophosphamide (R-FC) every 28 days or to eight cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) every 21 days. Patients who had a response underwent a second randomization to maintenance therapy with rituximab or interferon alfa, each given until progression. Of the 560 patients enrolled, 532 were included in the intention-to-treat analysis for response, and 485 in the primary analysis for response. The median age was 70 years. Although complete-remission rates were similar with R-FC and R-CHOP (40% and 34%, respectively; P=0.10), progressive disease was more frequent with R-FC (14%, vs. 5% with R-CHOP). Overall survival was significantly shorter with R-FC than with R-CHOP (4-year survival rate, 47% vs. 62%; P=0.005), and more patients in the R-FC group died during the first remission (10% vs. 4%). Hematologic toxic effects occurred more frequently in the R-FC group than in the R-CHOP group, but the frequency of grade 3 or 4 infections was balanced (17% and 14%, respectively). In 274 of the 316 patients who were randomly assigned to maintenance therapy, rituximab reduced the risk of progression or death by 45% (in remission after 4 years, 58%, vs. 29% with interferon alfa; hazard ratio for progression or death, 0.55; 95% confidence interval, 0.36 to 0.87; P=0.01). Among patients who had a response to R-CHOP, maintenance therapy with rituximab significantly improved overall survival (4-year survival rate, 87%, vs. 63% with interferon alfa; P=0.005). R-CHOP induction followed by maintenance therapy with rituximab is effective for older patients with mantle-cell lymphoma. (Funded by the European Commission and others; ClinicalTrials.gov number, NCT00209209.). Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. In an update of the randomized, open-label, phase III European Mantle Cell Lymphoma (MCL) Elderly trial (ClinicalTrials.gov identifier: NCT00209209), published in 2012, we aimed to confirm results on long-term outcome focusing on efficacy and safety of long-term use of rituximab maintenance. Five hundred sixty patients with newly diagnosed MCL underwent a first random assignment between rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and rituximab, fludarabine, and cyclophosphamide (R-FC) induction, followed by a second random assignment in 316 responders between rituximab and interferon alfa maintenance, to be continued until progression. We compared progression-free survival from the second randomization and overall survival (OS) from the first or second randomizations. After a median follow-up time of 7.6 years, the previously described difference in OS between the induction arms persisted (median, 6.4 years after R-CHOP [n = 280] v 3.9 years after R-FC [n = 280]; P = .0054). Patients responding to R-CHOP had median progression-free survival and OS times of 5.4 and 9.8 years, respectively, when randomly assigned to rituximab (n = 87), compared with 1.9 years (P < .001) and 7.1 years (P = .0026), respectively, when randomly assigned to interferon alfa (n = 97). In 58% and 32% of patients treated with R-CHOP, rituximab maintenance was still ongoing 2 and 5 years from start of maintenance, respectively. After R-FC, rituximab maintenance was associated with an unexpectedly high cumulative incidence of death in remission (22% at 5 years). Toxicity of rituximab maintenance was low after R-CHOP (grade 3-4 leukopenia or infection < 5%) but more prominent in patients on rituximab maintenance after R-FC, in whom grade 3-4 leukopenia (up to 40%) and infections were frequent (up to 15%). The excellent results of R-CHOP followed by rituximab maintenance until progression for older patients with MCL persisted in a mature follow-up. Prolongation of rituximab maintenance beyond 2 years is effective and safe.",22873532;31804876,R-CHOP,FCR,Mantle cell lymphoma,Non-curative first-line therapy,CR rate,Primary,no difference,R-CHOP no difference to FCR for Mantle cell lymphoma (Non-curative first-line therapy) [endpoint: CR rate],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the CR rate outcome of R-CHOP compared to FCR when used to treat Mantle cell lymphoma (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the CR rate outcome of R-CHOP versus FCR in treating Mantle cell lymphoma (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the CR rate results of R-CHOP compared to FCR for Mantle cell lymphoma (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the CR rate outcome of FCR compared to R-CHOP when used to treat Mantle cell lymphoma (Non-curative first-line therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Mantle cell lymphoma, Context: Non-curative first-line therapy, Endpoint: CR rate, Treatment 1: R-CHOP, Treatment 2: FCR Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Mantle cell lymphoma, Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2012,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Classical Hodgkin lymphoma, Context: Induction therapy, Endpoint: ORR, Treatment 1: Vinblastine monotherapy, Treatment 2: Cyclophosphamide monotherapy Response:",Vinblastine monotherapy superior to Cyclophosphamide monotherapy for Classical Hodgkin lymphoma (Induction therapy) [endpoint: ORR],False 2012-11-04,"Low-dose aspirin for preventing recurrent venous thromboembolism. Patients who have had a first episode of unprovoked venous thromboembolism have a high risk of recurrence after anticoagulants are discontinued. Aspirin may be effective in preventing a recurrence of venous thromboembolism. We randomly assigned 822 patients who had completed initial anticoagulant therapy after a first episode of unprovoked venous thromboembolism to receive aspirin, at a dose of 100 mg daily, or placebo for up to 4 years. The primary outcome was a recurrence of venous thromboembolism. During a median follow-up period of 37.2 months, venous thromboembolism recurred in 73 of 411 patients assigned to placebo and in 57 of 411 assigned to aspirin (a rate of 6.5% per year vs. 4.8% per year; hazard ratio with aspirin, 0.74; 95% confidence interval [CI], 0.52 to 1.05; P=0.09). Aspirin reduced the rate of the two prespecified secondary composite outcomes: the rate of venous thromboembolism, myocardial infarction, stroke, or cardiovascular death was reduced by 34% (a rate of 8.0% per year with placebo vs. 5.2% per year with aspirin; hazard ratio with aspirin, 0.66; 95% CI, 0.48 to 0.92; P=0.01), and the rate of venous thromboembolism, myocardial infarction, stroke, major bleeding, or death from any cause was reduced by 33% (hazard ratio, 0.67; 95% CI, 0.49 to 0.91; P=0.01). There was no significant between-group difference in the rates of major or clinically relevant nonmajor bleeding episodes (rate of 0.6% per year with placebo vs. 1.1% per year with aspirin, P=0.22) or serious adverse events. In this study, aspirin, as compared with placebo, did not significantly reduce the rate of recurrence of venous thromboembolism but resulted in a significant reduction in the rate of major vascular events, with improved net clinical benefit. These results substantiate earlier evidence of a therapeutic benefit of aspirin when it is given to patients after initial anticoagulant therapy for a first episode of unprovoked venous thromboembolism. (Funded by National Health and Medical Research Council [Australia] and others; Australian New Zealand Clinical Trials Registry number, ACTRN12605000004662.).",23121403,Aspirin monotherapy,Placebo,Venous thromboembolism,Prophylaxis,rate of VTE recurrence,Primary,inferior,Aspirin monotherapy inferior to Placebo for Venous thromboembolism (Prophylaxis) [endpoint: rate of VTE recurrence],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the rate of VTE recurrence outcome of Aspirin monotherapy compared to Placebo when used to treat Venous thromboembolism (Prophylaxis). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the rate of VTE recurrence outcome of Aspirin monotherapy versus Placebo in treating Venous thromboembolism (Prophylaxis). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the rate of VTE recurrence results of Aspirin monotherapy compared to Placebo for Venous thromboembolism (Prophylaxis)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the rate of VTE recurrence outcome of Placebo compared to Aspirin monotherapy when used to treat Venous thromboembolism (Prophylaxis). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Venous thromboembolism, Context: Prophylaxis, Endpoint: rate of VTE recurrence, Treatment 1: Aspirin monotherapy, Treatment 2: Placebo Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Venous thromboembolism, Context: Prophylaxis Treatment: ",superior,inferior,no difference,2012,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 2012-11-05,"Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. To evaluate induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) followed by surgery and postoperative radiotherapy versus up-front surgery and postoperative radiotherapy in patients with locally advanced resectable oral squamous cell carcinoma (OSCC). A prospective open-label phase III trial was conducted. Eligibility criteria included untreated stage III or IVA locally advanced resectable OSCC. Patients received two cycles of TPF induction chemotherapy (docetaxel 75 mg/m(2) on day 1, cisplatin 75 mg/m(2) on day 1, and fluorouracil 750 mg/m(2) on days 1 to 5) followed by radical surgery and postoperative radiotherapy (54 to 66 Gy) versus up-front radical surgery and postoperative radiotherapy. The primary end point was overall survival (OS). Secondary end points included local control and safety. Of the 256 patients enrolled onto this trial, 222 completed the full treatment protocol. There were no unexpected toxicities, and induction chemotherapy did not increase perioperative morbidity. The clinical response rate to induction chemotherapy was 80.6%. After a median follow-up of 30 months, there was no significant difference in OS (hazard ratio [HR], 0.977; 95% CI, 0.634 to 1.507; P = .918) or disease-free survival (HR, 0.974; 95% CI, 0.654 to 1.45; P = .897) between patients treated with and without TPF induction. Patients in the induction chemotherapy arm with a clinical response or favorable pathologic response (≤ 10% viable tumor cells) had superior OS and locoregional and distant control. Our study failed to demonstrate that TPF induction chemotherapy improves survival compared with up-front surgery in patients with resectable stage III or IVA OSCC. Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma. Previously, we conducted a randomized phase III trial of TPF (docetaxel, cisplatin, and 5-fluorouracil) induction chemotherapy in surgically managed locally advanced oral squamous cell carcinoma (OSCC) and found no improvement in overall survival. This study reports long-term follow-up results from our initial trial. All patients had clinical stage III or IVA locally advanced OSCC. In the experimental group, patients received two cycles of TPF induction chemotherapy (75mg/m2 docetaxel d1, 75mg/m2 cisplatin d1, and 750mg/m2/day 5-fluorouracil d1-5) followed by radical surgery and post-operative radiotherapy; in the control group, patients received upfront radical surgery and post-operative radiotherapy. The primary endpoint was overall survival. Among 256 enrolled patients with a median follow-up of 70 months, estimated 5-year overall survival, disease-free survival, locoregional recurrence-free survival, and distant metastasis-free survival rates were 61.1%, 52.7%, 55.2%, and 60.4%, respectively. There were no significant differences in survival rates between experimental and control groups. However, patients with favorable pathologic responses had improved outcomes compared to those with unfavorable pathologic responses and to those in the control group. Although TPF induction chemotherapy did not improve long-term survival compared to surgery upfront in patients with stage III and IVA OSCC, a favorable pathologic response after induction chemotherapy may be used as a major endpoint and prognosticator in future studies. Furthermore, the negative results observed in this trial may be represent type II error from an underpowered study. Future larger scale phase III trials are warranted to investigate whether a significant benefit exists for TPF induction chemotherapy in surgically managed OSCC.",23129742;26124084,No induction,DCF,Head and neck cancer,Induction therapy,OS,Primary,no difference,No induction no difference to DCF for Head and neck cancer (Induction therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of No induction compared to DCF when used to treat Head and neck cancer (Induction therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of No induction versus DCF in treating Head and neck cancer (Induction therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of No induction compared to DCF for Head and neck cancer (Induction therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of DCF compared to No induction when used to treat Head and neck cancer (Induction therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Head and neck cancer, Context: Induction therapy, Endpoint: OS, Treatment 1: No induction, Treatment 2: DCF Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Head and neck cancer, Context: Induction therapy Treatment: ",superior,inferior,no difference,2012,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Nasopharyngeal carcinoma, Context: Definitive therapy, Endpoint: OS, Treatment 1: Cisplatin and RT, Treatment 2: Radiation therapy Response:",Cisplatin and RT superior to Radiation therapy for Nasopharyngeal carcinoma (Definitive therapy) [endpoint: OS],True 2012-12-17,"Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide. The treatment of intermediate- to high-risk prostate cancer with radical radiotherapy is usually in combination with neoadjuvant androgen deprivation therapy. The aim of the present trial was to investigate whether degarelix achieves comparable efficacy with that of goserelin plus bicalutamide as neoadjuvant therapy before radiotherapy. The study was a randomised, parallel-arm, active-controlled, open-label trial in 244 men with a UICC prostate cancer TNM category T2b-T4, N0, M0, Gleason score ≥7, or prostate-specific antigen ≥10 ng/ml and a total prostate volume >30 ml, who were scheduled to undergo radical radiotherapy and in whom neoadjuvant androgen deprivation therapy was indicated. Eligible patients received treatment with either monthly degarelix (240/80 mg) or goserelin (3.6 mg) for 12 weeks, the latter patients also receiving bicalutamide (50 mg) for 17 days initially. The primary efficacy measure was the mean percentage reduction in total prostate volume from baseline at week 12 measured by transrectal ultrasound. The severity and relief of lower urinary tract symptoms were assessed by the International Prostate Symptom Score questionnaire. Quality of life was assessed by the eighth question of the International Prostate Symptom Score. About 50% of the patients had moderate to severe lower urinary tract symptoms at baseline. The total prostate volume decreased significantly from baseline to week 12 in both treatment groups, reaching -36.0 ± 14.5% in degarelix-treated patients and -35.3 ± 16.7% in goserelin-treated patients (adjusted difference: -0.3%; 95% confidence interval: -4.74; 4.14%). At the end of the therapy, more degarelix- than goserelin-treated patients reported International Prostate Symptom Score decreases of ≥3 points (37% versus 27%, P = 0.21). In addition, in patients with a baseline International Prostate Symptom Score of ≥13, the magnitude of the decrease was larger in degarelix- (n = 53) versus goserelin-treated patients (n = 17) (6.04 versus 3.41, P = 0.06). The efficacy of degarelix in terms of prostate shrinkage is non-inferior to that of goserelin plus bicalutamide. The added benefits of degarelix in terms of more pronounced lower urinary tract symptom relief in symptomatic patients could be the reflection of differences in the direct effects on extra-pituitary receptors in the lower urinary tract [Clinicaltrials.gov ID: NCT00833248].",23257248,Bicalutamide and Goserelin,Degarelix monotherapy,Prostate cancer,Induction therapy,total prostate volume reduction,Primary,no difference,Bicalutamide and Goserelin no difference to Degarelix monotherapy for Prostate cancer (Induction therapy) [endpoint: total prostate volume reduction],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the total prostate volume reduction outcome of Bicalutamide and Goserelin compared to Degarelix monotherapy when used to treat Prostate cancer (Induction therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the total prostate volume reduction outcome of Bicalutamide and Goserelin versus Degarelix monotherapy in treating Prostate cancer (Induction therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the total prostate volume reduction results of Bicalutamide and Goserelin compared to Degarelix monotherapy for Prostate cancer (Induction therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the total prostate volume reduction outcome of Degarelix monotherapy compared to Bicalutamide and Goserelin when used to treat Prostate cancer (Induction therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Prostate cancer, Context: Induction therapy, Endpoint: total prostate volume reduction, Treatment 1: Bicalutamide and Goserelin, Treatment 2: Degarelix monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Prostate cancer, Context: Induction therapy Treatment: ",superior,inferior,no difference,2012,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Wilms tumor, Context: Adjuvant therapy, Endpoint: RFS, Treatment 1: Vincristine monotherapy, Treatment 2: Dactinomycin and Vincristine Response:",Vincristine monotherapy inferior to Dactinomycin and Vincristine for Wilms tumor (Adjuvant therapy) [endpoint: RFS],False 2013-04-01,"Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. The present phase III study was designed to investigate the noninferiority of S-1 alone and superiority of gemcitabine plus S-1 compared with gemcitabine alone with respect to overall survival. The participants were chemotherapy-naive patients with locally advanced or metastatic pancreatic cancer. Patients were randomly assigned to receive only gemcitabine (1,000 mg/m(2) on days 1, 8, and 15 of a 28-day cycle), only S-1 (80, 100, or 120 mg/d according to body-surface area on days 1 through 28 of a 42-day cycle), or gemcitabine plus S-1 (gemcitabine 1,000 mg/m(2) on days 1 and 8 plus S-1 60, 80, or 100 mg/d according to body-surface area on days 1 through 14 of a 21-day cycle). In the total of 834 enrolled patients, median overall survival was 8.8 months in the gemcitabine group, 9.7 months in the S-1 group, and 10.1 months in the gemcitabine plus S-1 group. The noninferiority of S-1 to gemcitabine was demonstrated (hazard ratio, 0.96; 97.5% CI, 0.78 to 1.18; P < .001 for noninferiority), whereas the superiority of gemcitabine plus S-1 was not (hazard ratio, 0.88; 97.5% CI, 0.71 to 1.08; P = .15). All treatments were generally well tolerated, although hematologic and GI toxicities were more severe in the gemcitabine plus S-1 group than in the gemcitabine group. Monotherapy with S-1 demonstrated noninferiority to gemcitabine in overall survival with good tolerability and presents a convenient oral alternative for locally advanced and metastatic pancreatic cancer. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. The GEST study showed non-inferiority of S-1 but not superiority of gemcitabine plus S-1 (GS) to gemcitabine alone for overall survival with the data by the cut-off date of 31st July in 2010 for chemo-naïve patients with advanced pancreatic cancer. We considered it important to determine whether S-1 maintains non-inferiority after a long-term follow-up in the GEST study and to obtain a firm positive conclusion. In addition, it may be an interesting challenge to explore the efficacious profile of GS in the long-term follow-up study. Using the data from the follow-up period, background and efficacy in patients from Taiwan and Japan, as well as the rates of tumor shrinkage in locally advanced and metastatic patients (Waterfall plot) were also analyzed. The results of the primary analysis were reconfirmed, and subset analysis of overall survival and progression-free survival was performed based on the overall survival data updated by the cut-off date of 31st July in 2011. The median follow-up period was 29.8 months, and 795 deaths occurred (95.6%). The median overall survival was 8.8 months for gemcitabine, 9.7 months for S-1 (hazard ratio [HR], 0.96; 97.5% confidence interval [CI], 0.79-1.17), and 9.9 months for GS (HR 0.91; 97.5% CI 0.75-1.11). In patients with performance status (PS) 0, the median overall survival was 9.8 months for gemcitabine, 10.9 months for S-1, and 10.5 months for GS. In patients with PS 1, the median overall survival was 6.2 months for gemcitabine, 6.3 months for S-1, and 9.6 months for GS. Our survey reconfirmed the non-inferiority of S-1 to gemcitabine and showed S-1 can be used as one of the standard treatment options for advanced pancreatic cancer. ClinicalTrials.gov: NCT00498225. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study. This study was performed to compare health-related quality of life (HRQOL) of gemcitabine plus S-1 (GS), S-1 alone and gemcitabine alone as first-line chemotherapy for locally advanced or metastatic pancreatic cancer in the GEST (Gemcitabine and TS-1 Trial) study and to assess the impacts of adverse events and tumour response on HRQOL. Patients were randomly assigned to receive gemcitabine alone (1000 mg/m2 weekly for 3 of 4 weeks), S-1 alone (80, 100 or 120 mg/day twice daily for 4 of 6 weeks) or GS (gemcitabine at 1000 mg/m2 weekly plus S-1 at 60, 80 or 100 mg/day twice daily for 2 of 3 weeks). HRQOL was assessed using the EuroQoL-5D (EQ-5D) questionnaire at baseline and weeks 6, 12, 24, 48 and 72. EQ-5D scores, quality-adjusted life months (QALMs), quality-adjusted progression-free months (QAPFMs) and time until definitive HRQOL deterioration (TUDD) were compared among the three groups. The impacts of adverse events and tumour response on EQ-5D scores were analysed. Including EQ-5D scores after death as 0, the mean profile was significantly better in the GS than gemcitabine group (difference, 0.069; p=0.003), but not the S-1 group (difference, -0.011; p=0.613). The mean profiles until death were similar in the three groups. QALMs, QAPFMs and TUDD were significantly longer in the GS than gemcitabine group (p<0.001, p<0.001 and p=0.004, respectively), but not the S-1 group (p=0.563, p=0.741 and p=0.701, respectively). Fatigue, anorexia and tumour response were significantly associated with changes in EQ-5D scores. GS achieved better HRQOL than gemcitabine alone, resulting a good balance between overall survival and HRQOL benefits. S-1 alone provides HRQOL similar to that provided by gemcitabine alone. Preventing fatigue and anorexia and maintaining better response would improve HRQOL.",23547081;28210843;28761731,Gemcitabine monotherapy,S-1 monotherapy,Pancreatic cancer,Non-curative first-line therapy,OS,Primary,no difference,Gemcitabine monotherapy no difference to S-1 monotherapy for Pancreatic cancer (Non-curative first-line therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Gemcitabine monotherapy compared to S-1 monotherapy when used to treat Pancreatic cancer (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Gemcitabine monotherapy versus S-1 monotherapy in treating Pancreatic cancer (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Gemcitabine monotherapy compared to S-1 monotherapy for Pancreatic cancer (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of S-1 monotherapy compared to Gemcitabine monotherapy when used to treat Pancreatic cancer (Non-curative first-line therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Pancreatic cancer, Context: Non-curative first-line therapy, Endpoint: OS, Treatment 1: Gemcitabine monotherapy, Treatment 2: S-1 monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Pancreatic cancer, Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2013,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Colon cancer, Context: Adjuvant therapy, Endpoint: DFS, Treatment 1: Observation, Treatment 2: Fluorouracil monotherapy Response:",Observation inferior to Fluorouracil monotherapy for Colon cancer (Adjuvant therapy) [endpoint: DFS],False 2013-04-08,"Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. The primary purpose of our study was to evaluate whether maintenance chemotherapy with paclitaxel/gemcitabine (PG) was superior to observation in improving progression-free survival (PFS) in patients with metastatic breast cancer (MBC) who achieved disease control with an initial six cycles of PG as their first-line treatment. The study was a prospective, randomized, multicenter, phase III trial. Patients MBC with who achieved disease control after six cycles of PG chemotherapy were randomly assigned to maintenance chemotherapy or observation until progression. Of 324 patients from 10 centers enrolled, 231 patients with MBC exhibited disease control (complete response + partial response + stable disease) with first-line PG and were randomly assigned to maintenance chemotherapy (n = 116) or observation (n = 115). The median age was 48 years (range, 28 to 76 years), median follow-up was 33 months, and median number of chemotherapy cycles in the maintenance group after random assignment was six. The median PFS time after random assignment was longer in the maintenance group than in the observation group (7.5 v 3.8 months, respectively; P = .026). The median overall survival (OS) time was longer in the maintenance group than in the observation group (32.3 v 23.5 months, respectively; P = .047). The rate of grade 3 or higher neutropenia after random assignment was higher in the maintenance group than in the observation group (61% v 0.9%, respectively; P < .001). In patients with MBC who achieved disease control with an initial six cycles of PG chemotherapy, maintenance PG chemotherapy resulted in better PFS and OS compared with observation. Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). The therapeutic goals are palliative for metastatic breast cancer (MBC) and include prolongation of survival with good quality of life (QoL) and symptom control. The purpose of this study was to examine QoL among women with MBC treated on KCSG-BR07-02 with maintenance of paclitaxel plus gemcitabine (PG) chemotherapy after achieving disease control to initial six cycles of PG chemotherapy or observation. Patients were randomized to either maintenance chemotherapy or observation until progression. QoL was assessed using EORTC QLQ-C30 and BR-23. QoL at each cycle was compared between the two treatment arms using the 2-sample t test. Generalized estimating equation method was used to examine the overall difference between the two treatments in QoL. All reported p-values are 2 sided. There were no statistically significant differences between two arms in most of the component of the EORTC QLQ-C30 and BR-23 (p > 0.05). There was no significant difference between two treatments (p = 0.6094 for QLQ-C30, p = 0.5516 for BR23) at baseline, and there did not exist significant change over the cycle (p = 0.0914 for QLQ-C30, p = 0.7981 for BR23). There was no significant interaction effect between treatment and cycle (p = 0.5543 for QLQ-C30. p = 0.5817 for BR23). Maintenance PG chemotherapy in patients with MBC achieving disease control with an initial six cycles of PG chemotherapy resulted in better PFS and OS compared to observation without impeding QoL.",23569309;26033708,Observation,Gemcitabine and Paclitaxel,Breast cancer,Non-curative first-line maintenance therapy,PFS,Primary,inferior,Observation inferior to Gemcitabine and Paclitaxel for Breast cancer (Non-curative first-line maintenance therapy) [endpoint: PFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of Observation compared to Gemcitabine and Paclitaxel when used to treat Breast cancer (Non-curative first-line maintenance therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the PFS outcome of Observation versus Gemcitabine and Paclitaxel in treating Breast cancer (Non-curative first-line maintenance therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the PFS results of Observation compared to Gemcitabine and Paclitaxel for Breast cancer (Non-curative first-line maintenance therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of Gemcitabine and Paclitaxel compared to Observation when used to treat Breast cancer (Non-curative first-line maintenance therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer, Context: Non-curative first-line maintenance therapy, Endpoint: PFS, Treatment 1: Observation, Treatment 2: Gemcitabine and Paclitaxel Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Breast cancer, Context: Non-curative first-line maintenance therapy Treatment: ",superior,inferior,no difference,2013,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer (Node Positive), Context: Adjuvant therapy, Endpoint: OS, Treatment 1: CMFT and BCG, Treatment 2: CMF Response:",CMFT and BCG no difference to CMF for Breast cancer (Node Positive) (Adjuvant therapy) [endpoint: OS],False 2013-10-21,"PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combined with carboplatin area under the curve 6 and bevacizumab 15 mg/kg every 3 weeks for up to four cycles. Eligible patients received maintenance until disease progression: pemetrexed plus bevacizumab (for the PemCBev group) or bevacizumab (for the PacCBev group). The primary end point of this superiority study was overall survival (OS). Patients were randomly assigned to PemCBev (n = 472) or PacCBev (n = 467). For PemCBev versus PacCBev, OS hazard ratio (HR) was 1.00 (median OS, 12.6 v 13.4 months; P = .949); progression-free survival (PFS) HR was 0.83 (median PFS, 6.0 v 5.6 months; P = .012); overall response rate was 34.1% versus 33.0%; and disease control rate was 65.9% versus 69.8%. Significantly more study drug-related grade 3 or 4 anemia (14.5% v 2.7%), thrombocytopenia (23.3% v 5.6%), and fatigue (10.9% v 5.0%) occurred with PemCBev; significantly more grade 3 or 4 neutropenia (40.6% v 25.8%), febrile neutropenia (4.1% v 1.4%), sensory neuropathy (4.1% v 0%), and alopecia (grade 1 or 2; 36.8% v 6.6%) occurred with PacCBev. OS did not improve with the PemCBev regimen compared with the PacCBev regimen, although PFS was significantly improved with PemCBev. Toxicity profiles differed; both regimens demonstrated tolerability. Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Treatment impact on quality of life (QoL) informs treatment management decisions in advanced nonsquamous non-small-cell lung cancer (NS NSCLC). QoL outcomes from the phase III PointBreak trial are reported. Chemonaive patients (n = 939) with stage IIIB/IV nonsquamous non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status 0 to 1 were randomized (1:1) to pemetrexed-carboplatin-bevacizumab (pemetrexed arm) or paclitaxel-carboplatin-bevacizumab (paclitaxel arm). Patients without progressive disease received maintenance pemetrexed-bevacizumab (pemetrexed arm) or bevacizumab (paclitaxel arm). QoL was assessed using Functional Assessment of Cancer Therapy (FACT)-General (FACT-G), FACT-Lung (FACT-L), and FACT/Gynecologic Oncology Group-Neurotoxicity (FACT-Ntx) instruments. Subscale scores, total scores, and trial outcome indices were analyzed using linear mixed-effects models. Post hoc analyses examined the association between baseline FACT scores and overall survival (OS). Mean score differences in change from baseline significantly favored the pemetrexed arm for the neurotoxicity subscale score, FACT-Ntx total scores, and FACT-Ntx trial outcome index. They occurred at cycle 2 (p < 0.001) and persisted through induction cycles 2 to 4 and six maintenance cycles. Investigator-assessed, qualitative, drug-related differences in grade 2 (1.6% versus 10.6%) and grade 3 (0.0% versus 4.1%) sensory neuropathy and grade 3/4 fatigue (10.9% versus 5.0%, p = 0.0012) were observed between the pemetrexed and paclitaxel arms. Baseline FACT-G, FACT-L, and FACT-Ntx scores were significant prognostic factors for OS (p < 0.001). Randomized patients reported similar changes in QoL, except for less change from baseline in neurotoxicity on the pemetrexed arm; investigators reported greater neurotoxicity on the paclitaxel arm and greater fatigue on the pemetrexed arm. Higher baseline FACT scores were favorable prognostic factors for OS.",24145346;25611228,"Carboplatin and Paclitaxel (CP) and Bevacizumab, then Bevacizumab monotherapy","Carboplatin, Pemetrexed, Bevacizumab",Non-small cell lung cancer nonsquamous,Non-curative first-line therapy,OS,Primary,no difference,"Carboplatin and Paclitaxel (CP) and Bevacizumab, then Bevacizumab monotherapy no difference to Carboplatin, Pemetrexed, Bevacizumab for Non-small cell lung cancer nonsquamous (Non-curative first-line therapy) [endpoint: OS]","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Carboplatin and Paclitaxel (CP) and Bevacizumab, then Bevacizumab monotherapy compared to Carboplatin, Pemetrexed, Bevacizumab when used to treat Non-small cell lung cancer nonsquamous (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Carboplatin and Paclitaxel (CP) and Bevacizumab, then Bevacizumab monotherapy versus Carboplatin, Pemetrexed, Bevacizumab in treating Non-small cell lung cancer nonsquamous (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Carboplatin and Paclitaxel (CP) and Bevacizumab, then Bevacizumab monotherapy compared to Carboplatin, Pemetrexed, Bevacizumab for Non-small cell lung cancer nonsquamous (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Carboplatin, Pemetrexed, Bevacizumab compared to Carboplatin and Paclitaxel (CP) and Bevacizumab, then Bevacizumab monotherapy when used to treat Non-small cell lung cancer nonsquamous (Non-curative first-line therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Non-small cell lung cancer nonsquamous, Context: Non-curative first-line therapy, Endpoint: OS, Treatment 1: Carboplatin and Paclitaxel (CP) and Bevacizumab, then Bevacizumab monotherapy, Treatment 2: Carboplatin, Pemetrexed, Bevacizumab Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Non-small cell lung cancer nonsquamous, Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2013,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Classical Hodgkin lymphoma, Context: Induction therapy, Endpoint: ORR, Treatment 1: Vinblastine monotherapy, Treatment 2: Cyclophosphamide monotherapy Response:",Vinblastine monotherapy superior to Cyclophosphamide monotherapy for Classical Hodgkin lymphoma (Induction therapy) [endpoint: ORR],False 2016-02-29,"A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients. EGFR is a well-validated target for patients with non-small cell lung cancer (NSCLC). CIMAvax-EGF is a therapeutic cancer vaccine composed of human recombinant EGF conjugated to a carrier protein and Montanide ISA51 as adjuvant. The vaccine is intended to induce antibodies against self EGFs that block EGF-EGFR interaction. To evaluate overall survival, safety, immunogenicity, and EGF concentration in serum after CIMAvax-EGF, a randomized phase III trial was done in patients with advanced NSCLC. Four to 6 weeks after first-line chemotherapy, 405 patients with stage IIIB/IV NSCLC were randomly assigned to a vaccine group, which received CIMAvax-EGF or a control group, treated with best supportive care. Long-term vaccination was very safe. Most frequent adverse reactions were grade 1 or 2 injection-site pain, fever, vomiting, and headache. Vaccination induced anti-EGF antibodies and decreased serum EGF concentration. In the safety population, median survival time (MST) was 10.83 months in the vaccine arm versus 8.86 months in the control arm. These differences were not significant according the standard log rank (HR, 0.82; P = 0.100), but according a weighted log rank (P = 0.04) that was applied once the nonproportionality of the HR was verified. Survival benefit was significant (HR, 0.77; P = 0.036) in the per-protocol setting (patients receiving at least four vaccine doses): MST was 12.43 months for the vaccine arm versus 9.43 months for the control arm. MST was higher (14.66 months) for vaccinated patients with high EGF concentration at baseline. Switch maintenance with CIMAvax-EGF was well tolerated and significantly increased MST of patients that completed induction vaccination. Baseline EGF concentration predicted survival benefit. Clin Cancer Res; 22(15); 3782-90. ©2016 AACR.",26927662,Observation,CIMAvax-EGF monotherapy,Non-small cell lung cancer,Non-curative first-line maintenance therapy,OS,Undesignated,inferior,Observation inferior to CIMAvax-EGF monotherapy for Non-small cell lung cancer (Non-curative first-line maintenance therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Observation compared to CIMAvax-EGF monotherapy when used to treat Non-small cell lung cancer (Non-curative first-line maintenance therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Observation versus CIMAvax-EGF monotherapy in treating Non-small cell lung cancer (Non-curative first-line maintenance therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Observation compared to CIMAvax-EGF monotherapy for Non-small cell lung cancer (Non-curative first-line maintenance therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of CIMAvax-EGF monotherapy compared to Observation when used to treat Non-small cell lung cancer (Non-curative first-line maintenance therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Non-small cell lung cancer, Context: Non-curative first-line maintenance therapy, Endpoint: OS, Treatment 1: Observation, Treatment 2: CIMAvax-EGF monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Non-small cell lung cancer, Context: Non-curative first-line maintenance therapy Treatment: ",superior,inferior,no difference,2016,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 2016-07-07,"Adaptive Randomization of Neratinib in Early Breast Cancer. The heterogeneity of breast cancer makes identifying effective therapies challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy for high-risk clinical stage II or III breast cancer, evaluated multiple new agents added to standard chemotherapy to assess the effects on rates of pathological complete response (i.e., absence of residual cancer in the breast or lymph nodes at the time of surgery). We used adaptive randomization to compare standard neoadjuvant chemotherapy plus the tyrosine kinase inhibitor neratinib with control. Eligible women were categorized according to eight biomarker subtypes on the basis of human epidermal growth factor receptor 2 (HER2) status, hormone-receptor status, and risk according to a 70-gene profile. Neratinib was evaluated against control with regard to 10 biomarker signatures (prospectively defined combinations of subtypes). The primary end point was pathological complete response. Volume changes on serial magnetic resonance imaging were used to assess the likelihood of such a response in each patient. Adaptive assignment to experimental groups within each disease subtype was based on Bayesian probabilities of the superiority of the treatment over control. Enrollment in the experimental group was stopped when the 85% Bayesian predictive probability of success in a confirmatory phase 3 trial of neoadjuvant therapy reached a prespecified threshold for any biomarker signature (""graduation""). Enrollment was stopped for futility if the probability fell to below 10% for every biomarker signature. Neratinib reached the prespecified efficacy threshold with regard to the HER2-positive, hormone-receptor-negative signature. Among patients with HER2-positive, hormone-receptor-negative cancer, the mean estimated rate of pathological complete response was 56% (95% Bayesian probability interval [PI], 37 to 73%) among 115 patients in the neratinib group, as compared with 33% among 78 controls (95% PI, 11 to 54%). The final predictive probability of success in phase 3 testing was 79%. Neratinib added to standard therapy was highly likely to result in higher rates of pathological complete response than standard chemotherapy with trastuzumab among patients with HER2-positive, hormone-receptor-negative breast cancer. (Funded by QuantumLeap Healthcare Collaborative and others; I-SPY 2 TRIAL ClinicalTrials.gov number, NCT01042379.). Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. The genetic and clinical heterogeneity of breast cancer makes the identification of effective therapies challenging. We designed I-SPY 2, a phase 2, multicenter, adaptively randomized trial to screen multiple experimental regimens in combination with standard neoadjuvant chemotherapy for breast cancer. The goal is to match experimental regimens with responding cancer subtypes. We report results for veliparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, combined with carboplatin. In this ongoing trial, women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter; cancers are categorized into eight biomarker subtypes on the basis of status with regard to human epidermal growth factor receptor 2 (HER2), hormone receptors, and a 70-gene assay. Patients undergo adaptive randomization within each biomarker subtype to receive regimens that have better performance than the standard therapy. Regimens are evaluated within 10 biomarker signatures (i.e., prospectively defined combinations of biomarker subtypes). Veliparib-carboplatin plus standard therapy was considered for HER2-negative tumors and was therefore evaluated in 3 signatures. The primary end point is pathological complete response. Tumor volume changes measured by magnetic resonance imaging during treatment are used to predict whether a patient will have a pathological complete response. Regimens move on from phase 2 if and when they have a high Bayesian predictive probability of success in a subsequent phase 3 neoadjuvant trial within the biomarker signature in which they performed well. With regard to triple-negative breast cancer, veliparib-carboplatin had an 88% predicted probability of success in a phase 3 trial. A total of 72 patients were randomly assigned to receive veliparib-carboplatin, and 44 patients were concurrently assigned to receive control therapy; at the completion of chemotherapy, the estimated rates of pathological complete response in the triple-negative population were 51% (95% Bayesian probability interval [PI], 36 to 66%) in the veliparib-carboplatin group versus 26% (95% PI, 9 to 43%) in the control group. The toxicity of veliparib-carboplatin was greater than that of the control. The process used in our trial showed that veliparib-carboplatin added to standard therapy resulted in higher rates of pathological complete response than standard therapy alone specifically in triple-negative breast cancer. (Funded by the QuantumLeap Healthcare Collaborative and others; I-SPY 2 TRIAL ClinicalTrials.gov number, NCT01042379.).",27406346;27406347,TH-AC (Paclitaxel)|TH-ddAC (Paclitaxel),"Neratinib and Paclitaxel, then AC",Breast cancer,Neoadjuvant therapy,pCR rate,Primary,inferior,"TH-AC (Paclitaxel)|TH-ddAC (Paclitaxel) inferior to Neratinib and Paclitaxel, then AC for Breast cancer (Neoadjuvant therapy) [endpoint: pCR rate]","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the pCR rate outcome of TH-AC (Paclitaxel)|TH-ddAC (Paclitaxel) compared to Neratinib and Paclitaxel, then AC when used to treat Breast cancer (Neoadjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the pCR rate outcome of TH-AC (Paclitaxel)|TH-ddAC (Paclitaxel) versus Neratinib and Paclitaxel, then AC in treating Breast cancer (Neoadjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the pCR rate results of TH-AC (Paclitaxel)|TH-ddAC (Paclitaxel) compared to Neratinib and Paclitaxel, then AC for Breast cancer (Neoadjuvant therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the pCR rate outcome of Neratinib and Paclitaxel, then AC compared to TH-AC (Paclitaxel)|TH-ddAC (Paclitaxel) when used to treat Breast cancer (Neoadjuvant therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer, Context: Neoadjuvant therapy, Endpoint: pCR rate, Treatment 1: TH-AC (Paclitaxel)|TH-ddAC (Paclitaxel), Treatment 2: Neratinib and Paclitaxel, then AC Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Breast cancer, Context: Neoadjuvant therapy Treatment: ",superior,inferior,no difference,2016,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer (Node Positive), Context: Adjuvant therapy, Endpoint: OS, Treatment 1: CMFT and BCG, Treatment 2: CMF Response:",CMFT and BCG no difference to CMF for Breast cancer (Node Positive) (Adjuvant therapy) [endpoint: OS],False 2016-07-07,"Adaptive Randomization of Neratinib in Early Breast Cancer. The heterogeneity of breast cancer makes identifying effective therapies challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy for high-risk clinical stage II or III breast cancer, evaluated multiple new agents added to standard chemotherapy to assess the effects on rates of pathological complete response (i.e., absence of residual cancer in the breast or lymph nodes at the time of surgery). We used adaptive randomization to compare standard neoadjuvant chemotherapy plus the tyrosine kinase inhibitor neratinib with control. Eligible women were categorized according to eight biomarker subtypes on the basis of human epidermal growth factor receptor 2 (HER2) status, hormone-receptor status, and risk according to a 70-gene profile. Neratinib was evaluated against control with regard to 10 biomarker signatures (prospectively defined combinations of subtypes). The primary end point was pathological complete response. Volume changes on serial magnetic resonance imaging were used to assess the likelihood of such a response in each patient. Adaptive assignment to experimental groups within each disease subtype was based on Bayesian probabilities of the superiority of the treatment over control. Enrollment in the experimental group was stopped when the 85% Bayesian predictive probability of success in a confirmatory phase 3 trial of neoadjuvant therapy reached a prespecified threshold for any biomarker signature (""graduation""). Enrollment was stopped for futility if the probability fell to below 10% for every biomarker signature. Neratinib reached the prespecified efficacy threshold with regard to the HER2-positive, hormone-receptor-negative signature. Among patients with HER2-positive, hormone-receptor-negative cancer, the mean estimated rate of pathological complete response was 56% (95% Bayesian probability interval [PI], 37 to 73%) among 115 patients in the neratinib group, as compared with 33% among 78 controls (95% PI, 11 to 54%). The final predictive probability of success in phase 3 testing was 79%. Neratinib added to standard therapy was highly likely to result in higher rates of pathological complete response than standard chemotherapy with trastuzumab among patients with HER2-positive, hormone-receptor-negative breast cancer. (Funded by QuantumLeap Healthcare Collaborative and others; I-SPY 2 TRIAL ClinicalTrials.gov number, NCT01042379.). Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. The genetic and clinical heterogeneity of breast cancer makes the identification of effective therapies challenging. We designed I-SPY 2, a phase 2, multicenter, adaptively randomized trial to screen multiple experimental regimens in combination with standard neoadjuvant chemotherapy for breast cancer. The goal is to match experimental regimens with responding cancer subtypes. We report results for veliparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, combined with carboplatin. In this ongoing trial, women are eligible for participation if they have stage II or III breast cancer with a tumor 2.5 cm or larger in diameter; cancers are categorized into eight biomarker subtypes on the basis of status with regard to human epidermal growth factor receptor 2 (HER2), hormone receptors, and a 70-gene assay. Patients undergo adaptive randomization within each biomarker subtype to receive regimens that have better performance than the standard therapy. Regimens are evaluated within 10 biomarker signatures (i.e., prospectively defined combinations of biomarker subtypes). Veliparib-carboplatin plus standard therapy was considered for HER2-negative tumors and was therefore evaluated in 3 signatures. The primary end point is pathological complete response. Tumor volume changes measured by magnetic resonance imaging during treatment are used to predict whether a patient will have a pathological complete response. Regimens move on from phase 2 if and when they have a high Bayesian predictive probability of success in a subsequent phase 3 neoadjuvant trial within the biomarker signature in which they performed well. With regard to triple-negative breast cancer, veliparib-carboplatin had an 88% predicted probability of success in a phase 3 trial. A total of 72 patients were randomly assigned to receive veliparib-carboplatin, and 44 patients were concurrently assigned to receive control therapy; at the completion of chemotherapy, the estimated rates of pathological complete response in the triple-negative population were 51% (95% Bayesian probability interval [PI], 36 to 66%) in the veliparib-carboplatin group versus 26% (95% PI, 9 to 43%) in the control group. The toxicity of veliparib-carboplatin was greater than that of the control. The process used in our trial showed that veliparib-carboplatin added to standard therapy resulted in higher rates of pathological complete response than standard therapy alone specifically in triple-negative breast cancer. (Funded by the QuantumLeap Healthcare Collaborative and others; I-SPY 2 TRIAL ClinicalTrials.gov number, NCT01042379.).",27406346;27406347,"Neratinib and Paclitaxel, then AC|Neratinib and Paclitaxel, then ddAC",TH-AC (Paclitaxel),Breast cancer,Neoadjuvant therapy,pCR rate,Primary,superior,"Neratinib and Paclitaxel, then AC|Neratinib and Paclitaxel, then ddAC superior to TH-AC (Paclitaxel) for Breast cancer (Neoadjuvant therapy) [endpoint: pCR rate]","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the pCR rate outcome of Neratinib and Paclitaxel, then AC|Neratinib and Paclitaxel, then ddAC compared to TH-AC (Paclitaxel) when used to treat Breast cancer (Neoadjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the pCR rate outcome of Neratinib and Paclitaxel, then AC|Neratinib and Paclitaxel, then ddAC versus TH-AC (Paclitaxel) in treating Breast cancer (Neoadjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the pCR rate results of Neratinib and Paclitaxel, then AC|Neratinib and Paclitaxel, then ddAC compared to TH-AC (Paclitaxel) for Breast cancer (Neoadjuvant therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the pCR rate outcome of TH-AC (Paclitaxel) compared to Neratinib and Paclitaxel, then AC|Neratinib and Paclitaxel, then ddAC when used to treat Breast cancer (Neoadjuvant therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer, Context: Neoadjuvant therapy, Endpoint: pCR rate, Treatment 1: Neratinib and Paclitaxel, then AC|Neratinib and Paclitaxel, then ddAC, Treatment 2: TH-AC (Paclitaxel) Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Breast cancer, Context: Neoadjuvant therapy Treatment: ",superior,inferior,no difference,2016,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer (Node Positive), Context: Adjuvant therapy, Endpoint: RFS, Treatment 1: CMF, Treatment 2: CMFT Response:",CMF inferior to CMFT for Breast cancer (Node Positive) (Adjuvant therapy) [endpoint: RFS],False 2016-08-26,"Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial. No novel chemotherapeutic combinations have demonstrated superior efficacy to etoposide/cisplatin (EP), a standard treatment regimen for extensive-stage small cell lung carcinoma (ES-SCLC) over the past decade. We aimed to compare the efficacy and safety of belotecan/cisplatin (BP) and EP regimens in chemotherapy- and radiotherapy-naïve patients with previously untreated ES-SCLC. We conducted a multi-center, randomized, open-label, parallel-group, phase III clinical study. A total of 157 patients were recruited at 14 centers with 147 patients meeting the inclusion/exclusion criteria and randomized to either BP (n = 71) or EP (n = 76) treatment arms. A non-inferior response rate (RR) in the BP arm, analyzed by intent-to-treat analysis according to Response Evaluation Criteria in Solid Tumors version 1.0 criteria, was used as the primary endpoint. The secondary endpoints were progression-free survival (PFS) and overall survival (OS). In the BP arm, one patient had a complete response, 41 had a partial response (PR), and 17 had stable disease (SD). In the EP arm, 35 patients had PR and 28 had SD. The RR in the BP arm was non-inferior to the EP regimen in patients with ES-SCLC (BP: 59.2 %, EP: 46.1 %, difference: 13.1 %, 90 % two-sided confidence interval: -0.3-26.5, meeting the predefined non-inferiority criterion of -15.0 %). No significant differences in OS or PFS were observed between the treatment arms. Hematologic toxicities, including grade 3/4 anemia and thrombocytopenia, were significantly more prevalent in the BP arm than the EP arm. The RR to the BP regimen was non-inferior to the EP regimen in chemotherapy- and radiotherapy-naïve patients with previously untreated ES-SCLC. Hematologic toxicities were significantly more prevalent in the BP group, indicating that BP should be used with care, particularly in patients with a poor performance status. Further studies assessing PFS and OS are required to validate the superiority of the BP regimen. ClinicalTrials.gov identifier NCT00826644 . Date of Registration: January 21, 2009.",27566413,Cisplatin and Etoposide (EP),Belotecan and Cisplatin,Small cell lung cancer,Induction therapy,RR,Primary,no difference,Cisplatin and Etoposide (EP) no difference to Belotecan and Cisplatin for Small cell lung cancer (Induction therapy) [endpoint: RR],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the RR outcome of Cisplatin and Etoposide (EP) compared to Belotecan and Cisplatin when used to treat Small cell lung cancer (Induction therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the RR outcome of Cisplatin and Etoposide (EP) versus Belotecan and Cisplatin in treating Small cell lung cancer (Induction therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the RR results of Cisplatin and Etoposide (EP) compared to Belotecan and Cisplatin for Small cell lung cancer (Induction therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the RR outcome of Belotecan and Cisplatin compared to Cisplatin and Etoposide (EP) when used to treat Small cell lung cancer (Induction therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Small cell lung cancer, Context: Induction therapy, Endpoint: RR, Treatment 1: Cisplatin and Etoposide (EP), Treatment 2: Belotecan and Cisplatin Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Small cell lung cancer, Context: Induction therapy Treatment: ",superior,inferior,no difference,2016,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Multiple myeloma, Context: Non-curative therapy, Endpoint: OS, Treatment 1: Placebo, Treatment 2: Urethane monotherapy Response:",Placebo superior to Urethane monotherapy for Multiple myeloma (Non-curative therapy) [endpoint: OS],False 2016-12-06,"Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer. The efficacy of osimertinib as compared with platinum-based therapy plus pemetrexed in such patients is unknown. In this randomized, international, open-label, phase 3 trial, we assigned 419 patients with T790M-positive advanced non-small-cell lung cancer, who had disease progression after first-line EGFR-TKI therapy, in a 2:1 ratio to receive either oral osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles; maintenance pemetrexed was allowed. In all the patients, disease had progressed during receipt of first-line EGFR-TKI therapy. The primary end point was investigator-assessed progression-free survival. The median duration of progression-free survival was significantly longer with osimertinib than with platinum therapy plus pemetrexed (10.1 months vs. 4.4 months; hazard ratio; 0.30; 95% confidence interval [CI], 0.23 to 0.41; P<0.001). The objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with platinum therapy plus pemetrexed (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001). Among 144 patients with metastases to the central nervous system (CNS), the median duration of progression-free survival was longer among patients receiving osimertinib than among those receiving platinum therapy plus pemetrexed (8.5 months vs. 4.2 months; hazard ratio, 0.32; 95% CI, 0.21 to 0.49). The proportion of patients with adverse events of grade 3 or higher was lower with osimertinib (23%) than with platinum therapy plus pemetrexed (47%). Osimertinib had significantly greater efficacy than platinum therapy plus pemetrexed in patients with T790M-positive advanced non-small-cell lung cancer (including those with CNS metastases) in whom disease had progressed during first-line EGFR-TKI therapy. (Funded by AstraZeneca; AURA3 ClinicalTrials.gov number, NCT02151981 .). Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial. Purpose Capturing patient-reported outcome data is important for evaluating the overall clinical benefits of new cancer therapeutics. We assessed self-reported symptoms of advanced non-small-cell lung cancer in patients treated with osimertinib or chemotherapy in the AURA3 phase III trial. Patients and Methods Patients completed the European Organisation for Research and Treatment of Cancer 13-item Quality of Life Questionnaire-Lung Cancer Module (EORTC QLQ-LC13) questionnaire on disease-specific symptoms and the EORTC 30-item Core Quality of Life Questionnaire (EORTC QLC-C30) on general cancer symptoms, functioning, global health status/quality of life. We assessed differences between treatments in time to deterioration of individual symptoms and odds of improvement (a deterioration or improvement was defined as a change in score from baseline of ≥ 10). Hazard ratios (HRs) were calculated using a log-rank test stratified by ethnicity; odds ratios (ORs) were assessed using logistic regression adjusted for ethnicity. Results At baseline, the questionnaires were completed by 82% to 88% of patients, and 30% to 70% had individual key symptoms. Time to deterioration was longer with osimertinib than with chemotherapy for cough (HR, 0.74; 95% CI, 0.53 to 1.05), chest pain (HR, 0.52; 95% CI, 0.37 to 0.73), and dyspnea (HR, 0.42; 95% CI, 0.31 to 0.58). The proportion of symptomatic patients with improvement in global health status/quality of life was higher with osimertinib (80 [37%] of 215) than with chemotherapy (23 [22%] of 105; OR, 2.11; 95% CI, 1.24 to 3.67; P = .007). Proportions were also higher for appetite loss (OR, 2.50; 95% CI, 1.31 to 4.84) and fatigue (OR, 1.96; 95% CI, 1.20 to 3.22). Conclusion Time to deterioration of key symptoms was longer with osimertinib than with chemotherapy, and a higher proportion of patients had improvement in global health status/quality of life, demonstrating improved patient outcomes with osimertinib. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). Purpose In patients with epidermal growth factor receptor ( EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC), there is an unmet need for EGFR-tyrosine kinase inhibitors with improved CNS penetration and activity against CNS metastases, either at initial diagnosis or time of progression. We report the first comparative evidence of osimertinib CNS efficacy versus platinum-pemetrexed from a phase III study (AURA3; ClinicalTrials.gov identifier: NCT02151981) in patients with EGFR T790M-positive advanced NSCLC who experience disease progression with prior EGFR-tyrosine kinase inhibitor treatment. Methods Patients with asymptomatic, stable CNS metastases were eligible for enrollment and were randomly assigned 2:1 to osimertinib 80 mg once daily or platinum-pemetrexed. A preplanned subgroup analysis was conducted in patients with measurable and/or nonmeasurable CNS lesions on baseline brain scan by blinded independent central neuroradiological review. The CNS evaluable for response set included only patients with one or more measurable CNS lesions. The primary objective for this analysis was CNS objective response rate (ORR). Results Of 419 patients randomly assigned to treatment, 116 had measurable and/or nonmeasurable CNS lesions, including 46 patients with measurable CNS lesions. At data cutoff (April 15, 2016), CNS ORR in patients with one or more measurable CNS lesions was 70% (21 of 30; 95% CI, 51% to 85%) with osimertinib and 31% (5 of 16; 95% CI, 11% to 59%) with platinum-pemetrexed (odds ratio, 5.13; 95% CI, 1.44 to 20.64; P = .015); the ORR was 40% (30 of 75; 95% CI, 29% to 52%) and 17% (7 of 41; 95% CI, 7% to 32%), respectively, in patients with measurable and/or nonmeasurable CNS lesions (odds ratio, 3.24; 95% CI, 1.33 to 8.81; P = .014). Median CNS duration of response in patients with measurable and/or nonmeasurable CNS lesions was 8.9 months (95% CI, 4.3 months to not calculable) for osimertinib and 5.7 months (95% CI, 4.4 to 5.7 months) for platinum-pemetrexed; median CNS progression-free survival was 11.7 months and 5.6 months, respectively (hazard ratio, 0.32; 95% CI, 0.15 to 0.69; P = .004). Conclusion Osimertinib demonstrated superior CNS efficacy versus platinum-pemetrexed in T790M-positive advanced NSCLC. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged progression-free survival and improved response in patients with EGFR T790M advanced non-small-cell lung cancer (NSCLC) and progression on prior EGFR-TKI treatment. We report the final AURA3 overall survival (OS) analysis. Adult patients were randomized 2 : 1 to osimertinib (80 mg orally, once daily) or pemetrexed plus carboplatin/cisplatin (platinum-pemetrexed) intravenously, every 3 weeks (≤6 cycles). Patients could crossover to osimertinib on progression confirmed by blinded independent central review. OS and safety were secondary end points. A total of 279 patients were randomly assigned to receive osimertinib and 140 to platinum-pemetrexed (136 received treatment). At data cut-off (DCO; 15 March 2019), 188 patients (67%) receiving osimertinib versus 93 (66%) receiving platinum-pemetrexed had died. The hazard ratio (HR) for OS was 0.87 [95% confidence interval (CI) 0.67-1.12; P = 0.277]; the median OS was 26.8 months (95% CI 23.5-31.5) versus 22.5 months (95% CI 20.2-28.8) for osimertinib and platinum-pemetrexed, respectively. The estimated 24- and 36-month survival was 55% versus 43% and 37% versus 30%, respectively. After crossover adjustment, there was an HR of 0.54 (95% CI 0.18-1.6). Time to first subsequent therapy or death showed a clinically meaningful advantage toward osimertinib (HR 0.21, 95% CI 0.16-0.28; P < 0.001). At DCO, 99/136 (73%) patients in the platinum-pemetrexed arm had crossed over to osimertinib, 66/99 (67%) of whom had died. The most common adverse events possibly related to study treatment were diarrhea (32%; grade ≥3, 1%) and rash (grouped term; 32%; grade ≥3, <1%) in the osimertinib arm, versus nausea (47%; grade ≥3, 3%) in the platinum-pemetrexed arm. In patients with T790M advanced NSCLC, no statistically significant benefit in OS was observed for osimertinib versus platinum-pemetrexed, which possibly reflects the high crossover rate of patients from platinum-pemetrexed to osimertinib. ClinicalTrials.gov NCT02151981; https://clinicaltrials.gov/ct2/show/NCT02151981.",27959700;29733770;30059262;32861806,Carboplatin and Pemetrexed|Cisplatin and Pemetrexed,Osimertinib monotherapy,Non-small cell lung cancer (Metastatic),All lines of therapy,ORR,Secondary,inferior,Carboplatin and Pemetrexed|Cisplatin and Pemetrexed inferior to Osimertinib monotherapy for Non-small cell lung cancer (Metastatic) (All lines of therapy) [endpoint: ORR],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the ORR outcome of Carboplatin and Pemetrexed|Cisplatin and Pemetrexed compared to Osimertinib monotherapy when used to treat Non-small cell lung cancer (Metastatic) (All lines of therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the ORR outcome of Carboplatin and Pemetrexed|Cisplatin and Pemetrexed versus Osimertinib monotherapy in treating Non-small cell lung cancer (Metastatic) (All lines of therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the ORR results of Carboplatin and Pemetrexed|Cisplatin and Pemetrexed compared to Osimertinib monotherapy for Non-small cell lung cancer (Metastatic) (All lines of therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the ORR outcome of Osimertinib monotherapy compared to Carboplatin and Pemetrexed|Cisplatin and Pemetrexed when used to treat Non-small cell lung cancer (Metastatic) (All lines of therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Non-small cell lung cancer (Metastatic), Context: All lines of therapy, Endpoint: ORR, Treatment 1: Carboplatin and Pemetrexed|Cisplatin and Pemetrexed, Treatment 2: Osimertinib monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Non-small cell lung cancer (Metastatic), Context: All lines of therapy Treatment: ",superior,inferior,no difference,2016,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 2016-12-22,"Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial. The randomized phase III JO21095 trial compared the efficacy and safety of low-dose capecitabine plus docetaxel combination therapy (XT) versus single-agent administration of docetaxel in anthracycline-pretreated HER2-negative metastatic breast cancer. Patients were randomized to either low-dose XT (capecitabine 825 mg/m2 twice daily, days 1-14; docetaxel 60 mg/m2, day 1 every 3 weeks) or docetaxel (70 mg/m2, day 1 every 3 weeks). The primary objective was to demonstrate superior progression-free survival (PFS) with low-dose XT versus single-agent docetaxel. Overall survival (OS) and safety were secondary endpoints. In total, 162 patients were treated. Median PFS was 10.5 months with low-dose XT and 9.8 months with single-agent docetaxel (hazard ratio [HR] 0.62 [95% confidence interval (CI) 0.40-0.97]; p = 0.03). The OS HR was 0.89 (95% CI 0.52-1.53; p = 0.68). Grade ≥3 treatment-related toxicities occurred in 74% of XT-treated patients and 76% of docetaxel-treated patients. The main differences in grade ≥3 treatment-related toxicities were hand-foot syndrome (7.3% of XT-treated patients vs 0% receiving docetaxel), fatigue/malaise (2.4 vs 10.0%), and peripheral edema (1.2 vs 7.5%). Dose modifications were required in 100% of low-dose XT and 49% of docetaxel patients. Toxicity-related treatment discontinuations occurred in 18 and 33%, respectively. The improved PFS with low-dose XT versus docetaxel alone is consistent with higher-dose XT phase III experience, but the safety profile was more favorable and manageable.",28005247,Docetaxel monotherapy,Capecitabine and Docetaxel (TX),Breast cancer,Non-curative subsequent-line therapy,OS,Undesignated,inferior,Docetaxel monotherapy inferior to Capecitabine and Docetaxel (TX) for Breast cancer (Non-curative subsequent-line therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Docetaxel monotherapy compared to Capecitabine and Docetaxel (TX) when used to treat Breast cancer (Non-curative subsequent-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Docetaxel monotherapy versus Capecitabine and Docetaxel (TX) in treating Breast cancer (Non-curative subsequent-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Docetaxel monotherapy compared to Capecitabine and Docetaxel (TX) for Breast cancer (Non-curative subsequent-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Capecitabine and Docetaxel (TX) compared to Docetaxel monotherapy when used to treat Breast cancer (Non-curative subsequent-line therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer, Context: Non-curative subsequent-line therapy, Endpoint: OS, Treatment 1: Docetaxel monotherapy, Treatment 2: Capecitabine and Docetaxel (TX) Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Breast cancer, Context: Non-curative subsequent-line therapy Treatment: ",superior,inferior,no difference,2016,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer (Node Positive), Context: Adjuvant therapy, Endpoint: OS, Treatment 1: CMFT and BCG, Treatment 2: CMF Response:",CMFT and BCG no difference to CMF for Breast cancer (Node Positive) (Adjuvant therapy) [endpoint: OS],False 2017-02-11,"Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial. Utidelone, a genetically engineered epothilone analogue, has shown promise as a potential treatment for breast cancer in phase 1 and 2 trials. The aim of this phase 3 trial was to compare the efficacy and safety of utidelone plus capecitabine versus capecitabine alone in patients with metastatic breast cancer. We did a multicentre, open-label, superiority, phase 3, randomised controlled trial in 26 hospitals in China. Eligible participants were female patients with metastatic breast cancer refractory to anthracycline and taxane chemotherapy regimens. We randomly assigned participants (2:1) using computer based randomisation and block sizes of 6 to a 21-day cycle of either utidelone (30 mg/m2 intravenously once per day on days 1-5) plus capecitabine (1000 mg/m2 orally twice per day on days 1-14), or capecitabine alone (1250 mg/m2 orally twice per day on days 1-14), until disease progression or unacceptable toxicity occurred. Patients, physicians, and assessors were not masked to treatment allocation; however, an independent radiology review committee used to additionally assess response was masked to allocation. The primary endpoint was centrally assessed (by an independent radiology review committee) progression-free survival, and analysed using the Kaplan-Meier product-limit method in the intention-to-treat population. Safety was assessed in all participants who received at least one dose of study drug. Follow-up is ongoing. This study is registered at ClinicalTrials.gov, number NCT02253459. Between Aug 8, 2014, and Dec 14, 2015, we enrolled and randomly assigned 270 patients to treatment with utidelone plus capecitabine, and 135 to capecitabine alone. Median follow-up for progression-free survival was 6·77 months (IQR 3·81-10·32) for the utidelone plus capecitabine group and 4·55 months (2·55-9·39) for the capecitabine alone group. Median progression-free survival by central review in the utidelone plus capecitabine group was 8·44 months (95% CI 7·95-9·92) compared with 4·27 months (3·22-5·68) in the capecitabine alone group; hazard ratio 0·46, 95% CI 0·36-0·59; p<0·0001. Peripheral neuropathy was the most common grade 3 adverse event in the utidelone plus capecitabine group (58 [22%] of 267 patients vs 1 [<1%] of 130 patients in the capecitabine alone group). Palmar-plantar erythrodysaesthesia was the most prominent grade 3 adverse event in the capacitabine alone group (in 10 [8%] of 130 patients) and was the next most frequent grade 3 event in the utidelone plus capecitabine group (in 18 [7%] of 267 patients). 16 serious adverse events were reported in the combination therapy group (diarrhoea was the most common, in three [1%] patients) and 14 serious adverse events were reported in the monotherapy group (the most common were diarrhoea, increased blood bilirubin, and anaemia, in two [2%] patients for each event). 155 patients died (99 in the combination therapy arm, 56 in the monotherapy arm). All deaths were related to disease progression except for one in each group (attributed to pericardial effusion in the combination therapy group and dyspnoea in the monotherapy group) that were considered possibly or probably treatment-related. Despite disease progression with previous chemotherapies, utidelone plus capecitabine was more efficacious compared with capecitabine alone for the outcome of progression-free survival, with mild toxicity except for peripheral sensory neuropathy, which was manageable. The findings from this study support the use of utidelone plus capecitabine as an effective option for patients with metastatic breast cancer. Beijing Biostar Technologies, Beijing, China. Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial. Primary analysis of the phase III trial BG01-1323L demonstrated that utidelone plus capecitabine significantly improved progression-free survival (PFS) and overall response rate (ORR) versus capecitabine alone in heavily-pretreated patients with metastatic breast cancer (MBC). Here, we report the final overall survival (OS) analysis and updates of other endpoints. In total, 405 patients were randomised 2:1 to receive utidelone (30 mg/m2 IV daily, days 1-5, over 90 min) plus capecitabine (1000 mg/m2 orally b.i.d., days 1-14) or capecitabine alone (1250 mg/m2 orally b.i.d., days 1-14) every 21 days. The secondary endpoint, OS, was estimated using the Kaplan-Meier product-limit approach at a two-sided alpha level of 0.05 after the prespecified 310 death events had been reached. Exploratory analyses of the primary endpoint, PFS, and the secondary endpoint, ORR, were also done. Safety was analysed in patients who had at least one dose of study drug. At the final OS analysis, the median duration of follow-up was 19.6 months in the utidelone plus capecitabine group and 15.4 months in the capecitabine alone group. In the intention-to-treat population, 313 deaths had occurred at data cut-off, 203 of 270 patients in the combination group and 110 of 135 in the monotherapy group. Median OS in the combination group was 19.8 months compared with 16.0 months in the monotherapy group [hazard ratio (HR) = 0.75, 95% confidence intervals (CI) 0.59-0.94, P = 0.0142]. The updated analysis of PFS and ORR showed that the combination therapy remained superior to monotherapy. Safety results were similar to those previously reported with respect to incidence, severity and specificity. No late-emerging toxicities or new safety concerns occurred. For heavily-pretreated, anthracycline- and taxane-resistant MBC patients, utidelone plus capecitabine significantly improved OS versus capecitabine alone. These results support the use of utidelone plus capecitabine as a novel therapeutic regimen for patients with MBC.",28209298;33188874,Capecitabine monotherapy,Capecitabine and Utidelone,Breast cancer,Non-curative subsequent-line therapy,PFS,Primary,inferior,Capecitabine monotherapy inferior to Capecitabine and Utidelone for Breast cancer (Non-curative subsequent-line therapy) [endpoint: PFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of Capecitabine monotherapy compared to Capecitabine and Utidelone when used to treat Breast cancer (Non-curative subsequent-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the PFS outcome of Capecitabine monotherapy versus Capecitabine and Utidelone in treating Breast cancer (Non-curative subsequent-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the PFS results of Capecitabine monotherapy compared to Capecitabine and Utidelone for Breast cancer (Non-curative subsequent-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of Capecitabine and Utidelone compared to Capecitabine monotherapy when used to treat Breast cancer (Non-curative subsequent-line therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer, Context: Non-curative subsequent-line therapy, Endpoint: PFS, Treatment 1: Capecitabine monotherapy, Treatment 2: Capecitabine and Utidelone Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Breast cancer, Context: Non-curative subsequent-line therapy Treatment: ",superior,inferior,no difference,2017,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer (Node Positive), Context: Adjuvant therapy, Endpoint: OS, Treatment 1: CMFT and BCG, Treatment 2: CMF Response:",CMFT and BCG no difference to CMF for Breast cancer (Node Positive) (Adjuvant therapy) [endpoint: OS],False 2017-04-01,"Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. The optimal chemotherapy regimen administered currently with radiation in patients with stage III non-small cell lung cancer (NSCLC) remains unclear. A multicenter phase III trial was conducted to compare the efficacy of concurrent thoracic radiation therapy with either etoposide/cisplatin (EP) or carboplatin/paclitaxel (PC) in patients with stage III NSCLC. Patients were randomly received 60-66 Gy of thoracic radiation therapy concurrent with either etoposide 50 mg/m2 on days 1-5 and cisplatin 50 mg/m2 on days 1 and 8 every 4 weeks for two cycles (EP arm), or paclitaxel 45 mg/m2 and carboplatin (AUC 2) on day 1 weekly (PC arm). The primary end point was overall survival (OS). The study was designed with 80% power to detect a 17% superiority in 3-year OS with a type I error rate of 0.05. A total of 200 patients were randomized and 191 patients were treated (95 in the EP arm and 96 in the PC arm). With a median follow-up time of 73 months, the 3-year OS was significantly higher in the EP arm than that of the PC arm. The estimated difference was 15.0% (95% CI 2.0%-28.0%) and P value of 0.024. Median survival times were 23.3 months in the EP arm and 20.7 months in the PC arm (log-rank test P = 0.095, HR 0.76, 95%CI 0.55-1.05). The incidence of Grade ≥2 radiation pneumonitis was higher in the PC arm (33.3% versus 18.9%, P = 0.036), while the incidence of Grade ≥3 esophagitis was higher in the EP arm (20.0% versus 6.3%, P = 0.009). EP might be superior to weekly PC in terms of OS in the setting of concurrent chemoradiation for unresectable stage III NSCLC. NCT01494558.",28137739,Carboplatin and Paclitaxel (CP) and RT,Cisplatin and Etoposide (EP) and RT,Non-small cell lung cancer,Definitive therapy,OS,Primary,inferior,Carboplatin and Paclitaxel (CP) and RT inferior to Cisplatin and Etoposide (EP) and RT for Non-small cell lung cancer (Definitive therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Carboplatin and Paclitaxel (CP) and RT compared to Cisplatin and Etoposide (EP) and RT when used to treat Non-small cell lung cancer (Definitive therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Carboplatin and Paclitaxel (CP) and RT versus Cisplatin and Etoposide (EP) and RT in treating Non-small cell lung cancer (Definitive therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Carboplatin and Paclitaxel (CP) and RT compared to Cisplatin and Etoposide (EP) and RT for Non-small cell lung cancer (Definitive therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Cisplatin and Etoposide (EP) and RT compared to Carboplatin and Paclitaxel (CP) and RT when used to treat Non-small cell lung cancer (Definitive therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Non-small cell lung cancer, Context: Definitive therapy, Endpoint: OS, Treatment 1: Carboplatin and Paclitaxel (CP) and RT, Treatment 2: Cisplatin and Etoposide (EP) and RT Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Non-small cell lung cancer, Context: Definitive therapy Treatment: ",superior,inferior,no difference,2017,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 2017-08-03,"Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Hypomethylating agents (HMAs) improve survival in patients with higher-risk myelodysplastic syndromes (MDS) but are less well-studied in lower-risk disease. We compared the safety and efficacy of low-dose decitabine vs low-dose azacitidine in this group of patients. Adults with low- or intermediate 1-risk MDS or MDS/myeloproliferative neoplasm (MPN), including chronic myelomonocytic leukemia, according to the International Prognostic Scoring System, were randomly assigned using a Bayesian adaptive design to receive either azacitidine 75 mg/m2 intravenously/subcutaneously daily or decitabine 20 mg/m2 intravenously daily for 3 consecutive days on a 28-day cycle. The primary outcome was overall response rate (ORR). Between November 2012 and February 2016, 113 patients were treated: 40 (35%) with azacitidine and 73 (65%) with decitabine. The median age was 70 years; 81% of patients were intermediate 1-risk patients. The median number of cycles received was 9. The ORRs were 70% and 49% (P = .03) for patients treated with decitabine and azacitidine, respectively. Thirty-two percent of patients treated with decitabine became transfusion independent compared with 16% of patients treated with azacitidine (P = .2). Cytogenetic response rates were 61% and 25% (P = .02), respectively. With a median follow-up of 20 months, the overall median event-free survival was 18 months: 20 and 13 months for patients treated with decitabine and azacitidine, respectively (P = .1). Treatment was well tolerated, with a 6-week mortality rate of 0%. The use of low-dose HMAs is safe and effective in patients with lower-risk MDS and MDS/MPN. Their effect on the natural history of lower-risk disease needs to be further studied. This trial was registered at clinicaltrials.gov (identifier NCT01720225).",28774880,Decitabine monotherapy,Azacitidine monotherapy,Myelodysplastic syndrome,Non-curative first-line therapy,ORR,Primary,superior,Decitabine monotherapy superior to Azacitidine monotherapy for Myelodysplastic syndrome (Non-curative first-line therapy) [endpoint: ORR],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the ORR outcome of Decitabine monotherapy compared to Azacitidine monotherapy when used to treat Myelodysplastic syndrome (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the ORR outcome of Decitabine monotherapy versus Azacitidine monotherapy in treating Myelodysplastic syndrome (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the ORR results of Decitabine monotherapy compared to Azacitidine monotherapy for Myelodysplastic syndrome (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the ORR outcome of Azacitidine monotherapy compared to Decitabine monotherapy when used to treat Myelodysplastic syndrome (Non-curative first-line therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Myelodysplastic syndrome, Context: Non-curative first-line therapy, Endpoint: ORR, Treatment 1: Decitabine monotherapy, Treatment 2: Azacitidine monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Myelodysplastic syndrome, Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2017,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 2017-10-30,"Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study. This randomized, international, multicenter, open-label phase III study investigated the effects of experimental retreatment with subcutaneous bortezomib plus dexamethasone (VD) followed by prolonged bortezomib therapy vs standard VD retreatment in patients with relapsed/refractory multiple myeloma. Patients were randomized (2:1) to receive either experimental (n = 53) or standard (n = 27) retreatment, stratified by the number of prior therapy lines. The study was terminated prematurely with insufficient enrollment to adequately compare the retreatment therapies; results should be considered descriptive. After a median follow-up of 21.2 and 20.0 months in the experimental and standard arms, respectively, the median progression-free survival (primary endpoint) was 7.2 months (95% confidence interval 5.7-9.0) vs 7.8 months (4.9-11.7). The overall response rate was 66% and 52% for experimental and standard retreatment regimens, respectively. Thrombocytopenia was the most common and most differentially observed grade ≥3 adverse event (experimental: 9% vs standard: 22%). Any-grade peripheral neuropathies (including peripheral sensory neuropathies) were reported in 23% vs 37% of patients. This study showed no significant benefit with experimental vs standard VD retreatment therapy. Further investigations are required to determine whether the experimental retreatment regimen is a suitable alternative to the current standard retreatment regimen.",28801967,Bortezomib and Dexamethasone (Vd),"Bortezomib and Dexamethasone (Vd), then Bortezomib monotherapy",Multiple myeloma,Non-curative therapy,PFS,Primary,no difference,"Bortezomib and Dexamethasone (Vd) no difference to Bortezomib and Dexamethasone (Vd), then Bortezomib monotherapy for Multiple myeloma (Non-curative therapy) [endpoint: PFS]","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of Bortezomib and Dexamethasone (Vd) compared to Bortezomib and Dexamethasone (Vd), then Bortezomib monotherapy when used to treat Multiple myeloma (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the PFS outcome of Bortezomib and Dexamethasone (Vd) versus Bortezomib and Dexamethasone (Vd), then Bortezomib monotherapy in treating Multiple myeloma (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the PFS results of Bortezomib and Dexamethasone (Vd) compared to Bortezomib and Dexamethasone (Vd), then Bortezomib monotherapy for Multiple myeloma (Non-curative therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of Bortezomib and Dexamethasone (Vd), then Bortezomib monotherapy compared to Bortezomib and Dexamethasone (Vd) when used to treat Multiple myeloma (Non-curative therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Multiple myeloma, Context: Non-curative therapy, Endpoint: PFS, Treatment 1: Bortezomib and Dexamethasone (Vd), Treatment 2: Bortezomib and Dexamethasone (Vd), then Bortezomib monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Multiple myeloma, Context: Non-curative therapy Treatment: ",superior,inferior,no difference,2017,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Classical Hodgkin lymphoma, Context: Induction therapy, Endpoint: ORR, Treatment 1: Vinblastine monotherapy, Treatment 2: Cyclophosphamide monotherapy Response:",Vinblastine monotherapy superior to Cyclophosphamide monotherapy for Classical Hodgkin lymphoma (Induction therapy) [endpoint: ORR],False 2017-11-09,"Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Adjuvant chemotherapy for resected early-stage non-small-cell lung cancer (NSCLC) provides a modest survival benefit. Bevacizumab, a monoclonal antibody directed against VEGF, improves outcomes when added to platinum-based chemotherapy in advanced-stage non-squamous NSCLC. We aimed to evaluate the addition of bevacizumab to adjuvant chemotherapy in early-stage resected NSCLC. We did an open-label, randomised, phase 3 trial of adult patients (aged ≥18 years) with an Eastern Cooperative Oncology Group performance status of 0 or 1 and who had completely resected stage IB (≥4 cm) to IIIA (defined by the American Joint Committee on Cancer 6th edition) NSCLC. We enrolled patients from across the US National Clinical Trials Network, including patients from the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) affiliates in Europe and from the Canadian Cancer Trials Group, within 6-12 weeks of surgery. The chemotherapy regimen for each patient was selected before randomisation and administered intravenously; it consisted of four 21-day cycles of cisplatin (75 mg/m2 on day 1 in all regimens) in combination with investigator's choice of vinorelbine (30 mg/m2 on days 1 and 8), docetaxel (75 mg/m2 on day 1), gemcitabine (1200 mg/m2 on days 1 and 8), or pemetrexed (500 mg/m2 on day 1). Patients in the bevacizumab group received bevacizumab 15 mg/kg intravenously every 21 days starting with cycle 1 of chemotherapy and continuing for 1 year. We randomly allocated patients (1:1) to group A (chemotherapy alone) or group B (chemotherapy plus bevacizumab), centrally, using permuted blocks sizes and stratified by chemotherapy regimen, stage of disease, histology, and sex. No one was masked to treatment assignment, except the Data Safety and Monitoring Committee. The primary endpoint was overall survival, analysed by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00324805. Between June 1, 2007, and Sept 20, 2013, 1501 patients were enrolled and randomly assigned to the two treatment groups: 749 to group A (chemotherapy alone) and 752 to group B (chemotherapy plus bevacizumab). 383 (26%) of 1458 patients (with complete staging information) had stage IB, 636 (44%) had stage II, and 439 (30%) had stage IIIA disease (stage of disease data were missing for 43 patients). Squamous cell histology was reported for 422 (28%) of 1501 patients. All four cisplatin-based chemotherapy regimens were used: 377 (25%) patients received vinorelbine, 343 (23%) received docetaxel, 283 (19%) received gemcitabine, and 497 (33%) received pemetrexed. At a median follow-up of 50·3 months (IQR 32·9-68·0), the estimated median overall survival in group A has not been reached, and in group B was 85·8 months (95% CI 74·9 to not reached); hazard ratio (group B vs group A) 0·99 (95% CI 0·82-1·19; p=0·90). Grade 3-5 toxicities of note (all attributions) that were reported more frequently in group B (the bevacizumab group) than in group A (chemotherapy alone) were overall worst grade (ie, all grade 3-5 toxicities; 496 [67%] of 738 in group A vs 610 [83%] of 735 in group B), hypertension (60 [8%] vs 219 [30%]), and neutropenia (241 [33%] vs 275 [37%]). The number of deaths on treatment did not differ between the groups (15 deaths in group A vs 19 in group B). Of these deaths, three in group A and ten in group B were considered at least possibly related to treatment. Addition of bevacizumab to adjuvant chemotherapy did not improve overall survival for patients with surgically resected early-stage NSCLC. Bevacizumab does not have a role in this setting and should not be considered as an adjuvant therapy for patients with resected early-stage NSCLC. National Cancer Institute of the National Institutes of Health.",29129443,Cisplatin and Docetaxel (DC),"Cisplatin and Docetaxel (DC) and Bevacizumab|Cisplatin and Gemcitabine (GC) and Bevacizumab|Cisplatin, Pemetrexed, Bevacizumab|Cisplatin and Vinorelbine (CVb) and Bevacizumab",Non-small cell lung cancer,Adjuvant therapy,OS,Primary,no difference,"Cisplatin and Docetaxel (DC) no difference to Cisplatin and Docetaxel (DC) and Bevacizumab|Cisplatin and Gemcitabine (GC) and Bevacizumab|Cisplatin, Pemetrexed, Bevacizumab|Cisplatin and Vinorelbine (CVb) and Bevacizumab for Non-small cell lung cancer (Adjuvant therapy) [endpoint: OS]","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Cisplatin and Docetaxel (DC) compared to Cisplatin and Docetaxel (DC) and Bevacizumab|Cisplatin and Gemcitabine (GC) and Bevacizumab|Cisplatin, Pemetrexed, Bevacizumab|Cisplatin and Vinorelbine (CVb) and Bevacizumab when used to treat Non-small cell lung cancer (Adjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Cisplatin and Docetaxel (DC) versus Cisplatin and Docetaxel (DC) and Bevacizumab|Cisplatin and Gemcitabine (GC) and Bevacizumab|Cisplatin, Pemetrexed, Bevacizumab|Cisplatin and Vinorelbine (CVb) and Bevacizumab in treating Non-small cell lung cancer (Adjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Cisplatin and Docetaxel (DC) compared to Cisplatin and Docetaxel (DC) and Bevacizumab|Cisplatin and Gemcitabine (GC) and Bevacizumab|Cisplatin, Pemetrexed, Bevacizumab|Cisplatin and Vinorelbine (CVb) and Bevacizumab for Non-small cell lung cancer (Adjuvant therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Cisplatin and Docetaxel (DC) and Bevacizumab|Cisplatin and Gemcitabine (GC) and Bevacizumab|Cisplatin, Pemetrexed, Bevacizumab|Cisplatin and Vinorelbine (CVb) and Bevacizumab compared to Cisplatin and Docetaxel (DC) when used to treat Non-small cell lung cancer (Adjuvant therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Non-small cell lung cancer, Context: Adjuvant therapy, Endpoint: OS, Treatment 1: Cisplatin and Docetaxel (DC), Treatment 2: Cisplatin and Docetaxel (DC) and Bevacizumab|Cisplatin and Gemcitabine (GC) and Bevacizumab|Cisplatin, Pemetrexed, Bevacizumab|Cisplatin and Vinorelbine (CVb) and Bevacizumab Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Non-small cell lung cancer, Context: Adjuvant therapy Treatment: ",superior,inferior,no difference,2017,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Classical Hodgkin lymphoma, Context: Induction therapy, Endpoint: ORR, Treatment 1: Vinblastine monotherapy, Treatment 2: Cyclophosphamide monotherapy Response:",Vinblastine monotherapy superior to Cyclophosphamide monotherapy for Classical Hodgkin lymphoma (Induction therapy) [endpoint: ORR],False 2018-02-23,"Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole. We investigated the schedule and type of aromatase inhibitors to be used as adjuvant treatment for hormone receptor-positive early breast cancer. FATA-GIM3 is a multicentre, open-label, randomised, phase 3 trial of six different treatments in postmenopausal women with hormone receptor-positive early breast cancer. Eligible patients had histologically confirmed invasive hormone receptor-positive breast cancer that had been completely removed by surgery, any pathological tumour size, and axillary nodal status. Key exclusion criteria were hormone replacement therapy, recurrent or metastatic disease, previous treatment with tamoxifen, and another malignancy in the previous 10 years. Patients were randomly assigned in an equal ratio to one of six treatment groups: oral anastrozole (1 mg per day), exemestane (25 mg per day), or letrozole (2·5 mg per day) tablets upfront for 5 years (upfront strategy) or oral tamoxifen (20 mg per day) for 2 years followed by oral administration of one of the three aromatase inhibitors for 3 years (switch strategy). Randomisation was done by a computerised minimisation procedure stratified for oestrogen receptor, progesterone receptor, and HER2 status; previous chemotherapy; and pathological nodal status. Neither the patients nor the physicians were masked to treatment allocation. The primary endpoint was disease-free survival. The minimum cutoff to declare superiority of the upfront strategy over the switch strategy was assumed to be a 2% difference in disease-free survival at 5 years. Primary efficacy analyses were done by intention to treat; safety analyses included all patients for whom at least one safety case report form had been completed. Follow-up is ongoing. This trial is registered with the European Clinical Trials Database, number 2006-004018-42, and ClinicalTrials.gov, number NCT00541086. Between March 9, 2007, and July 31, 2012, 3697 patients were enrolled into the study. After a median follow-up of 60 months (IQR 46-72), 401 disease-free survival events were reported, including 211 (11%) of 1850 patients allocated to the switch strategy and 190 (10%) of 1847 patients allocated to upfront treatment. 5-year disease-free survival was 88·5% (95% CI 86·7-90·0) with the switch strategy and 89·8% (88·2-91·2) with upfront treatment (hazard ratio 0·89, 95% CI 0·73-1·08; p=0·23). 5-year disease-free survival was 90·0% (95% CI 87·9-91·7) with anastrozole (124 events), 88·0% (85·8-89·9) with exemestane (148 events), and 89·4% (87·3 to 91·1) with letrozole (129 events; p=0·24). No unexpected serious adverse reactions or treatment-related deaths occurred. Musculoskeletal side-effects were the most frequent grade 3-4 events, reported in 130 (7%) of 1761 patients who received the switch strategy and 128 (7%) of 1766 patients who received upfront treatment. Grade 1 musculoskeletal events were more frequent with the upfront schedule than with the switch schedule (924 [52%] of 1766 patients vs 745 [42%] of 1761 patients). All other grade 3-4 adverse events occurred in less than 2% of patients in either group. 5 years of treatment with aromatase inhibitors was not superior to 2 years of tamoxifen followed by 3 years of aromatase inhibitors. None of the three aromatase inhibitors was superior to the others in terms of efficacy. Therefore, patient preference, tolerability, and financial constraints should be considered when deciding the optimal treatment approach in this setting. Italian Drug Agency.",29482983,Tamoxifen-Exemestane,Tamoxifen-Letrozole,Breast cancer,Adjuvant therapy,DFS,Primary,no difference,Tamoxifen-Exemestane no difference to Tamoxifen-Letrozole for Breast cancer (Adjuvant therapy) [endpoint: DFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the DFS outcome of Tamoxifen-Exemestane compared to Tamoxifen-Letrozole when used to treat Breast cancer (Adjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the DFS outcome of Tamoxifen-Exemestane versus Tamoxifen-Letrozole in treating Breast cancer (Adjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the DFS results of Tamoxifen-Exemestane compared to Tamoxifen-Letrozole for Breast cancer (Adjuvant therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the DFS outcome of Tamoxifen-Letrozole compared to Tamoxifen-Exemestane when used to treat Breast cancer (Adjuvant therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer, Context: Adjuvant therapy, Endpoint: DFS, Treatment 1: Tamoxifen-Exemestane, Treatment 2: Tamoxifen-Letrozole Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Breast cancer, Context: Adjuvant therapy Treatment: ",superior,inferior,no difference,2018,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer (Metastatic), Context: Non-curative therapy, Endpoint: PFS, Treatment 1: Tamoxifen monotherapy, Treatment 2: Bilateral oophorectomy monotherapy Response:",Tamoxifen monotherapy superior to Bilateral oophorectomy monotherapy for Breast cancer (Metastatic) (Non-curative therapy) [endpoint: PFS],False 2018-04-03,"Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Tivantinib (ARQ 197), a selective, oral MET inhibitor, improved overall survival and progression-free survival compared with placebo in a randomised phase 2 study in patients with high MET expression (MET-high) hepatocellular carcinoma previously treated with sorafenib. The aim of this phase 3 study was to confirm the results of the phase 2 trial. We did a phase 3, randomised, double-blind, placebo-controlled study in 90 centres in Australia, the Americas, Europe, and New Zealand. Eligible patients were 18 years or older and had unresectable, histologically confirmed, hepatocellular carcinoma, an Eastern Cooperative Oncology Group performance status of 0-1, high MET expression (MET-high; staining intensity score ≥2 in ≥50% of tumour cells), Child-Pugh A cirrhosis, and radiographically-confirmed disease progression after receiving sorafenib-containing systemic therapy. We randomly assigned patients (2:1) in block sizes of three using a computer-generated randomisation sequence to receive oral tivantinib (120 mg twice daily) or placebo (twice daily); patients were stratified by vascular invasion, extrahepatic spread, and α-fetoprotein concentrations (≤200 ng/mL or >200 ng/mL). The primary endpoint was overall survival in the intention-to-treat population. Efficacy analyses were by intention to treat and safety analyses were done in all patients who received any amount of study drug. This study is registered with ClinicalTrials.gov, number NCT01755767. Between Dec 27, 2012, and Dec 10, 2015, 340 patients were randomly assigned to receive tivantinib (n=226) or placebo (n=114). At a median follow-up of 18·1 months (IQR 14·1-23·1), median overall survival was 8·4 months (95% CI 6·8-10·0) in the tivantinib group and 9·1 months (7·3-10·4) in the placebo group (hazard ratio 0·97; 95% CI 0·75-1·25; p=0·81). Grade 3 or worse treatment-emergent adverse events occurred in 125 (56%) of 225 patients in the tivantinib group and in 63 (55%) of 114 patients in the placebo group, with the most common being ascites (16 [7%] patients]), anaemia (11 [5%] patients), abdominal pain (nine [4%] patients), and neutropenia (nine [4%] patients) in the tivantinib group. 50 (22%) of 226 patients in the tivantinib group and 18 (16%) of 114 patients in the placebo group died within 30 days of the last dose of study medication, and general deterioration (eight [4%] patients) and hepatic failure (four [2%] patients) were the most common causes of death in the tivantinib group. Three (1%) of 225 patients in the tivantinib group died from a treatment-related adverse event (one sepsis, one anaemia and acute renal failure, and one acute coronary syndrome). Tivantinib did not improve overall survival compared with placebo in patients with MET-high advanced hepatocellular carcinoma previously treated with sorafenib. Although this METIV-HCC trial was negative, the study shows the feasibility of doing integral tissue biomarker studies in patients with advanced hepatocellular carcinoma. Additional randomised studies are needed to establish whether MET inhibition could be a potential therapy for some subsets of patients with advanced hepatocellular carcinoma. ArQule Inc and Daiichi Sankyo (Daiichi Sankyo Group).",29625879,Placebo,Tivantinib monotherapy,Hepatocellular carcinoma,Non-curative second-line therapy,OS,Primary,no difference,Placebo no difference to Tivantinib monotherapy for Hepatocellular carcinoma (Non-curative second-line therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Placebo compared to Tivantinib monotherapy when used to treat Hepatocellular carcinoma (Non-curative second-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Placebo versus Tivantinib monotherapy in treating Hepatocellular carcinoma (Non-curative second-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Placebo compared to Tivantinib monotherapy for Hepatocellular carcinoma (Non-curative second-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Tivantinib monotherapy compared to Placebo when used to treat Hepatocellular carcinoma (Non-curative second-line therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Hepatocellular carcinoma, Context: Non-curative second-line therapy, Endpoint: OS, Treatment 1: Placebo, Treatment 2: Tivantinib monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Hepatocellular carcinoma, Context: Non-curative second-line therapy Treatment: ",superior,inferior,no difference,2018,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Colon cancer, Context: Adjuvant therapy, Endpoint: DFS, Treatment 1: Observation, Treatment 2: Fluorouracil monotherapy Response:",Observation inferior to Fluorouracil monotherapy for Colon cancer (Adjuvant therapy) [endpoint: DFS],False 2018-05-10,"Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). Purpose Venous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous low molecular weight heparin has been standard treatment for such patients. The purpose of this study was to assess if an oral factor Xa inhibitor, rivaroxaban, would offer an alternative treatment for VTE in patients with cancer. Patient and Methods In this multicenter, randomized, open-label, pilot trial in the United Kingdom, patients with active cancer who had symptomatic pulmonary embolism (PE), incidental PE, or symptomatic lower-extremity proximal deep vein thrombosis (DVT) were recruited. Allocation was to dalteparin (200 IU/kg daily during month 1, then 150 IU/kg daily for months 2-6) or rivaroxaban (15 mg twice daily for 3 weeks, then 20 mg once daily for a total of 6 months). The primary outcome was VTE recurrence over 6 months. Safety was assessed by major bleeding and clinically relevant nonmajor bleeding (CRNMB). A sample size of 400 patients would provide estimates of VTE recurrence to within ± 4.5%, assuming a VTE recurrence rate at 6 months of 10%. Results A total of 203 patients were randomly assigned to each group, 58% of whom had metastases. Twenty-six patients experienced recurrent VTE (dalteparin, n = 18; rivaroxaban, n = 8). The 6-month cumulative VTE recurrence rate was 11% (95% CI, 7% to 16%) with dalteparin and 4% (95% CI, 2% to 9%) with rivaroxaban (hazard ratio [HR], 0.43; 95% CI, 0.19 to 0.99). The 6-month cumulative rate of major bleeding was 4% (95% CI, 2% to 8%) for dalteparin and 6% (95% CI, 3% to 11%) for rivaroxaban (HR, 1.83; 95% CI, 0.68 to 4.96). Corresponding rates of CRNMB were 4% (95% CI, 2% to 9%) and 13% (95% CI, 9% to 19%), respectively (HR, 3.76; 95% CI, 1.63 to 8.69). Conclusion Rivaroxaban was associated with relatively low VTE recurrence but higher CRNMB compared with dalteparin.",29746227,Dalteparin monotherapy,Rivaroxaban monotherapy,Venous thromboembolism,All lines of therapy,rate of VTE recurrence over 6 months,Primary,superior,Dalteparin monotherapy superior to Rivaroxaban monotherapy for Venous thromboembolism (All lines of therapy) [endpoint: rate of VTE recurrence over 6 months],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the rate of VTE recurrence over 6 months outcome of Dalteparin monotherapy compared to Rivaroxaban monotherapy when used to treat Venous thromboembolism (All lines of therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the rate of VTE recurrence over 6 months outcome of Dalteparin monotherapy versus Rivaroxaban monotherapy in treating Venous thromboembolism (All lines of therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the rate of VTE recurrence over 6 months results of Dalteparin monotherapy compared to Rivaroxaban monotherapy for Venous thromboembolism (All lines of therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the rate of VTE recurrence over 6 months outcome of Rivaroxaban monotherapy compared to Dalteparin monotherapy when used to treat Venous thromboembolism (All lines of therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Venous thromboembolism, Context: All lines of therapy, Endpoint: rate of VTE recurrence over 6 months, Treatment 1: Dalteparin monotherapy, Treatment 2: Rivaroxaban monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Venous thromboembolism, Context: All lines of therapy Treatment: ",superior,inferior,no difference,2018,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 2019-02-07,"The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)-cT3 rectal cancer. Capecitabine-based radiochemotherapy (cbRCT) is standard for preoperative long-course radiochemotherapy of locally advanced rectal cancer. This prospective, parallel-group, randomised controlled trial investigated two intensification regimens. cT4 lesions were excluded. pathological outcome (TRG 1-2) among arms. Low-located cT2N0-2M0, cT3N0-2M0 (up to 12 cm from anal verge) presentations were treated with cbRCT randomly intensified by either radiotherapy boost (Xelac arm) or multidrug concomitant chemotherapy (Xelox arm). Xelac: concomitant boost to bulky site (45 Gy/1.8 Gy/die, 5 sessions/week to the pelvis, +10 Gy at 1 Gy twice/week to the bulky) plus concurrent capecitabine (1650 mg/mq/die). Xelox: 45 Gy to the pelvis + 5.4 Gy/1.8 Gy/die, 5 sessions/week to the bulky site + concurrent capecitabine (1300 mg/mq/die) and oxaliplatin (130 mg/mq on days 1,19,38). Surgery was planned 7-9 weeks after radiochemotherapy. From June 2005 to September 2013, 534 patients were analysed: 280 in Xelac, 254 in Xelox arm. Xelox arm presented higher G ≥ 3 haematologic (p = 0.01) and neurologic toxicity (p < 0.001). Overall, 98.5% patients received curative surgery. The tumour regression grade distribution did not differ between arms (p = 0.102). TRG 1+2 rate significantly differed: Xelac arm 61.7% vs. Xelox 52.3% (p = 0.039). Pathological complete response (ypT0N0) rates were 24.4 and 23.8%, respectively (p non-significant). Median follow-up:5.62 years. Five-year disease-free survival rate were 74.7% (Xelac) and 73.8% (Xelox), respectively (p = 0.444). Five-year overall survival rate were 80.4% (Xelac) and 85.5% (Xelox), respectively (p = 0.155). Xelac arm significantly obtained higher TRG1-2 rates. No differences were found about clinical outcome. Because of efficacy on TRG, inferior toxicity and good compliance, Xelac schedules or similar radiotherapy dose intensification schemes could be considered as reference treatments for cT3 lesions.",31005204,Capecitabine and RT,CapeOx and RT,Rectal cancer,Neoadjuvant therapy,Could not be determined,Undesignated,no difference,Capecitabine and RT no difference to CapeOx and RT for Rectal cancer (Neoadjuvant therapy) [endpoint: Could not be determined],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the efficacy of Capecitabine and RT compared to CapeOx and RT when used to treat Rectal cancer (Neoadjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the effectiveness of Capecitabine and RT versus CapeOx and RT in treating Rectal cancer (Neoadjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the comparative efficacy of Capecitabine and RT and CapeOx and RT for managing Rectal cancer (Neoadjuvant therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the efficacy of CapeOx and RT compared to Capecitabine and RT when used to treat Rectal cancer (Neoadjuvant therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Rectal cancer, Context: Neoadjuvant therapy, Treatment 1: Capecitabine and RT, Treatment 2: CapeOx and RT Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Rectal cancer, Context: Neoadjuvant therapy Treatment: ",superior,inferior,no difference,2019,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Colon cancer, Context: Adjuvant therapy, Endpoint: DFS, Treatment 1: Observation, Treatment 2: Fluorouracil monotherapy Response:",Observation inferior to Fluorouracil monotherapy for Colon cancer (Adjuvant therapy) [endpoint: DFS],False 2019-06-15,"Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial. Anthracycline dose optimisation in the treatment of diffuse large B-cell lymphoma has rarely been tested. We aimed to find out whether R-CEOP70 was non-inferior to R-CHOP50 with less cardiotoxicity, and whether R-CEOP90 had a superior efficacy to R-CHOP50 or R-CEOP70 with acceptable toxic effects. In this multicentre, phase 3, randomised, controlled study (NHL-001), patients with newly diagnosed diffuse large B-cell lymphoma or follicular lymphoma grade 3B were enrolled from 20 centres of the Multicenter Hematology-Oncology Programs Evaluation System in China. Young patients (16-60 years) were randomly assigned 1:1:1 (block size of six) to six courses of R-CHOP50, R-CEOP70, or R-CEOP90, and older patients (61-80 years) were assigned 1:1 (block size of four) to R-CHOP50 or R-CEOP70. Patients were randomly assigned using computer-assisted permuted-block randomisation. Investigators and patients were not masked to treatment assignment. In the R-CHOP50 group, patients were given rituximab 375 mg/m2 intravenously on day 0, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1·4 mg/m2 (maximum dose 2 mg) intravenously on day 1, and prednisone 60 mg/m2 (maximum dose 100 mg) orally from day 1-5; in the R-CEOP70 group, epirubicin 70 mg/m2 replaced doxorubicin; and in the R-CEOP90 group, high dose epirubicin 90 mg/m2 replaced doxorubicin. All patients received two additional courses of rituximab 375 mg/m2 intravenously every 21 days. Consolidation radiotherapy was given to patients with bulky disease at diagnosis or residual disease at the end of treatment. The primary endpoint was 2-year progression-free survival. The non-inferiority margin for R-CEOP70 versus R-CHOP50 was defined by hazard ratio [HR] as the upper limit of its 95% CI being no greater than 1·50. Analysis of efficacy and safety were of the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT01852435. From May 15, 2013, to March 16, 2016, a total of 648 patients were enrolled, including 404 (62%) young patients (R-CHOP50 [n=135], R-CEOP70 [n=134], or R-CEOP90 [n=135]), and 244 (38%) older patients (R-CHOP50 [n=122] or R-CEOP70 [n=122]). Four patients were excluded from the study for consent withdrawal and one patient for misdiagnosis before treatment. The 2-year progression-free survival in the R-CHOP50 group was 72·5% (95% CI 66·6-77·6) and in the R-CEOP70 group was 72·4% ([66·5-77·5]; HR 1·00 [0·73-1·38]; p=0·99). The non-inferiority was met and adverse events were similar between the two groups. Fewer patients in the R-CEOP70 group (14 [13%] of 110) presented with over 10% decrease in left ventricular ejection fraction (LVEF) than those in the R-CHOP50 group (31 [29%] of 108) at 3 years after remission. For young patients, the 2-year progression-free survival in the R-CEOP90 group was 88·8% (82·1-93·1) and was significantly improved compared with the R-CHOP50 group (75·9% [67·7-82·3]; 0·44 [0·25-0·76]; p=0·0047) and the R-CEOP70 group (77·4% [69·4-83·7%]; 0·49 [0·27-0·86]; p=0·017). Grade 3-4 neutropenia occurred more frequently in the R-CEOP90 group (97 [72%] of 134) than in the R-CHOP50 group (87 [65%] of 133) and R-CEOP70 group (84 [63%] of 133) in young patients but without further increase of clinically significant infections. Fewer patients in the R-CEOP70 group (7 [11%] of 66) and in the R-CEOP90 group (10 [13%] of 79) presented with more than 10% decrease in LVEF than those in the R-CHOP50 group (17 [26%] of 66) at 3 years after remission. R-CEOP70 could serve as an alternative regimen to R-CHOP50 with mild long-term cardiotoxicity. Young patients with diffuse large B-cell lymphoma might benefit from high-dose epirubicin. Epirubicin is an alternative drug to doxorubicin in regular R-CHOP with mild long-term cardiotoxicity. National Natural Science Foundation of China, National Key Research and Development Program, Shanghai Commission of Science and Technology, Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant Support, Multicenter Clinical Research Project by Shanghai Jiao Tong University School of Medicine, Clinical Research Plan of Shanghai Hospital Development Center, and Chang Jiang Scholars Program.",31126528,R-CHOP,R-CEOP90,Diffuse large B-cell lymphoma,Induction therapy,PFS,Primary,inferior,R-CHOP inferior to R-CEOP90 for Diffuse large B-cell lymphoma (Induction therapy) [endpoint: PFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of R-CHOP compared to R-CEOP90 when used to treat Diffuse large B-cell lymphoma (Induction therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the PFS outcome of R-CHOP versus R-CEOP90 in treating Diffuse large B-cell lymphoma (Induction therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the PFS results of R-CHOP compared to R-CEOP90 for Diffuse large B-cell lymphoma (Induction therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of R-CEOP90 compared to R-CHOP when used to treat Diffuse large B-cell lymphoma (Induction therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Diffuse large B-cell lymphoma, Context: Induction therapy, Endpoint: PFS, Treatment 1: R-CHOP, Treatment 2: R-CEOP90 Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Diffuse large B-cell lymphoma, Context: Induction therapy Treatment: ",superior,inferior,no difference,2019,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Multiple myeloma, Context: Non-curative therapy, Endpoint: OS, Treatment 1: Placebo, Treatment 2: Urethane monotherapy Response:",Placebo superior to Urethane monotherapy for Multiple myeloma (Non-curative therapy) [endpoint: OS],False 2019-12-27,"Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L). Patients with non-small-cell lung cancer (NSCLC) have been shown to benefit from maintenance therapy. COMPASS evaluated the efficacy and safety of bevacizumab with or without pemetrexed as continuation maintenance therapy after carboplatin, pemetrexed, and bevacizumab induction therapy. Patients with untreated advanced nonsquamous NSCLC without confirmed EGFR 19 deletion or L858R mutation received first-line therapy with carboplatin area under the curve 6, pemetrexed 500 mg/m2, and bevacizumab 15 mg/kg once every 3 weeks for 4 cycles. Patients without disease progression during the induction therapy were randomly assigned 1:1 for maintenance therapy with pemetrexed 500 mg/m2 plus bevacizumab 15 mg/kg or bevacizumab 15 mg/kg once every 3 weeks until disease progression or unacceptable toxicity. The primary end point was overall survival (OS) after random assignment. Between September 2010 and September 2015, 907 patients received induction therapy. Of those, 599 were randomly assigned: 298 received pemetrexed plus bevacizumab, and 301 received bevacizumab. The median OS was 23.3 v 19.6 months (hazard ratio [HR], 0.87; 95% CI, 0.73 to 1.05; 1-sided stratified log-rank P = .069). In the wild-type EGFR subset, the OS HR was 0.82 (95% CI, 0.68 to 0.99; 1-sided unstratified log-rank P = .020). The median progression-free survival (PFS) was 5.7 v 4.0 months (HR, 0.67; 95% CI, 0.57 to 0.79; 2-sided log-rank P < .001). The safety data were consistent with previous reports of treatment regimens. In terms of the primary end point of OS, no statistically significant benefit was observed; however, PFS in the total patient population and OS in patients with wild-type EGFR was prolonged with the addition of pemetrexed to bevacizumab maintenance therapy.",31880966,Pemetrexed and Bevacizumab,Bevacizumab monotherapy,Non-small cell lung cancer nonsquamous,Non-curative first-line maintenance therapy,OS,Primary,superior,Pemetrexed and Bevacizumab superior to Bevacizumab monotherapy for Non-small cell lung cancer nonsquamous (Non-curative first-line maintenance therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Pemetrexed and Bevacizumab compared to Bevacizumab monotherapy when used to treat Non-small cell lung cancer nonsquamous (Non-curative first-line maintenance therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Pemetrexed and Bevacizumab versus Bevacizumab monotherapy in treating Non-small cell lung cancer nonsquamous (Non-curative first-line maintenance therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Pemetrexed and Bevacizumab compared to Bevacizumab monotherapy for Non-small cell lung cancer nonsquamous (Non-curative first-line maintenance therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Bevacizumab monotherapy compared to Pemetrexed and Bevacizumab when used to treat Non-small cell lung cancer nonsquamous (Non-curative first-line maintenance therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Non-small cell lung cancer nonsquamous, Context: Non-curative first-line maintenance therapy, Endpoint: OS, Treatment 1: Pemetrexed and Bevacizumab, Treatment 2: Bevacizumab monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Non-small cell lung cancer nonsquamous, Context: Non-curative first-line maintenance therapy Treatment: ",superior,inferior,no difference,2019,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],True 2020-02-27,"Pembrolizumab for Early Triple-Negative Breast Cancer. Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patients with early triple-negative breast cancer who have a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery is unclear. In this phase 3 trial, we randomly assigned (in a 2:1 ratio) patients with previously untreated stage II or stage III triple-negative breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 mg) every 3 weeks plus paclitaxel and carboplatin (784 patients; the pembrolizumab-chemotherapy group) or placebo every 3 weeks plus paclitaxel and carboplatin (390 patients; the placebo-chemotherapy group); the two groups then received an additional four cycles of pembrolizumab or placebo, and both groups received doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide. After definitive surgery, the patients received adjuvant pembrolizumab or placebo every 3 weeks for up to nine cycles. The primary end points were a pathological complete response at the time of definitive surgery and event-free survival in the intention-to-treat population. At the first interim analysis, among the first 602 patients who underwent randomization, the percentage of patients with a pathological complete response was 64.8% (95% confidence interval [CI], 59.9 to 69.5) in the pembrolizumab-chemotherapy group and 51.2% (95% CI, 44.1 to 58.3) in the placebo-chemotherapy group (estimated treatment difference, 13.6 percentage points; 95% CI, 5.4 to 21.8; P<0.001). After a median follow-up of 15.5 months (range, 2.7 to 25.0), 58 of 784 patients (7.4%) in the pembrolizumab-chemotherapy group and 46 of 390 patients (11.8%) in the placebo-chemotherapy group had disease progression that precluded definitive surgery, had local or distant recurrence or a second primary tumor, or died from any cause (hazard ratio, 0.63; 95% CI, 0.43 to 0.93). Across all treatment phases, the incidence of treatment-related adverse events of grade 3 or higher was 78.0% in the pembrolizumab-chemotherapy group and 73.0% in the placebo-chemotherapy group, including death in 0.4% (3 patients) and 0.3% (1 patient), respectively. Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among those who received placebo plus neoadjuvant chemotherapy. (Funded by Merck Sharp & Dohme [a subsidiary of Merck]; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.). Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. The addition of pembrolizumab to neoadjuvant chemotherapy led to a significantly higher percentage of patients with early triple-negative breast cancer having a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery in an earlier analysis of this phase 3 trial of neoadjuvant and adjuvant therapy. The primary results regarding event-free survival in this trial have not been reported. We randomly assigned, in a 2:1 ratio, patients with previously untreated stage II or III triple-negative breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 mg) or placebo every 3 weeks plus paclitaxel and carboplatin, followed by four cycles of pembrolizumab or placebo plus doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide. After definitive surgery, patients received adjuvant pembrolizumab (pembrolizumab-chemotherapy group) or placebo (placebo-chemotherapy group) every 3 weeks for up to nine cycles. The primary end points were pathological complete response (the results for which have been reported previously) and event-free survival, defined as the time from randomization to the date of disease progression that precluded definitive surgery, local or distant recurrence, occurrence of a second primary cancer, or death from any cause. Safety was also assessed. Of the 1174 patients who underwent randomization, 784 were assigned to the pembrolizumab-chemotherapy group and 390 to the placebo-chemotherapy group. The median follow-up at this fourth planned interim analysis (data cutoff, March 23, 2021) was 39.1 months. The estimated event-free survival at 36 months was 84.5% (95% confidence interval [CI], 81.7 to 86.9) in the pembrolizumab-chemotherapy group, as compared with 76.8% (95% CI, 72.2 to 80.7) in the placebo-chemotherapy group (hazard ratio for event or death, 0.63; 95% CI, 0.48 to 0.82; P<0.001). Adverse events occurred predominantly during the neoadjuvant phase and were consistent with the established safety profiles of pembrolizumab and chemotherapy. In patients with early triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab after surgery, resulted in significantly longer event-free survival than neoadjuvant chemotherapy alone. (Funded by Merck Sharp and Dohme, a subsidiary of Merck; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.). Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study. In KEYNOTE-522 (NCT03036488), neoadjuvant pembrolizumab plus chemotherapy and then adjuvant pembrolizumab significantly improved pathological complete response and event-free survival vs neoadjuvant chemotherapy in early-stage triple-negative breast cancer (TNBC). We report patient-reported outcomes (PROs) from KEYNOTE-522. Patients were randomized 2:1 to neoadjuvant pembrolizumab 200 mg or placebo every 3 weeks, plus 4 cycles of paclitaxel plus carboplatin and then 4 cycles of doxorubicin (or epirubicin) plus cyclophosphamide. After surgery, patients received adjuvant pembrolizumab or placebo for up to 9 cycles. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and EORTC Breast Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR23) were prespecified secondary objectives. Between-group differences in least squares (LS) mean change from baseline (day 1 of cycle 1 in both neoadjuvant and adjuvant phases) to the prespecified latest time point with at least 60% completion and at least 80% compliance were assessed using a longitudinal model (no alpha error assigned). Week 21 (neoadjuvant phase) and week 24 (adjuvant phase) were the latest time points at which completion/compliance rates were ≥60%/80%. In the neoadjuvant phase, between-group differences (pembrolizumab plus chemotherapy [n = 762] vs placebo plus chemotherapy [n = 383]) in LS mean change from baseline to week 21 in QLQ-C30 global health status/quality of life (GHS/QoL), emotional functioning, and physical functioning were -1.04 (95% confidence interval = -3.46 to 1.38), -0.69 (95% CI = -3.13 to 1.75), and -2.85 (95% CI = -5.11 to -0.60), respectively. In the adjuvant phase, between-group differences (pembrolizumab [n = 539] vs placebo [n = 308]) in LS mean change from baseline to week 24 were -0.41 (95% CI = -2.60 to 1.77), -0.60 (95% CI = -2.99 to 1.79), and -1.57 (95% CI = -3.36 to 0.21). No substantial differences in PRO assessments were observed between neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab vs neoadjuvant placebo plus chemotherapy in early-stage TNBC. ClinicalTrials.gov, NCT03036488. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the addition of pembrolizumab to platinum-containing chemotherapy. Here we report the final results for overall survival. We randomly assigned, in a 2:1 ratio, patients with previously untreated stage II or III triple-negative breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 mg) or placebo every 3 weeks plus paclitaxel and carboplatin, followed by four cycles of pembrolizumab or placebo plus doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide. After definitive surgery, patients received adjuvant pembrolizumab (pembrolizumab-chemotherapy group) or placebo (placebo-chemotherapy group) every 3 weeks for up to nine cycles. The primary end points were pathological complete response and event-free survival. Overall survival was a secondary end point. Of the 1174 patients who underwent randomization, 784 were assigned to the pembrolizumab-chemotherapy group and 390 to the placebo-chemotherapy group. At the data-cutoff date (March 22, 2024), the median follow-up was 75.1 months (range, 65.9 to 84.0). The estimated overall survival at 60 months was 86.6% (95% confidence interval [CI], 84.0 to 88.8) in the pembrolizumab-chemotherapy group, as compared with 81.7% (95% CI, 77.5 to 85.2) in the placebo-chemotherapy group (P = 0.002). Adverse events were consistent with the established safety profiles of pembrolizumab and chemotherapy. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab resulted in a significant improvement, as compared with neoadjuvant chemotherapy alone, in overall survival among patients with early-stage triple-negative breast cancer. (Funded by Merck Sharp and Dohme, a subsidiary of Merck [Rahway, NJ]; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).",32101663;35139274;38913881;39282906,CP-AC and Pembrolizumab|CP-EC and Pembrolizumab,CP-AC,"Breast cancer (Early, Locally Recurrent Unresectable or Metastatic)",Neoadjuvant therapy,EFS,Co-primary,superior,"CP-AC and Pembrolizumab|CP-EC and Pembrolizumab superior to CP-AC for Breast cancer (Early, Locally Recurrent Unresectable or Metastatic) (Neoadjuvant therapy) [endpoint: EFS]","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the EFS outcome of CP-AC and Pembrolizumab|CP-EC and Pembrolizumab compared to CP-AC when used to treat Breast cancer (Early, Locally Recurrent Unresectable or Metastatic) (Neoadjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the EFS outcome of CP-AC and Pembrolizumab|CP-EC and Pembrolizumab versus CP-AC in treating Breast cancer (Early, Locally Recurrent Unresectable or Metastatic) (Neoadjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the EFS results of CP-AC and Pembrolizumab|CP-EC and Pembrolizumab compared to CP-AC for Breast cancer (Early, Locally Recurrent Unresectable or Metastatic) (Neoadjuvant therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the EFS outcome of CP-AC compared to CP-AC and Pembrolizumab|CP-EC and Pembrolizumab when used to treat Breast cancer (Early, Locally Recurrent Unresectable or Metastatic) (Neoadjuvant therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer (Early, Locally Recurrent Unresectable or Metastatic), Context: Neoadjuvant therapy, Endpoint: EFS, Treatment 1: CP-AC and Pembrolizumab|CP-EC and Pembrolizumab, Treatment 2: CP-AC Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Breast cancer (Early, Locally Recurrent Unresectable or Metastatic), Context: Neoadjuvant therapy Treatment: ",superior,inferior,no difference,2020,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 2020-04-28,"Olaparib for Metastatic Castration-Resistant Prostate Cancer. Multiple loss-of-function alterations in genes that are involved in DNA repair, including homologous recombination repair, are associated with response to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition in patients with prostate and other cancers. We conducted a randomized, open-label, phase 3 trial evaluating the PARP inhibitor olaparib in men with metastatic castration-resistant prostate cancer who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone). All the men had a qualifying alteration in prespecified genes with a direct or indirect role in homologous recombination repair. Cohort A (245 patients) had at least one alteration in BRCA1, BRCA2, or ATM; cohort B (142 patients) had alterations in any of 12 other prespecified genes, prospectively and centrally determined from tumor tissue. Patients were randomly assigned (in a 2:1 ratio) to receive olaparib or the physician's choice of enzalutamide or abiraterone (control). The primary end point was imaging-based progression-free survival in cohort A according to blinded independent central review. In cohort A, imaging-based progression-free survival was significantly longer in the olaparib group than in the control group (median, 7.4 months vs. 3.6 months; hazard ratio for progression or death, 0.34; 95% confidence interval, 0.25 to 0.47; P<0.001); a significant benefit was also observed with respect to the confirmed objective response rate and the time to pain progression. The median overall survival in cohort A was 18.5 months in the olaparib group and 15.1 months in the control group; 81% of the patients in the control group who had progression crossed over to receive olaparib. A significant benefit for olaparib was also seen for imaging-based progression-free survival in the overall population (cohorts A and B). Anemia and nausea were the main toxic effects in patients who received olaparib. In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role in homologous recombination repair, olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone. (Funded by AstraZeneca and Merck Sharp & Dohme; PROfound ClinicalTrials.gov number, NCT02987543.). Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician's choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes and whose disease had progressed during previous treatment with a next-generation hormonal agent. The results of the final analysis of overall survival have not yet been reported. In an open-label, phase 3 trial, we randomly assigned patients in a 2:1 ratio to receive olaparib (256 patients) or the physician's choice of enzalutamide or abiraterone plus prednisone as the control therapy (131 patients). Cohort A included 245 patients with at least one alteration in BRCA1, BRCA2, or ATM, and cohort B included 142 patients with at least one alteration in any of the other 12 prespecified genes. Crossover to olaparib was allowed after imaging-based disease progression for patients who met certain criteria. Overall survival in cohort A, a key secondary end point, was analyzed with the use of an alpha-controlled, stratified log-rank test at a data maturity of approximately 60%. The primary and other key secondary end points were reported previously. The median duration of overall survival in cohort A was 19.1 months with olaparib and 14.7 months with control therapy (hazard ratio for death, 0.69; 95% confidence interval [CI], 0.50 to 0.97; P = 0.02). In cohort B, the median duration of overall survival was 14.1 months with olaparib and 11.5 months with control therapy. In the overall population (cohorts A and B), the corresponding durations were 17.3 months and 14.0 months. Overall, 86 of 131 patients (66%) in the control group crossed over to receive olaparib (56 of 83 patients [67%] in cohort A). A sensitivity analysis that adjusted for crossover to olaparib showed hazard ratios for death of 0.42 (95% CI, 0.19 to 0.91) in cohort A, 0.83 (95% CI, 0.11 to 5.98) in cohort B, and 0.55 (95% CI, 0.29 to 1.06) in the overall population. Among men with metastatic castration-resistant prostate cancer who had tumors with at least one alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent, those who were initially assigned to receive olaparib had a significantly longer duration of overall survival than those who were assigned to receive enzalutamide or abiraterone plus prednisone as the control therapy, despite substantial crossover from control therapy to olaparib. (Funded by AstraZeneca and Merck Sharp and Dohme; PROfound ClinicalTrials.gov number, NCT02987543.). Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. The PROfound study showed significantly improved radiographical progression-free survival and overall survival in men with metastatic castration-resistant prostate cancer with alterations in homologous recombination repair genes and disease progression on a previous next-generation hormonal drug who received olaparib then those who received control. We aimed to assess pain and patient-centric health-related quality of life (HRQOL) measures in patients in the trial. In this open-label, randomised, phase 3 study, patients (aged ≥18 years) with metastatic castration-resistant prostate cancer and gene alterations to one of 15 genes (BRCA1, BRCA2, or ATM [cohort A] and BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L [cohort B]) and disease progression after a previous next-generation hormonal drug were randomly assigned (2:1) to receive olaparib tablets (300 mg orally twice daily) or a control drug (enzalutamide tablets [160 mg orally once daily] or abiraterone tablets [1000 mg orally once daily] plus prednisone tablets [5 mg orally twice daily]), stratified by previous taxane use and measurable disease. The primary endpoint (radiographical progression-free survival in cohort A) has been previously reported. The prespecified secondary endpoints reported here are on pain, HRQOL, symptomatic skeletal-related events, and time to first opiate use for cancer-related pain in cohort A. Pain was assessed with the Brief Pain Inventory-Short Form, and HRQOL was assessed with the Functional Assessment of Cancer Therapy-Prostate (FACT-P). All endpoints were analysed in patients in cohort A by modified intention-to-treat. The study is registered with ClinicalTrials.gov, NCT02987543. Between Feb 6, 2017, and June 4, 2019, 245 patients were enrolled in cohort A and received study treatment (162 [66%] in the olaparib group and 83 [34%] in the control group). Median duration of follow-up at data cutoff in all patients was 6·2 months (IQR 2·2-10·4) for the olaparib group and 3·5 months (1·7-4·9) for the control group. In cohort A, median time to pain progression was significantly longer with olaparib than with control (median not reached [95% CI not reached-not reached] with olaparib vs 9·92 months [5·39-not reached] with control; HR 0·44 [95% CI 0·22-0·91]; p=0·019). Pain interference scores were also better in the olaparib group (difference in overall adjusted mean change from baseline score -0·85 [95% CI -1·31 to -0·39]; pnominal=0·0004). Median time to progression of pain severity was not reached in either group (95% CI not reached-not reached for both groups; HR 0·56 [95% CI 0·25-1·34]; pnominal=0·17). In patients who had not used opiates at baseline (113 in the olaparib group, 58 in the control group), median time to first opiate use for cancer-related pain was 18·0 months (95% CI 12·8-not reached) in the olaparib group versus 7·5 months (3·2-not reached) in the control group (HR 0·61; 95% CI 0·38-0·99; pnominal=0·044). The proportion of patients with clinically meaningful improvement in FACT-P total score during treatment was higher for the olaparib group than the control group: 15 (10%) of 152 evaluable patients had a response in the olaparib group compared with one (1%) of evaluable 77 patients in the control group (odds ratio 8·32 [95% CI 1·64-151·84]; pnominal=0·0065). Median time to first symptomatic skeletal-related event was not reached for either treatment group (olaparib group 95% CI not reached-not reached; control group 7·8-not reached; HR 0·37 [95% CI 0·20-0·70]; pnominal=0·0013). Olaparib was associated with reduced pain burden and better-preserved HRQOL compared with the two control drugs in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations who had disease progression after a previous next-generation hormonal drug. Our findings support the clinical benefit of improved radiographical progression-free survival and overall survival identified in PROfound. AstraZeneca and Merck Sharp & Dohme.",32343890;32955174;35157830,Abiraterone monotherapy|Enzalutamide monotherapy,Olaparib monotherapy,Prostate cancer (Metastatic),Non-curative therapy,rPFS,Primary,inferior,Abiraterone monotherapy|Enzalutamide monotherapy inferior to Olaparib monotherapy for Prostate cancer (Metastatic) (Non-curative therapy) [endpoint: rPFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the rPFS outcome of Abiraterone monotherapy|Enzalutamide monotherapy compared to Olaparib monotherapy when used to treat Prostate cancer (Metastatic) (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the rPFS outcome of Abiraterone monotherapy|Enzalutamide monotherapy versus Olaparib monotherapy in treating Prostate cancer (Metastatic) (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the rPFS results of Abiraterone monotherapy|Enzalutamide monotherapy compared to Olaparib monotherapy for Prostate cancer (Metastatic) (Non-curative therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the rPFS outcome of Olaparib monotherapy compared to Abiraterone monotherapy|Enzalutamide monotherapy when used to treat Prostate cancer (Metastatic) (Non-curative therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Prostate cancer (Metastatic), Context: Non-curative therapy, Endpoint: rPFS, Treatment 1: Abiraterone monotherapy|Enzalutamide monotherapy, Treatment 2: Olaparib monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Prostate cancer (Metastatic), Context: Non-curative therapy Treatment: ",superior,inferior,no difference,2020,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Wilms tumor, Context: Adjuvant therapy, Endpoint: RFS, Treatment 1: Dactinomycin and Vincristine, Treatment 2: Vincristine monotherapy Response:",Dactinomycin and Vincristine superior to Vincristine monotherapy for Wilms tumor (Adjuvant therapy) [endpoint: RFS],False 2020-04-28,"Olaparib for Metastatic Castration-Resistant Prostate Cancer. Multiple loss-of-function alterations in genes that are involved in DNA repair, including homologous recombination repair, are associated with response to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition in patients with prostate and other cancers. We conducted a randomized, open-label, phase 3 trial evaluating the PARP inhibitor olaparib in men with metastatic castration-resistant prostate cancer who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone). All the men had a qualifying alteration in prespecified genes with a direct or indirect role in homologous recombination repair. Cohort A (245 patients) had at least one alteration in BRCA1, BRCA2, or ATM; cohort B (142 patients) had alterations in any of 12 other prespecified genes, prospectively and centrally determined from tumor tissue. Patients were randomly assigned (in a 2:1 ratio) to receive olaparib or the physician's choice of enzalutamide or abiraterone (control). The primary end point was imaging-based progression-free survival in cohort A according to blinded independent central review. In cohort A, imaging-based progression-free survival was significantly longer in the olaparib group than in the control group (median, 7.4 months vs. 3.6 months; hazard ratio for progression or death, 0.34; 95% confidence interval, 0.25 to 0.47; P<0.001); a significant benefit was also observed with respect to the confirmed objective response rate and the time to pain progression. The median overall survival in cohort A was 18.5 months in the olaparib group and 15.1 months in the control group; 81% of the patients in the control group who had progression crossed over to receive olaparib. A significant benefit for olaparib was also seen for imaging-based progression-free survival in the overall population (cohorts A and B). Anemia and nausea were the main toxic effects in patients who received olaparib. In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role in homologous recombination repair, olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone. (Funded by AstraZeneca and Merck Sharp & Dohme; PROfound ClinicalTrials.gov number, NCT02987543.). Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician's choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes and whose disease had progressed during previous treatment with a next-generation hormonal agent. The results of the final analysis of overall survival have not yet been reported. In an open-label, phase 3 trial, we randomly assigned patients in a 2:1 ratio to receive olaparib (256 patients) or the physician's choice of enzalutamide or abiraterone plus prednisone as the control therapy (131 patients). Cohort A included 245 patients with at least one alteration in BRCA1, BRCA2, or ATM, and cohort B included 142 patients with at least one alteration in any of the other 12 prespecified genes. Crossover to olaparib was allowed after imaging-based disease progression for patients who met certain criteria. Overall survival in cohort A, a key secondary end point, was analyzed with the use of an alpha-controlled, stratified log-rank test at a data maturity of approximately 60%. The primary and other key secondary end points were reported previously. The median duration of overall survival in cohort A was 19.1 months with olaparib and 14.7 months with control therapy (hazard ratio for death, 0.69; 95% confidence interval [CI], 0.50 to 0.97; P = 0.02). In cohort B, the median duration of overall survival was 14.1 months with olaparib and 11.5 months with control therapy. In the overall population (cohorts A and B), the corresponding durations were 17.3 months and 14.0 months. Overall, 86 of 131 patients (66%) in the control group crossed over to receive olaparib (56 of 83 patients [67%] in cohort A). A sensitivity analysis that adjusted for crossover to olaparib showed hazard ratios for death of 0.42 (95% CI, 0.19 to 0.91) in cohort A, 0.83 (95% CI, 0.11 to 5.98) in cohort B, and 0.55 (95% CI, 0.29 to 1.06) in the overall population. Among men with metastatic castration-resistant prostate cancer who had tumors with at least one alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent, those who were initially assigned to receive olaparib had a significantly longer duration of overall survival than those who were assigned to receive enzalutamide or abiraterone plus prednisone as the control therapy, despite substantial crossover from control therapy to olaparib. (Funded by AstraZeneca and Merck Sharp and Dohme; PROfound ClinicalTrials.gov number, NCT02987543.). Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. The PROfound study showed significantly improved radiographical progression-free survival and overall survival in men with metastatic castration-resistant prostate cancer with alterations in homologous recombination repair genes and disease progression on a previous next-generation hormonal drug who received olaparib then those who received control. We aimed to assess pain and patient-centric health-related quality of life (HRQOL) measures in patients in the trial. In this open-label, randomised, phase 3 study, patients (aged ≥18 years) with metastatic castration-resistant prostate cancer and gene alterations to one of 15 genes (BRCA1, BRCA2, or ATM [cohort A] and BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L [cohort B]) and disease progression after a previous next-generation hormonal drug were randomly assigned (2:1) to receive olaparib tablets (300 mg orally twice daily) or a control drug (enzalutamide tablets [160 mg orally once daily] or abiraterone tablets [1000 mg orally once daily] plus prednisone tablets [5 mg orally twice daily]), stratified by previous taxane use and measurable disease. The primary endpoint (radiographical progression-free survival in cohort A) has been previously reported. The prespecified secondary endpoints reported here are on pain, HRQOL, symptomatic skeletal-related events, and time to first opiate use for cancer-related pain in cohort A. Pain was assessed with the Brief Pain Inventory-Short Form, and HRQOL was assessed with the Functional Assessment of Cancer Therapy-Prostate (FACT-P). All endpoints were analysed in patients in cohort A by modified intention-to-treat. The study is registered with ClinicalTrials.gov, NCT02987543. Between Feb 6, 2017, and June 4, 2019, 245 patients were enrolled in cohort A and received study treatment (162 [66%] in the olaparib group and 83 [34%] in the control group). Median duration of follow-up at data cutoff in all patients was 6·2 months (IQR 2·2-10·4) for the olaparib group and 3·5 months (1·7-4·9) for the control group. In cohort A, median time to pain progression was significantly longer with olaparib than with control (median not reached [95% CI not reached-not reached] with olaparib vs 9·92 months [5·39-not reached] with control; HR 0·44 [95% CI 0·22-0·91]; p=0·019). Pain interference scores were also better in the olaparib group (difference in overall adjusted mean change from baseline score -0·85 [95% CI -1·31 to -0·39]; pnominal=0·0004). Median time to progression of pain severity was not reached in either group (95% CI not reached-not reached for both groups; HR 0·56 [95% CI 0·25-1·34]; pnominal=0·17). In patients who had not used opiates at baseline (113 in the olaparib group, 58 in the control group), median time to first opiate use for cancer-related pain was 18·0 months (95% CI 12·8-not reached) in the olaparib group versus 7·5 months (3·2-not reached) in the control group (HR 0·61; 95% CI 0·38-0·99; pnominal=0·044). The proportion of patients with clinically meaningful improvement in FACT-P total score during treatment was higher for the olaparib group than the control group: 15 (10%) of 152 evaluable patients had a response in the olaparib group compared with one (1%) of evaluable 77 patients in the control group (odds ratio 8·32 [95% CI 1·64-151·84]; pnominal=0·0065). Median time to first symptomatic skeletal-related event was not reached for either treatment group (olaparib group 95% CI not reached-not reached; control group 7·8-not reached; HR 0·37 [95% CI 0·20-0·70]; pnominal=0·0013). Olaparib was associated with reduced pain burden and better-preserved HRQOL compared with the two control drugs in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations who had disease progression after a previous next-generation hormonal drug. Our findings support the clinical benefit of improved radiographical progression-free survival and overall survival identified in PROfound. AstraZeneca and Merck Sharp & Dohme.",32343890;32955174;35157830,Olaparib monotherapy,Abiraterone monotherapy,Prostate cancer (Metastatic),Non-curative therapy,rPFS,Primary,superior,Olaparib monotherapy superior to Abiraterone monotherapy for Prostate cancer (Metastatic) (Non-curative therapy) [endpoint: rPFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the rPFS outcome of Olaparib monotherapy compared to Abiraterone monotherapy when used to treat Prostate cancer (Metastatic) (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the rPFS outcome of Olaparib monotherapy versus Abiraterone monotherapy in treating Prostate cancer (Metastatic) (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the rPFS results of Olaparib monotherapy compared to Abiraterone monotherapy for Prostate cancer (Metastatic) (Non-curative therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the rPFS outcome of Abiraterone monotherapy compared to Olaparib monotherapy when used to treat Prostate cancer (Metastatic) (Non-curative therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Prostate cancer (Metastatic), Context: Non-curative therapy, Endpoint: rPFS, Treatment 1: Olaparib monotherapy, Treatment 2: Abiraterone monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Prostate cancer (Metastatic), Context: Non-curative therapy Treatment: ",superior,inferior,no difference,2020,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Wilms tumor, Context: Adjuvant therapy, Endpoint: RFS, Treatment 1: Vincristine monotherapy, Treatment 2: Dactinomycin and Vincristine Response:",Vincristine monotherapy inferior to Dactinomycin and Vincristine for Wilms tumor (Adjuvant therapy) [endpoint: RFS],False 2020-05-16,"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Atezolizumab can induce sustained responses in metastatic urothelial carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab with or without platinum-based chemotherapy versus placebo plus platinum-based chemotherapy in first-line metastatic urothelial carcinoma. In this multicentre, phase 3, randomised trial, untreated patients aged 18 years or older with locally advanced or metastatic urothelial carcinoma, from 221 sites in 35 countries, were randomly assigned to receive atezolizumab plus platinum-based chemotherapy (group A), atezolizumab monotherapy (group B), or placebo plus platinum-based chemotherapy (group C). Patients received 21-day cycles of gemcitabine (1000 mg/m2 body surface area, administered intravenously on days 1 and 8 of each cycle), plus either carboplatin (area under the curve of 4·5 mg/mL per min administered intravenously) or cisplatin (70 mg/m2 body surface area administered intravenously) on day 1 of each cycle with either atezolizumab (1200 mg administered intravenously on day 1 of each cycle) or placebo. Group B patients received 1200 mg atezolizumab, administered intravenously on day 1 of each 21-day cycle. The co-primary efficacy endpoints for the intention-to-treat population were investigator-assessed Response Evaluation Criteria in Solid Tumours 1.1 progression-free survival and overall survival (group A vs group C) and overall survival (group B vs group C), which was to be formally tested only if overall survival was positive for group A versus group C. The trial is registered with ClinicalTrials.gov, NCT02807636. Between July 15, 2016, and July 20, 2018, we enrolled 1213 patients. 451 (37%) were randomly assigned to group A, 362 (30%) to group B, and 400 (33%) to group C. Median follow-up for survival was 11·8 months (IQR 6·1-17·2) for all patients. At the time of final progression-free survival analysis and interim overall survival analysis (May 31, 2019), median progression-free survival in the intention-to-treat population was 8·2 months (95% CI 6·5-8·3) in group A and 6·3 months (6·2-7·0) in group C (stratified hazard ratio [HR] 0·82, 95% CI 0·70-0·96; one-sided p=0·007). Median overall survival was 16·0 months (13·9-18·9) in group A and 13·4 months (12·0-15·2) in group C (0·83, 0·69-1·00; one-sided p=0·027). Median overall survival was 15·7 months (13·1-17·8) for group B and 13·1 months (11·7-15·1) for group C (1·02, 0·83-1·24). Adverse events that led to withdrawal of any agent occurred in 156 (34%) patients in group A, 22 (6%) patients in group B, and 132 (34%) patients in group C. 50 (11%) patients in group A, 21 (6%) patients in group B, and 27 (7%) patients in group C had adverse events that led to discontinuation of atezolizumab or placebo. Addition of atezolizumab to platinum-based chemotherapy as first-line treatment prolonged progression-free survival in patients with metastatic urothelial carcinoma. The safety profile of the combination was consistent with that observed with the individual agents. These results support the use of atezolizumab plus platinum-based chemotherapy as a potential first-line treatment option for metastatic urothelial carcinoma. F Hoffmann-La Roche and Genentech. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study. The primary analysis of IMvigor130 showed a significant progression-free survival benefit with first-line atezolizumab plus platinum-based chemotherapy (group A) versus placebo plus platinum-based chemotherapy (group C) in patients with locally advanced or metastatic urothelial cancer. However, this finding did not translate into significant overall survival benefit for group A versus group C at the final analysis, precluding formal statistical testing of outcomes with atezolizumab monotherapy (group B) versus group C. Here we report the final overall survival results for group B versus group C; this report is descriptive and should be considered exploratory due to the study's statistical design. In this global, partially blinded, randomised, controlled, phase 3 study, patients (aged ≥18 years) who had locally advanced or metastatic urothelial cancer previously untreated in the metastatic setting and Eastern Cooperative Oncology Group performance status of 0-2 were enrolled at 221 hospitals and oncology centres in 35 countries. Patients were randomly assigned (1:1:1), using a permuted block method (block size of six) and an interactive voice and web response system, stratified by PD-L1 status, Bajorin score, and investigator's choice of platinum-based chemotherapy, to receive either atezolizumab plus platinum-based chemotherapy (group A), atezolizumab alone (group B), or placebo plus platinum-based chemotherapy (group C). Sponsors, investigators, and patients were masked to assignment to atezolizumab or placebo in group A and group C; atezolizumab monotherapy in group B was open label. For groups B and C, atezolizumab (1200 mg) or placebo was administered intravenously every 3 weeks. Chemotherapy involved 21-day cycles of gemcitabine (1000 mg/m2 body surface area on day 1 and day 8 of each cycle) plus the investigator's choice of carboplatin (area under the curve 4·5 mg/mL per min or 5 mg/mL per min) or cisplatin (70 mg/m2 body surface area), administered intravenously. Co-primary endpoints were progression-free survival and overall survival in group A versus group C, and overall survival in group B versus group C, tested hierarchically, in the intention-to-treat (ITT) population, and then the populations with high PD-L1 tumour expression (immune cell [IC] expression score of IC2/3) if the results from group A versus group C were significant. Here, we report the co-primary endpoint of overall survival for group B versus group C in the ITT and IC2/3 populations. The ITT population for this analysis comprised concurrently enrolled patients in groups B and C who were randomly assigned to treatment. For the safety analysis, all patients enrolled in group B and group C who received any study treatment were included. The trial is registered with ClinicalTrials.gov, NCT02807636, and is active but no longer recruiting. Between July 15, 2016, and July 20, 2018, 1213 patients were enrolled and randomly assigned to treatment, of whom 362 patients were assigned to group B and 400 to group C, of whom 360 and 359, respectively, were enrolled concurrently (ITT population). 543 (76%) of 719 patients were male, 176 (24%) were female, and 534 (74%) were White. As of data cutoff (Aug 31, 2022), after a median follow-up of 13·4 months (IQR 6·2-30·8), median overall survival was 15·2 months (95% CI 13·1-17·7; 271 deaths) in group B and 13·3 months (11·9-15·6; 275 deaths) in group C (stratified hazard ratio 0·98 [95% CI 0·82-1·16]). The most common grade 3-4 treatment-related adverse events were anaemia (two [1%] in patients who received atezolizumab monotherapy vs 133 [34%] in those who received placebo plus chemotherapy), neutropenia (one [<1%] vs 115 [30%]), decreased neutrophil count (0 vs 95 [24%]), and decreased platelet count (one [<1%] vs 92 [24%]). Serious adverse events occurred in 163 (46%) patients versus 196 (50%). Treatment-related deaths occurred in three (1%; n=1 each, pneumonia, interstitial lung disease, large intestinal obstruction) patients who received atezolizumab monotherapy and four (1%; n=1 each, diarrhoea, febrile neutropenia, unexplained death, toxic hepatitis) who received placebo plus chemotherapy. The final analysis from IMvigor130 did not show a significant improvement in overall survival with first-line atezolizumab monotherapy compared with platinum-based chemotherapy in the intention-to-treat population. The safety profile of atezolizumab monotherapy remained acceptable after extended follow-up, with no new safety signals. F Hoffmann-La Roche. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study. IMvigor130 demonstrated statistically significant investigator-assessed progression-free survival benefit with first-line atezolizumab plus platinum-based chemotherapy (group A) versus placebo plus platinum-based chemotherapy (group C) in patients with locally advanced or metastatic urothelial carcinoma. Overall survival was not improved in interim analyses. Here we report the final overall analysis for group A versus group C. In this global, partially blinded, randomised, controlled, phase 3 study, patients (aged ≥18 years) with previously untreated locally advanced or metastatic urothelial cancer and who had an Eastern Cooperative Oncology Group performance status of 0-2 were enrolled at 221 hospitals and oncology centres in 35 countries. Patients were randomly assigned (1:1:1), with a permuted block method (block size of six) and an interactive voice and web response system, stratified by PD-L1 status, Bajorin risk factor score, and investigator's choice of platinum-based chemotherapy, to receive atezolizumab plus platinum-based chemotherapy (group A), atezolizumab monotherapy (group B), or placebo plus platinum-based chemotherapy (group C). Sponsors, investigators, and patients were masked to assignment to atezolizumab or placebo (ie, group A and group C) and atezolizumab monotherapy (group B) was open label. For groups A and C, all patients received gemcitabine (1000 mg/m2 intravenously; day 1 and day 8 of each 21-day cycle), plus investigator's choice of carboplatin (area under curve 4·5 mg/mL per min or 5 mg/mL per min; intravenously) or cisplatin (70 mg/m2 intravenously), plus either atezolizumab (1200 mg intravenously) or placebo on day 1 of each cycle. Co-primary endpoints of the study were investigator-assessed progression-free survival and overall survival for group A versus group C in the intention-to-treat (ITT) population (ie, all randomised patients), and overall survival for group B versus group C, tested hierarchically. Final overall survival and updated safety outcomes (safety population; all patients who received any amount of any study treatment component) for group A versus group C are reported here. The final prespecified boundary for significance of the overall survival analysis was one-sided p=0·021. The trial is registered with ClinicalTrials.gov, NCT02807636, and is active but no longer recruiting. Between July 15, 2016, and July 20, 2018, 1213 patients were enrolled and randomly assigned to treatment, of whom 851 were assigned to group A (n=451) and group C (n=400). 338 (75%) patients in group A and 298 (75%) in group C were male, 113 (25%) in group A and 102 (25%) in group C were female, and 346 (77%) in group A and 304 (76%) in group C were White. At data cutoff (Aug 31, 2022), after a median follow up of 13·4 months (IQR 6·2-30·8), median overall survival was 16·1 months (95% CI 14·2-18·8; 336 deaths) in group A versus 13·4 months (12·0-15·3; 310 deaths) in group C (stratified hazard ratio 0·85 [95% CI 0·73-1·00]; one-sided p=0·023). The most common grade 3-4 treatment-related adverse events were anaemia (168 [37%] of 454 patients who received atezolizumab plus chemotherapy vs 133 [34%] of 389 who received placebo plus chemotherapy), neutropenia (167 [37%] vs 115 [30%]), decreased neutrophil count (98 [22%] vs 95 [24%]), thrombocytopenia (95 [21%] vs 70 [18%]), and decreased platelet count (92 [20%] vs 92 [24%]). Serious adverse events occurred in 243 (54%) patients who received atezolizumab plus chemotherapy and 196 (50%) patients who received placebo plus chemotherapy. Treatment-related deaths occurred in nine (2%; acute kidney injury, dyspnoea, hepatic failure, hepatitis, neutropenia, pneumonitis, respiratory failure, sepsis, and thrombocytopenia [n=1 each]) patients who received atezolizumab plus chemotherapy and four (1%; unexplained death, diarrhoea, febrile neutropenia, and toxic hepatitis [n=1 each]) who received placebo plus chemotherapy. Progression-free survival benefit with first-line combination of atezolizumab plus platinum-based chemotherapy did not translate into a significant improvement in overall survival in the ITT population of IMvigor130. Further research is needed to understand which patients might benefit from first-line combination treatment. No new safety signals were observed. F Hoffmann-La Roche.",32416780;38101431;38101433,Carboplatin and Gemcitabine (GCb) and Atezolizumab|Cisplatin and Gemcitabine (GC) and Atezolizumab,Cisplatin and Gemcitabine (GC),"Urothelial carcinoma (Locally Advanced or Metastatic, Not Applicable)",Non-curative first-line therapy,OS,Co-primary,superior,"Carboplatin and Gemcitabine (GCb) and Atezolizumab|Cisplatin and Gemcitabine (GC) and Atezolizumab superior to Cisplatin and Gemcitabine (GC) for Urothelial carcinoma (Locally Advanced or Metastatic, Not Applicable) (Non-curative first-line therapy) [endpoint: OS]","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Carboplatin and Gemcitabine (GCb) and Atezolizumab|Cisplatin and Gemcitabine (GC) and Atezolizumab compared to Cisplatin and Gemcitabine (GC) when used to treat Urothelial carcinoma (Locally Advanced or Metastatic, Not Applicable) (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Carboplatin and Gemcitabine (GCb) and Atezolizumab|Cisplatin and Gemcitabine (GC) and Atezolizumab versus Cisplatin and Gemcitabine (GC) in treating Urothelial carcinoma (Locally Advanced or Metastatic, Not Applicable) (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Carboplatin and Gemcitabine (GCb) and Atezolizumab|Cisplatin and Gemcitabine (GC) and Atezolizumab compared to Cisplatin and Gemcitabine (GC) for Urothelial carcinoma (Locally Advanced or Metastatic, Not Applicable) (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Cisplatin and Gemcitabine (GC) compared to Carboplatin and Gemcitabine (GCb) and Atezolizumab|Cisplatin and Gemcitabine (GC) and Atezolizumab when used to treat Urothelial carcinoma (Locally Advanced or Metastatic, Not Applicable) (Non-curative first-line therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Urothelial carcinoma (Locally Advanced or Metastatic, Not Applicable), Context: Non-curative first-line therapy, Endpoint: OS, Treatment 1: Carboplatin and Gemcitabine (GCb) and Atezolizumab|Cisplatin and Gemcitabine (GC) and Atezolizumab, Treatment 2: Cisplatin and Gemcitabine (GC) Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Urothelial carcinoma (Locally Advanced or Metastatic, Not Applicable), Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2020,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 2020-10-29,"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Venetoclax is a highly selective, potent, oral BCL-2 inhibitor, which induces apoptosis in multiple myeloma cells. Venetoclax plus bortezomib and dexamethasone has shown encouraging clinical efficacy with acceptable safety and tolerability in a phase 1 trial. The aim of this study was to evaluate venetoclax plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. In this randomised, double-blind, multicentre, phase 3 trial, patients aged 18 years or older with relapsed or refractory multiple myeloma, an Eastern Cooperative Oncology Group performance status of 2 or less, who had received one to three previous therapies were enrolled from 90 hospitals in 16 countries. Eligible patients were randomly assigned (2:1) centrally using an interactive response technology system and a block size of three to receive venetoclax (800 mg per day orally) or placebo with bortezomib (1·3 mg/m2 subcutaneously or intravenously and dexamethasone (20 mg orally). Treatment was given in 21-day cycles for the first eight cycles and 35-day cycles from the ninth cycle until disease progression, unacceptable toxicity, or patient withdrawal. Randomisation was stratified by previous exposure to a proteasome inhibitor and the number of previous therapies. Sponsors, investigators, study site personnel, and patients were masked to the treatment allocation throughout the study. The primary endpoint was independent review committee-assessed progression-free survival in the intention-to-treat population. Safety analyses were done in patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, NCT02755597. Between July 19, 2016, and Oct 31, 2017, 291 patients were randomly assigned to receive venetoclax (n=194) or placebo (n=97). With a median follow-up of 18·7 months (IQR 16·6-21·0), median progression-free survival according to independent review committee was 22·4 months (95% CI 15·3-not estimable) with venetoclax versus 11·5 months (9·6-15·0) with placebo (hazard ratio [HR] 0·63 [95% CI 0·44-0·90]; p=0·010). The most common grade 3 or worse treatment-emergent adverse events were neutropenia (35 [18%] of 193 patients in the venetoclax group vs seven [7%] of 96 patients in the placebo group), pneumonia (30 [16%] vs nine [9%]), thrombocytopenia (28 [15%] vs 29 [30%]), anaemia (28 [15%] vs 14 [15%]), and diarrhoea (28 [15%] vs 11 [11%]). Serious treatment-emergent adverse events occurred in 93 (48%) patients in the venetoclax group and 48 (50%) patients in the placebo group, with eight (4%) treatment-emergent fatal infections reported in the venetoclax group and none reported in the placebo group. Three deaths in the venetoclax group (two from pneumonia and one from septic shock) were considered treatment-related; no deaths in the placebo group were treatment-related. The primary endpoint was met with a significant improvement in independent review committee-assessed progression-free survival with venetoclax versus placebo plus bortezomib and dexamethasone. However, increased mortality was seen in the venetoclax group, mostly because of an increased rate of infections, highlighting the importance of appropriate selection of patients for this treatment option. AbbVie and Genentech. Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study. The phase 3 BELLINI primary endpoint was met, showing superior progression-free survival with venetoclax versus placebo plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma as assessed by an independent review committee. However, venetoclax showed increased early mortality. Here, we report the final overall survival analysis. The randomised, double-blind, multicentre, phase 3 BELLINI study enrolled patients aged 18 years or older with relapsed or refractory multiple myeloma, Eastern Cooperative Oncology Group performance status of 2 or less, and one to three previous therapies, across 90 hospitals in 16 countries. Eligible patients were centrally randomly assigned (2:1, stratified by previous proteasome inhibitor exposure and number of previous lines of therapies) via interactive response technology system (block size 3) to once-daily venetoclax (800 mg orally) or placebo with bortezomib (1·3 mg/m2 subcutaneously or intravenously) and dexamethasone (20 mg orally), administered in 21-day cycles for initial eight cycles, followed by 35-day cycles until discontinuation. The primary endpoint was progression-free survival as assessed by an independent review committee in the intention-to-treat population; this analysis reports overall survival and investigator-assessed progression-free survival in the intention-to-treat population. Safety analyses were done in patients who received at least one dose of the study drug. This study is registered with ClinicalTrials.gov (NCT02755597) and is completed. From July 19, 2016, to Oct 31, 2017, 291 patients were assigned to venetoclax (n=194) or placebo (n=97); 33 patients (28 in the venetoclax group and five in the placebo group) remained on treatment at the time of this analysis. Of the 291 patients, 152 (52%) were men and 139 (48%) were women. 87 (30%) of 291 patients were Asian, 12 (4%) were Black or African American, 190 (65%) were White, and 32 (11%) were Hispanic or Latino. At 45·6 months (IQR 43·6-48·3) median follow-up, median overall survival was not reached in the venetoclax group (not reached [NR] [95% CI 44·4-not estimable]) or in the placebo group (NR [95% CI 44·0-not estimable]; HR 1·19 [95% CI 0·80-1·77]); p=0·39). Median progression-free survival was 23·4 months (95% CI 16·2-26·4) with venetoclax versus 11·4 months (95% CI 9·5-14·6) with placebo (HR 0·58 [95% CI 0·43-0·78]; p=0·00026). The most common grade 3 or 4 adverse events were thrombocytopenia (51 [26%] of 193 in the venetoclax group vs 38 [40%] of 96 in the placebo group]) and neutropenia (58 [30%] of 193 vs eight [8%] of 96 patients). Treatment-related adverse events led to death in four (2%) of 193 patients in the venetoclax group (two patients with pneumonia, one with death, and one with both multiple organ dysfunction syndrome and septic shock) and none in the placebo group. Final overall survival analysis in the BELLINI study showed overall survival favouring placebo over venetoclax and progression-free survival favouring venetoclax over placebo, indicating venetoclax usage should be avoided in the general relapsed or refractory multiple myeloma population. AbbVie and Genentech.",33129376;40587991,Bortezomib and Dexamethasone (Vd),Bortezomib and Dexamethasone (Vd) and Venetoclax,Multiple myeloma,Non-curative therapy,PFS,Primary,inferior,Bortezomib and Dexamethasone (Vd) inferior to Bortezomib and Dexamethasone (Vd) and Venetoclax for Multiple myeloma (Non-curative therapy) [endpoint: PFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of Bortezomib and Dexamethasone (Vd) compared to Bortezomib and Dexamethasone (Vd) and Venetoclax when used to treat Multiple myeloma (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the PFS outcome of Bortezomib and Dexamethasone (Vd) versus Bortezomib and Dexamethasone (Vd) and Venetoclax in treating Multiple myeloma (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the PFS results of Bortezomib and Dexamethasone (Vd) compared to Bortezomib and Dexamethasone (Vd) and Venetoclax for Multiple myeloma (Non-curative therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of Bortezomib and Dexamethasone (Vd) and Venetoclax compared to Bortezomib and Dexamethasone (Vd) when used to treat Multiple myeloma (Non-curative therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Multiple myeloma, Context: Non-curative therapy, Endpoint: PFS, Treatment 1: Bortezomib and Dexamethasone (Vd), Treatment 2: Bortezomib and Dexamethasone (Vd) and Venetoclax Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Multiple myeloma, Context: Non-curative therapy Treatment: ",superior,inferior,no difference,2020,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 2020-11-15,"FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial. 5-Fluorouracil/leucovorin, oxaliplatin, irinotecan (FOLFOXIRI) plus bevacizumab is more effective than doublets plus bevacizumab as first-line therapy for metastatic colorectal cancer, but is not widely used because of concerns about toxicity and lack of predictive biomarkers. This study was designed to explore the role of circulating tumour cell (CTC) count as a biomarker to select patients for therapy with FOLFOXIRI-bevacizumab. VISNÚ-1 was a multicentre, open-label, randomised, phase III study in patients with previously untreated, unresectable, metastatic colorectal carcinoma and ≥3 CTC/7.5 mL blood. Patients received bevacizumab 5 mg/kg plus FOLFOXIRI (irinotecan 165 mg/m2, oxaliplatin 85 mg/m2, leucovorin 400 mg/m2 and 5-fluorouracil 3200 mg/m2) or FOLFOX (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2 then 2400 mg/m2) by intravenous administration every 2 weeks. The primary outcome was progression-free survival (PFS). The intention-to-treat population comprised 349 patients (FOLFOXIRI-bevacizumab, n=172; FOLFOX-bevacizumab, n=177). Median PFS was 12.4 months (95% CI 11.2 to 14.0) with FOLFOXIRI bevacizumab and 9.3 months (95% CI 8.5 to 10.7) with FOLFOX-bevacizumab (stratified HR, 0.64; 95% CI 0.49 to 0.82; p=0.0006). Grade≥3 adverse events were more common with FOLFOXIRI-bevacizumab 85.3% vs 75.1% with FOLFOX-bevacizumab (p=0.0178). Treatment-related deaths occurred in 8 (4.7%) and 6 (3.4%) patients, respectively. First-line FOLFOXIRI-bevacizumab significantly improved PFS compared with FOLFOX-bevacizumab in patients with metastatic colorectal cancer and ≥3 CTCs at baseline, which indicate a poor prognosis. CTC count may be a useful non-invasive biomarker to assist with the selection of patients for intensive first-line therapy.",33148620,FOLFIRINOX and Bevacizumab,mFOLFOX6-B,Colorectal cancer,Non-curative first-line therapy,PFS,Primary,superior,FOLFIRINOX and Bevacizumab superior to mFOLFOX6-B for Colorectal cancer (Non-curative first-line therapy) [endpoint: PFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of FOLFIRINOX and Bevacizumab compared to mFOLFOX6-B when used to treat Colorectal cancer (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the PFS outcome of FOLFIRINOX and Bevacizumab versus mFOLFOX6-B in treating Colorectal cancer (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the PFS results of FOLFIRINOX and Bevacizumab compared to mFOLFOX6-B for Colorectal cancer (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of mFOLFOX6-B compared to FOLFIRINOX and Bevacizumab when used to treat Colorectal cancer (Non-curative first-line therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Colorectal cancer, Context: Non-curative first-line therapy, Endpoint: PFS, Treatment 1: FOLFIRINOX and Bevacizumab, Treatment 2: mFOLFOX6-B Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Colorectal cancer, Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2020,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Colon cancer, Context: Adjuvant therapy, Endpoint: DFS, Treatment 1: Observation, Treatment 2: Fluorouracil monotherapy Response:",Observation inferior to Fluorouracil monotherapy for Colon cancer (Adjuvant therapy) [endpoint: DFS],False 2021-02-12,"Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). Andecaliximab (ADX) is a monoclonal antibody that inhibits matrix metalloproteinase 9, an extracellular enzyme involved in matrix remodeling, tumor growth, and metastases. A phase I and Ib study of modified oxaliplatin, leucovorin, and fluorouracil (mFOLFOX6) with ADX revealed encouraging antitumor activity in patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma. This phase III, randomized, double-blinded, placebo (PBO)-controlled multicenter study investigated the efficacy and safety of mFOLFOX6 with and without ADX in patients with untreated human epidermal growth factor receptor 2-negative gastric or GEJ adenocarcinoma. Random assignment was 1:1 to mFOLFOX6 + ADX or mFOLFOX6 + PBO. ADX/PBO 800 mg was infused on days 1 and 15 of each 28-day cycle. Protocol therapy was given until disease progression or intolerance. The primary end point was overall survival (OS), and secondary end points were progression-free survival (PFS), objective response rate (RECIST 1.1), and safety. Between September 2015 and May 2017, 432 patients were randomly assigned, 218 to ADX and 214 to PBO. The median OS was 12.5 versus 11.8 months in the ADX and PBO groups, respectively. The median PFS was 7.5 versus 7.1 months in the ADX and PBO groups, respectively. The objective response rate was 51% in the ADX group and 41% in the PBO group. Among the subgroup analyses, patients of age ≥ 65 years had an improved OS and PFS with ADX versus PBO; the P values and CIs were not adjusted for multiplicity. There were no meaningful differences in the safety profile of the ADX versus PBO groups. The addition of ADX to mFOLFOX6 did not improve OS in unselected patients with untreated human epidermal growth factor receptor 2-negative gastric or GEJ adenocarcinoma.",33577358,mFOLFOX6 (L-Leucovorin),mFOLFOX6 and Andecaliximab,Gastric cancer,Non-curative first-line therapy,OS,Primary,no difference,mFOLFOX6 (L-Leucovorin) no difference to mFOLFOX6 and Andecaliximab for Gastric cancer (Non-curative first-line therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of mFOLFOX6 (L-Leucovorin) compared to mFOLFOX6 and Andecaliximab when used to treat Gastric cancer (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of mFOLFOX6 (L-Leucovorin) versus mFOLFOX6 and Andecaliximab in treating Gastric cancer (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of mFOLFOX6 (L-Leucovorin) compared to mFOLFOX6 and Andecaliximab for Gastric cancer (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of mFOLFOX6 and Andecaliximab compared to mFOLFOX6 (L-Leucovorin) when used to treat Gastric cancer (Non-curative first-line therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Gastric cancer, Context: Non-curative first-line therapy, Endpoint: OS, Treatment 1: mFOLFOX6 (L-Leucovorin), Treatment 2: mFOLFOX6 and Andecaliximab Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Gastric cancer, Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2021,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Colon cancer, Context: Adjuvant therapy, Endpoint: DFS, Treatment 1: Observation, Treatment 2: Fluorouracil monotherapy Response:",Observation inferior to Fluorouracil monotherapy for Colon cancer (Adjuvant therapy) [endpoint: DFS],False 2021-06-04,"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Isatuximab is an anti-CD38 monoclonal antibody approved in combination with pomalidomide-dexamethasone and carfilzomib-dexamethasone for relapsed or refractory multiple myeloma. This phase 3, open-label study compared the efficacy of isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma. This was a prospective, randomised, open-label, parallel-group, phase 3 study done at 69 study centres in 16 countries across North America, South America, Europe, and the Asia-Pacific region. Patients with relapsed or refractory multiple myeloma aged at least 18 years who had received one to three previous lines of therapy and had measurable serum or urine M-protein were eligible. Patients were randomly assigned (3:2) to isatuximab plus carfilzomib-dexamethasone (isatuximab group) or carfilzomib-dexamethasone (control group). Patients in the isatuximab group received isatuximab 10 mg/kg intravenously weekly for the first 4 weeks, then every 2 weeks. Both groups received the approved schedule of intravenous carfilzomib and oral or intravenous dexamethasone. Treatment continued until progression or unacceptable toxicity. The primary endpoint was progression-free survival and was assessed in the intention-to-treat population according to assigned treatment. Safety was assessed in all patients who received at least one dose according to treatment received. The study is registered at ClinicalTrials.gov, NCT03275285. Between Nov 15, 2017, and March 21, 2019, 302 patients with a median of two previous lines of therapy were enrolled. 179 were randomly assigned to the isatuximab group and 123 to the control group. Median progression-free survival was not reached in the isatuximab group compared with 19·15 months (95% CI 15·77-not reached) in the control group, with a hazard ratio of 0·53 (99% CI 0·32-0·89; one-sided p=0·0007). Treatment-emergent adverse events (TEAEs) of grade 3 or worse occurred in 136 (77%) of 177 patients in the isatuximab group versus 82 (67%) of 122 in the control group, serious TEAEs occurred in 105 (59%) versus 70 (57%) patients, and TEAEs led to discontinuation in 15 (8%) versus 17 (14%) patients. Fatal TEAEs during study treatment occurred in six (3%) versus four (3%) patients. The addition of isatuximab to carfilzomib-dexamethasone significantly improves progression-free survival and depth of response in patients with relapsed multiple myeloma, representing a new standard of care for this patient population. Sanofi. VIDEO ABSTRACT. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. Longer-term outcomes with the anti-CD38 antibody isatuximab in combination with carfilzomib-dexamethasone (Isa-Kd) were evaluated in the randomized Phase 3 trial IKEMA (NCT03275285), in a prespecified, follow-up analysis of progression-free survival (PFS, primary study endpoint), final complete response (CR) using Hydrashift Isa immunofixation assay, minimal residual disease (MRD) negativity, and safety. Enrolled patients had relapsed/refractory multiple myeloma (1-3 prior treatment lines). Isa 10 mg/kg was administered intravenously weekly in cycle 1 then biweekly. Efficacy analyses were performed in the intent-to-treat population (Isa-Kd: n = 179, Kd: n = 123) and safety evaluated in treated patients (Isa-Kd: n = 177, Kd: n = 122). Consistent with the primary interim analysis, the addition of Isa to Kd prolonged PFS (HR 0.58, 95.4% CI: 0.42-0.79; median PFS 35.7 [95% CI: 25.8-44.0] vs 19.2 [95% CI: 15.8-25.0] months). PFS benefit was observed with Isa-Kd across subgroups, including patients with poor prognosis. The stringent CR/CR rate was 44.1% vs 28.5% (odds-ratio: 2.09, 95% CI: 1.26-3.48), the MRD negativity rate 33.5% vs 15.4% (odds-ratio: 2.78, 95% CI: 1.55-4.99) and the MRD negativity CR rate 26.3% vs 12.2%, with Isa-Kd vs Kd. The safety profile of Isa-Kd was similar to that reported in the prior interim analysis. These findings further support Isa-Kd as a standard-of-care treatment for relapsed multiple myeloma patients.Clinical trial information: ClinicalTrials.gov, NCT03275285. Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial. Isatuximab is an anti-CD38 monoclonal antibody approved for the treatment of relapsed or refractory multiple myeloma. Previous analyses of the IKEMA trial showed prolonged progression-free survival in patients with this disease who received isatuximab in combination with carfilzomib-dexamethasone as compared with those who received carfilzomib-dexamethasone alone. Herein, we report the analysis of overall survival from the IKEMA trial. This prospective, randomised, open-label, active-controlled, phase 3 study included patients with relapsed or refractory multiple myeloma aged 18 years or older, who had received one to three previous lines of treatment from 69 study centres in 16 countries across North America, South America, Europe, and the Asia-Pacific region. Patients were randomly allocated (3:2) to treatment with either isatuximab plus carfilzomib-dexamethasone (isatuximab group) or carfilzomib-dexamethasone (control group). In the isatuximab group, patients received intravenous isatuximab (10 mg/kg on days 1, 8, 15, and 22 of the first 28-day cycle, and days 1 and 15 of subsequent 28-day cycles). In both treatment groups, intravenous carfilzomib (20 mg/m2 on days 1 and 2 of the first cycle; and 56 mg/m2 on days 8, 9, 15, and 16 of the first cycle, and days 1, 2, 8, 9, 15, and 16 of subsequent cycles) and intravenous or oral dexamethasone (20 mg on days 1, 2, 8, 9, 15, 16, 22, and 23) were administered. The primary endpoint of the trial was progression-free survival, which was reported previously. Treatment continued until progression, unacceptable toxicity, or patient request to discontine. The overall survival analysis reported here was planned to be conducted 3 years after the primary progression-free survival analysis in the intention-to-treat population. Additional analyses were conducted on the secondary endpoints of time to next treatment and second-progression-free survival. Reported p values are non-inferential due to hierarchical testing. This trial is registered with ClinicalTrials.gov (NCT03275285). Between Nov 15, 2017, and March 21, 2019, 302 patients were enrolled and randomly allocated: 179 (59%) to the isatuximab group and 123 (41%) to the control group. 169 (56%) patients were male, 133 (44%) were female, 214 (71%) were White, 50 (17%) were Asian, nine (3%) were Black or African American, and three (1%) were multiracial. At data cutoff for this overall survival analysis (Feb 7, 2023), 79 (44%) overall survival events in the isatuximab group and 59 (48%) in the control group had occurred (median follow-up 56·61 months [IQR 54·90-58·02]). Median overall survival (in months) was not reached (NR; 95% CI 52·17-NR) in the isatuximab group and was 50·60 months (38·93-NR) in the control group (hazard ratio [HR] 0·855 [95% CI 0·608-1·202], nominal one-sided p=0·18). Survival probability at 48 months was 59·7% (95% CI 52·0-66·7) in the isatuximab group and 52·2% (95% CI 42·7-60·8) in the control group (based on Kaplan-Meier analysis). Improvements in time to next treatment (HR 0·583 [95% CI 0·429-0·792], nominal one-sided p=0·0002) and second-progression-free survival (0·663 [0·491-0·895], nominal one-sided p=0·0035) were observed in the isatuximab group. The most common treatment-emergent adverse events were infusion reactions (82 [46%] patients in the isatuximab group and four [3%] in the control group) and upper respiratory tract infections (71 [40%] and 34 [28%], respectively). Discontinuations due to treatment-emergent adverse events were similar between treatment groups (24 [14%] in the isatuximab group and 22 [18%] in the control group), despite an additional 30 weeks of exposure in the isatuximab group. 12 (7%) patients in the isatuximab group and six (5%) patients in the control group had a treatment-related adverse event with a fatal outcome during study treatment. At the time of the current analysis, a difference in overall survival could not be detected between the treatment groups, and no new safety signals were observed. Collectively, the evidence suggests that isatuximab plus carfilzomib-dexamethasone is a key treatment for patients with relapsed or refractory multiple myeloma. Sanofi.",34097854;37156782;39067465,Isa-Kd,Carfilzomib and Dexamethasone (Kd),Multiple myeloma (Relapsed or Refractory),Non-curative therapy,PFS,Primary,superior,Isa-Kd superior to Carfilzomib and Dexamethasone (Kd) for Multiple myeloma (Relapsed or Refractory) (Non-curative therapy) [endpoint: PFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of Isa-Kd compared to Carfilzomib and Dexamethasone (Kd) when used to treat Multiple myeloma (Relapsed or Refractory) (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the PFS outcome of Isa-Kd versus Carfilzomib and Dexamethasone (Kd) in treating Multiple myeloma (Relapsed or Refractory) (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the PFS results of Isa-Kd compared to Carfilzomib and Dexamethasone (Kd) for Multiple myeloma (Relapsed or Refractory) (Non-curative therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of Carfilzomib and Dexamethasone (Kd) compared to Isa-Kd when used to treat Multiple myeloma (Relapsed or Refractory) (Non-curative therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Multiple myeloma (Relapsed or Refractory), Context: Non-curative therapy, Endpoint: PFS, Treatment 1: Isa-Kd, Treatment 2: Carfilzomib and Dexamethasone (Kd) Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Multiple myeloma (Relapsed or Refractory), Context: Non-curative therapy Treatment: ",superior,inferior,no difference,2021,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 2021-09-01,"Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial. Patients with breast cancer remain at risk of relapse after adjuvant therapy. Celecoxib has shown antitumor effects in preclinical models of human breast cancer, but clinical evidence is lacking. To evaluate the role of celecoxib as an addition to conventional therapy for women with ERBB2 (formerly HER2)-negative primary breast cancer. The Randomized European Celecoxib Trial (REACT) was a phase 3, randomized, double-blind study conducted in 160 centers across the UK and Germany testing 2 years of adjuvant celecoxib vs placebo among 2639 patients recruited between January 19, 2007, and November 1, 2012, with follow-up 10 years after treatment completion. Eligible patients had completely resected breast cancer with local and systemic therapy according to local practice. Patients with ERBB2-positive or node-negative and T1, grade 1 tumors were not eligible. Randomization was in a 2:1 ratio between celecoxib or placebo. Statistical analysis was performed from May 5, 2019, to March 5, 2020. Patients received celecoxib, 400 mg, or placebo once daily for 2 years. The primary end point was disease-free survival (DFS), analyzed in the intention-to-treat population using Cox proportional hazards regression and log-rank analysis. Follow-up is complete. A total of 2639 patients (median age, 55.2 years [range, 26.8-86.0 years]) were recruited; 1763 received celecoxib, and 876 received placebo. Most patients' tumors (1930 [73%]) were estrogen receptor positive or progesterone receptor positive and ERBB2 negative. A total of 1265 patients (48%) had node-positive disease, and 1111 (42%) had grade 3 tumors. At a median follow-up of 74.3 months (interquartile range, 61.4-93.6 years), DFS events had been reported for 487 patients (19%): 18% for those who received celecoxib (n = 323; 5-year DFS rate = 84%) vs 19% for those who received placebo (n = 164; 5-year DFS rate = 83%); the unadjusted hazard ratio was 0.97 (95% CI, 0.80-1.17; log-rank P = .75). Rates of toxic effects were low across both treatment groups, with no evidence of a difference. In this randomized clinical trial, patients showed no evidence of a DFS benefit for 2 years' treatment with celecoxib compared with placebo as adjuvant treatment of ERBB2-negative breast cancer. Longer-term treatment or use of a higher dose of celecoxib may lead to a DFS benefit, but further studies would be required to test this possibility. ClinicalTrials.gov Identifier: NCT02429427 and isrctn.org Identifier: ISRCTN48254013.",34264305,Placebo,Celecoxib monotherapy,Breast cancer,Adjuvant therapy,DFS,Primary,no difference,Placebo no difference to Celecoxib monotherapy for Breast cancer (Adjuvant therapy) [endpoint: DFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the DFS outcome of Placebo compared to Celecoxib monotherapy when used to treat Breast cancer (Adjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the DFS outcome of Placebo versus Celecoxib monotherapy in treating Breast cancer (Adjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the DFS results of Placebo compared to Celecoxib monotherapy for Breast cancer (Adjuvant therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the DFS outcome of Celecoxib monotherapy compared to Placebo when used to treat Breast cancer (Adjuvant therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer, Context: Adjuvant therapy, Endpoint: DFS, Treatment 1: Placebo, Treatment 2: Celecoxib monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Breast cancer, Context: Adjuvant therapy Treatment: ",superior,inferior,no difference,2021,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer (Metastatic), Context: Non-curative therapy, Endpoint: PFS, Treatment 1: Tamoxifen monotherapy, Treatment 2: Bilateral oophorectomy monotherapy Response:",Tamoxifen monotherapy superior to Bilateral oophorectomy monotherapy for Breast cancer (Metastatic) (Non-curative therapy) [endpoint: PFS],False 2022-01-14,"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. PD-1 inhibitor plus chemotherapy had been shown to be an effective first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC). However, there was no robust evidence showing a PD-L1 inhibitor combined with chemotherapy benefited patients with squamous and non-squamous NSCLC. GEMSTONE-302 aimed to evaluate the efficacy and safety of a PD-L1 inhibitor, sugemalimab, plus chemotherapy for patients with metastatic squamous or non-squamous NSCLC. This randomised, double-blind, phase 3 trial was done in 35 hospitals and academic research centres in China. Eligible patients were aged 18-75 years, had histologically or cytologically confirmed stage IV squamous or non-squamous NSCLC without known EGFR sensitising mutations, ALK, ROS1, or RET fusions, no previous systemic treatment for metastatic disease, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Patients were randomly assigned (2:1) to receive sugemalimab (1200 mg, intravenously, every 3 weeks) plus platinum-based chemotherapy (carboplatin [area under the curve (AUC) 5 mg/mL per min, intravenously] and paclitaxel [175 mg/m2, intravenously] for squamous NSCLC, or carboplatin [AUC 5 mg/mL per min, intravenously] and pemetrexed [500 mg/m2, intravenously] for non-squamous NSCLC; sugemalimab group) or placebo plus the same platinum-based chemotherapy regimens for squamous or non-squamous NSCLC as in the sugemalimab group; placebo group) for up to four cycles, followed by maintenance therapy with sugemalimab or placebo for squamous NSCLC, and intravenous sugemalimab 500 mg/m2 or matching placebo plus pemetrexed for non-squamous NSCLC. Randomisation was done by an interactive voice-web-response system via permuted blocks (block size was a mixture of three and six with a random order within each stratum) and stratified by ECOG performance status, PD-L1 expression, and tumour pathology. The investigators, patients, and the sponsor were masked to treatment assignment. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population. Safety was analysed in all patients who received at least one treatment dose. Results reported are from a prespecified interim analysis (ie, when the study met the primary endpoint) and an updated analysis (prespecified final analysis for progression-free survival) with a longer follow-up. This study is registered with ClinicalTrials.gov (NCT03789604), is closed to new participants, and follow-up is ongoing. Between Dec 13, 2018, and May 15, 2020, 846 patients were assessed for eligibility; 367 were ineligible, and the remaining 479 patients were randomly assigned to the sugemalimab group (n=320) or placebo group (n=159). At the preplanned interim analysis (data cutoff June 8, 2020; median follow-up 8·6 months [IQR 6·1-11·4]), GEMSTONE-302 met its primary endpoint, with significantly longer progression-free survival in the sugemalimab group compared with the placebo group (median 7·8 months [95% CI 6·9-9·0] vs 4·9 months [4·7-5·0]; stratified hazard ratio [HR] 0·50 [95% CI 0·39-0·64], p<0·0001]). At the final analysis (March 15, 2021) with a median follow-up of 17·8 months (IQR 15·1-20·9), the improvement in progression-free survival was maintained (median 9·0 months [95% CI 7·4-10·8] vs 4·9 months [4·8-5·1]; stratified HR 0·48 [95% CI 0·39-0·60], p<0·0001). The most common grade 3 or 4 any treatment-related adverse events were neutrophil count decreased (104 [33%] of 320 with sugemalimab vs 52 [33%] of 159 with placebo), white blood cell count decreased (45 [14%] vs 27 [17%]), anaemia (43 [13%] vs 18 [11%]), platelet count decreased (33 [10%] vs 15 [9%]), and neutropenia (12 [4%] vs seven [4%]). Any treatment-related serious adverse events occurred in 73 (23%) patients in the sugemalimab group and 31 (20%) patients in the placebo group. Any treatment-related deaths were reported in ten (3%) patients in the sugemalimab group (pneumonia with respiratory failure in one patient; myelosuppression with septic shock in one patient; pneumonia in two patients; respiratory failure, abdominal pain, cardiac failure, and immune-mediated pneumonitis in one patient each; the other two deaths had an unspecified cause) and in two (1%) patients in the placebo group (pneumonia and multiple organ dysfunction syndrome). Sugemalimab plus chemotherapy showed a statistically significant and clinically meaningful progression-free survival improvement compared with placebo plus chemotherapy, in patients with previously untreated squamous and non-squamous metastatic NSCLC, regardless of PD-L1 expression, and could be a newfirst-line treatment option for both squamous and non-squamous metastatic NSCLC. CStone Pharmaceuticals. For the Chinese translation of the abstract see Supplementary Materials section. Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC. The randomized, double-blinded, multi-center, phase III GEMSTONE-302 ( NCT03789604 ) study evaluated the efficacy and safety of sugemalimab versus placebo in combination with chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (NSCLC). In this study, 479 treatment-naive patients with stage IV squamous or non-squamous NSCLC without known EGFR sensitizing mutations, ALK, ROS1 or RET fusions were randomized (2:1) to receive 1,200 mg of sugemalimab (n = 320) or placebo (n = 159) every 3 weeks in combination with platinum-based chemotherapy for up to four cycles, followed by maintenance therapy with sugemalimab or placebo for squamous NSCLC and sugemalimab or placebo plus pemetrexed for non-squamous NSCLC. Placebo-treated patients could cross over to receive sugemalimab monotherapy on disease progression. The primary endpoint was investigator-assessed progression-free survival (PFS) and the secondary endpoints included overall survival (OS) and objective response rate. Sugemalimab plus chemotherapy has demonstrated significant PFS prolongation in the primary analysis as reported previously. As of 22 November 2021, the prespecified interim OS analysis showed significant improvement with the addition of sugemalimab to chemotherapy (median OS = 25.4 versus 16.9 months; hazard ratio = 0.65; 95% confidence interval = 0.50-0.84; P = 0.0008). Sugemalimab plus chemotherapy provided superior PFS and OS compared to placebo plus chemotherapy, supporting the use of sugemalimab as a first-line treatment option for metastatic NSCLC. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial. GEMSTONE-302 was a phase 3 trial in patients with treatment-naive metastatic squamous or non-squamous non-small-cell lung cancer (NSCLC), showed significant improvement in progression-free survival and overall survival with sugemalimab, a PD-L1 inhibitor, plus chemotherapy versus placebo plus chemotherapy. We report the 4-year outcomes from this study. This randomised, double-blind, phase 3 trial was conducted across 35 hospitals and academic research centres in China. Eligible patients were aged 18-75 years; had treatment-naive, histologically or cytologically confirmed stage IV NSCLC, irrespective of PD-L1 expression levels; and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomised (2:1) by investigators using an interactive web response or voice response system via permuted blocks (block sizes of three or six, randomised within each stratum). Patients received histology-specific platinum-based chemotherapy combined with either sugemalimab (1200 mg; sugemalimab group) or placebo (placebo group) for up to four cycles, followed by for up to 35 cycles of maintenance therapy with sugemalimab alone for patients with squamous NSCLC and sugemalimab plus pemetrexed for patients with non-squamous NSCLC in the sugemalimab group, or placebo for patients with squamous NSCLC and placebo plus pemetrexed for patients with non-squamous NSCLC in the placebo group, administered intravenously. Treatment beyond 35 cycles was permitted at the investigator's discretion. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population. Here, we report post-hoc 4-year efficacy and safety outcomes from GEMSTONE-302. This study is registered with ClinicalTrials.gov (NCT03789604) and concluded on May 15, 2023, with all patients discontinued. Between December 13, 2018, and May 15, 2020, 846 patients were assessed for eligibility. 479 patients were randomly assigned into the sugemalimab group (n=320) and placebo group (n=159). 254 (79%) patients were men and 66 (21%) were women in the sugemalimab group and 129 (81%) were men and 30 (19%) were women in the placebo group. All patients were Asian. As of the data cutoff on May 15, 2023, median follow-up durations were 43·5 months (IQR 41·2-46·9) in the sugemalimab group and 43·0 months (40·7-44·8) in the placebo group; median treatment durations were 7·2 months (4·2-18·8) with sugemalimab and 4·6 months (2·8-6·9) with placebo. Median progression-free survival was 9·0 months (95% CI 7·4-10·9) in the sugemalimab group versus 4·9 months (4·8-5·2) in the placebo group (hazard ratio [HR] 0·49 [95% CI 0·39-0·60]). Median overall survival was 25·2 months (20·1-30·2) in the sugemalimab group versus 16·9 months (12·8-20·7) in the placebo group (HR 0·68 [0·54-0·85]). The 4-year overall survival rates were 32·1% (95% CI 26·7-37·6) in the sugemalimab group versus 17·3% (11·1-24·7) in the placebo group. The most common grade 3-4 treatment related adverse events were decreased neutrophil count (105 [33%] with sugemalimab vs 52 [33%] with placebo), decreased white blood cell count (48 [15%] vs 27 [17%]), anaemia (44 [14%] vs 18 [11%]), and decreased platelet count (35 [11%] vs 15 [9%]). Treatment-related serious adverse events occurred in 82 (26%) patients with sugemalimab and 31 (20%) with placebo. No additional treatment-related deaths occurred since the previous overall survival interim analysis. No new safety signals were identified. Sugemalimab with chemotherapy showed a superior long-term overall survival benefit compared with placebo with chemotherapy, as a first-line treatment for patients with NSCLC with no known sensitising EGFR, ALK, ROS1, or RET genomic alterations. These results underscore the efficacy of sugemalimab plus platinum-based chemotherapy as a standard first-line treatment option for both squamous and non-squamous metastatic NSCLC while maintaining a manageable safety profile. CStone Pharmaceuticals. For the Chinese translation of the abstract see Supplementary Materials section.",35038432;37322367;40523368,Carboplatin and Paclitaxel (CP) and Sugemalimab,Carboplatin and Paclitaxel (CP),Non-small cell lung cancer squamous,Non-curative first-line therapy,PFS,Primary,superior,Carboplatin and Paclitaxel (CP) and Sugemalimab superior to Carboplatin and Paclitaxel (CP) for Non-small cell lung cancer squamous (Non-curative first-line therapy) [endpoint: PFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of Carboplatin and Paclitaxel (CP) and Sugemalimab compared to Carboplatin and Paclitaxel (CP) when used to treat Non-small cell lung cancer squamous (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the PFS outcome of Carboplatin and Paclitaxel (CP) and Sugemalimab versus Carboplatin and Paclitaxel (CP) in treating Non-small cell lung cancer squamous (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the PFS results of Carboplatin and Paclitaxel (CP) and Sugemalimab compared to Carboplatin and Paclitaxel (CP) for Non-small cell lung cancer squamous (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of Carboplatin and Paclitaxel (CP) compared to Carboplatin and Paclitaxel (CP) and Sugemalimab when used to treat Non-small cell lung cancer squamous (Non-curative first-line therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Non-small cell lung cancer squamous, Context: Non-curative first-line therapy, Endpoint: PFS, Treatment 1: Carboplatin and Paclitaxel (CP) and Sugemalimab, Treatment 2: Carboplatin and Paclitaxel (CP) Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Non-small cell lung cancer squamous, Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2022,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 2022-06-05,"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. In patients with newly diagnosed multiple myeloma, the effect of adding autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib, and dexamethasone [RVD]), followed by lenalidomide maintenance therapy until disease progression, is unknown. In this phase 3 trial, adults (18 to 65 years of age) with symptomatic myeloma received one cycle of RVD. We randomly assigned these patients, in a 1:1 ratio, to receive two additional RVD cycles plus stem-cell mobilization, followed by either five additional RVD cycles (the RVD-alone group) or high-dose melphalan plus ASCT followed by two additional RVD cycles (the transplantation group). Both groups received lenalidomide until disease progression, unacceptable side effects, or both. The primary end point was progression-free survival. Among 357 patients in the RVD-alone group and 365 in the transplantation group, at a median follow-up of 76.0 months, 328 events of disease progression or death occurred; the risk was 53% higher in the RVD-alone group than in the transplantation group (hazard ratio, 1.53; 95% confidence interval [CI], 1.23 to 1.91; P<0.001); median progression-free survival was 46.2 months and 67.5 months. The percentage of patients with a partial response or better was 95.0% in the RVD-alone group and 97.5% in the transplantation group (P = 0.55); 42.0% and 46.8%, respectively, had a complete response or better (P = 0.99). Treatment-related adverse events of grade 3 or higher occurred in 78.2% and 94.2%, respectively; 5-year survival was 79.2% and 80.7% (hazard ratio for death, 1.10; 95% CI, 0.73 to 1.65). Among adults with multiple myeloma, RVD plus ASCT was associated with longer progression-free survival than RVD alone. No overall survival benefit was observed. (Funded by the National Heart, Lung, and Blood Institute and others; DETERMINATION ClinicalTrials.gov number, NCT01208662.).",35660812,RVD,Melphalan monotherapy,Multiple myeloma,Non-curative first-line consolidation therapy,PFS,Primary,inferior,RVD inferior to Melphalan monotherapy for Multiple myeloma (Non-curative first-line consolidation therapy) [endpoint: PFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of RVD compared to Melphalan monotherapy when used to treat Multiple myeloma (Non-curative first-line consolidation therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the PFS outcome of RVD versus Melphalan monotherapy in treating Multiple myeloma (Non-curative first-line consolidation therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the PFS results of RVD compared to Melphalan monotherapy for Multiple myeloma (Non-curative first-line consolidation therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of Melphalan monotherapy compared to RVD when used to treat Multiple myeloma (Non-curative first-line consolidation therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Multiple myeloma, Context: Non-curative first-line consolidation therapy, Endpoint: PFS, Treatment 1: RVD, Treatment 2: Melphalan monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Multiple myeloma, Context: Non-curative first-line consolidation therapy Treatment: ",superior,inferior,no difference,2022,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 2022-06-18,"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Patients with large B-cell lymphoma (LBCL) primary refractory to or relapsed within 12 months of first-line therapy are at high risk for poor outcomes with current standard of care, platinum-based salvage immunochemotherapy and autologous haematopoietic stem cell transplantation (HSCT). Lisocabtagene maraleucel (liso-cel), an autologous, CD19-directed chimeric antigen receptor (CAR) T-cell therapy, has previously demonstrated efficacy and manageable safety in third-line or later LBCL. In this Article, we report a prespecified interim analysis of liso-cel versus standard of care as second-line treatment for primary refractory or early relapsed (within 12 months after response to initial therapy) LBCL. TRANSFORM is a global, phase 3 study, conducted in 47 sites in the USA, Europe, and Japan, comparing liso-cel with standard of care as second-line therapy in patients with primary refractory or early (≤12 months) relapsed LBCL. Adults aged 18-75 years, Eastern Cooperative Oncology Group performance status score of 1 or less, adequate organ function, PET-positive disease per Lugano 2014 criteria, and candidates for autologous HSCT were randomly assigned (1:1), by use of interactive response technology, to liso-cel (100 × 106 CAR+ T cells intravenously) or standard of care. Standard of care consisted of three cycles of salvage immunochemotherapy delivered intravenously-R-DHAP (rituximab 375 mg/m2 on day 1, dexamethasone 40 mg on days 1-4, two infusions of cytarabine 2000 mg/m2 on day 2, and cisplatin 100 mg/m2 on day 1), R-ICE (rituximab 375 mg/m2 on day 1, ifosfamide 5000 mg/m2 on day 2, etoposide 100 mg/m2 on days 1-3, and carboplatin area under the curve 5 [maximum dose of 800 mg] on day 2), or R-GDP (rituximab 375 mg/m2 on day 1, dexamethasone 40 mg on days 1-4, gemcitabine 1000 mg/m2 on days 1 and 8, and cisplatin 75 mg/m2 on day 1)-followed by high-dose chemotherapy and autologous HSCT in responders. Primary endpoint was event-free survival, with response assessments by an independent review committee per Lugano 2014 criteria. Efficacy was assessed per intention-to-treat (ie, all randomly assigned patients) and safety in patients who received any treatment. This trial is registered with ClinicalTrials.gov, NCT03575351, and is ongoing. Between Oct 23, 2018, and Dec 8, 2020, 232 patients were screened and 184 were assigned to the liso-cel (n=92) or standard of care (n=92) groups. At the data cutoff for this interim analysis, March 8, 2021, the median follow-up was 6·2 months (IQR 4·4-11·5). Median event-free survival was significantly improved in the liso-cel group (10·1 months [95% CI 6·1-not reached]) compared with the standard-of-care group (2·3 months [2·2-4·3]; stratified hazard ratio 0·35; 95% CI 0·23-0·53; stratified Cox proportional hazards model one-sided p<0·0001). The most common grade 3 or worse adverse events were neutropenia (74 [80%] of 92 patients in the liso-cel group vs 46 [51%] of 91 patients in the standard-of-care group), anaemia (45 [49%] vs 45 [49%]), thrombocytopenia (45 [49%] vs 58 [64%]), and prolonged cytopenia (40 [43%] vs three [3%]). Grade 3 cytokine release syndrome and neurological events, which are associated with CAR T-cell therapy, occurred in one (1%) and four (4%) of 92 patients in the liso-cel group, respectively (no grade 4 or 5 events). Serious treatment-emergent adverse events were reported in 44 (48%) patients in the liso-cel group and 44 (48%) in the standard-of-care group. No new liso-cel safety concerns were identified in the second-line setting. There were no treatment-related deaths in the liso-cel group and one treatment-related death due to sepsis in the standard-of-care group. These results support liso-cel as a new second-line treatment recommendation in patients with early relapsed or refractory LBCL. Celgene, a Bristol-Myers Squibb Company. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. This global phase 3 study compared lisocabtagene maraleucel (liso-cel) with a standard of care (SOC) as second-line therapy for primary refractory or early relapsed (≤12 months) large B-cell lymphoma (LBCL). Adults eligible for autologous stem cell transplantation (ASCT; N = 184) were randomly assigned in a 1:1 ratio to liso-cel (100 × 106 chimeric antigen receptor-positive T cells) or SOC (3 cycles of platinum-based immunochemotherapy followed by high-dose chemotherapy and ASCT in responders). The primary end point was event-free survival (EFS). In this primary analysis with a 17.5-month median follow-up, median EFS was not reached (NR) for liso-cel vs 2.4 months for SOC. Complete response (CR) rate was 74% for liso-cel vs 43% for SOC (P < .0001) and median progression-free survival (PFS) was NR for liso-cel vs 6.2 months for SOC (hazard ratio [HR] = 0.400; P < .0001). Median overall survival (OS) was NR for liso-cel vs 29.9 months for SOC (HR = 0.724; P = .0987). When adjusted for crossover from SOC to liso-cel, 18-month OS rates were 73% for liso-cel and 54% for SOC (HR = 0.415). Grade 3 cytokine release syndrome and neurological events occurred in 1% and 4% of patients in the liso-cel arm, respectively (no grade 4 or 5 events). These data show significant improvements in EFS, CR rate, and PFS for liso-cel compared with SOC and support liso-cel as a preferred second-line treatment compared with SOC in patients with primary refractory or early relapsed LBCL. This trial was registered at www.clinicaltrials.gov as #NCT03575351. Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study. We report 3-year follow-up results from TRANSFORM comparing lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line primary refractory/early relapsed (≤12 months) large B-cell lymphoma (LBCL). Adults eligible for autologous stem cell transplantation (N = 184) were randomly assigned 1:1 to liso-cel (100 × 106 chimeric antigen receptor-positive T cells) or SOC. Results are reported descriptively. With a median follow-up of 33.9 months, median (95% CI) event-free survival was 29.5 months (9.5 to not reached [NR]) for liso-cel versus 2.4 months (2.2 to 4.9) for SOC (hazard ratio [HR], 0.375; 95% CI, 0.259 to 0.542). Median progression-free survival was NR (12.6-NR) for liso-cel versus 6.2 months (4.3-8.6) for SOC (HR, 0.422; 95% CI, 0.279 to 0.639) with 36-month rates of 51% versus 26.5%. Median overall survival (OS) was NR for both arms (HR, 0.757; 95% CI, 0.481 to 1.191), with 66% of patients crossing over to receive liso-cel; 36-month OS rate was 63% for liso-cel versus 52% for SOC. OS HR (0.566 [95% CI, 0.359 to 0.895]) favored liso-cel when accounting for the treatment effect of crossover. Safety results were consistent with previous reports. At 3-year follow-up, liso-cel confirmed superior, more durable efficacy versus SOC with a favorable safety profile and no new safety signals. These data support liso-cel as an effective second-line treatment with curative potential for relapsed/refractory LBCL.",35717989;36542826;40623279,Lisocabtagene maraleucel monotherapy,R-DHAP,Diffuse large B-cell lymphoma (Relapsed or Refractory),Salvage therapy,EFS,Primary,superior,Lisocabtagene maraleucel monotherapy superior to R-DHAP for Diffuse large B-cell lymphoma (Relapsed or Refractory) (Salvage therapy) [endpoint: EFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the EFS outcome of Lisocabtagene maraleucel monotherapy compared to R-DHAP when used to treat Diffuse large B-cell lymphoma (Relapsed or Refractory) (Salvage therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the EFS outcome of Lisocabtagene maraleucel monotherapy versus R-DHAP in treating Diffuse large B-cell lymphoma (Relapsed or Refractory) (Salvage therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the EFS results of Lisocabtagene maraleucel monotherapy compared to R-DHAP for Diffuse large B-cell lymphoma (Relapsed or Refractory) (Salvage therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the EFS outcome of R-DHAP compared to Lisocabtagene maraleucel monotherapy when used to treat Diffuse large B-cell lymphoma (Relapsed or Refractory) (Salvage therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Diffuse large B-cell lymphoma (Relapsed or Refractory), Context: Salvage therapy, Endpoint: EFS, Treatment 1: Lisocabtagene maraleucel monotherapy, Treatment 2: R-DHAP Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Diffuse large B-cell lymphoma (Relapsed or Refractory), Context: Salvage therapy Treatment: ",superior,inferior,no difference,2022,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 2022-07-01,"Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. Patients with breast cancer and brain metastases (BM) have a poor prognosis and high clinical need for novel treatments; however, historically, studies have often excluded these patients. Although the BEACON study did not meet its primary end point, treatment with etirinotecan pegol vs chemotherapy of the physician's choice for patients with advanced breast cancer demonstrated a significant improvement in overall survival (OS) for the prespecified patient subgroup with preexisting, pretreated, and nonprogressive BM. To compare clinical outcomes in patients with BM treated with etirinotecan pegol vs chemotherapy of the physician's choice in a confirmatory trial. This study was a phase 3, open-label, randomized clinical trial (ATTAIN) in patients with metastatic breast cancer and a history of stable pretreated BM who experienced disease progression while receiving chemotherapy in the metastatic setting. The trial took place at 47 sites in 10 countries, and patients were enrolled between March 7, 2017, and November 6, 2019. Patients were randomized to receive etirinotecan pegol, 145 mg/m2, every 21 days or chemotherapy (eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel). The primary end point was OS. Key secondary end points included progression-free survival, objective response rate, duration of response, and the clinical benefit rate. A total of 178 female patients (9 [5.1%] Asian, 8 [4.5%] Black or African American, and 123 [69.1] White individuals) were randomized to receive treatment with etirinotecan pegol (92 [51.7%]; median [range] age, 53 [27-79] years) or chemotherapy (86 [48.3%]; median [range] age, 52 [24-77] years). Median OS was similar in both groups (etirinotecan pegol, 7.8 months; chemotherapy, 7.5 months; hazard ratio [HR], 0.90; 95% CI, 0.61-1.33; P = .60). Median progression-free survival for non-central nervous system metastases per blinded independent central review for etirinotecan pegol vs chemotherapy was 2.8 and 1.9 months (HR, 0.72; 95% CI, 0.45-1.16; P = .18) and 3.9 vs 3.3 months, respectively, for central nervous system metastases (HR, 0.59; 95% CI, 0.33-1.05; P = .07). Safety profiles between the groups were largely comparable. The results of the ATTAIN randomized clinical trial found no statistically significant difference in outcomes between treatment with etirinotecan pegol and chemotherapy in patients with BM. However, this study represents one of the largest published trials dedicated to patients with breast cancer and BM and may help to inform further research. ClinicalTrials.gov Identifier: NCT02915744.",35552364,Paclitaxel monotherapy,Etirinotecan pegol monotherapy,Breast cancer,All lines of therapy,OS,Primary,no difference,Paclitaxel monotherapy no difference to Etirinotecan pegol monotherapy for Breast cancer (All lines of therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Paclitaxel monotherapy compared to Etirinotecan pegol monotherapy when used to treat Breast cancer (All lines of therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Paclitaxel monotherapy versus Etirinotecan pegol monotherapy in treating Breast cancer (All lines of therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Paclitaxel monotherapy compared to Etirinotecan pegol monotherapy for Breast cancer (All lines of therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Etirinotecan pegol monotherapy compared to Paclitaxel monotherapy when used to treat Breast cancer (All lines of therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer, Context: All lines of therapy, Endpoint: OS, Treatment 1: Paclitaxel monotherapy, Treatment 2: Etirinotecan pegol monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Breast cancer, Context: All lines of therapy Treatment: ",superior,inferior,no difference,2022,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer (Node Positive), Context: Adjuvant therapy, Endpoint: RFS, Treatment 1: CMF, Treatment 2: CMFT Response:",CMF inferior to CMFT for Breast cancer (Node Positive) (Adjuvant therapy) [endpoint: RFS],False 2022-12-15,"Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. This randomized, open-label trial compared the efficacy and safety of adjuvant nab-paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic ductal adenocarcinoma (ClinicalTrials.gov identifier: NCT01964430). We assigned 866 treatment-naive patients with pancreatic ductal adenocarcinoma to nab-paclitaxel (125 mg/m2) + gemcitabine (1,000 mg/m2) or gemcitabine alone to one 30-40 infusion on days 1, 8, and 15 of six 28-day cycles. The primary end point was independently assessed disease-free survival (DFS). Additional end points included investigator-assessed DFS, overall survival (OS), and safety. Two hundred eighty-seven of 432 patients and 310 of 434 patients completed nab-paclitaxel + gemcitabine and gemcitabine treatment, respectively. At primary data cutoff (December 31, 2018; median follow-up, 38.5 [interquartile range [IQR], 33.8-43 months), the median independently assessed DFS was 19.4 (nab-paclitaxel + gemcitabine) versus 18.8 months (gemcitabine; hazard ratio [HR], 0.88; 95% CI, 0.729 to 1.063; P = .18). The median investigator-assessed DFS was 16.6 (IQR, 8.4-47.0) and 13.7 (IQR, 8.3-44.1) months, respectively (HR, 0.82; 95% CI, 0.694 to 0.965; P = .02). The median OS (427 events; 68% mature) was 40.5 (IQR, 20.7 to not reached) and 36.2 (IQR, 17.7-53.3) months, respectively (HR, 0.82; 95% CI, 0.680 to 0.996; P = .045). At a 16-month follow-up (cutoff, April 3, 2020; median follow-up, 51.4 months [IQR, 47.0-57.0]), the median OS (511 events; 81% mature) was 41.8 (nab-paclitaxel + gemcitabine) versus 37.7 months (gemcitabine; HR, 0.82; 95% CI, 0.687 to 0.973; P = .0232). At the 5-year follow-up (cutoff, April 9, 2021; median follow-up, 63.2 months [IQR, 60.1-68.7]), the median OS (555 events; 88% mature) was 41.8 versus 37.7 months, respectively (HR, 0.80; 95% CI, 0.678 to 0.947; P = .0091). Eighty-six percent (nab-paclitaxel + gemcitabine) and 68% (gemcitabine) of patients experienced grade ≥ 3 treatment-emergent adverse events. Two patients per study arm died of treatment-emergent adverse events. The primary end point (independently assessed DFS) was not met despite favorable OS seen with nab-paclitaxel + gemcitabine.",36521097,Gemcitabine monotherapy,Gemcitabine and nab-Paclitaxel,Pancreatic cancer,Adjuvant therapy,DFS,Primary,no difference,Gemcitabine monotherapy no difference to Gemcitabine and nab-Paclitaxel for Pancreatic cancer (Adjuvant therapy) [endpoint: DFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the DFS outcome of Gemcitabine monotherapy compared to Gemcitabine and nab-Paclitaxel when used to treat Pancreatic cancer (Adjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the DFS outcome of Gemcitabine monotherapy versus Gemcitabine and nab-Paclitaxel in treating Pancreatic cancer (Adjuvant therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the DFS results of Gemcitabine monotherapy compared to Gemcitabine and nab-Paclitaxel for Pancreatic cancer (Adjuvant therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the DFS outcome of Gemcitabine and nab-Paclitaxel compared to Gemcitabine monotherapy when used to treat Pancreatic cancer (Adjuvant therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Pancreatic cancer, Context: Adjuvant therapy, Endpoint: DFS, Treatment 1: Gemcitabine monotherapy, Treatment 2: Gemcitabine and nab-Paclitaxel Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Pancreatic cancer, Context: Adjuvant therapy Treatment: ",superior,inferior,no difference,2022,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Colorectal cancer, Context: Non-curative first-line therapy, Endpoint: ORR, Treatment 1: Fluorouracil monotherapy, Treatment 2: Fluorouracil and Semustine Response:",Fluorouracil monotherapy inferior to Fluorouracil and Semustine for Colorectal cancer (Non-curative first-line therapy) [endpoint: ORR],False 2023-04-25,"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Patients with acute myeloid leukaemia (AML) positive for internal tandem duplication (ITD) mutations of FLT3 have poor outcomes. Quizartinib, an oral, highly potent, selective, type 2 FLT3 inhibitor, plus chemotherapy showed antitumour activity with an acceptable safety profile in patients with FLT3-ITD-positive newly diagnosed AML. The aim of the study was to compare the effect of quizartinib versus placebo on overall survival in patients with FLT3-ITD-positive newly diagnosed AML aged 18-75 years. We conducted a randomised, double-blind, placebo-controlled, phase 3 trial comparing quizartinib and placebo in combination with chemotherapy in induction and consolidation, followed by quizartinib or placebo single-agent continuation, in patients with FLT3-ITD-positive newly diagnosed AML at 193 hospitals and clinics in 26 countries in Europe; North America; and Asia, Australia, and South America. Patients aged 18-75 years were eligible. Patients were randomly assigned (1:1) to the quizartinib group or the placebo group by an independent biostatistician through an interactive web and voice response system, stratified by region, age, and white blood cell count at diagnosis. Patients, investigators, funders, and contract research organisations were masked to treatments assigned. Induction therapy comprised a standard 7 + 3 induction regimen of cytarabine 100 mg/m2 per day (or 200 mg/m2 per day allowed if institutional or local standard) by continuous intravenous infusion from day 1 to day 7 and anthracycline (daunorubicin 60 mg/m2 per day or idarubicin 12 mg/m2 per day) by intravenous infusion on days 1, 2, and 3, then quizartinib 40 mg orally or placebo once per day, starting on day 8, for 14 days. Patients with complete remission or complete remission with incomplete neutrophil or platelet recovery received standard consolidation with high-dose cytarabine plus quizartinib (40 mg per day orally) or placebo, allogeneic haematopoietic cell transplantation (allo-HCT), or both as consolidation therapy, followed by continuation of single-agent quizartinib or placebo for up to 3 years. The primary outcome was overall survival, defined as time from randomisation until death from any cause and assessed in the intention-to-treat population. Safety was evaluated in all patients who received at least one dose of quizartinib or placebo. This study is registered with ClinicalTrials.gov (NCT02668653). Between Sept 27, 2016, and Aug 14, 2019, 3468 patients with AML were screened and 539 patients (294 [55%] male patients and 245 [45%] female patients) with FLT3-ITD-positive AML were included and randomly assigned to the quizartinib group (n=268) or placebo group (n=271). 148 (55%) of 268 patients in the quizartinib group and 168 (62%) of 271 patients in the placebo group discontinued the study, primarily because of death (133 [90%] of 148 in the quizartinib group vs 158 [94%] of 168 in the placebo group) or withdrawal of consent (13 [9%] of 148 in the quizartinib group vs 9 [5%] of 168 in the placebo group). Median age was 56 years (range 20-75, IQR 46·0-65·0). At a median follow-up of 39·2 months (IQR 31·9-45·8), median overall survival was 31·9 months (95% CI 21·0-not estimable) for quizartinib versus 15·1 months (13·2-26·2) for placebo (hazard ratio 0·78, 95% CI 0·62-0·98, p=0·032). Similar proportions of patients in the quizartinib and placebo groups had at least one adverse event (264 [100%] of 265 in the quizartinib group and 265 [99%] of 268 in the placebo group) and one grade 3 or higher adverse event (244 [92%] of 265 in the quizartinib group and 240 [90%] of 268 in the placebo group). The most common grade 3 or 4 adverse events were febrile neutropenia, hypokalaemia, and pneumonia in both groups and neutropenia in the quizartinib group. The addition of quizartinib to standard chemotherapy with or without allo-HCT, followed by continuation monotherapy for up to 3 years, resulted in improved overall survival in adults aged 18-75 years with FLT3-ITD-positive newly diagnosed AML. Based on the results from the QuANTUM-First trial, quizartinib provides a new, effective, and generally well tolerated treatment option for adult patients with FLT3-ITD-positive newly diagnosed AML. Daiichi Sankyo.",37116523,7+3d and Quizartinib|7+3i and Quizartinib,7+3d,Acute myeloid leukemia,Induction therapy,OS,Primary,superior,7+3d and Quizartinib|7+3i and Quizartinib superior to 7+3d for Acute myeloid leukemia (Induction therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of 7+3d and Quizartinib|7+3i and Quizartinib compared to 7+3d when used to treat Acute myeloid leukemia (Induction therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of 7+3d and Quizartinib|7+3i and Quizartinib versus 7+3d in treating Acute myeloid leukemia (Induction therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of 7+3d and Quizartinib|7+3i and Quizartinib compared to 7+3d for Acute myeloid leukemia (Induction therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of 7+3d compared to 7+3d and Quizartinib|7+3i and Quizartinib when used to treat Acute myeloid leukemia (Induction therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia, Context: Induction therapy, Endpoint: OS, Treatment 1: 7+3d and Quizartinib|7+3i and Quizartinib, Treatment 2: 7+3d Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Acute myeloid leukemia, Context: Induction therapy Treatment: ",superior,inferior,no difference,2023,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Multiple myeloma, Context: Non-curative therapy, Endpoint: OS, Treatment 1: Urethane monotherapy, Treatment 2: Placebo Response:",Urethane monotherapy inferior to Placebo for Multiple myeloma (Non-curative therapy) [endpoint: OS],False 2023-05-01,"Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial. Polycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV, ruxolitinib controls blood counts and improves symptoms. MAJIC-PV is a randomized phase II trial of ruxolitinib versus best available therapy (BAT) in patients resistant/intolerant to hydroxycarbamide (HC-INT/RES). Primary outcome was complete response (CR) within 1 year. Secondary outcomes included duration of response, event-free survival (EFS), symptom, and molecular response. One hundred eighty patients were randomly assigned. CR was achieved in 40 (43%) patients on ruxolitinib versus 23 (26%) on BAT (odds ratio, 2.12; 90% CI, 1.25 to 3.60; P = .02). Duration of CR was superior for ruxolitinib (hazard ratio [HR], 0.38; 95% CI, 0.24 to 0.61; P < .001). Symptom responses were better with ruxolitinib and durable. EFS (major thrombosis, hemorrhage, transformation, and death) was superior for patients attaining CR within 1 year (HR, 0.41; 95% CI, 0.21 to 0.78; P = .01); and those on ruxolitinib (HR, 0.58; 95% CI, 0.35 to 0.94; P = .03). Serial analysis of JAK2V617F variant allele fraction revealed molecular response was more frequent with ruxolitinib and was associated with improved outcomes (progression-free survival [PFS] P = .001, EFS P = .001, overall survival P = .01) and clearance of JAK2V617F stem/progenitor cells. ASXL1 mutations predicted for adverse EFS (HR, 3.02; 95% CI, 1.47 to 6.17; P = .003). The safety profile of ruxolitinib was as previously reported. The MAJIC-PV study demonstrates ruxolitinib treatment benefits HC-INT/RES PV patients with superior CR, and EFS as well as molecular response; importantly also demonstrating for the first time, to our knowledge, that molecular response is linked to EFS, PFS, and OS.",37126762,Standard therapy,Ruxolitinib monotherapy,Polycythemia vera,Non-curative therapy,CR rate,Primary,inferior,Standard therapy inferior to Ruxolitinib monotherapy for Polycythemia vera (Non-curative therapy) [endpoint: CR rate],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the CR rate outcome of Standard therapy compared to Ruxolitinib monotherapy when used to treat Polycythemia vera (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the CR rate outcome of Standard therapy versus Ruxolitinib monotherapy in treating Polycythemia vera (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the CR rate results of Standard therapy compared to Ruxolitinib monotherapy for Polycythemia vera (Non-curative therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the CR rate outcome of Ruxolitinib monotherapy compared to Standard therapy when used to treat Polycythemia vera (Non-curative therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Polycythemia vera, Context: Non-curative therapy, Endpoint: CR rate, Treatment 1: Standard therapy, Treatment 2: Ruxolitinib monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Polycythemia vera, Context: Non-curative therapy Treatment: ",superior,inferior,no difference,2023,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 2023-08-31,"Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. Concizumab is an anti-tissue factor pathway inhibitor monoclonal antibody designed to achieve hemostasis in all hemophilia types, with subcutaneous administration. A previous trial of concizumab (explorer4) established proof of concept in patients with hemophilia A or B with inhibitors. We conducted the explorer7 trial to assess the safety and efficacy of concizumab in patients with hemophilia A or B with inhibitors. Patients were randomly assigned in a 1:2 ratio to receive no prophylaxis for at least 24 weeks (group 1) or concizumab prophylaxis for at least 32 weeks (group 2) or were nonrandomly assigned to receive concizumab prophylaxis for at least 24 weeks (groups 3 and 4). After a treatment pause due to nonfatal thromboembolic events in three patients receiving concizumab, including one from the explorer7 trial, concizumab therapy was restarted with a loading dose of 1.0 mg per kilogram of body weight, followed by 0.2 mg per kilogram daily (potentially adjusted on the basis of concizumab plasma concentration as measured at week 4). The primary end-point analysis compared treated spontaneous and traumatic bleeding episodes in group 1 and group 2. Safety, patient-reported outcomes, and pharmacokinetics and pharmacodynamics were also assessed. Of 133 enrolled patients, 19 were randomly assigned to group 1 and 33 to group 2; the remaining 81 were assigned to groups 3 and 4. The estimated mean annualized bleeding rate in group 1 was 11.8 episodes (95% confidence interval [CI], 7.0 to 19.9), as compared with 1.7 episodes (95% CI, 1.0 to 2.9) in group 2 (rate ratio, 0.14 [95% CI, 0.07 to 0.29]; P<0.001). The overall median annualized bleeding rate for patients receiving concizumab (groups 2, 3, and 4) was 0 episodes. No thromboembolic events were reported after concizumab therapy was restarted. The plasma concentrations of concizumab remained stable over time. Among patients with hemophilia A or B with inhibitors, the annualized bleeding rate was lower with concizumab prophylaxis than with no prophylaxis. (Funded by Novo Nordisk; explorer7 ClinicalTrials.gov number, NCT04083781.).",37646676,Observation,Concizumab monotherapy,Hemophilia B,All lines of therapy,bleeding rate,Primary,superior,Observation superior to Concizumab monotherapy for Hemophilia B (All lines of therapy) [endpoint: bleeding rate],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the bleeding rate outcome of Observation compared to Concizumab monotherapy when used to treat Hemophilia B (All lines of therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the bleeding rate outcome of Observation versus Concizumab monotherapy in treating Hemophilia B (All lines of therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the bleeding rate results of Observation compared to Concizumab monotherapy for Hemophilia B (All lines of therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the bleeding rate outcome of Concizumab monotherapy compared to Observation when used to treat Hemophilia B (All lines of therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Hemophilia B, Context: All lines of therapy, Endpoint: bleeding rate, Treatment 1: Observation, Treatment 2: Concizumab monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Hemophilia B, Context: All lines of therapy Treatment: ",superior,inferior,no difference,2023,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 2023-11-08,"Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI-sensitizing and EGFR T790M resistance mutations. Evidence suggests that the addition of chemotherapy may extend the benefits of EGFR-TKI therapy. In this phase 3, international, open-label trial, we randomly assigned in a 1:1 ratio patients with EGFR-mutated (exon 19 deletion or L858R mutation) advanced non-small-cell lung cancer (NSCLC) who had not previously received treatment for advanced disease to receive osimertinib (80 mg once daily) with chemotherapy (pemetrexed [500 mg per square meter of body-surface area] plus either cisplatin [75 mg per square meter] or carboplatin [pharmacologically guided dose]) or to receive osimertinib monotherapy (80 mg once daily). The primary end point was investigator-assessed progression-free survival. Response and safety were also assessed. A total of 557 patients underwent randomization. Investigator-assessed progression-free survival was significantly longer in the osimertinib-chemotherapy group than in the osimertinib group (hazard ratio for disease progression or death, 0.62; 95% confidence interval [CI], 0.49 to 0.79; P<0.001). At 24 months, 57% (95% CI, 50 to 63) of the patients in the osimertinib-chemotherapy group and 41% (95% CI, 35 to 47) of those in the osimertinib group were alive and progression-free. Progression-free survival as assessed according to blinded independent central review was consistent with the primary analysis (hazard ratio, 0.62; 95% CI, 0.48 to 0.80). An objective (complete or partial) response was observed in 83% of the patients in the osimertinib-chemotherapy group and in 76% of those in the osimertinib group; the median response duration was 24.0 months (95% CI, 20.9 to 27.8) and 15.3 months (95% CI, 12.7 to 19.4), respectively. The incidence of grade 3 or higher adverse events from any cause was higher with the combination than with monotherapy - a finding driven by known chemotherapy-related adverse events. The safety profile of osimertinib plus pemetrexed and a platinum-based agent was consistent with the established profiles of the individual agents. First-line treatment with osimertinib-chemotherapy led to significantly longer progression-free survival than osimertinib monotherapy among patients with EGFR-mutated advanced NSCLC. (Funded by AstraZeneca; FLAURA2 ClinicalTrials.gov number, NCT04035486.). CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer. We report CNS efficacy of first-line osimertinib plus chemotherapy versus osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) from the phase III FLAURA2 study according to baseline CNS metastasis status. Patients were randomly assigned to osimertinib plus platinum-pemetrexed (combination) or osimertinib monotherapy until disease progression or discontinuation. Brain scans were performed in all patients at baseline and progression and at scheduled assessments until progression for patients with baseline CNS metastases; scans were assessed by neuroradiologist CNS blinded independent central review (BICR). On the basis of baseline CNS BICR, 118 of 279 (combination) and 104 of 278 (monotherapy) randomly assigned patients had ≥one measurable and/or nonmeasurable CNS lesion and were included in the CNS full analysis set (cFAS); 40 of 118 and 38 of 104 had ≥one measurable target CNS lesion and were included in the post hoc CNS evaluable-for-response set (cEFR). In the cFAS, the hazard ratio (HR) for CNS progression or death was 0.58 (95% CI, 0.33 to 1.01). In patients without baseline CNS metastases, the HR for CNS progression or death was 0.67 (95% CI, 0.43 to 1.04). In the cFAS, CNS objective response rates (ORRs; 95% CI) were 73% (combination; 64 to 81) versus 69% (monotherapy; 59 to 78); 59% versus 43% had CNS complete response (CR). In the cEFR, CNS ORRs (95% CI) were 88% (73 to 96) versus 87% (72 to 96); 48% versus 16% had CNS CR. Osimertinib plus platinum-pemetrexed demonstrated improved CNS efficacy compared with osimertinib monotherapy, including delaying CNS progression, irrespective of baseline CNS metastasis status. These data support this combination as a new first-line treatment for patients with EGFR-mutated advanced NSCLC, including those with CNS metastases. Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC. The primary analysis of this trial showed that first-line treatment with osimertinib plus chemotherapy with a platinum-based agent and pemetrexed led to significantly longer progression-free survival than osimertinib monotherapy among patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC). Results from the planned final analysis of overall survival are needed. In this phase 3, international, open-label trial, we randomly assigned in a 1:1 ratio patients with EGFR-mutated (exon 19 deletion or L858R mutation) advanced NSCLC who had not previously received treatment for advanced disease to receive either osimertinib (80 mg once daily) plus chemotherapy with pemetrexed (500 mg per square meter of body-surface area) and a platinum-based agent (cisplatin [75 mg per square meter] or carboplatin [pharmacologically guided dose]) or osimertinib monotherapy (80 mg once daily). The key secondary end point was overall survival. A total of 557 patients were randomly assigned to the osimertinib plus platinum-pemetrexed group (279 patients) or the osimertinib monotherapy group (278 patients). The median overall survival was 47.5 months in the osimertinib plus platinum-pemetrexed group and 37.6 months in the osimertinib monotherapy group (hazard ratio for death, 0.77; 95% confidence interval, 0.61 to 0.96; P = 0.02). Grade 3 or higher adverse events of any cause were reported in 70% of the patients in the osimertinib plus platinum-pemetrexed group and in 34% of the patients in the osimertinib monotherapy group; adverse events leading to the discontinuation of osimertinib were reported in 12% and 7%, respectively. Among patients with EGFR-mutated advanced NSCLC, first-line treatment with osimertinib plus platinum-pemetrexed led to significantly longer overall survival than osimertinib monotherapy and was associated with an increased risk of reversible adverse events of grade 3 or higher. (Funded by AstraZeneca; FLAURA2 ClinicalTrials.gov number, NCT04035486.).",37937763;38042525;41104938,Osimertinib monotherapy,"Carboplatin, Osimertinib, Pemetrexed",Non-small cell lung cancer (Locally Advanced or Metastatic),Non-curative therapy,PFS,Primary,inferior,"Osimertinib monotherapy inferior to Carboplatin, Osimertinib, Pemetrexed for Non-small cell lung cancer (Locally Advanced or Metastatic) (Non-curative therapy) [endpoint: PFS]","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of Osimertinib monotherapy compared to Carboplatin, Osimertinib, Pemetrexed when used to treat Non-small cell lung cancer (Locally Advanced or Metastatic) (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the PFS outcome of Osimertinib monotherapy versus Carboplatin, Osimertinib, Pemetrexed in treating Non-small cell lung cancer (Locally Advanced or Metastatic) (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the PFS results of Osimertinib monotherapy compared to Carboplatin, Osimertinib, Pemetrexed for Non-small cell lung cancer (Locally Advanced or Metastatic) (Non-curative therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of Carboplatin, Osimertinib, Pemetrexed compared to Osimertinib monotherapy when used to treat Non-small cell lung cancer (Locally Advanced or Metastatic) (Non-curative therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Non-small cell lung cancer (Locally Advanced or Metastatic), Context: Non-curative therapy, Endpoint: PFS, Treatment 1: Osimertinib monotherapy, Treatment 2: Carboplatin, Osimertinib, Pemetrexed Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Non-small cell lung cancer (Locally Advanced or Metastatic), Context: Non-curative therapy Treatment: ",superior,inferior,no difference,2023,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 2023-12-07,"Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody-drug conjugate targeting folate receptor α (FRα), is approved for the treatment of platinum-resistant ovarian cancer in the United States. We conducted a phase 3, global, confirmatory, open-label, randomized, controlled trial to compare the efficacy and safety of MIRV with the investigator's choice of chemotherapy in the treatment of platinum-resistant, high-grade serous ovarian cancer. Participants who had previously received one to three lines of therapy and had high FRα tumor expression (≥75% of cells with ≥2+ staining intensity) were randomly assigned in a 1:1 ratio to receive MIRV (6 mg per kilogram of adjusted ideal body weight every 3 weeks) or chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan). The primary end point was investigator-assessed progression-free survival; key secondary analytic end points included objective response, overall survival, and participant-reported outcomes. A total of 453 participants underwent randomization; 227 were assigned to the MIRV group and 226 to the chemotherapy group. The median progression-free survival was 5.62 months (95% confidence interval [CI], 4.34 to 5.95) with MIRV and 3.98 months (95% CI, 2.86 to 4.47) with chemotherapy (P<0.001). An objective response occurred in 42.3% of the participants in the MIRV group and in 15.9% of those in the chemotherapy group (odds ratio, 3.81; 95% CI, 2.44 to 5.94; P<0.001). Overall survival was significantly longer with MIRV than with chemotherapy (median, 16.46 months vs. 12.75 months; hazard ratio for death, 0.67; 95% CI, 0.50 to 0.89; P = 0.005). During the treatment period, fewer adverse events of grade 3 or higher occurred with MIRV than with chemotherapy (41.7% vs. 54.1%), as did serious adverse events of any grade (23.9% vs. 32.9%) and events leading to discontinuation (9.2% vs. 15.9%). Among participants with platinum-resistant, FRα-positive ovarian cancer, treatment with MIRV showed a significant benefit over chemotherapy with respect to progression-free and overall survival and objective response. (Funded by ImmunoGen; MIRASOL ClinicalTrials.gov number, NCT04209855.). Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial. Mirvetuximab soravtansine-gynx (MIRV) is a first-in-class antibody-drug conjugate targeting folate receptor α (FRα), approved by the US Food and Drug Administration for the treatment of platinum-resistant ovarian cancer in the USA. Here, we report patient-reported outcomes for participants treated with MIRV compared with investigator's choice of chemotherapy from the phase 3 MIRASOL trial, which met its primary endpoint of progression-free survival and key secondary endpoints of objective response rate and overall survival. The MIRASOL trial was a confirmatory, phase 3, randomised, controlled, open-label trial, building on the phase 2 SORAYA trial which had previously demonstrated the safety and efficacy of MIRV in platinum-resistant ovarian cancer. Patients 18 years or older with a confirmed platinum-resistant, recurrent high-grade serous epithelial ovarian cancer diagnosis were recruited from 253 sites including hospitals, academic centres, and community centres in 21 countries. Patients must have received one to three previous systemic anticancer therapies, and have high FRα tumour expression (≥75% tumour cells with an immunohistochemistry score of ≥2+ membrane staining using the PS2+ scoring method), one or more lesions with measurable disease, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1) to MIRV or investigator's choice of chemotherapy, stratified by number of previous therapy lines and the type of investigator's choice of chemotherapy. Therapies were administered in an open-label manner; MIRV was administered intravenously at 6 mg/kg of adjusted ideal bodyweight every 3 weeks. The primary endpoint was progression-free survival. Key secondary endpoints were objective response rate, overall survival, and a 15·0-point or greater improvement at week 8 or 9 in abdominal and gastrointestinal symptoms using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Ovarian Cancer Module (EORTC QLQ-OV28) in the intention-to-treat population. The MIRASOL trial was registered at ClinicalTrials.gov (NCT04209855), the Gynecologic Oncology Group (GOG 3045), and the European Network of Gynaecological Oncological Trial Groups (ENGOT-ov55), and is complete. Between Feb 3, 2020, and Aug 3, 2022, 453 patients were enrolled and randomly assigned to treatment (227 to the MIRV group and 226 to the investigator's choice of chemotherapy group). All patients were female; 301 (66%) participants were White, 53 (12%) were Asian, 13 (3%) were Black, and 86 (19%) were of another race or not reported; 27 (6%) were Hispanic or Latino. The median follow-up for the study, determined by the reverse Kaplan-Meier method, was 13·1 months (95% CI 12·1-14). QLQ-OV28 completion rates were 86% (365 of 425) at baseline and 81% (282 of 349) at week 8 or 9. 34 (21·0%; 95% CI 15·0-28·1) of 162 patients treated with MIRV reported improvement in QLQ-OV28 abdominal and gastrointestinal scores, compared with 23 (15·3%; 10·0-22·1) of 150 patients treated with the investigator's choice of chemotherapy. These differences were not statistically significant (odds ratio 1·5 [95% CI 0·8-2·6]; p=0·26). MIRV did not seem to impair or improve patient quality of life compared with investigator's choice of chemotherapy. The similar quality-of-life outcomes in the two treatment groups, combined with the previously reported higher efficacy of MIRV compared with single-agent chemotherapy, support MIRV as new treatment option for FRα-positive platinum-resistant ovarian cancer. AbbVie.",38055253;40179908,Paclitaxel monotherapy,Mirvetuximab soravtansine monotherapy,Ovarian cancer,Non-curative therapy,PFS,Primary,inferior,Paclitaxel monotherapy inferior to Mirvetuximab soravtansine monotherapy for Ovarian cancer (Non-curative therapy) [endpoint: PFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of Paclitaxel monotherapy compared to Mirvetuximab soravtansine monotherapy when used to treat Ovarian cancer (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the PFS outcome of Paclitaxel monotherapy versus Mirvetuximab soravtansine monotherapy in treating Ovarian cancer (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the PFS results of Paclitaxel monotherapy compared to Mirvetuximab soravtansine monotherapy for Ovarian cancer (Non-curative therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of Mirvetuximab soravtansine monotherapy compared to Paclitaxel monotherapy when used to treat Ovarian cancer (Non-curative therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Ovarian cancer, Context: Non-curative therapy, Endpoint: PFS, Treatment 1: Paclitaxel monotherapy, Treatment 2: Mirvetuximab soravtansine monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Ovarian cancer, Context: Non-curative therapy Treatment: ",superior,inferior,no difference,2023,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Cervical cancer, Context: Definitive therapy, Endpoint: OS, Treatment 1: Hydroxyurea and RT, Treatment 2: Radiation therapy Response:",Hydroxyurea and RT superior to Radiation therapy for Cervical cancer (Definitive therapy) [endpoint: OS],True 2024-05-15,"IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. Immune checkpoint inhibitors improve the efficacy of first-line chemotherapy for patients with programmed death-ligand 1 (PD-L1)-positive unresectable locally advanced/metastatic triple-negative breast cancer (aTNBC), but randomised data in rapidly relapsing aTNBC are scarce. IMpassion132 (NCT03371017) enrolled patients with aTNBC relapsing <12 months after last chemotherapy dose (anthracycline and taxane required) or surgery for early TNBC. PD-L1 status was centrally assessed using SP142 before randomisation. Initially patients were enrolled irrespective of PD-L1 status. From August 2019, enrolment was restricted to PD-L1-positive (tumour immune cell ≥1%) aTNBC. Patients were randomised 1:1 to placebo or atezolizumab 1200 mg every 21 days with investigator-selected chemotherapy until disease progression or unacceptable toxicity. Stratification factors were chemotherapy regimen (carboplatin plus gemcitabine or capecitabine monotherapy), visceral (lung and/or liver) metastases and (initially) PD-L1 status. The primary endpoint was overall survival (OS), tested hierarchically in patients with PD-L1-positive tumours and then, if positive, in the modified intent-to-treat (mITT) population (all-comer patients randomised pre-August 2019). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR) and safety. Among 354 patients with rapidly relapsing PD-L1-positive aTNBC, 68% had a disease-free interval of <6 months and 73% received carboplatin/gemcitabine. The OS hazard ratio was 0.93 (95% confidence interval 0.73-1.20, P = 0.59; median 11.2 months with placebo versus 12.1 months with atezolizumab). mITT and subgroup results were consistent. Median PFS was 4 months across treatment arms and populations. ORRs were 28% with placebo versus 40% with atezolizumab. Adverse events (predominantly haematological) were similar between arms and as expected with atezolizumab plus carboplatin/gemcitabine or capecitabine following recent chemotherapy exposure. OS, which is dismal in patients with TNBC relapsing within <12 months, was not improved by adding atezolizumab to chemotherapy. A biology-based definition of intrinsic resistance to immunotherapy in aTNBC is urgently needed to develop novel therapies for these patients in next-generation clinical trials.",38755096,Carboplatin and Gemcitabine (GCb),Carboplatin and Gemcitabine (GCb) and Atezolizumab|Capecitabine and Atezolizumab,Breast cancer,Non-curative subsequent-line therapy,OS,Primary,no difference,Carboplatin and Gemcitabine (GCb) no difference to Carboplatin and Gemcitabine (GCb) and Atezolizumab|Capecitabine and Atezolizumab for Breast cancer (Non-curative subsequent-line therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Carboplatin and Gemcitabine (GCb) compared to Carboplatin and Gemcitabine (GCb) and Atezolizumab|Capecitabine and Atezolizumab when used to treat Breast cancer (Non-curative subsequent-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Carboplatin and Gemcitabine (GCb) versus Carboplatin and Gemcitabine (GCb) and Atezolizumab|Capecitabine and Atezolizumab in treating Breast cancer (Non-curative subsequent-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Carboplatin and Gemcitabine (GCb) compared to Carboplatin and Gemcitabine (GCb) and Atezolizumab|Capecitabine and Atezolizumab for Breast cancer (Non-curative subsequent-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Carboplatin and Gemcitabine (GCb) and Atezolizumab|Capecitabine and Atezolizumab compared to Carboplatin and Gemcitabine (GCb) when used to treat Breast cancer (Non-curative subsequent-line therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer, Context: Non-curative subsequent-line therapy, Endpoint: OS, Treatment 1: Carboplatin and Gemcitabine (GCb), Treatment 2: Carboplatin and Gemcitabine (GCb) and Atezolizumab|Capecitabine and Atezolizumab Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Breast cancer, Context: Non-curative subsequent-line therapy Treatment: ",superior,inferior,no difference,2024,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer (Node Positive), Context: Adjuvant therapy, Endpoint: RFS, Treatment 1: CMF, Treatment 2: CMFT Response:",CMF inferior to CMFT for Breast cancer (Node Positive) (Adjuvant therapy) [endpoint: RFS],False 2024-06-27,"Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study. Trastuzumab targets human epidermal growth factor receptor 2 (HER2) receptors and is indicated for treating HER2-positive metastatic breast cancer. BP02, a recombinant IgG1 kappa humanized monoclonal antibody, is being developed as a trastuzumab biosimilar. The objective of this study was to evaluate the equivalence of BP02 with reference trastuzumab (RT: Herceptin®-EU) in patients with HER2-positive metastatic breast cancer. This double-blinded, 1:1 randomized, parallel-group, active-controlled, phase III equivalence trial recruited women aged 18-75 years with histologically/cytologically confirmed HER2- positive, locally recurrent or metastatic breast cancer with systemic metastasis, from 59 sites in India. Patients were randomly allocated 1:1 stratified by estrogen receptor/progesterone receptor status to receive BP02/RT (8-mg/kg loading dose on day 1-cycle 1, 6 mg/kg on day 1-cycles 2-8, of each 3-week cycle) combined with docetaxel (75 mg/m2 on day 1-cycles 1-8) [induction phase]. Participants with complete or partial response, or stable disease at the end of the induction phase continued the study drug until disease progression/treatment discontinuation [maintenance phase]. The primary efficacy endpoint was the objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Between 23 September, 2020 and 16 September, 2022, 690 patients were recruited (n = 345 each to BP02/RT). At the end of the induction phase (intent-to-treat population), a similar proportion of patients achieved an objective response rate with BP02 (n = 231 [67.0%], 95% confidence interval [CI] 62.0, 71.9) and RT (n = 238 [69.0%], 95% CI 64.1, 73.9). The 95% CI of risk difference (-2.03, 95% CI -9.15, 5.09) and 90% CI of risk ratio (0.97, 90% CI 0.89, 1.06) were within equivalence margins of ± 13% and (0.80, 1.25), respectively. Treatment-emergent adverse events leading to treatment withdrawal were reported in 2.9% and 3.2% patients with BP02 and RT, respectively. BP02 showed an equivalent efficacy and similar safety profile to RT at the end of 24 weeks. CTRI Number: CTRI/2020/04/024456.",38937403,Docetaxel and Trastuzumab (TH),Docetaxel and BP-02,Breast cancer,Non-curative first-line therapy,ORR,Primary,no difference,Docetaxel and Trastuzumab (TH) no difference to Docetaxel and BP-02 for Breast cancer (Non-curative first-line therapy) [endpoint: ORR],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the ORR outcome of Docetaxel and Trastuzumab (TH) compared to Docetaxel and BP-02 when used to treat Breast cancer (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the ORR outcome of Docetaxel and Trastuzumab (TH) versus Docetaxel and BP-02 in treating Breast cancer (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the ORR results of Docetaxel and Trastuzumab (TH) compared to Docetaxel and BP-02 for Breast cancer (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the ORR outcome of Docetaxel and BP-02 compared to Docetaxel and Trastuzumab (TH) when used to treat Breast cancer (Non-curative first-line therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer, Context: Non-curative first-line therapy, Endpoint: ORR, Treatment 1: Docetaxel and Trastuzumab (TH), Treatment 2: Docetaxel and BP-02 Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Breast cancer, Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2024,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer (Node Positive), Context: Adjuvant therapy, Endpoint: RFS, Treatment 1: CMF, Treatment 2: CMFT Response:",CMF inferior to CMFT for Breast cancer (Node Positive) (Adjuvant therapy) [endpoint: RFS],False 2024-08-16,"Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial. The combination of platinum-based chemotherapy and an antibody to PD-1 or to its ligand PD-L1, with or without an antibody to CTLA-4, has improved the survival of individuals with metastatic non-small-cell lung cancer (NSCLC). However, no randomised controlled trial has evaluated the survival benefit of adding a CTLA-4 inhibitor to platinum-based chemotherapy plus a PD-1 or PD-L1 inhibitor. This open-label, randomised, phase 3 trial was conducted at 48 hospitals in Japan. Eligible patients were aged 20 years or older with previously untreated advanced NSCLC and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients with known driver oncogenes were excluded. Participants were randomly assigned (1:1) to receive platinum-based chemotherapy (four cycles) plus pembrolizumab (pembrolizumab group) or platinum-based chemotherapy (two cycles) plus nivolumab-ipilimumab (nivolumab-ipilimumab group). The primary endpoint was overall survival and assessed in all randomly assigned patients on an intention-to-treat basis. The trial is registered in the Japan Registry for Clinical Trials, jRCTs031210013, and is now closed to new enrolment and is ongoing. Between patient accrual initiation on April 6, 2021, and discontinuation of the trial on March 30, 2023, 11 (7%) of 148 patients in the nivolumab-ipilimumab group had a treatment-related death. Because of the high number of treatment-related deaths, patient accrual was terminated early, resulting in 295 patients (236 [80%] male and 59 [20%] female) enrolled; the primary analysis was done on the basis of 117 deaths (fewer than the required 329 deaths). By May 25, 2023 (data cutoff), overall survival did not differ significantly between the nivolumab-ipilimumab group and the pembrolizumab group (median 23·7 months [95% CI 17·6-not estimable] vs 20·5 months [17·6-not estimable], respectively; hazard ratio 0·98 [90% CI 0·72-1·34]; p=0·46). Non-haematological adverse events of grade 3 or worse occurred in 87 (60%) of 146 patients in the nivolumab-ipilimumab group and 59 (41%) of 144 patients in the pembrolizumab group. The pembrolizumab group tended to have a better quality of life compared with the nivolumab-ipilimumab group. The safety and efficacy data suggest an unfavourable benefit-risk profile for nivolumab-ipilimumab combined with platinum-based chemotherapy relative to pembrolizumab combined with platinum-based chemotherapy as a first-line treatment for patients with advanced NSCLC, although a definitive conclusion awaits an updated analysis of overall survival. The National Cancer Center Research and Development Fund and Japan Agency for Medical Research and Development.",39159638,Carboplatin and nab-Paclitaxel (CnP) and Pembrolizumab,"Carboplatin and Paclitaxel (CP), Ipilimumab, Nivolumab|Carboplatin and nab-Paclitaxel (CnP), Ipilimumab, Nivolumab",Non-small cell lung cancer squamous,Non-curative first-line therapy,OS,Primary,no difference,"Carboplatin and nab-Paclitaxel (CnP) and Pembrolizumab no difference to Carboplatin and Paclitaxel (CP), Ipilimumab, Nivolumab|Carboplatin and nab-Paclitaxel (CnP), Ipilimumab, Nivolumab for Non-small cell lung cancer squamous (Non-curative first-line therapy) [endpoint: OS]","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Carboplatin and nab-Paclitaxel (CnP) and Pembrolizumab compared to Carboplatin and Paclitaxel (CP), Ipilimumab, Nivolumab|Carboplatin and nab-Paclitaxel (CnP), Ipilimumab, Nivolumab when used to treat Non-small cell lung cancer squamous (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Carboplatin and nab-Paclitaxel (CnP) and Pembrolizumab versus Carboplatin and Paclitaxel (CP), Ipilimumab, Nivolumab|Carboplatin and nab-Paclitaxel (CnP), Ipilimumab, Nivolumab in treating Non-small cell lung cancer squamous (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Carboplatin and nab-Paclitaxel (CnP) and Pembrolizumab compared to Carboplatin and Paclitaxel (CP), Ipilimumab, Nivolumab|Carboplatin and nab-Paclitaxel (CnP), Ipilimumab, Nivolumab for Non-small cell lung cancer squamous (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Carboplatin and Paclitaxel (CP), Ipilimumab, Nivolumab|Carboplatin and nab-Paclitaxel (CnP), Ipilimumab, Nivolumab compared to Carboplatin and nab-Paclitaxel (CnP) and Pembrolizumab when used to treat Non-small cell lung cancer squamous (Non-curative first-line therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Non-small cell lung cancer squamous, Context: Non-curative first-line therapy, Endpoint: OS, Treatment 1: Carboplatin and nab-Paclitaxel (CnP) and Pembrolizumab, Treatment 2: Carboplatin and Paclitaxel (CP), Ipilimumab, Nivolumab|Carboplatin and nab-Paclitaxel (CnP), Ipilimumab, Nivolumab Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Non-small cell lung cancer squamous, Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2024,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Classical Hodgkin lymphoma, Context: Induction therapy, Endpoint: ORR, Treatment 1: Vinblastine monotherapy, Treatment 2: Cyclophosphamide monotherapy Response:",Vinblastine monotherapy superior to Cyclophosphamide monotherapy for Classical Hodgkin lymphoma (Induction therapy) [endpoint: ORR],False 2024-09-02,"Phase III randomized trial comparing neoadjuvant paclitaxel plus platinum with 5-fluorouracil plus platinum in esophageal or gastroesophageal junction squamous cell carcinoma. Standard neoadjuvant chemotherapy for locally advanced esophageal or gastroesophageal junction squamous cancer, 5-fluorouracil plus platinum, is toxic and logistically challenging; alternative regimens are needed. This was a phase III randomized open-label noninferiority trial at Tata Memorial Center, India, in resectable locally advanced esophageal or gastroesophageal junction squamous cancer. Patients were randomly assigned 1:1 to 3 cycles of 3-weekly platinum (cisplatin 75 mg/m2 or carboplatin area under the curve 6) with paclitaxel 175 mg/m2 (day 1) or 5-fluorouracil 1000 mg/m2 continuous infusion (days 1-4), followed by surgery. Between August 2014 and June 2022, we enrolled 420 patients; 210 to each arm. Statistically significantly more patients on paclitaxel plus platinum (n =194, 92.3%) received all 3 chemotherapy cycles than on 5-fluorouracil with platinum (n = 170, 85.9%; P = .009). 5-fluorouracil plus platinum caused more grade 3 or higher toxicities (n = 124, 69.7%) than paclitaxel plus platinum (n = 97, 51.9%; P = .001). Surgery was performed in 131 (62.4%) patients on 5-fluorouracil plus platinum vs 139 (66.2%) on paclitaxel plus platinum (P = .415). Paclitaxel plus platinum resulted in higher pathologic primary tumor clearance (n = 33, 25.8%, vs n = 17, 15%; P = .04) and pathologic complete responses in 21.9% compared with 12.4% from 5-fluorouracil plus platinum (P = .053). Median overall survival was 27.5 months (95% confidence interval [CI] = 18.6 to 43.5 months) from paclitaxel plus platinum, which was noninferior to 27.1 months (95% CI = 18.8 to 40.7 months) from 5-fluorouracil plus platinum (hazard ratio [HR] = 0.89, 95% CI = 0.72 to 1.09; P = .346). Neoadjuvant paclitaxel plus platinum chemotherapy is safer and results in similar R0 resections, higher pathologic tumor clearance and noninferior survival compared with 5-fluorouracil plus platinum. Paclitaxel plus platinum should replace 5-fluorouracil plus platinum as neoadjuvant chemotherapy for resectable locally advanced esophagealor gastroesophageal junction squamous cancer. CTRI/2014/04/004516.",39222012,Cisplatin and Fluorouracil (CF),Carboplatin and Paclitaxel (CP)|Cisplatin and Paclitaxel (TP),Esophageal squamous cell carcinoma,Induction therapy,OS,Primary,no difference,Cisplatin and Fluorouracil (CF) no difference to Carboplatin and Paclitaxel (CP)|Cisplatin and Paclitaxel (TP) for Esophageal squamous cell carcinoma (Induction therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Cisplatin and Fluorouracil (CF) compared to Carboplatin and Paclitaxel (CP)|Cisplatin and Paclitaxel (TP) when used to treat Esophageal squamous cell carcinoma (Induction therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Cisplatin and Fluorouracil (CF) versus Carboplatin and Paclitaxel (CP)|Cisplatin and Paclitaxel (TP) in treating Esophageal squamous cell carcinoma (Induction therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Cisplatin and Fluorouracil (CF) compared to Carboplatin and Paclitaxel (CP)|Cisplatin and Paclitaxel (TP) for Esophageal squamous cell carcinoma (Induction therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Carboplatin and Paclitaxel (CP)|Cisplatin and Paclitaxel (TP) compared to Cisplatin and Fluorouracil (CF) when used to treat Esophageal squamous cell carcinoma (Induction therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Esophageal squamous cell carcinoma, Context: Induction therapy, Endpoint: OS, Treatment 1: Cisplatin and Fluorouracil (CF), Treatment 2: Carboplatin and Paclitaxel (CP)|Cisplatin and Paclitaxel (TP) Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Esophageal squamous cell carcinoma, Context: Induction therapy Treatment: ",superior,inferior,no difference,2024,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Colon cancer, Context: Adjuvant therapy, Endpoint: DFS, Treatment 1: Observation, Treatment 2: Fluorouracil monotherapy Response:",Observation inferior to Fluorouracil monotherapy for Colon cancer (Adjuvant therapy) [endpoint: DFS],False 2024-09-16,"Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. For patients with metastatic hormone-sensitive prostate cancer (mHSPC), delaying progression to castration-resistant disease is important not only for overall survival (OS) but also for patients' quality of life. Darolutamide plus androgen-deprivation therapy (ADT) with docetaxel improved OS versus ADT and docetaxel in patients with mHSPC. The ARANOTE trial evaluated darolutamide and ADT without chemotherapy in patients with mHSPC. In this global phase III trial, patients were randomly assigned 2:1 to receive darolutamide 600 mg twice daily or placebo, with concomitant ADT. The primary end point was radiological progression-free survival (rPFS). From March 2021 to August 2022, 669 patients were randomly assigned (darolutamide n = 446; placebo n = 223). At the primary cutoff date (June 7, 2024), darolutamide plus ADT significantly improved rPFS, reducing the risk of radiological progression or death by 46% versus placebo plus ADT (hazard ratio [HR], 0.54 [95% CI, 0.41 to 0.71]; P < .0001), with consistent benefits across subgroups, including high- and low-volume disease. OS results were suggestive of benefit with darolutamide versus placebo (HR, 0.81 [95% CI, 0.59 to 1.12]), and clinical benefits were seen across all other secondary end points, including delayed time to metastatic castration-resistant prostate cancer (HR, 0.40 [95% CI, 0.32 to 0.51]) and time to pain progression (HR, 0.72 [95% CI, 0.54 to 0.96]). Adverse events were similar in the two groups. Notably, the incidence of fatigue was lower in patients receiving darolutamide (5.6%) versus those receiving placebo (8.1%), and fewer patients receiving darolutamide (6.1%) versus placebo (9.0%) discontinued treatment because of adverse events. These results confirm the efficacy and tolerability of darolutamide plus ADT in patients with mHSPC, demonstrating clinically and statistically significant improvement in rPFS and a favorable safety profile consistent with prior phase III darolutamide trials.",39279580,ADT,ADT and Darolutamide,Prostate cancer (Metastatic),Non-curative therapy,rPFS,Primary,inferior,ADT inferior to ADT and Darolutamide for Prostate cancer (Metastatic) (Non-curative therapy) [endpoint: rPFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the rPFS outcome of ADT compared to ADT and Darolutamide when used to treat Prostate cancer (Metastatic) (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the rPFS outcome of ADT versus ADT and Darolutamide in treating Prostate cancer (Metastatic) (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the rPFS results of ADT compared to ADT and Darolutamide for Prostate cancer (Metastatic) (Non-curative therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the rPFS outcome of ADT and Darolutamide compared to ADT when used to treat Prostate cancer (Metastatic) (Non-curative therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Prostate cancer (Metastatic), Context: Non-curative therapy, Endpoint: rPFS, Treatment 1: ADT, Treatment 2: ADT and Darolutamide Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Prostate cancer (Metastatic), Context: Non-curative therapy Treatment: ",superior,inferior,no difference,2024,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Wilms tumor, Context: Adjuvant therapy, Endpoint: RFS, Treatment 1: Dactinomycin and Vincristine, Treatment 2: Vincristine monotherapy Response:",Dactinomycin and Vincristine superior to Vincristine monotherapy for Wilms tumor (Adjuvant therapy) [endpoint: RFS],False 2024-11-16,"Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study. PEARL (NCT03003962) is an open-label, phase 3 study comparing first-line durvalumab monotherapy with chemotherapy in patients with metastatic NSCLC (mNSCLC [EGFR/ALK wild type]) with programmed cell death ligand 1 (PD-L1) tumor cell (TC) membrane expression status of 25% or higher. We report the final analysis of PEARL. Adults (N = 669) with previously untreated stage IV mNSCLC were randomized (1:1) to durvalumab 20 mg/kg every four weeks or chemotherapy every three weeks for four to six cycles. The dual primary endpoints were overall survival (OS) in the population with PD-L1 TC of 25% or higher and OS in the population at low risk of early mortality (LREM) with PD-L1 TC of 25% or higher. Durvalumab was associated with a numerical reduction in the risk of death versus chemotherapy in the 25% and higher PD-L1 TC population (OS hazard ratio [HR] = 0.84, 95% confidence interval [CI]: 0.71-0.99, p = 0.037; median OS 14.6 months, 95% CI: 12.2-16.9 versus 12.8 months, 95% CI: 10.1-14.7, respectively). In the 25% and higher PD-L1 TC low risk of early mortality population the OS hazard ratio for durvalumab versus chemotherapy was 0.96 (95% CI: 0.79-1.15, p = 0.628); median OS 14.6 months (95% CI: 12.6-17.2) versus 15.0 months (95% CI: 13.1-16.8), respectively. In the safety population, the incidence of grade 3 or 4 treatment-related adverse events was 15.5% (durvalumab) and 45.9% (chemotherapy). Durvalumab did not statistically significantly improve OS versus chemotherapy as first-line treatment in patients with mNSCLC and 25% and higher PD-L1 TC. The numerical improvement in OS was consistent with previous studies of first-line immune checkpoint inhibitor monotherapy in patients with mNSCLC.",39521433,Durvalumab monotherapy,Carboplatin and Paclitaxel (CP)|Carboplatin and Gemcitabine (GCb)|Cisplatin and Gemcitabine (GC)|Carboplatin and Pemetrexed|Cisplatin and Pemetrexed,Non-small cell lung cancer,Non-curative first-line therapy,OS,Co-primary,superior,Durvalumab monotherapy superior to Carboplatin and Paclitaxel (CP)|Carboplatin and Gemcitabine (GCb)|Cisplatin and Gemcitabine (GC)|Carboplatin and Pemetrexed|Cisplatin and Pemetrexed for Non-small cell lung cancer (Non-curative first-line therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Durvalumab monotherapy compared to Carboplatin and Paclitaxel (CP)|Carboplatin and Gemcitabine (GCb)|Cisplatin and Gemcitabine (GC)|Carboplatin and Pemetrexed|Cisplatin and Pemetrexed when used to treat Non-small cell lung cancer (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Durvalumab monotherapy versus Carboplatin and Paclitaxel (CP)|Carboplatin and Gemcitabine (GCb)|Cisplatin and Gemcitabine (GC)|Carboplatin and Pemetrexed|Cisplatin and Pemetrexed in treating Non-small cell lung cancer (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Durvalumab monotherapy compared to Carboplatin and Paclitaxel (CP)|Carboplatin and Gemcitabine (GCb)|Cisplatin and Gemcitabine (GC)|Carboplatin and Pemetrexed|Cisplatin and Pemetrexed for Non-small cell lung cancer (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Carboplatin and Paclitaxel (CP)|Carboplatin and Gemcitabine (GCb)|Cisplatin and Gemcitabine (GC)|Carboplatin and Pemetrexed|Cisplatin and Pemetrexed compared to Durvalumab monotherapy when used to treat Non-small cell lung cancer (Non-curative first-line therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Non-small cell lung cancer, Context: Non-curative first-line therapy, Endpoint: OS, Treatment 1: Durvalumab monotherapy, Treatment 2: Carboplatin and Paclitaxel (CP)|Carboplatin and Gemcitabine (GCb)|Cisplatin and Gemcitabine (GC)|Carboplatin and Pemetrexed|Cisplatin and Pemetrexed Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Non-small cell lung cancer, Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2024,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Acute myeloid leukemia pediatric, Context: Induction therapy, Treatment 1: Azaserine and Mercaptopurine, Treatment 2: Mercaptopurine monotherapy Response:",Azaserine and Mercaptopurine no difference to Mercaptopurine monotherapy for Acute myeloid leukemia pediatric (Induction therapy) [endpoint: Could not be determined],False 2024-12-11,"Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα (ESR1). In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer that recurred or progressed during or after aromatase inhibitor therapy, administered alone or with a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. Patients were assigned in a 1:1:1 ratio to receive imlunestrant, standard endocrine monotherapy, or imlunestrant-abemaciclib. Primary end points were investigator-assessed progression-free survival with imlunestrant as compared with standard therapy among patients with ESR1 mutations and among all patients and with imlunestrant-abemaciclib as compared with imlunestrant among all patients who had undergone randomization concurrently. Overall, 874 patients underwent randomization, with 331 assigned to imlunestrant, 330 to standard therapy, and 213 to imlunestrant-abemaciclib. Among 256 patients with ESR1 mutations, the median progression-free survival was 5.5 months with imlunestrant and 3.8 months with standard therapy. The estimated restricted mean survival time at 19.4 months was 7.9 months (95% confidence interval [CI], 6.8 to 9.1) with imlunestrant and 5.4 months (95% CI, 4.6 to 6.2) with standard therapy (difference, 2.6 months; 95% CI, 1.2 to 3.9; P<0.001). In the overall population, the median progression-free survival was 5.6 months with imlunestrant and 5.5 months with standard therapy (hazard ratio for progression or death, 0.87; 95% CI, 0.72 to 1.04; P = 0.12). Among 426 patients in the comparison of imlunestrant-abemaciclib with imlunestrant, the median progression-free survival was 9.4 months and 5.5 months, respectively (hazard ratio, 0.57; 95% CI, 0.44 to 0.73; P<0.001). The incidence of grade 3 or higher adverse events was 17.1% with imlunestrant, 20.7% with standard therapy, and 48.6% with imlunestrant-abemaciclib. Among patients with ER-positive, HER2-negative advanced breast cancer, treatment with imlunestrant led to significantly longer progression-free survival than standard therapy among those with ESR1 mutations but not in the overall population. Imlunestrant-abemaciclib significantly improved progression-free survival as compared with imlunestrant, regardless of ESR1-mutation status. (Funded by Eli Lilly; EMBER-3 ClinicalTrials.gov number, NCT04975308.).",39660834,Imlunestrant monotherapy,Exemestane monotherapy,Breast cancer,Non-curative subsequent-line therapy,PFS,Undesignated,superior,Imlunestrant monotherapy superior to Exemestane monotherapy for Breast cancer (Non-curative subsequent-line therapy) [endpoint: PFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of Imlunestrant monotherapy compared to Exemestane monotherapy when used to treat Breast cancer (Non-curative subsequent-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the PFS outcome of Imlunestrant monotherapy versus Exemestane monotherapy in treating Breast cancer (Non-curative subsequent-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the PFS results of Imlunestrant monotherapy compared to Exemestane monotherapy for Breast cancer (Non-curative subsequent-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of Exemestane monotherapy compared to Imlunestrant monotherapy when used to treat Breast cancer (Non-curative subsequent-line therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer, Context: Non-curative subsequent-line therapy, Endpoint: PFS, Treatment 1: Imlunestrant monotherapy, Treatment 2: Exemestane monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Breast cancer, Context: Non-curative subsequent-line therapy Treatment: ",superior,inferior,no difference,2024,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Breast cancer (Node Positive), Context: Adjuvant therapy, Endpoint: RFS, Treatment 1: CMF, Treatment 2: CMFT Response:",CMF inferior to CMFT for Breast cancer (Node Positive) (Adjuvant therapy) [endpoint: RFS],False 2025-04-23,"Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal Carcinoma. Cisplatin-based concurrent chemoradiotherapy (CCRT) is the mainstay treatment for locoregionally advanced nasopharyngeal carcinoma (LA-NPC), which usually leads to intolerable toxicities. We investigated whether or not induction chemotherapy (IC) plus intensity-modulated radiation therapy (IMRT) could replace CCRT. This is an open-label, phase 3, noninferiority trial. Patients with stage T1-4N2-3 or T3-4N0-1 LA-NPC were randomly assigned (1:1) to receive gemcitabine (1000 mg/m2) and cisplatin (80 mg/m2) for two cycles followed by IMRT, or IMRT plus concomitant weekly cisplatin (40 mg/m2) for up to seven cycles. Two-year failure-free survival (FFS) was the primary end point, and noninferiority was confirmed by an upper limit of the 95% confidence interval (CI) for a hazard ratio of less than 2.12 (absolute margin of -10 percentage points). Secondary end points include overall survival, locoregional recurrence-free survival, distant metastasis-free survival, toxicity profile, and quality of life (QoL). We enrolled 124 patients in the IC group and 125 patients in the CCRT group. The median follow-up was 60 months. Two-year FFS was 90.2% for IC versus 86.3% for CCRT, with a hazard ratio of 0.636 (95% CI, 0.267 to 1.514) and an absolute difference of 3.9 percentage points (95% CI, -5.2 to 13.0). Compared with the CCRT group, fewer grade ≥3 adverse events occurred in the IC group (47.5% vs. 61.5%; P=0.029), including leukopenia, anemia, mucositis, nausea, and dysphagia. IC was associated with better QoL, including global health status, social and cognitive functioning, fatigue, nausea and vomiting, pain, appetite loss, and constipation. For 2-year FFS for LA-NPC, gemcitabine and cisplatin IC plus IMRT alone was noninferior to CCRT. (Funded by Key-Area Research and Development of Guangdong Province and others.).",40261119,Cisplatin and Gemcitabine (GC),Cisplatin and RT,Nasopharyngeal carcinoma,Induction therapy,FFS,Primary,no difference,Cisplatin and Gemcitabine (GC) no difference to Cisplatin and RT for Nasopharyngeal carcinoma (Induction therapy) [endpoint: FFS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the FFS outcome of Cisplatin and Gemcitabine (GC) compared to Cisplatin and RT when used to treat Nasopharyngeal carcinoma (Induction therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the FFS outcome of Cisplatin and Gemcitabine (GC) versus Cisplatin and RT in treating Nasopharyngeal carcinoma (Induction therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the FFS results of Cisplatin and Gemcitabine (GC) compared to Cisplatin and RT for Nasopharyngeal carcinoma (Induction therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the FFS outcome of Cisplatin and RT compared to Cisplatin and Gemcitabine (GC) when used to treat Nasopharyngeal carcinoma (Induction therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Nasopharyngeal carcinoma, Context: Induction therapy, Endpoint: FFS, Treatment 1: Cisplatin and Gemcitabine (GC), Treatment 2: Cisplatin and RT Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Nasopharyngeal carcinoma, Context: Induction therapy Treatment: ",superior,inferior,no difference,2025,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Head and neck cancer, Context: Definitive therapy, Endpoint: OS, Treatment 1: Radiation therapy, Treatment 2: Fluorouracil and RT Response:",Radiation therapy inferior to Fluorouracil and RT for Head and neck cancer (Definitive therapy) [endpoint: OS],False 2025-05-15,"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Patients with unresectable hepatocellular carcinoma have a poor prognosis, and treatments with long-term benefits are needed. We report results from the preplanned interim analysis of the CheckMate 9DW trial assessing nivolumab plus ipilimumab versus lenvatinib or sorafenib for unresectable hepatocellular carcinoma in the first-line setting. This open-label, randomised, phase 3 trial enrolled patients aged 18 years or older with unresectable hepatocellular carcinoma without previous systemic therapy at 163 hospitals and cancer centres across 25 countries in Asia, Australia, Europe, North America, and South America. Patients had at least one measurable untreated lesion per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1, a Child-Pugh score of 5 or 6, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1) via an interactive response technology system to receive nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) intravenously every 3 weeks for up to four doses, followed by nivolumab 480 mg every 4 weeks or investigator's choice of either oral lenvatinib (8 mg or 12 mg mg daily depending on bodyweight) or oral sorafenib (400 mg twice daily). Randomisation was stratified by aetiology; the presence of macrovascular invasion, extrahepatic spread, or both; and baseline alpha-fetoprotein concentration. The primary endpoint was overall survival, which was assessed in all randomly assigned patients; safety was an exploratory endpoint and was assessed in all randomly assigned patients who received at least one dose of study medication. This trial is registered with ClinicalTrials.gov, NCT04039607 (ongoing). Between Jan 6, 2020, and Nov 8, 2021, 668 patients were randomly assigned to nivolumab plus ipilimumab (n=335) or lenvatinib or sorafenib (n=333). Early crossing of the overall survival Kaplan-Meier curves reflected a higher number of deaths during the first 6 months after randomisation with nivolumab plus ipilimumab (hazard ratio 1·65 [95% CI 1·12-2·43]) but was followed by a sustained separation of the curves thereafter in favour of nivolumab plus ipilimumab (0·61 [0·48-0·77]). After a median follow-up of 35·2 months (IQR 31·1-39·9), overall survival was significantly improved with nivolumab plus ipilimumab versus lenvatinib or sorafenib (median 23·7 months [95% CI 18·8-29·4] vs 20·6 months [17·5-22·5]; hazard ratio 0·79 [0·65-0·96]; two-sided stratified log-rank p=0·018); respective overall survival rates were 49% (95% CI 44-55) versus 39% (34-45) at 24 months and 38% (32-43) versus 24% (19-30) at 36 months. Overall, 137 (41%) of 332 patients receiving nivolumab plus ipilimumab and 138 (42%) of 325 patients receiving lenvatinib or sorafenib had grade 3-4 treatment-related adverse events. 12 deaths were attributed to treatment with nivolumab plus ipilimumab and three were attributed to treatment with lenvatinib or sorafenib. Nivolumab plus ipilimumab showed a significant overall survival benefit versus lenvatinib or sorafenib and manageable safety in patients with previously untreated unresectable hepatocellular carcinoma. These results support nivolumab plus ipilimumab as a first-line treatment in this setting. Bristol Myers Squibb.",40349714,Ipilimumab and Nivolumab,Lenvatinib monotherapy|Sorafenib monotherapy,Hepatocellular carcinoma (Unresectable or Metastatic),Non-curative first-line therapy,OS,Primary,superior,Ipilimumab and Nivolumab superior to Lenvatinib monotherapy|Sorafenib monotherapy for Hepatocellular carcinoma (Unresectable or Metastatic) (Non-curative first-line therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Ipilimumab and Nivolumab compared to Lenvatinib monotherapy|Sorafenib monotherapy when used to treat Hepatocellular carcinoma (Unresectable or Metastatic) (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of Ipilimumab and Nivolumab versus Lenvatinib monotherapy|Sorafenib monotherapy in treating Hepatocellular carcinoma (Unresectable or Metastatic) (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of Ipilimumab and Nivolumab compared to Lenvatinib monotherapy|Sorafenib monotherapy for Hepatocellular carcinoma (Unresectable or Metastatic) (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Lenvatinib monotherapy|Sorafenib monotherapy compared to Ipilimumab and Nivolumab when used to treat Hepatocellular carcinoma (Unresectable or Metastatic) (Non-curative first-line therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Hepatocellular carcinoma (Unresectable or Metastatic), Context: Non-curative first-line therapy, Endpoint: OS, Treatment 1: Ipilimumab and Nivolumab, Treatment 2: Lenvatinib monotherapy|Sorafenib monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Hepatocellular carcinoma (Unresectable or Metastatic), Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2025,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Colon cancer, Context: Adjuvant therapy, Endpoint: DFS, Treatment 1: Observation, Treatment 2: Fluorouracil monotherapy Response:",Observation inferior to Fluorouracil monotherapy for Colon cancer (Adjuvant therapy) [endpoint: DFS],False 2025-07-28,"Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial. Modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) and nab-paclitaxel + gemcitabine are recommended as first-line treatments for metastatic pancreatic cancer. S-1, irinotecan, and oxaliplatin (S-IROX) demonstrated activity in a phase Ib trial in this population. Therefore, these three regimens were directly compared. This randomized phase II/III trial was performed at 45 centers in Japan. Eligible patients age 20-75 years with an Eastern Cooperative Oncology Group performance status of 0 or 1 and pathologically confirmed metastatic or recurrent pancreatic cancer were randomly assigned (1:1:1) to receive mFOLFIRINOX (oxaliplatin 85 mg/m2 over 2 hours, irinotecan 150 mg/m2 over 90 minutes, l-leucovorin 200 mg/m2 over 2 hours, each once daily on day 1, and fluorouracil 2,400 mg/m2 over 46 hours on days 1-3, every 2 weeks), S-IROX (oxaliplatin 85 mg/m2 over 2 hours, irinotecan 150 mg/m2 over 90 minutes on day 1, and S-1 80 mg/m2/day administered orally twice daily on days 1-7, every 2 weeks), or nab-paclitaxel (125 mg/m2) + gemcitabine (1,000 mg/m2) on days 1, 8, and 15 every 4 weeks. The primary end point was overall survival (OS). A total of 527 patients were enrolled, with 426 included in the planned interim analysis. The median OS was 14.0 months (hazard ratio [HR], 1.31 [95% CI, 0.97 to 1.77]) and 13.6 months (HR, 1.35 [95% CI, 1.00 to 1.82]) in the mFOLFIRINOX and S-IROX groups, respectively, as compared with 17.1 months in the nab-paclitaxel + gemcitabine group. The predictive probability of achieving superiority in the final analysis was <1% in both groups. Thus, the trial was terminated owing to its futility. Grade 3 to 4 anorexia was more frequent in the mFOLFIRINOX (23.3%) and S-IROX (27.5%) groups than in the nab-paclitaxel + gemcitabine group (5.0%). Neither mFOLFIRINOX nor S-IROX appeared to be superior compared with nab-paclitaxel + gemcitabine as the first-line treatment for metastatic or recurrent pancreatic cancer.",40720715,mFOLFIRINOX,Gemcitabine and nab-Paclitaxel,Pancreatic cancer,Non-curative first-line therapy,OS,Primary,inferior,mFOLFIRINOX inferior to Gemcitabine and nab-Paclitaxel for Pancreatic cancer (Non-curative first-line therapy) [endpoint: OS],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of mFOLFIRINOX compared to Gemcitabine and nab-Paclitaxel when used to treat Pancreatic cancer (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the OS outcome of mFOLFIRINOX versus Gemcitabine and nab-Paclitaxel in treating Pancreatic cancer (Non-curative first-line therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the OS results of mFOLFIRINOX compared to Gemcitabine and nab-Paclitaxel for Pancreatic cancer (Non-curative first-line therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the OS outcome of Gemcitabine and nab-Paclitaxel compared to mFOLFIRINOX when used to treat Pancreatic cancer (Non-curative first-line therapy). Response:",superior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Pancreatic cancer, Context: Non-curative first-line therapy, Endpoint: OS, Treatment 1: mFOLFIRINOX, Treatment 2: Gemcitabine and nab-Paclitaxel Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Pancreatic cancer, Context: Non-curative first-line therapy Treatment: ",superior,inferior,no difference,2025,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Colon cancer, Context: Adjuvant therapy, Endpoint: DFS, Treatment 1: Fluorouracil monotherapy, Treatment 2: Observation Response:",Fluorouracil monotherapy superior to Observation for Colon cancer (Adjuvant therapy) [endpoint: DFS],False 2025-10-03,"Metformin Active Surveillance Trial in Low-Risk Prostate Cancer. Active surveillance (AS) is a standard management strategy for low-risk prostate cancer (PCa), but a significant proportion of patients ultimately experience disease progression. Metformin, a commonly prescribed antidiabetic agent, has demonstrated antitumor activity in preclinical studies and observational data, prompting investigation into its potential to delay PCa progression. The Metformin Active Surveillance Trial (MAST) was a multicenter, randomized, double-blind, placebo-controlled phase III trial evaluating the efficacy of metformin in men with low-risk, localized PCa managed with AS. Eligible participants were randomly assigned 1:1 to receive either metformin (850 mg twice daily) or placebo and were followed for up to 36 months. The primary end point was time to progression, defined as therapeutic and/or pathologic progression. Progression-free survival (PFS) was assessed using Kaplan-Meier analysis and Cox proportional hazards models. A total of 408 patients were randomly assigned (205 metformin, 203 placebo). After a median follow-up of 36 months, 144 participants experienced progression (70 metformin, 74 placebo), with no significant difference in PFS (hazard ratio [HR], 1.09 [95% CI, 0.79 to 1.52]; P = .59). Negative biopsy rates at 36 months were 41.0% (metformin) versus 31.1% (placebo; P = .181). In prespecified subgroup analysis, metformin was associated with increased pathologic progression among obese patients (BMI ≥ 30; HR, 2.36 [95% CI, 1.21 to 4.59]; P = .0092). Metformin did not reduce progression in men with low-risk PCa on AS. The observed adverse effect in obese patients merits further investigation.",41166665,Active surveillance and Metformin,Active surveillance,Prostate cancer,Definitive therapy,TTP,Primary,no difference,Active surveillance and Metformin no difference to Active surveillance for Prostate cancer (Definitive therapy) [endpoint: TTP],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the TTP outcome of Active surveillance and Metformin compared to Active surveillance when used to treat Prostate cancer (Definitive therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the TTP outcome of Active surveillance and Metformin versus Active surveillance in treating Prostate cancer (Definitive therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the TTP results of Active surveillance and Metformin compared to Active surveillance for Prostate cancer (Definitive therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the TTP outcome of Active surveillance compared to Active surveillance and Metformin when used to treat Prostate cancer (Definitive therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Prostate cancer, Context: Definitive therapy, Endpoint: TTP, Treatment 1: Active surveillance and Metformin, Treatment 2: Active surveillance Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Prostate cancer, Context: Definitive therapy Treatment: ",superior,inferior,no difference,2025,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Wilms tumor, Context: Adjuvant therapy, Endpoint: RFS, Treatment 1: Vincristine monotherapy, Treatment 2: Dactinomycin and Vincristine Response:",Vincristine monotherapy inferior to Dactinomycin and Vincristine for Wilms tumor (Adjuvant therapy) [endpoint: RFS],False 2025-10-13,"Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study. Immunotherapy targeting PD-L1 improves outcomes in patients with unresectable stage III non-small cell lung cancer (NSCLC) and no progression after definitive, concurrent chemoradiotherapy (cCRT). Earlier administration of immunotherapy, simultaneously with cCRT, may improve outcomes further. Eligible patients were randomly assigned (2:1) to receive either durvalumab or placebo administered from the start of cCRT. Patients without progression after completing cCRT received consolidation durvalumab or placebo (per initial random assignment) until progression. The primary end point was progression-free survival (PFS) by blinded independent central review. Key secondary end points included objective response rate (ORR), overall survival (OS), the proportion of patients alive at 24 months (OS24), and safety. In total, 328 patients were randomly assigned to receive durvalumab (n = 219) or placebo (n = 109). There was no statistically significant difference with durvalumab versus placebo in PFS (hazard ratio [HR], 0.85 [95% CI, 0.65 to 1.12]; P = .247) or OS (HR, 1.03 [95% CI, 0.78 to 1.39]; P = .823); OS24 was 58.4% versus 59.5%, respectively. Confirmed ORR was 60.7% with durvalumab versus 60.6% with placebo (difference, 0.2% [95% CI, -15.2 to 16.3%]; P = .976). With durvalumab versus placebo, respectively, maximum grade 3 or 4 adverse events (AEs) occurred in 53.4% versus 59.3% of patients, pneumonitis or radiation pneumonitis (group term) in 28.8% (grade ≥3: 4.6%) versus 28.7% (grade ≥3: 5.6%), AEs leading to discontinuation of durvalumab or placebo in 25.6% versus 12.0%, and fatal AEs in 13.7% versus 10.2%. Among patients with unresectable stage III NSCLC, durvalumab administered from the start of cCRT failed to demonstrate additional benefit compared with cCRT plus placebo. Consolidation durvalumab following definitive cCRT remains the standard of care in this setting.",41082707,"Carboplatin and Paclitaxel (CP), Durvalumab, RT|Carboplatin, Pemetrexed, Durvalumab, RT|Cisplatin, Pemetrexed, Durvalumab, RT|Cisplatin and Etoposide (EP), Durvalumab, RT","Cisplatin, Pemetrexed, RT",Non-small cell lung cancer nonsquamous,Definitive therapy,PFS,Primary,no difference,"Carboplatin and Paclitaxel (CP), Durvalumab, RT|Carboplatin, Pemetrexed, Durvalumab, RT|Cisplatin, Pemetrexed, Durvalumab, RT|Cisplatin and Etoposide (EP), Durvalumab, RT no difference to Cisplatin, Pemetrexed, RT for Non-small cell lung cancer nonsquamous (Definitive therapy) [endpoint: PFS]","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of Carboplatin and Paclitaxel (CP), Durvalumab, RT|Carboplatin, Pemetrexed, Durvalumab, RT|Cisplatin, Pemetrexed, Durvalumab, RT|Cisplatin and Etoposide (EP), Durvalumab, RT compared to Cisplatin, Pemetrexed, RT when used to treat Non-small cell lung cancer nonsquamous (Definitive therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the PFS outcome of Carboplatin and Paclitaxel (CP), Durvalumab, RT|Carboplatin, Pemetrexed, Durvalumab, RT|Cisplatin, Pemetrexed, Durvalumab, RT|Cisplatin and Etoposide (EP), Durvalumab, RT versus Cisplatin, Pemetrexed, RT in treating Non-small cell lung cancer nonsquamous (Definitive therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the PFS results of Carboplatin and Paclitaxel (CP), Durvalumab, RT|Carboplatin, Pemetrexed, Durvalumab, RT|Cisplatin, Pemetrexed, Durvalumab, RT|Cisplatin and Etoposide (EP), Durvalumab, RT compared to Cisplatin, Pemetrexed, RT for Non-small cell lung cancer nonsquamous (Definitive therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the PFS outcome of Cisplatin, Pemetrexed, RT compared to Carboplatin and Paclitaxel (CP), Durvalumab, RT|Carboplatin, Pemetrexed, Durvalumab, RT|Cisplatin, Pemetrexed, Durvalumab, RT|Cisplatin and Etoposide (EP), Durvalumab, RT when used to treat Non-small cell lung cancer nonsquamous (Definitive therapy). Response:",no difference,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Non-small cell lung cancer nonsquamous, Context: Definitive therapy, Endpoint: PFS, Treatment 1: Carboplatin and Paclitaxel (CP), Durvalumab, RT|Carboplatin, Pemetrexed, Durvalumab, RT|Cisplatin, Pemetrexed, Durvalumab, RT|Cisplatin and Etoposide (EP), Durvalumab, RT, Treatment 2: Cisplatin, Pemetrexed, RT Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Non-small cell lung cancer nonsquamous, Context: Definitive therapy Treatment: ",superior,inferior,no difference,2025,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Classical Hodgkin lymphoma, Context: Induction therapy, Endpoint: ORR, Treatment 1: Vinblastine monotherapy, Treatment 2: Cyclophosphamide monotherapy Response:",Vinblastine monotherapy superior to Cyclophosphamide monotherapy for Classical Hodgkin lymphoma (Induction therapy) [endpoint: ORR],False 2025-10-19,"Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China. People with recurrent or metastatic nasopharyngeal carcinoma that progressed after chemotherapy and programmed cell death protein 1 (PD-1) and its ligand (PD-L1) inhibitors have few treatment options and a poor prognosis. We therefore aimed to investigate the efficacy and safety of the bispecific antibody-drug conjugate izalontamab brengitecan (iza-bren) in heavily pretreated individuals with recurrent or metastatic nasopharyngeal carcinoma. This multicentre, randomised, open-label, phase 3 study was conducted at 55 hospitals in China. Eligible participants were aged 18-75 years with histologically or cytologically confirmed recurrent or metastatic nasopharyngeal carcinoma that had progressed after at least two lines of systemic chemotherapy including at least one platinum-containing regimen and PD-1 or PD-L1 inhibitors. Participants were randomly assigned (1:1) to receive either iza-bren at 2·5 mg/kg intravenously on days 1 and 8 of each 3-week cycle or chemotherapy. Random assignment was done through an interactive web-based response system, stratified by baseline Eastern Cooperative Oncology Group performance status (0 vs 1), liver metastases, and previous lines of platinum-based chemotherapy (one line vs two or more lines), with a variable block size. The dual primary efficacy endpoints were objective response rate (ORR) assessed by masked independent central review as per Response Evaluation Criteria in Solid Tumours version 1.1 criteria, and overall survival. Progression-free survival, duration of response, and safety were the secondary endpoints. This report is the first planned interim analysis. This trial is registered with ClinicalTrials.gov (NCT06118333) and is ongoing. From Dec 4, 2023, to Feb 21, 2025, 522 patients were screened, of whom 386 were enrolled and randomly assigned to receive either iza-bren (n=191) or chemotherapy (n=195). At a median follow-up of 7·66 months for the iza-bren group and 7·10 months for the chemotherapy group, the ORR by masked independent central review was 54·6% (95% CI 45·2-63·8%) with iza-bren and 27·0% (19·1-36·0%) with chemotherapy (difference 27·9%, 95% CI 15·5-39·4%; p<0·0001). Overall survival data were not mature at data cutoff. Grade 3 or higher treatment-related adverse events occurred in 80% of patients receiving iza-bren and 62% of those receiving chemotherapy. The most common grade 3 or higher treatment-related adverse events in the iza-bren group were haematological, including anaemia (50% vs 10%), decreased white blood cell count (43% vs 44%), decreased platelet count (43% vs 7%), and decreased neutrophil count (38% vs 41%). Non-haematological treatment-related adverse events in the iza-bren group were mostly grade 1 or 2. Serious treatment-related adverse events occurred in 43% of patients receiving iza-bren and 27% of those receiving chemotherapy. Four (2%) treatment-related deaths occurred in the iza-bren group. Iza-bren significantly improved the ORR compared with chemotherapy in individuals with heavily pretreated recurrent or metastatic nasopharyngeal carcinoma, with a manageable safety profile. These findings suggest iza-bren might represent a new therapeutic standard for this population. Further analysis will help to fully understand the benefit of this new therapy. Baili-Bio (Chengdu) Pharmaceutical.",41125110,Izalontamab brengitecan monotherapy,Gemcitabine monotherapy,Nasopharyngeal carcinoma,Non-curative therapy,ORR,Co-primary,superior,Izalontamab brengitecan monotherapy superior to Gemcitabine monotherapy for Nasopharyngeal carcinoma (Non-curative therapy) [endpoint: ORR],"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the ORR outcome of Izalontamab brengitecan monotherapy compared to Gemcitabine monotherapy when used to treat Nasopharyngeal carcinoma (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Select the option that most accurately reflects the ORR outcome of Izalontamab brengitecan monotherapy versus Gemcitabine monotherapy in treating Nasopharyngeal carcinoma (Non-curative therapy). Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Which option best summarizes the ORR results of Izalontamab brengitecan monotherapy compared to Gemcitabine monotherapy for Nasopharyngeal carcinoma (Non-curative therapy)? Response:","You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a clinical question, compare two treatment options with respect to a specific outcome endpoint and determine their relative efficacy based on current clinical evidence. Answer with exactly one of the following three options: - superior (Treatment 1 outperforms Treatment 2 on the specified endpoint) - inferior (Treatment 1 underperforms Treatment 2 on the specified endpoint) - no difference (no meaningful difference between the two treatments on the specified endpoint) Do not include any explanation or additional text. Task: Choose an option that best describes the ORR outcome of Gemcitabine monotherapy compared to Izalontamab brengitecan monotherapy when used to treat Nasopharyngeal carcinoma (Non-curative therapy). Response:",inferior,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Nasopharyngeal carcinoma, Context: Non-curative therapy, Endpoint: ORR, Treatment 1: Izalontamab brengitecan monotherapy, Treatment 2: Gemcitabine monotherapy Response:"," You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition and clinical context, your task is to provide a concise overview over the relevant components of a treatment that is consistent with current clinical guidelines. Be as specific as possible, including: (1) Drug components, (2) Timing and sequencing, (3) Dosage and duration, (4) Route of administration. Condition: Nasopharyngeal carcinoma, Context: Non-curative therapy Treatment: ",superior,inferior,no difference,2025,"You are a knowledgeable medical assistant supporting oncologists and hematologists in evaluating treatment options. Given a condition, context, and endpoint, compare two treatment options with respect to the specific outcome endpoint and summarize their relative efficacy based on current clinical evidence. Task: Condition: Head and neck cancer, Context: Definitive therapy, Endpoint: OS, Treatment 1: Radiation therapy, Treatment 2: Fluorouracil and RT Response:",Radiation therapy inferior to Fluorouracil and RT for Head and neck cancer (Definitive therapy) [endpoint: OS],False